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1 INTRODUCTION INTRODUCTION 
2 
1.1 Oxygen and oxidative stress 
Considering the role of oxygen for life on our planet, it is a Janus-faced molecule. It is 
indispensable to aerobic bacteria, fungi and higher organisms for metabolism, while at 
the same time its metabolites can exhibit deleterious effects towards almost any kind of 
biological molecule. When oxygen first appeared in significant amounts in the 
atmosphere about 2.5 to 3 billion years ago, it set off an ecological catastrophe. Blue-
green algae had acquired the ability to split water and release molecular oxygen by 
photosynthesis. Other primitive organisms at that time were essentially anaerobes, and 
the rising amounts of oxygen in the atmosphere put severe stress on them. Many 
organisms of that time must have died out, while others receded to environments into 
which oxygen did not penetrate and survived as anaerobic organisms. But rising oxygen 
levels also started an evolutionary process of adaptation by development of antioxidant 
defense systems. Organisms that acquired defenses against oxidative toxicity were able 
to evolve new metabolic pathways and moreover use oxygen for energy production. The 
evolution of oxidative phosphorylation in mitochondria for ATP production provided a 
highly efficient way to produce energy and thus boosted the emergence of multicellular 
organisms that have formed the unimaginable diversity and variety of living beings on 
our planet today (Ohno, 1997). 
1.1.1 Formation of reactive oxygen species 
Reactive oxygen species (ROS) are either free radicals or non-radical molecules. For 
estimation of potentially damaging effects, the reactivity of each individual ROS as well 
as its ability to cross biological membranes has to be considered. 
Molecular oxygen O2 contains two unpaired electrons in its outer orbital and is a 
biradical. This triplet oxygen is by itself relatively unreactive towards electron pair 
donators. However, it can be activated, e.g. by light, to singlet oxygen with antiparallel 
electrons and a free π orbital that readily accepts paired electrons. 
Apart from these molecular forms of oxygen, radicals and other non-radical derivatives 
of oxygen can be formed in aerobic organisms. These are collectively referred to as 
reactive oxygen species ROS in this thesis. Although several ROS contain nitrogen and 
are therefore sometimes referred to as reactive nitrogen species, the oxygen in these 
molecules is the driving force for reactivity. Therefore, the term ROS is used for any of 
these species in this thesis. Important ROS and their main sources in living organisms INTRODUCTION 
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are given in Table 1.1. 
Table 1.1: Important ROS, their chemical formula and major sources. 
nomenclature  formula  sources 
superoxide  O2
•- 
mitochondria, 
xanthine oxidase, 
nitric oxide synthase, 
NAD(P)H oxidase, 
oxidation of dopamine, 
adrenaline and noradrenaline 
hydrogen peroxide  H2O2 
superoxide dismutase, 
several oxidases 
hydroperoxides ROOH 
cyclooxygenase, 
lipoxygenase, 
lipid peroxidation reactions 
hydroxyl radical  HO
• 
Fenton reaction, 
hypochlorous acid, 
UV-induced fission of 
hydrogen peroxide 
nitric oxide  NO
•  nitric oxide synthases 
peroxynitrite ONOO
-  reaction of superoxide with 
nitric oxide 
hypochlorous acid  HOCl  myeloperoxidase 
 
In a first step of electron transfer to molecular oxygen, superoxide radical anions are 
formed. The main source for this radical under physiological conditions is the 
respiratory chain in mitochondria. During the flow of electrons along the respiratory 
chain, leakage of electrons can occur. Electrons are then transferred directly to 
molecular oxygen under formation of the superoxide radical anion O2
•-. It is estimated 
that about 1-3 % of oxygen consumed in mitochondria are transformed to superoxide 
even under physiological conditions (Boveris and Chance, 1973). The exact step in the 
respiratory chain where electron leakage occurs is still under debate, but constituents of 
complex I (NADH dehydrogenase), semiquinones in complex II and cytochromes b 
from complex III have all been implicated. Leakage from complex IV (cytochrome c 
oxidase) is considered negligible (Turrens, 1997). Other sources of superoxide radicals 
include nitric oxide synthase enzymes (Xia et al., 1996; Xia and Zweier, 1997; Xia et 
al., 1998), and high levels of superoxide are also produced by NADPH oxidases in 
activated phagocytic cells (Rossi, 1986; Rosen et al., 1995). Superoxide radicals are 
highly reactive, but their damaging effect in cells is limited since diffusion across 
biological membranes is minimal due to the negative charge. However, other ROS can 
be derived from superoxide reactions, among these are hydrogen peroxide derived from 
further reduction as well as peroxynitrite formed in a reaction of superoxide with nitric 
oxide. Hydrogen peroxide has been detected in concentrations up to 100  µM in 
extracellular fluids under experimental conditions (Hyslop et al., 1995). Hydrogen INTRODUCTION 
4 
peroxide shows limited reactivity but can readily diffuse across membranes. It can be 
activated by transition metal ions like ferrous iron to form the highly reactive hydroxyl 
radical in the Fenton reaction (I): 
(I)    Fe
2+ + H2O2 → Fe
3+ +HO
• + OH
- 
Superoxide radicals can participate in Fenton reactions by reducing Fe
3+ to Fe
2+ and can 
thus propagate reaction (I) by providing reduced transition metal ions (II): 
(II)    O2
•- + Fe
3+ → O2 + Fe
2+ 
The net reaction of (I) and (II) is the so-called Haber-Weiss reaction (III): 
(III)    O2
•- + H2O2 → O2 + HO
• + OH
- 
Apart from iron, other transition metal ions, especially copper ions, can participate in 
the above reactions. 
Nitrogen-containing ROS are derived from nitric oxide. Physiological levels of nitric 
oxide (NO) are estimated to range between 0.1 and 100 nM (Brown and Cooper, 1994). 
NO is to the largest part synthesized by nitric oxide synthases NOS. At least 3 different 
types of NOS have been identified, of which the endothelial eNOS and neuronal nNOS 
isoforms can be activated by increased intracellular calcium levels, whereas inducible 
iNOS is a calcium-independent enzyme (Bredt, 1999). iNOS activity leads to formation 
of higher NO levels than the other isoforms. Recently, a mitochondrial isoform of NOS 
has been identified, which is probably a splice variant of nNOS (Kanai et al., 2001). The 
main action of NO is the activation of soluble guanylate cyclase. NO can furthermore 
act as an antioxidant (Kanner et al., 1991), but can also form S-nitrosothiols with 
protein thiol groups thereby modulating or impairing protein function. NO can 
moreover inhibit complex IV of the mitochondrial respiratory chain or interact with 
superoxide anions to form peroxynitrite which exerts several toxic functions (Radi et 
al., 2002). Peroxynitrite can inhibit all mitochondrial respiratory chain complexes, 
initiate lipid peroxidation reactions and cause apoptotic cell death signaling (Brown and 
Borutaite, 2002). 
1.1.2 Physiological roles of reactive oxygen species 
Reactive oxygen species are not only by-products of aerobic respiration in 
mitochondria. ROS take part in a huge variety of enzymatic oxidation and reduction 
reactions involved in metabolism, cell signaling and neurotransmission. As an example, INTRODUCTION 
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the reactions of lipoxygenases and cyclooxygenases are dependent on as well as 
generate ROS. But ROS can also directly exert physiological functions, most 
importantly in immune functions, where phagocytic cells can form large amounts of 
superoxide anions and hypochlorous acid, which aid in the elimination of bacterial 
infections (Knight, 2000). 
Also nitric oxide exerts several important physiological functions. Since its 
identification as vasorelexant factor derived from endothelial cells (Ignarro et al., 1987), 
it has been detected in other cells and several physiological functions are still under 
investigation. Among these, NO seems to play important roles in immune function in 
the periphery, but also as a neurotransmitter and/or neuromodulator in the central 
nervous system (Hawkins et al., 1998). 
1.1.3 Oxidative stress 
In general, oxidative stress describes a state of imbalance between the production and 
detoxification of reactive oxygen species (Sies, 1991). Therefore, increased production 
of ROS as well as impaired antioxidant defense can both contribute to increased 
accumulation of ROS. ROS can be detrimental to almost any component of cells, 
including DNA, proteins and lipids. Cells react upon oxidative stress either by adaptive 
responses leading to activation of repair mechanisms or – if the damage is severe – by 
induction of cell death responses. 
1.1.3.1 Increased production of ROS from endogenous sources 
Under physiological conditions, ROS are mainly produced in mitochondria due to 
respiration. As stated in 1.1.1 (page 3), some leakage of electrons occurs along the 
respiratory chain resulting in production of superoxide radical anions. However, 
respiratory chain complexes are arranged in a manner that keeps leakage at low levels 
resulting in only 1-3 % production of superoxide relative to total oxygen consumption. 
If mitochondria are damaged by pathological conditions, superoxide production can be 
exacerbated due to disarrangement of mitochondrial respiratory chain complexes which 
results in higher electron leakage (Lenaz, 2001). 
Another mechanism for ROS formation is an increased intracellular level of calcium. 
Endothelial and neuronal nitric oxide synthases eNOS and nNOS are activated by high 
intracellular calcium concentrations resulting in increased NO production (Bredt, 1999). 
In combination with superoxide anions, nitric oxide can react to form peroxynitrite. INTRODUCTION 
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Furthermore, calcium activates phospholipase A2 to release arachidonic acid from 
membrane phospholipids for synthesis of prostaglandins and leukotrienes by 
cyclooxygenase and lipoxygenase reactions, respectively. These reactions are 
accompanied by formation of lipid hydroperoxides (Kanner et al., 1987). Calcium also 
activates conversion of xanthine dehydrogenase to xanthin oxidase resulting in 
increased superoxide production (McCord, 1985). Finally, an important mechanism for 
calcium-induced ROS formation lies in mitochondrial calcium buffering. High 
intracellular calcium levels can be buffered by calcium uptake into mitochondria. High 
calcium levels however facilitate opening of the mitochondrial permeability transition 
pore resulting in mitochondrial swelling and release of mitochondrial factors into the 
cytosol, which is followed by a large increase in ROS formation and apoptotic signaling 
(Rego and Oliveira, 2003) (see 1.1.3.5, page 15 et seqq.). 
Increased production of ROS has also been associated with ischemia/reperfusion injury 
and inflammatory conditions (McCord, 1985; Guzik et al., 2003; Ferrari et al., 2004). 
During ischemia, oxygen deprivation leads to a drop in ATP levels as well as collapse 
of the mitochondrial membrane potential and cellular damage. Once perfusion is 
restored, oxygen is provided to dysfunctional mitochondria which results in high ROS 
leakage from the inhibited respiratory chain [reviewed in (Halestrap et al., 2004)]. High 
levels of ROS are also produced from several cell types of the immune system, 
especially upon inflammatory activation. Inflammatory signals lead to activation of 
lipoxygenases and cyclooxygenases. Activated phagocytes and microglia in the brain 
can synthesize large amounts of superoxide radicals from NADPH oxidase reactions 
(Sankarapandi et al., 1998). Furthermore, hypochlorous acid is synthesized by 
myeloperoxidase reaction in neutrophils (Winterbourn, 2002). Therefore, inflammation 
is almost inevitably associated with oxidative stress. 
As stated in 1.1.1 (page 4), free transition metal ions can favour Fenton chemistry and 
lead to formation of free radicals. Hence free metal ions – often derived from 
decomposition of metal-containing proteins or from exogenous sources – lead to 
increased ROS formation or formation of more reactive ROS. The toxicity of excess 
free metal ions is evident for example in haemochromatosis, where iron uptake is 
increased and exceeds the binding capacity of transferrin resulting in liver fibrosis, 
cardiac problems, arthritis and other symptoms, or in Wilson’s disease, where copper 
overload causes liver dysfunction, metabolic deficiencies and mental retardation. Both 
disease states have been associated with increased markers of oxidative stress INTRODUCTION 
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(Brittenham et al., 2000; Hussain et al., 2000). 
1.1.3.2 Antioxidant defense 
Since ROS are produced even under physiological conditions, organisms need 
antioxidant defenses for their detoxification. Among these are low-molecular-mass 
antioxidants as well as antioxidant enzymes that often act in a complex interplay. 
1.1.3.2.1 Low-molecular-mass antioxidants 
Low-molecular-mass antioxidants are either produced endogenously, for example 
glutathione, uric acid, coenzyme Q, lipoic acid and bilirubin, or they are taken up by the 
diet. The most important endogenous antioxidant is the tripeptide glutathione. 
Glutathione is composed of the amino acids γ-glutamate, cysteine and glycin. The 
antioxidant properties of glutathione are due to the thiol residue in cysteine. Glutathione 
is found in millimolar concentrations in most mammalian cells (Cooper and Kristal, 
1997). It can react either directly with ROS like superoxide, nitric oxide or the hydroxyl 
radical (Winterbourn and Metodiewa, 1994; Clancy et al., 1994) or act as cofactor for 
the enzymatic antioxidant defense by glutathione peroxidases. In brain, glutathione 
metabolism seems to be a complex interplay between astrocytes and neurons, where 
astrocytes have an essential function in providing neurons with glutathione precursors 
(Dringen, 2000). 
The most prominent dietary antioxidants are vitamin C (ascorbic acid) and vitamin E 
(tocopherols). Vitamin C can donate one electron to free radicals under formation of the 
ascorbyl radical. Due to mesomeric stabilization of the free electron in the ascorbyl 
radical, this radical is very stable. Hence, vitamin C has the ability to intercept highly 
reactive free radicals. As a water-soluble antioxidant it can however not directly 
inactivate radicals in lipid bilayers of cell membranes, which are especially prone to 
free radical attack. This is afforded by tocopheroles and tocotrienoles that constitute the 
vitamin E family of molecules. Tocopheroles and tocotrienoles are lipid-soluble 
molecules that insert into cell membranes. They can donate a single electron to lipid 
peroxyl radicals and thus effectively inhibit radical chain reactions. In addition, 
tocopherols can quench singlet oxygen. Notably, vitamin C acts to regenerate oxidized 
vitamin E (Packer et al., 1979; Leung et al., 1981). INTRODUCTION 
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1.1.3.2.2 Antioxidant enzymes 
Aerobic organisms possess a variety of antioxidant enzymes that mostly act in concert 
to detoxify ROS (see Figure 1.1). 
O2 
- .
H2O2
SOD
OH
Fe2+/3+
.
GPx
GSH GSSG
H2O
GR
NADPH NADP+
NO.
NOS
Mitochondria
NADPH oxidase
ONOO-
Catalase
H2O + O2
Protein
oxidation
Lipid
peroxidation
DNA
oxidation
Cell death
Trx PH-GPx
GSH GSSG
GR
 
Figure 1.1: Pathways of formation and enzymatic detoxification of ROS. 
GPx = glutathione peroxidase, GR = glutathione reductase, GSH = reduced glutathione, NOS = 
nitric oxide synthases, PH-GPx = phospholipidhydroperoxide glutathione peroxidase, SOD = 
superoxide dismutases, Trx = Thioredoxin. 
 
Superoxide radicals are derived from a first step of electron donation to molecular 
oxygen, and most other ROS can arise directly or indirectly from superoxide. Therefore 
superoxide-detoxifying enzymes act in the first line of enzymatic ROS defenses. 
Superoxide itself can undergo a dismutation reaction where two molecules of 
superoxide react to from molecular oxygen and hydrogen peroxide. This reaction is 
accelerated by superoxide dismutase SOD enzymes (I). 
(I) 2  H
+ + 2 O2
•- → O2 + H2O2 
In eukaryotes, two different forms of superoxide dismutases have been identified: 
copper-zinc-dependent Cu/Zn-SOD (also termed SOD-1) and manganese-dependent 
Mn-SOD (SOD-2). While Mn-SOD is mainly localized to mitochondria, Cu/Zn-SOD 
has been found in high levels in cytosol but also in the intermembrane space between INTRODUCTION 
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the inner and outer mitochondrial membrane (Okado-Matsumoto and Fridovich, 2001). 
Furthermore, an extracellular form of Cu/Zn-SOD has also been identified (Fridovich, 
1989). Since superoxide radicals are produced in mitochondria, mitochondrial Mn-SOD 
and Cu/Zn-SOD in the intermembrane space have important functions in preventing 
superoxide from entering the cytosol. Catalytic activity of Cu/Zn-SOD is dependent on 
copper ions, whereas zinc ions only help to stabilize protein structure (Fridovich, 1989). 
Superoxide dismutase reactions result in formation of hydrogen peroxide which has to 
be decomposed further. This can be achieved by the reactions of catalase or glutathione 
peroxidases. While catalase activity directly inactivates hydrogen peroxide yielding 
water and molecular oxygen (II), glutathione peroxidases need reduced glutathione 
GSH as cosubstrate (III). 
(II) 2  H2O2 → O2 + 2 H2O 
(III) H2O2 + 2 GSH → GSSG + 2 H2O 
In view of the high Km of catalase, glutathione peroxidases seem to be in large part 
responsible for removal of physiological hydrogen peroxide levels, whereas catalase 
activity becomes important at high hydrogen peroxide concentrations (Makino et al., 
1994). Of note, catalase activity is low in brain (Marklund et al., 1982). 
Four different types of glutathione peroxidases have been identified: (i) the “classical” 
glutathione peroxidase GPx, which is found intracellularly, (ii) phospholipid 
hydroperoxide glutathione peroxidase PH-GPx, which is located at the plasma 
membrane and can directly reduce lipid peroxidation products to the native lipids, (iii) 
an extracellular form of glutathione peroxidase as well as (iv ) intestinal glutathione 
peroxidase in gastrointestinal tract and liver (Brigelius-Flohe, 1999). All of them are 
selenium-containing proteins. Classical glutathione peroxidase can convert hydrogen 
peroxide as well as simple organic hydroperoxides. Additionally, it can efficiently 
scavenge peroxynitrite (Sies and Arteel, 2000). Its subcellular localization is in the 
cytosol as well as mitochondrial matrix (Vitorica et al., 1984), where it may act in 
concert with SODs to decompose mitochondria-derived ROS. In brain tissue, GPx 
activity was mainly localized to astroglia (Damier et al., 1993; Takizawa et al., 1994), 
where also a high content of reduced glutathione was observed (Raps et al., 1989), 
indicating a prominent role for this antioxidant pathway in astroglia. GPx deficiency in 
mice sensitizes to oxidants (de Haan et al., 1998; Klivenyi et al., 2000) and ischemia 
(Crack et al., 2001). PH-GPx can also react with phospholipid hydroperoxides, which INTRODUCTION 
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makes it an especially important enzyme for inhibition of lipid peroxidation chain 
reactions. PH-GPx seems to play a very important physiological role since knockout of 
the gene proved to be embryonic lethal (Imai et al., 2003). 
The reduced glutathione consumed by GPx reactions is restored from oxidized 
glutathione GSSG by the glutathione reductase GR reaction (IV). 
(IV)    GSSG + NADPH + H
+ → 2 GSH + NADP
+ 
The cofactor NADPH in this reaction is predominantly generated via the pentose 
phosphate pathway (Salvemini et al., 1999). 
Further important enzymatic systems contributing to antioxidant defense include the 
thioredoxin/thioredoxin reductase system as well as glutathione S-transferases. 
Thioredoxin is a polypeptide containing two adjacent thiol groups that can undergo 
redox reactions with multiple proteins. Reduced thioredoxin is regenerated by 
thioredoxin reductases (Chae et al., 1999). Hence the main function of thioredoxin is the 
regeneration of proteins by reduction of disulfide bonds formed under oxidative 
conditions. 
Glutathione S-transferases catalyse the formation of glutathione conjugates, which is 
especially important in the metabolism of xenobiotics. They also react with organic 
peroxides to form GSSG and the respective alcohols, which is essentially a glutathione 
peroxidase-like reaction. Glutathione S-transferases are also involved in detoxification 
of 4-hydroxynonenal (Goon et al., 1993; Hartley et al., 1995), a cytotoxic aldehyde 
derived from lipid peroxidation reactions (see 1.1.3.3, page 13). 
1.1.3.3 Oxidative attack on cellular molecules 
If ROS are not intercepted by antioxidant enzymes, they can lead to oxidative 
modification of essentially any cellular macromolecule or low-molecular weight 
component. The resulting products usually lose their function or even exhibit further 
damaging effects. 
Lipid peroxidation 
Whereas saturated lipids are usually very resistant to oxidative attack, fatty acids 
containing one or more double bonds (polyunsaturated fatty acids, PUFAs) readily 
participate in radical chain reactions. Lipid peroxidation reactions can be initiated by an 
attack of hydroxyl radicals on PUFAs (I): INTRODUCTION 
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(I)    R1-CH2-R2 + HO
• → R1-HC
•-R2 + H2O 
Lipid radicals R1-HC
•-R2 can then react with further lipid radicals and thus halt 
peroxidation reactions. However, lipid radicals can also react with molecular oxygen. 
Molecular oxygen O2 is a hydrophobic molecule that concentrates into the interior of 
membranes. Reaction with lipid radicals leads to formation of lipid peroxyl radicals (II): 
(II)    R1-HC
•-R2 + O2 → R1-HC(OO)
•-R2 
Peroxyl radicals are highly reactive and can absorb hydrogen atoms from other fatty 
acids resulting in propagation of lipid peroxidation reactions (III): 
(III)    R1-HC(OO)
•-R2 + R1-CH2-R2 → R1-HCOOH-R2 + R1-HC
•-R2 
The lipid radical formed can then again react with O2 to form another peroxyl radical 
and thus the chain reaction of lipid peroxidation can continue. Lipid hydroperoxides can 
however be reduced by the enzyme PH-GPx (Imai et al., 2003), which is an important 
factor for the termination of lipid peroxidation chain reactions. 
Lipid radicals can also be formed by reaction of lipids with perhydroxyl radicals (HO2
•), 
the protonated form of superoxide radicals (IV): 
(IV)    R1-CH2-R2 + HOO
• → R1-HC
•-R2 + H2O2 
The superoxide radical anion by itself is insufficiently reactive and furthermore should 
not enter the hydrophobic membrane due to the negative charge. The pKa of superoxide 
is approximately 4.8 (De Grey, 2002), therefore only a very small proportion of 
superoxide is protonated at physiological conditions. However the high reactivity as 
well as the ability to enter membranes make perhydroxyl radicals an important 
candidate for initiation of lipid peroxidation. 
Perhydroxyl radicals can also stimulate peroxidation reactions by reaction with pre-
formed lipid hydroperoxides (V): 
(V)    R1-HCOOH-R2 + HOO
• → R1-HC(OO)
•-R2 + H2O2 
In vitro studies of lipid peroxidation suggest a pivotal role for transition metal ions in 
lipid peroxidation. Whether hydroxyl radicals generated by Fenton chemistry or rather 
some yet unidentified oxo-iron species are directly involved is still a matter of debate. 
Nevertheless, lipid peroxidation reactions can be greatly accelerated by Fenton systems 
containing e.g. copper or iron ions (Stohs and Bagchi, 1995). 
Lipid peroxides can decompose to form various aldehydes and ketones which is INTRODUCTION 
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accelerated by transition metal ions [(VI) and (VII)]: 
(VI)    R1-HC(OO)
•-R2 + Me
x+ + H
+ → R1-HCO
•-R2 + Me
(x+1)+ + HO
• 
(VII)    R1-HCO
•-R2 → R1
• + HCO-R2 
The main products of lipid decomposition are malondialdehyde MDA and 4-
hydroxynonenal HNE. These aldehydes both exhibit cytotoxic properties. 
MDA can undergo toxic condensation reactions with amino residues in DNA bases and 
proteins. Mutagenic lesions from attack of MDA on guanine bases have been described 
(Benamira et al., 1995). Furthermore, MDA displays neurotoxic properties (Keller and 
Mattson, 1998). 
Toxicity of HNE seems to be even higher than that of MDA, although its levels are 
smaller than those of MDA due to more structural requirements of PUFAs for HNE 
formation. HNE is formed during peroxidation of n-6 PUFAs such as linoleic and 
arachidonic acid (Pryor and Porter, 1990; Esterbauer et al., 1991). HNE can undergo 
several reactions that are supposedly cytotoxic. As is the case with MDA, HNE can 
react with guanine bases in nucleic acids and exhibits genotoxic properties (Eckl et al., 
1993). Moreover, HNE can react with membrane proteins like Na
+/K
+-ATPases and 
Ca
2+ channels (Siems et al., 1996; Lu et al., 2002) leading to disturbance of cell 
membrane potential and ion homeostasis, it can impair metabolic enzymes like pyruvate 
dehydrogenase and α-ketoglutarate dehydrogenase (an enyzme of the Krebs cycle) 
(Humphries and Szweda, 1998), damage mitochondria, inactivate cytoprotective NFκB 
signaling (Camandola et al., 2000b) and increase AP-1 DNA binding (Parola et al., 
1998; Camandola et al., 2000a). In addition, HNE has been reported to mediate 
oxidative stress-induced apoptosis in PC12 cells (Kruman et al., 1997). 
Like MDA, HNE can be transformed by aldehyde dehydrogenases to the carboxylic 
acid or by aldose reductase or alcohol dehydrogenase to the alcohol (Chen and Yu, 
1996). Furthermore, glutathione seems to play an important role in HNE detoxification 
by forming conjugates either nonenzymatically or catalysed by glutathione S-tranferases 
(Goon et al., 1993; Hartley et al., 1995) (see also 1.1.3.2.2, page 10). 
Nucleic acid oxidation 
Oxidative damage to DNA and RNA can either affect the bases or the sugar residues. 
Oxidative attack on bases can be mutagenic, whereas oxidation of the sugar leads to 
strand breaks. Desoxyribose is much more prone to oxidation compared to ribose, and INTRODUCTION 
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among the bases, guanine is most sensitive towards oxidation due to its electron-rich 
amino moieties. The most abundant product of DNA base oxidation is 8-
hydroxyguanine, which is often used as a marker for oxidative stress. Apart from direct 
attack of ROS on nucleic acids, bases can also be oxidized via lipid peroxidation 
products as described above. 
Oxidatively modified DNA can be repaired either by base excision and resynthesis from 
the opposite strand or by recombination synthesis during replication. However, repair 
mechanisms fail to repair all defects so that oxidative DNA damage usually 
accumulates with age (Piperakis et al., 1998; Mendoza-Nunez et al., 2001). As a 
consequence, accumulation of DNA defects leads to expression of dysfunctional 
proteins that finally may result in cell death. Cell death can also result from activation 
of p53 by DNA damage followed by apoptotic signaling (see 1.1.3.5, page 15). 
Protein oxidation 
Oxidative protein modifications include a wide variety of reactions depending on the 
type of amino acids that are affected: sulfur-containing moieties in cysteine and 
methionine are easily oxidized to disulfides or sulfoxides respectively, basic amino 
acids arginine and lysine can be oxidized to aldehydes, aromatic rings in amino acids 
can be oxidized or nitrated and aliphatic carbon atoms can be oxidized to alcohols. 
Apart from direct attack of ROS, proteins can also be oxidatively modified by lipid 
peroxidation products or by sugars and aldehydes like glyoxal and methylglyoxal that 
lead to formation of advanced glycation end products AGEs (Münch et al., 1997). 
The only repair mechanisms for proteins identified so far are restoration of cysteine 
thiol groups from disulfides, e.g. by thioredoxin, and restoration of methionine from 
sulfoxides by methionine sulfoxide reductase (Stadtman, 2004). Whether further 
mechanisms of protein oxidation repair exist is a matter of further research. However, 
oxidized proteins can be removed by proteolysis via the proteasome complex. 
1.1.3.4 Intracellular signaling and transcription factors activated by ROS 
Increased levels of ROS can either induce adaptive responses or elicit cell death. Often, 
mild oxidative stress leads to activation of antioxidant responses and resistance to 
higher ROS levels. By which mechanisms this adaption takes place is still under 
investigation, but there is growing evidence that ROS can activate discrete signaling 
pathways and gene transcription patterns. INTRODUCTION 
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Intracellular signaling triggered by ROS is very complex [reviewed in (Finkel, 1998; 
Dalton et al., 1999; Allen and Tresini, 2000)]. One of the most extensively studied 
intracellular signaling cascades activated by ROS is the MAP-kinase pathway. Four 
MAP kinase subfamilies have been identified to date: ERK, JNK/SAP kinase, p38 
kinase and big MAP kinase pathways. All these pathways contain redox-sensitive sites 
(Lo et al., 1996). Although exceptions are known, antioxidant compounds inducing 
ERK isoforms often elicit cytoprotective signaling, whereas oxidative stress activates 
JNK, p38 and big MAP kinase pathways that mostly result in cell death signaling. MAP 
kinases lead to phosphorylation of transcription factors c-jun and c-fos thereby affecting 
gene transcription, e.g. by the transcription factor AP-1 (see below). 
Several transcription factors can be affected by ROS [reviewed in (Sun and Oberley, 
1996; Sen and Packer, 1996; Dalton et al., 1999)], of which the most extensively 
studied are NF-κB and AP-1 (Meyer et al., 1994; Muller et al., 1997). Upon activation, 
NF-κB enters the nucleus, binds to DNA and can activate the transcription of several 
target genes like cytokines, growth factors and iNOS but also antioxidant genes like 
Mn-SOD and γ-glutamylcysteine synthetase, an enzyme involved in glutathione 
synthesis (White et al., 2000; Yang et al., 2001; Lee et al., 2003a). 
AP-1 is a transcription factor that can be activated by prooxidant hydrogen peroxide but 
also by antioxidants. AP-1 is a dimer of two proteins, c-fos and c-jun, existing either as 
a inactive homodimer of phosphorylated c-jun or an active heterodimer of c-jun and c-
fos. Therefore, activation of AP-1 can be due to either increased synthesis of AP-1 
components or changes in phosphorylation state. Furthermore, binding of AP-1 to DNA 
is redox-sensitive via cysteine residues in the DNA-binding domains of c-jun and c-fos: 
thioredoxin increases DNA binding whereas oxidation decreases DNA binding (Abate 
et al., 1990). Thus, AP-1 corresponds not only to oxidative stress but also to certain 
antioxidants. A consensus sequence for AP-1 binding has been found in the antioxidant 
response element (ARE). Among the genes containing ARE sequences are glutathione-
S-transferase and the amyloid precursor protein APP (La Fauci et al., 1989; Trejo et al., 
1994), suggesting that APP expression can be modulated by ROS, which may be 
important in the pathogenesis of Alzheimer’s disease. 
Despite the above considerations, it has to be noted that the induction of NF-κB or AP-1 
transcriptional activity by ROS is cell-type dependent, furthermore DNA binding is 
negatively affected by oxidation. In addition, various intracellular factors as well as INTRODUCTION 
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DNA binding motifs contain thiol groups and are thus redox-sensitive (Hayashi et al., 
1993). Hence the overall effects of ROS on gene transcription can be very variable. 
Moreover, whether NF-κB or AP-1 activation exert an overall cytoprotective or 
cytotoxic effect is difficult to elucidate (Kamata and Hirata, 1999; Leong and Karsan, 
2000; Shaulian and Karin, 2001; Das and Maulik, 2003; Ameyar et al., 2003; Gaur and 
Aggarwal, 2003). 
1.1.3.5 Role of ROS in cell death 
Damage of cellular components by ROS and insufficient repair mechanisms usually 
lead to a cell death response. Whether cells die by apoptosis or necrosis is largely 
dependent on the severity of insult: the apoptotic process, which is an energy-
consuming process, requires some residual functionality of cellular proteins and ATP 
(Richter et al., 1996), whereas severe oxidative damage with destruction of cellular 
integrity and dissipation of ATP levels usually elicits necrotic cell death (Leist et al., 
1997; Eguchi et al., 1997). 
Apoptosis 
Apoptotic cell death (Kerr et al., 1972) is different from necrotic cell death (see below) 
in that cells undergo an active suicidal program which leads to degradation of cellular 
components and release of apoptotic bodies without excretion of intracellular 
components. Apoptotic bodies are finally taken up by macrophages. Surrounding cells 
are usually not much affected by this process. Apoptosis is an essential part of normal 
development, homeostasis and elimination of damaged cells, but it can be disturbed 
under pathological conditions, e.g. in Alzheimer’s disease, where neurons increasingly 
die by apoptosis (Su et al., 1994), or in neoplastic diseases, where apoptosis is impaired 
leading to abnormal growth of cells. 
In recent years, mitochondria have gained the center of attention in apoptosis research 
[reviewed in (Susin et al., 1998; Tatton and Olanow, 1999; Eckert et al., 2003b)]. Figure 
1.2 illustrates major apoptotic signaling pathways triggered by or associated with 
increased ROS levels. INTRODUCTION 
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Figure 1.2: Major pathways in ROS-induced apoptotic signaling. 
Abbreviations: AIF = apoptosis inducing factor, Casp = caspase, Cyt c = cytochrome c, GSH = 
reduced glutathione, IAPs = inhibitor of apoptosis proteins, JNK = c-jun amino terminal kinase 
pathway. 
 
Activation of caspases – cysteine-dependent aspartyl proteases that lead to degradation 
of cellular components as characteristic feature of apoptosis – is in most cases at the 
center of the apoptotic process. Apoptotic signals can be derived from extracellular 
(“extrinsic pathway”) or intracellular sources (“intrinsic pathway”). Oxidative stress can 
cause apoptotic signaling (Buttke and Sandstrom, 1994), where several pathways can be 
activated: either direct oxidative toxicity to mitochondria can cause mitochondrial 
dysfunction associated with decreased mitochondrial membrane potential Ψm and 
release of mitochondrial factors initiating apoptotic signaling, or oxidative stress can 
activate or modulate death receptor singalling via Fas receptors (Bajt et al., 2002; 
Devadas et al., 2003). Several ROS can sensitize opening of the mitochondrial 
permeability transition pore, which is redox-regulated by mitochondrial glutathione 
levels [reviewed in (Zoratti and Szabo, 1995)]. Also, apoptotic signaling via p53 leads 
to ROS formation (Polyak et al., 1997). Consequently, overexpression of anti-oxidant 
enzymes like Cu/Zn-superoxide dismutase was able to prevent apoptosis (Greenlund et 
al., 1995; Przedborski et al., 1996), whereas underexpression pro-voked apoptosis (Troy INTRODUCTION 
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and Shelanski, 1994). The antiapoptotic effect of Bcl-2 has also been attributed to 
antioxidant properties (Garcia et al., 1992; Hockenbery et al., 1993; Kane et al., 1993; 
Steinman, 1995). 
But ROS are not only initiators but also features of apoptosis: mitochondrial 
dysfunction can lead to increased leakage of electrons from the respiratory chain 
resulting in increased ROS formation (Zamzami et al., 1995). 
ROS also seem to be involved in excytotoxicity caused by glutamate stimulation in 
neurons. Extracellular glutamate leads to activation of NMDA and/or AMPA/kainate 
receptors, rise in intracellular Na
+ and Ca
2+ levels and several metabolic consequences. 
As stated in 1.1.3.1 (page 5 et seqq.), elevated Ca
2+ levels result in increased production 
of ROS via nitric oxide synthases, phospholipase A activation and mitochondrial 
calcium overload. All these mechanisms can induce ROS accumulation and elicit cell 
death signaling. 
Necrosis 
In contrast to apoptosis, necrosis occurs under severe tissue damage that leads to 
disruption of cell membrane integrity, swelling of cells and organelles, rupture of the 
cell membrane and release of intracellular factors. Neighboring cells are affected and a 
local inflammatory reaction is initiated. Necrosis has been shown to occur under 
ischemic conditions or mechanic trauma. Also, severe oxidative stress causes necrosis 
(Lemasters et al., 1998). And vice versa, necrosis can be accompanied by increased 
ROS formation due to the release of transition metal ions from proteins or inflammatory 
reactions. 
 
In summary, ROS are major activators but also features of different types of cell death. 
However, it is often difficult to elucidate the role of ROS in vivo, i.e. whether ROS are 
causal agents or only bystanders of cell death. INTRODUCTION 
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1.2 Oxidative stress in brain aging 
1.2.1 Aging theories 
Aging seems to be a very complex, multicausal phenomenon, which can not be fully 
explained by any single theory. Aging can be regarded as a time-dependent irreversible 
accumulation of cell damage or dysfunction that leads to morbitity and mortality. 
Inherent properties of cells in multicellular organisms encoded by the genome as well as 
epigenetic and environmental factors seemingly contribute to the aging phenomenon. 
On a cellular basis, replicative senescence, i.e. the inability of cells to undergo further 
mitotic divisions, has been attributed to telomere shortening. Telomeres are DNA base 
sequence repeats at the ends of chromosomes which are shortened during each mitotic 
cell division. Shortened or disrupted telomeres mimic DNA damage and result in p53 
activation leading to cell-cycle arrest (Blackburn, 2000). Telomere shortening can be 
counteracted by expression of telomerase, an enzyme that restores telomeres. 
Telomerase expression has been shown to confer immortality to cells that would 
otherwise undergo replicative senescence (Bodnar et al., 1998). However, telomerase-
independent pathways of initiating cellular senescence must exist, since rodent cells in 
culture possess exceptionally long telomeres, express telomerase and keep telomere 
length but nevertheless have limited proliferative capacity in vitro (Blasco et al., 1997). 
The somatic mutation theory of aging tries to explain the aging phenomenon by 
accumulation of spontaneous DNA mutations during life. As a result, protein expression 
or function becomes impaired which leads to age-associated defects and finally death 
(Corral-Debrinski et al., 1992). The mitochondrial genome seems to be especially 
vulnerable to DNA mutations since mitochondrial DNA, unlike nuclear DNA, is not 
protected by DNA-associated proteins like histones and is furthermore localized within 
the mitochondrial matrix, where ROS are continuously produced by electron leakage 
from the respiratory chain. Oxidative damage to mitochondrial DNA and impaired 
production of ATP have been suggested to play a role in age-associated degeneration 
(Miquel et al., 1980; Wallace et al., 1992). 
Deficits caused by aging have also been tried to be explained by an attack of the 
immune system on body cells (Smith and Walford, 1977). Increased levels of 
autoantibodies have been detected in aged humans (Hijmans et al., 1984). It is therefore 
conceivable that elimination of cells by an overactive immune system leads to INTRODUCTION 
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insufficient restorage of cells and age-related deficits. 
Evidence that genetic factors are involved in the aging phenomenon stems from the 
identification of genes or gene mutations that influence life span. Several factors have 
been identified in C. elegans and Drosophila [reviewed in (Finkel and Holbrook, 2000)]. 
In mammals, mice with a knockout of the klotho gene – coding for a protein with 
unidentified funtion – and p53 mutant mice display a shortened life span (Tyner et al., 
2002). Conversely, a mutation in the shc gene encoding an intracellular adaptor protein 
that controls oxidative stress response increases the life span of mice (Migliaccio et al., 
1999). Unknown genetic factors accelerate aging in the senescence-accelerated mouse 
model (Troen, 2003). Overexpression of growth hormone is associated with decreased 
life span (Bartke et al., 1994), whereas growth hormone deficiency in dwarf mice 
prolongs life span (Brown-Borg et al., 1996; Bartke et al., 1998). In addition, 
inactivation of the receptor for insulin-like growth factor IGF-1 slowed growth, but 
increased resistance to oxidative stress and prolonged life span (Bartke et al., 2003). 
These observations point to a role for growth factor signaling and metabolic activity in 
aging. 
Candidate genes that determine life span in humans include the major histocompatibility 
complex (Caruso et al., 2001), the apolipoprotein E (Smith, 2000) and the angiotensin-
converting-enzyme (Schachter et al., 1994). It is noteworthy that a pronounced 
difference in life expectancy between males and females exhists in humans, which is 
also found in some other mammalian species (Smith and Warner, 1989). Which factors 
determine these gender differences have yet to be explored. 
1.2.2 The free radical theory of aging 
The free radical theory of aging, as initially proposed by Denham Harman in the 1950s 
(Harman, 1956), is compelling in that it can unite several aspects of aging. In its 
original version, it assumes that free radical reactions, modified by genes and 
environment, are the single basic cause of aging. These free radical reactions can arise 
from ionising radiation, non-enzymatic reactions and from enzymatic reactions, 
particularly those employed in the reduction of molecular oxygen to water by the 
respiratory chain in mitochondria. 
There is a vast body of evidence arguing in favour of this hypothesis, which is often 
thought of synonymously with the rate-of-living hypothesis that was already proposed 
in the 1920s (Mccoy et al., 1935). Life span seems to be correlated with metabolic rate INTRODUCTION 
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or even better with mitochondrial radical formation: a high metabolic rate, consistent 
with increased mitochondrial respiration and increased radical formation, was 
associated with a low average life span (Ku et al., 1993; Sohal et al., 1995). 
Consequently, caloric restriction can efficiently increase life span of rodents (Sohal and 
Weindruch, 1996) and possibly also of primates (Lane et al., 2001), and is associated 
with reduced ROS formation (Tian et al., 1995; Gabbita et al., 1997; Lopez-Torres et 
al., 2002). Antioxidants, antioxidant enzyme mimetics and similarly overexpression of 
antioxidant enzymes have been shown to increase the life span of several different 
species (Harman, 1981; Orr and Sohal, 1994; Stoll et al., 1997; Melov et al., 2000), 
whereas mutation of antioxidant genes reduced life span (Taub et al., 1999). 
Furthermore, reduced levels of antioxidants as well increased markers of oxidative 
stress were found in aged animals (Chen et al., 1989; Ravindranath et al., 1989; Carney 
et al., 1991) and humans (Ando et al., 1995; Yang et al., 1995; Shemyakov and 
Mikhailova, 2003). 
It must however be noted that species differences (Igarashi and Satoh, 1989; Sohal et 
al., 1990) as well as a different vulnerability of various organs exist (Carrillo et al., 
1992). Therefore, findings from aging studies in insects or even rodents should not be 
uncritically transferred to the situation in humans. Similarly, conclusions from studies 
on e.g. changes in oxidative parameters in blood as to the actual situation in a specific 
organ should be drawn carefully. 
1.2.3 A role for oxidative stress in brain aging? 
The brain is considered to be especially vulnerable towards oxidative stress due to 
several reasons (Halliwell, 1992): 
(i) The brain operates at a high metabolic rate. It accounts for less than 2 % of the body 
weight, but consumes 20 % of the basal oxygen uptake. High oxygen consumption via 
mitochondria is linked to leakage of electrons along the respiratory chain with 
subsequent radical formation. 
(ii) There is a high content of polyunsaturated fatty acids PUFAs in brain cell 
membranes. PUFAs are especially prone to undergo lipid peroxidation reactions (see 
1.1.3.3, page 10 et seqq.) resulting in formation of cytotoxic aldehydes MDA and HNE. 
Furthermore, some brain regions contain high levels of iron, which is for example 
contained in neurotransmitter-synthesizing enzymes tyrosine and tryptophane 
hydroxylase. Upon tissue injury, free iron ions can be released and give rise to radical INTRODUCTION 
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formation derived from Fenton chemistry (see 1.1.1, equation (I), page 4). 
(iii) Neuronal activity is linked to signaling and metabolic pathways that favour 
formation of ROS. The consequences of increased intracellular calcium levels during 
neuronal depolarization have been described in 1.1.3.1. (page 5). Furthermore, the brain 
contains relatively high levels of nitric oxide that can give rise to formation of highly 
reactive peroxynitrite. Also, catecholamine metabolism involves increased ROS 
formation: superoxide can be generated from semiquinone formation, and hydrogen 
peroxide is released as by-product of catecholamine degradation by monoamonoxidase 
(Cadenas and Davies, 2000). 
(iv) The brain possesses only relatively low levels of antioxidant defenses. Catalase 
activity is extremely low in brain tissue, and glutathione peroxidase and superoxide 
dismutase show low activity compared with other organs like liver, heart and kidney 
(Marklund et al., 1982). 
(v) Neurons as postmitotic cells can not divide to substitute for dying cells. Therefore, it 
was long thought that tissue damage can not be reconstituted by neuronal cell growth. 
Although stem cells, which have the potential to differentiate into neurons and glial 
cells, have been identified in certain rodent brain areas [(Altman, 1962), recently 
reviewed in (Scheffler et al., 1999; Cameron and McKay, 1999)], it is questionable 
whether this actually occurs to a relevant extent in vulnerable brain regions in vivo. 
While (i) to (iii) contribute to increased ROS formation, (iv) and (v) limit regeneration 
of brain cells. As a consequence, increased levels of oxidative stress during aging can 
be especially detrimental to brain tissue. 
Experimental evidence that oxidative stress is involved in brain aging comes from 
studies that markers of oxidative damage are increased in aged animals. Mostly rodents 
have been studied, however results are controversial (Ceballos-Picot et al., 1992; 
Bonnes-Taourel et al., 1993; Mo et al., 1995; Leutner et al., 2001; Hamilton et al., 
2001). 
Since increased oxidative damage can be a consequence of ROS accumulation due to 
impaired detoxification, antioxidant factors have also been studied, again, with 
conflicting results. Reduced glutathione has mainly been reported to be reduced in aged 
mouse brains (Chen et al., 1989; Sasaki et al., 2001), but increased glutathione levels 
have also been found (Hussain et al., 1995). Similarly conflicting results have been 
obtained for activities of antioxidant enzymes, which were reported to be either INTRODUCTION 
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increased (Ceballos-Picot et al., 1992; Leutner et al., 2001), decreased (Mo et al., 1995) 
or unchanged (Cardozo-Pelaez et al., 1999), and moreover results were not uniform for 
different antioxidant enzymes (Ceballos-Picot et al., 1992; Leutner et al., 2001). 
Obviously, brain aging is accompanied by various adaptive changes in oxidative stress 
parameters which are however not uniform under different conditions. The conflicting 
results may be due to differences in methodology, differences between brain regions 
(Benzi et al., 1988; Carrillo et al., 1992), animal strains or animal maintenance. This 
necessitates a careful analysis of changes in oxidative stress parameters in each 
individual animal strain under the respective housing conditions when this animal strain 
is the genetic background for studies of further age-related degenerative processes in 
transgenic mice. Furthermore, the relevance of studies on rodent brains with respect to 
degenerative processes in the aging human brain remains to be elucidated. INTRODUCTION 
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1.3 Oxidative stress and Alzheimer’s disease 
1.3.1 Alzheimer’s disease – clinical symptoms, pathology and 
risk factors 
1.3.1.1 Clinical picture of Alzheimer’s disease 
When Alois Alzheimer described the symptoms and pathology of a quickly progredient 
dementia in a female patient in 1907 (Alzheimer, 1907), he probably couldn’t have 
imagined the impact that the disease named after him would receive at the end of the 
century. Alzheimer’s dementia (AD) is a neurodegenerative brain disease and the most 
common form of dementia among the elderly. From epidemiological studies it can be 
estimated that about 60 to 70 % of the dementia cases can be attributed to AD (Ritchie 
and Lovestone, 2002). In Western countries, AD represents one of the most frequent 
causes of death among the elderly – ranking 7
th after cardiovascular diseases, cancer, 
stroke, chronic diseases of the lower respiratory tract, pneumonia and diabetes 
(Anderson and Smith, 2003). Since AD is an age-related disease, during Alzheimer’s 
lifetime only few persons were able to live to an age where the risk to develop the 
disease is greatly increased. But as life expectancy in industrialized countries has been 
ever increasing, AD poses and will pose an ever heavier burden on societies. 
Alzheimer’s dementia is clinically characterized by progressive loss of intellectual 
function, memory, language skills as well as spatial and temporal orientation. This is 
accompanied by loss of activities of daily living, mood and personality changes, 
depression, agitation, anxiety or hallucinations and problems recognizing friends and 
family members. From the time of diagnosis, the average disease duration is 
approximately 5 to 8 years (Molsa et al., 1986; McDonnell et al., 2001; Wolfson et al., 
2001). In the late stages of the disease, patients are completely disorientated, confined 
to bed and malnourished due to difficulty with swallowing. Most patients die from 
pneumonia (Wada et al., 2001). 
Diagnosis of AD is complex and based on an exclusion of other causes of cognitive 
symptoms – e.g. vitamin B12 deficiency, depression, infectious CNS diseases, multiple 
sclerosis or brain tumors. Furthermore, other types of dementia like vascular dementia 
must be excluded. Several cognitive tests can be used to quantify the extent of cognitive 
impairment (McDougall, 1990; Storey et al., 2002). The most widely used are the Mini 
Mental Status Examination MMSE – a short test of cognitive abilities giving a score INTRODUCTION 
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from 30 (no cognitive impairment) to 0 (severe dementia) – , the global deterioration 
scale (GDS) – where a range of symptoms is judged by the physician – or the 
Alzheimer’s Disease Assesment Scale (ADAS) – a comprehensive analysis of cognitive 
and non-cognitive symptoms. Furthermore, morphological and functional imaging of 
AD brains can be used for diagnosis and monitoring the progress of AD. In AD patients, 
brain atrophy – especially in the medial temporal lobe – due to neurodegeneration can 
be detected by imaging methods (Scheltens and Korf, 2000), and glucose utilization in 
the temporal lobe – as measured by 18-F-desoxy-glucose positron emission tomography 
(PET) – is decreased (Herholz, 2003). 
1.3.1.2 AD neuropathology 
However, the definite confirmation of the diagnosis of AD can only be derived from 
pathological brain analysis after the death of the patient. Macroscopically, AD brains 
are characterized by reduced brain weight, atrophy of several brain regions, enlarged 
sulci and liquor ventricles. Degeneration affects several brain regions to a different 
extent, of which hippocampal structures and – at later stages – neocortical areas are 
severely degenerated. The neuropathological hallmarks of Alzheimer’s disease are 
increased numbers of senile plaques – extracellular 5-200  µm aggregates that are 
composed of amyloid beta Aβ peptides (Glenner and Wong, 1984) and surrounded by 
dystrophic neurites – and intracellular neurofibrillary tangles that are composed of 
hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986; Goedert et al., 1992) (see 
Figure 1.3). 80 % of AD cases also have vascular deposition of Aβ in cerebral blood 
vessels (Masters et al., 1985a). Furthermore, plaque-only AD without the presence of 
neurofibrillary tangles – but with hyperphosphorylated tau – has also been described 
(Terry et al., 1987; Tiraboschi et al., 2004c). INTRODUCTION 
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Figure 1.3: Neuropathological hallmarks of Alzheimer’s disease: senile plaques (left 
panel) and neurofibrillary tangles (right panel). 
Left panel: Staining of senile plaques with anti-Aβ antibody [taken from (Steiner and Haass, 
2000)]. 
Right panel: Silver staining of intracellular neurofibrillary tangles. Hyperphosphorylated and 
abnormally aggregated tau protein is found in pyramidal neurons (arrow) and in neurites 
surrounding amyloid plaques (arrowhead) [taken from (Mattson, 2000)]. 
 
The presence of plaques and tangles is, however, not specific for AD. Even the brains of 
healthy subjects without clinical symptoms of dementia before death can contain several 
plaques, which are however largely of the diffuse type in contrast to the predominantly 
senile type of plaques in AD brains. Numbers and density of plaques and tangles are 
higher in AD brains and show a typical distribution in certain brain regions. The number 
of plaques does not correlate with clinical severity of AD (Braak and Braak, 1991; Nagy 
et al., 1995; Gomez-Isla et al., 1997; Giannakopoulos et al., 2003; Guillozet et al., 
2003), but the distribution and quantity of neurofibrillary tangles gives a good correlate 
with the clinical cognitive state, and it moreover correlates with measures of 
neurodegeneration. Braak and Braak have staged the neurodegenerative progress in AD 
according to the distribution of neurofibrillary degeneration (Braak and Braak, 1991). In 
stages I and II, only entorhinal structures are affected, without cognitive impairment of 
the patient. In stages III and IV, hippocampal structures are also affected and mild 
cognitive impairment is present. In stages V and VI, neurodegeneration proceeds to INTRODUCTION 
26 
cortical areas which represents the full clinical picture of AD. 
Despite extensive research in the field, no causal therapies exist until today – almost a 
hundred years since Alzheimer’s case report. The only drugs approved so far are 
inhibitors of acetyl choline esterase and Memantine, a NMDA-receptor antagonist. The 
clinical efficacy of these substances is limited, as none of these drugs is able to halt the 
progression of AD, only a reduction in the rate of progression is achieved, which retards 
progression for about one year. It is therefore essentially necessary to understand more 
about the pathology leading to the development of AD for generation of new drug 
targets that will finally enable a causal therapy of AD. 
1.3.1.3 Genetic and non-genetic risk factors for AD 
Identification of factors that contribute to the pathology of AD comes from 
epidemiological as well as genetic studies. Alzheimer’s disease can be classified into 
two different forms, rare early-onset forms where the disease onset is at an age younger 
than 60 years, and the vast majority of cases where onset occurs at an age over 60. Both 
forms of AD show the same clinical symptoms and neuropathology. In the sporadic 
form of the disease, several factors have been found that increase the risk to develop the 
disease, but – unlike familial AD (FAD) mutations – do not necessarily lead to 
development of AD. Aging is by far the most important risk factor for AD, but also the 
apolipoprotein E4 allele and female gender predispose to the development of AD 
(Figure 1.4). Genetic studies in FAD patients have identified mutations in the genes 
encoding for the amyloid precursor protein APP on chromosome 21 and for the 
presenilins PS1 and PS2 on chromosomes 14 and 1 that cause an autosomal inherited 
form of AD with 100 % penetrance. Onset of clinical symptoms in FAD patients is 
often much earlier in life, especially for carriers of PS1 mutations
1 (see Figure 1.4). 
                                                 
1 The progressive loss of cognitive abilities of a patient suffering from early-onset FAD has been very 
authentically portrayed in the movie “Claire – Se souvenir des belles choses” by Zabou Breitman 
(www.sesouvenirdesbelleschoses.com). INTRODUCTION 
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Alzheimer‘s disease
familial
• < 10 % of cases
• onset mostly < 60 years  
• familial mutations: APP, PS1
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• further unidentified gene
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• > 90 % of cases
• onset mostly > 60 years 
• sporadic risk factors: age,       
Apo E4 allele, female 
gender, ...
• further unidentified risk 
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Figure 1.4: Classification of Alzheimer’s disease. 
Familial AD cases represent the minority of cases, which usually show an early onset at an age 
younger than 60 years. Mutations in the amyloid precursor protein APP or the presenilins PS1 
and PS2 have been identified as causal factors. Sporadic AD cases constitute the majority of 
cases, where age of onset is usually above 60 years. Aging is the most important risk factor for 
sporadic AD, but also the apolipoprotein E4 allele and female gender increase the risk to 
develop AD. However, yet unknown genetic mutations and risk factors probably exist in both 
forms of AD. 
 
1.3.2 Risk factors for sporadic AD 
The most important risk factor for sporadic AD is aging. Several epidemiological 
studies have evidenced that the prevalence of AD is greatly increased among aged 
people, and prospective studies have confirmed that the incidence of AD is higher in 
aged subjects [reviewed in (Jorm et al., 1987; Gao et al., 1998; Fratiglioni et al., 1999)]. 
For example, prevalence of AD is 20 % in people aged 80 to 89 years and 40 % in 
subjects aged more than 90 years (Katzman, 1976). The incidence rates for AD increase 
from 0.07 % in the age group of 65 to 69 years to 6.6 % in persons aged 90 years or 
older (Letenneur et al., 1994), i.e. the risk for a person aged 90 years or older to develop 
AD within 1 year is 100 times higher than the risk of a person at the age of 65 to 69. 
Genetic studies have furthermore elucidated a role for apolipoprotein E alleles in the 
etiology of AD. The gene for apolipoprotein E (Apo E) is encoded on chromosome 19, 
with three different allelic variations: Apo E 2, 3 or 4. Carriers of apolipoprotein E4 
alleles have a higher risk to develop AD (Saunders et al., 1993; Poirier et al., 1993; 
Corder et al., 1993; Strittmatter et al., 1993; Dal Forno et al., 1996), which shows a gene INTRODUCTION 
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dosage effect: risk is highest in homozygous and lowest in non-Apo E4 carriers. In 
contrast to Apo E4, Apo E2 alleles seem to exert a protective effect (Corder et al., 1994; 
Talbot et al., 1994; Locke et al., 1995; Polvikoski et al., 1995; Hyman et al., 1996; 
Lippa et al., 1997). The higher risk for AD conferred by the Apo E4 allele is probably 
due to a lower age at onset of AD, but not to an overall increased lifetime susceptibility 
(Khachaturian et al., 2004). 
Several studies have reported a higher prevalence and incidence of AD in women 
compared to age-matched men (Jorm et al., 1987; Zhang et al., 1990; Fratiglioni et al., 
1997; Andersen et al., 1999; Copeland et al., 1999; Ruitenberg et al., 2001), although 
these findings are still controversial (Rocca et al., 1998; Hebert et al., 2001). Women 
have an approximately 1.5- to 3-fold increased risk to develop AD compared to men. 
This risk is even higher in very old women aged more than 90 years (Fratiglioni et al., 
1997). Furthermore, polymorphisms in the estrogen receptor alpha gene (Brandi et al., 
1999; Ji et al., 2000) and aromatase (Iivonen et al., 2004) were in some studies 
associated with an increased risk for AD.  
In addition to the above-mentioned risk factors, further genetic and life-style factors 
have been elucidated that modulate the risk to develop AD, although some are still 
controversially discussed. For example, some studies have shown an inverse correlation 
between education and risk of dementia: low education increased the risk to suffer from 
dementia up to twofold (Zhang et al., 1990; Karp et al., 2004). Futhermore, several 
studies have repeatedly reported that a history of head injury increases the risk for AD 
by about 1.5-fold (Fleminger et al., 2003). 
Apart from Apo E status and female gender, further genetic factors have been identified 
that could contribute to the risk for AD, although confirmation of most of these factors 
is needed in further studies. Candidates are several oxidative stress-related genes like 
methionine synthase (Beyer et al., 2003), glutathione-S-transferase (Li et al., 2004b), 
oxidized LDL-receptor 1 (Lambert et al., 2003), myeloperoxidase (Reynolds et al., 
1999; Leininger-Muller et al., 2003) as well as alpha-2-macroglobulin (Liao et al., 
1998; Chen et al., 2004) and other inflammatory genes (McGeer and McGeer, 2001). 
Recently, an interaction of alpha-2-macroglobulin and myeloperoxidase polymorphisms 
leading to an increased risk for AD has also been reported (Zappia et al., 2004). INTRODUCTION 
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1.3.3 Familial AD mutations and the amyloid beta hypothesis 
1.3.3.1 The amyloid precursor protein APP – physiological processing and 
effect of APP mutations 
Research on Alzheimer’s disease was boosted at the end of the 1980s by the discoveries 
(i) that the 39 to 42 amino acid amyloid beta peptide Aβ is the primary component of 
the senile plaques present in Alzheimer’s disease patients (Glenner and Wong, 1984; 
Masters et al., 1985b; Iwatsubo et al., 1994), (ii) that Aβ is derived from its precursor 
protein APP encoded on chromosome 21 (Kang et al., 1987; Tanzi et al., 1987) and (iii) 
that mutations in the APP gene lead to the development of early-onset forms of AD in 
very few families worldwide (Levy et al., 1990; Chartier-Harlin et al., 1991; Goate et 
al., 1991; Van Broeckhoven et al., 1992; Mullan et al., 1992; Hendriks et al., 1992). 
Several other mutations in the APP gene have been discovered so far, all of which are 
within or proximate to the Aβ sequence and for most of which an increased processing 
of APP towards higher formation of Aβ or especially the 1-42 amino acid form of Aβ 
has been shown. 
APP is a type I integral membrane protein with glycosylation sites on the extracellular 
C-terminus. Subcellular localization of APP is in the ER, trans-golgi network and the 
cell membrane, but it has recently also been identified in mitochondria in APP 
transgenic mice (Selkoe et al., 1996; Hartmann et al., 1997; Anandatheerthavarada et 
al., 2003). In general, APP can be processed by two distinctive pathways: either by α-
secretase cleavage (Sisodia et al., 1990) yielding sAPPα and C83, which is cut 
intramembraneously by γ-secretase to release p3 and AICD (APP intracellular domain), 
or by β-secretase resulting in formation of sAPPβ and C99, followed by γ-secretase 
cleavage with production of Aβ and AICD (Haass et al., 1993) (see Figure 1.5). The γ-
secretase cut can take place at different amino acids in the Aβ sequence, which leads to 
formation of Aβ1-40 or Aβ1-42. The main species generated is Aβ1-40 with approximately 
90%, while only 10% Aβ1-42 are formed (Seubert et al., 1992; Haass et al., 1992a). INTRODUCTION 
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Figure 1.5: Formation of Aβ peptides from cleavage of of APP 
a. Structure of APP, cell membrane topology and cleavage by secretases. Cleavage of APP by 
α-secretase results in formation of N-terminal sAPPα and the 83 amino acid C-terminal peptide 
C83, which is subsequently cut by γ-secretase to release the p3 peptide and the APP 
intracellular domain AICD. β-amyloidogenic cleavage of APP is effected by β-secretase 
cleavage yielding sAPPβ and the C99 peptide followed by γ-secretase cleavage resulting in 
formation of Aβ and AICD. The longer 751 or 770 amino acid isoforms of APP contain the kunitz 
protease inhibitor insert KPI. 
b. Amino acid sequence of APP in the Aβ region. Bold and underline letters represent amino 
acids where FAD mutations have been identified. Of note, FAD mutations lie close to or within 
secretase cleavage sites. Amino acid numbering refers to the 770 amino acid isoform of APP. 
 
α-secretase has not been unambigously identified, but the metalloproteases ADAM10 
and ADAM17 (TACE) have been suggested (Buxbaum et al., 1998b; Lammich et al., 
1999), and in vivo evidence has been provided that moderate overexpression of 
ADAM10 in APP transgenic mice can increase α-secretase cleavage of APP (Postina et 
al., 2004). β-secretase (BACE) has recently been identified (Vassar et al., 1999; Yan et 
al., 1999; Sinha et al., 1999). Two homologs exist, BACE, which was first identified 
and is mainly expressed in brain, and BACE 2, which is expressed predominantly in 
peripheral tissues and only at low levels in brain (Bennett et al., 2000). BACE knockout 
mice show no apparent deficits (Luo et al., 2001; Roberds et al., 2001), while BACE 
transgenic mice show increased formation of Aβ (Mohajeri et al., 2004). γ-secretase 
activity is effected by a multiprotein complex containing the presenilins (Ray et al., INTRODUCTION 
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1999; Xia et al., 2000; Yu et al., 2000). 
APP is widely expressed throughout the body, in the central nervous system as well as 
in peripheral cells. The APP gene contains 18 exons, and different splice variants lead 
to formation of multiple isoforms (Hattori et al., 1997). In brain tissue, the most 
abundant forms are the isoforms containing 695, 751 and 770 amino acids (Sola et al., 
1993). The 695 isoform is mainly localized in neurons, whereas glial cell express 
mostly the 751 isoform (Forloni et al., 1992; Shioi et al., 1995). The 751 and 770 amino 
acid isoforms contain the Kunitz protease inhibitor KPI region (Tanzi et al., 1988). 
Although still controversial [reviewed in (Rockenstein et al., 1995)], APP isoforms with 
KPI regions were found to be increased in brains from AD patients compared to 
controls in more recent publications (Tanaka et al., 1992; Zhan et al., 1995; Moir et al., 
1998; Preece et al., 2004). Furthermore, processing of the two isoforms is different in 
that the 751 isoform is cleaved to yield more Aβ than the 695 isoform (Ho et al., 1996), 
which suggests a pathological role for the 751 isoform in AD pathogenesis. 
Among the mutations in APP associated with early-onset FAD are mutations in amino 
acid 717 of APP (“London” mutation), i.e. close to the γ-secretase cleavage site, that 
lead to increased production of the longer Aβ1-42 species (Suzuki et al., 1994; Scheuner 
et al., 1996; Eckman et al., 1997), a double mutation at the β-secretase cleavage site in 
position 670/671 identified in a Swedish family leading to 6- to 8-fold higher 
production of total Aβ species (Citron et al., 1992; Mullan et al., 1992) and the “Dutch” 
mutation E693Q in vicinity of the α-secretase cleavage site, which leads to reduced α- 
and conversely increased β-secretase cleavage of APP (Haass et al., 1994). 
Furthermore, this mutation lies within the Aβ sequence and causes a structural change 
of Aβ thereby accelerating fibril formation (Levy et al., 1990; Wisniewski et al., 1991; 
Clements et al., 1993). 
Aβ peptides tend to aggregate, which is more pronounced for the longer Aβ1-42 
compared to Aβ1-40 (Pike et al., 1991b; Harper et al., 1997). Aβ1-42 seems to be the 
initial component giving rise to formation of amyloid plaques detected in the brains of 
AD patients (Iwatsubo et al., 1994). These findings and the observation that Down’s 
syndrome patients with trisomy 21, the chromosome that contains the APP sequence, 
develop Alzheimer’s disease neuropathology led to the development of the amyloid 
cascade hypothesis (Hardy and Higgins, 1992). It states that the development of AD is 
due to abnormal accumulation of Aβ in the brains of AD patients causing INTRODUCTION 
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neurodegeneration and finally the clinical symptoms of dementia (Figure 1.6). Support 
for this hypothesis not only stems from the identification of FAD mutations that 
increase production of Aβ, but also from association of sporadic AD risk factors with 
increased Aβ production, which was shown for aging (Fukumoto et al., 2003; Fukumoto 
et al., 2004) and the Apo E4 allele (Schmechel et al., 1993; Olichney et al., 1996; Berg 
et al., 1998; Johnson et al., 1998; Lue et al., 1999; Ghebremedhin et al., 2001; 
Tiraboschi et al., 2004a). 
A   
APP 
mutations
PS1 or PS2 
mutations
Alzheimer‘s disease
familial sporadic
aging
ApoE4 allele
gradually rising A  levels with age
neurotoxicity triggered by A  accumulation
further risk 
factors ?
further genetic 
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Figure 1.6: The amyloid cascade hypothesis of Alzheimer’s disease. 
As initially suggested by Hardy and Higgins (Hardy and Higgins, 1992), the accumulation of 
Amyloid beta peptide Aβ constitutes the central event in the pathogenesis of Alzheimer’s 
disease. Either mutations in the APP gene or the presenilins PS1 or PS2 cause increased 
formation and aggregation of Aβ leading to accumulation of the peptide and neurotoxicity with 
the final clinical outcome of Alzheimer’s disease. The hypothesis states that other genetic or 
sporadic risk factors for the disease similarly favour the accumulation of Aβ resulting in the 
same neurotoxic cascades as seen in the familial forms of the disease with the same clinical 
endpoint of Alzheimer’s disease. 
 
It must however be noted that criticism of the Amyloid cascade hypothesis has been put 
forward (Bishop and Robinson, 2002), which is mainly based on findings (i) that Aβ is 
produced in substantial amounts also under physiological conditions (Haass et al., 
1992b), (ii) that neurotoxicity was not reproduced under all experimental conditions 
(Podlisny et al., 1992; Stein-Behrens et al., 1992) and (iii) Aβ plaques in AD brains do INTRODUCTION 
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not correlate with the severity of cognitive impairment (Braak and Braak, 1991; Nagy et 
al., 1995; Gomez-Isla et al., 1997; Giannakopoulos et al., 2003; Guillozet et al., 2003). 
Therefore, different toxicities of isoforms of Aβ (Zou et al., 2003), aggregation state 
(Pike et al., 1993) and subcellular localization might help to modify the amyloid beta 
hypothesis to better fit all exprimental evidence (Hardy and Selkoe, 2002). 
1.3.3.1.1 Putative physiological functions of APP 
Physiological roles for APP and the derived species are not completely understood. 
Properties of APP that could play a role in cell signaling have been proposed, among 
these are a role of APP as a cell surface receptor (Kang et al., 1987), interaction of APP 
with G0-proteins (Nishimoto et al., 1993) and a role of the APP intracellular domain 
(AICD) as a transcription factor regulating calcium homeostasis (Leissring et al., 2002). 
But also trophic functions especially of sAPPα (Mucke et al., 1994; Mucke et al., 1996; 
Bour et al., 2004) or a role for APP in cell-cell contacts are discussed (Ghiso et al., 
1992; Breen, 1992). 
APP knockout mice show no apparent abnormalities (Zheng et al., 1996), which can 
probably be attributed to the substitution of APP functions by homologous APP-like 
proteins APLP1 and APLP2 (Heber et al., 2000). However, double knockouts of APP 
and APLP2 show early lethality (Von Koch et al., 1997; Heber et al., 2000) while 
double knockouts of APP and the nervous system-specific APLP1 display no apparent 
abnormalities (Heber et al., 2000). Consequently, the putative functional overlap of APP 
and APLPs precludes an assessment of the contribution of only APP in these knockout 
mice. 
Similarly, the roles of Aβ, which is also produced under physiological conditions, are 
obscure. Recently, a role in neuronal activity has been proposed by Kamenetz and 
coworkers, who showed that Aβ is formed in response to neuronal activity, inhibiting 
further excitation of surrounding neurons in a kind of feedback mechanism (Kamenetz 
et al., 2003; Esteban, 2004). 
1.3.3.1.2 APP transgenic mice 
Various transgenic mouse lines have been generated in recent years in an attempt to 
mimic AD pathology in brain tissue, among these mice expressing full-length APP, the 
C-terminal fragment or only the Aβ sequence [reviewed in (Seabrook and Rosahl, 1999; 
Hock, Jr. and Lamb, 2001)]. Despite differences in promotors, genetic background, INTRODUCTION 
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number and kind of APP mutations and amino acid isoform of APP expressed, most of 
these transgenic mice consistently show an age-dependent accumulation of Aβ. Also 
formation of Aβ plaques, similar to the plaques detected in human AD patients, could 
be mimicked in some transgenic models. However, plaques could not be detected in 
models where Aβ formation is very low (Czech et al., 1994; Malherbe et al., 1996). 
Obviously, the relatively short life span of mice with approximately 24 to 30 months on 
average is not sufficiently long to result in detectable formation of Aβ plaques when Aβ 
levels are very low. Albeit Aβ plaques in transgenic mice are somewhat different from 
the plaques in human AD brains (Kuo et al., 2001; Kalback et al., 2002), APP 
transgenic mice nevertheless represent one of the best animal models to study 
pathogenic events relevant to AD. 
It must be mentioned, however, that – despite the presence of plaques in brains from 
APP transgenic mice and detectable hyperphosphorylated tau protein (Sturchler-Pierrat 
et al., 1997; Moechars et al., 1999a) – the formation of neurofibrillary tangles could not 
be reproduced in single APP transgenic mice. Tangle formation could only be detected 
in mice double transgenic for mutant APP and a mutant form of human tau (Lewis et 
al., 2001). Of note, tangle formation was accelerated by the presence of mutant APP in 
these mice, and similarly tangle formation could be accelerated by injection of Aβ1-42 
fibrils into the brains of mutant tau transgenic mice (Götz et al., 2001), suggesting a 
primary role for Aβ and/or APP in the initiation of tau phosphorylation and tangle 
formation. 
Expression of mutant APP in cell culture models induces cell death (Yamatsuji et al., 
1996; Zhao et al., 1997) or sensitizes towards apoptotic stimuli (Eckert et al., 2001c). 
Similarly, neuronal death has been detected in brains of transgenic mice expressing Aβ, 
the C-terminal fragment or full-length APP (LaFerla et al., 1995; Oster-Granite et al., 
1996; Calhoun et al., 1998; Moechars et al., 1999b; Urbanc et al., 2002). Although these 
results are controversial (Irizarry et al., 1997; Takeuchi et al., 2000), APP transgenic 
mice exhibit cognitive deficits (Gordon et al., 2001; Chishti et al., 2001; Higgins and 
Jacobsen, 2003; Van Dam et al., 2003), which have been detected also in the absence of 
plaques, suggesting that plaque-independent mechanisms of APP toxicity cause 
cognitive impairment. Neurotoxic mechanisms triggered by overexpression of mutant 
APP or Aβ accumulation have been intensively studied and several explanatory 
hypotheses have been proposed, among these also oxidative toxicity of Aβ (see 1.3.4.2). INTRODUCTION 
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1.3.3.2 Presenilins 
The presenilins (PS) 1 and 2 are integral membrane proteins with probably 8 
transmembraneous domains (Li and Greenwald, 1998), although other conformations 
with 7 or up to 10 transmembrane domains have also been suggested (Doan et al., 1996; 
De Strooper et al., 1997; Lehmann et al., 1997; Dewji and Singer, 1997b). PS1 and PS2 
show 80 % amino acid homology. They are are widely expressed throughout the body 
in the CNS as well as the periphery. PS1 and PS2 show similar distribution in the brain, 
where they are mainly localized to neurons and are subcellularly located mainly in the 
ER and Golgi complex (Kovacs et al., 1996; Walter et al., 1996), but have also been 
identified on the nuclear membrane (Li et al., 1997) and at the cell surface (Dewji and 
Singer, 1997a). Presenilins are posttranslationally modified by phosphorylation and, 
most prominently, by autoproteolytical cleavage yielding an approximately 30 kDA N-
terminal fragment and an approximately 20 kDa C-terminal fragment (Thinakaran et al., 
1996; Podlisny et al., 1997) so that only low amounts of full-length presenilin can be 
detected in brain tissue (Podlisny et al., 1997) (see Figure 1.7). 
So far, more than 100 different mutations in the PS1 gene have been identified that 
account for the majority of familial early-onset cases of AD [reviewed in (Lleo et al., 
2004)]. Some mutations produce phenotypes with a very early onset – even patients 
with an age of onset before the third decade of life were described (Campion et al., 
1995; Dowjat et al., 2004). In contrast, only few mutations have been identified in the 
PS2 gene. PS mutations are always single amino acid mutations with the exception of 
one deletion mutant identified in PS1. The mutations leading to FAD identified so far 
are spread accross the whole length of the proteins – unlike the FAD APP mutations 
which are in or close to the Aβ sequence – and are mostly located in the hydrophobic 
transmembrane regions, suggesting some kind of altered membrane insertion properties 
of presenilins in pathogenic events causing AD. However, some mutations have also 
been detected in the extramembraneous loops. INTRODUCTION 
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Figure 1.7: Membrane topology of presenilin 1. 
Presenilin 1 contains 10 hydrophobic domains which are either transmembrane domains or 
membrane-associated. A topology with 8 transmembrane regions has been suggested by Li 
and Greenwald (Li and Greenwald, 1998). Presenilins are proteolytically processed within the 
large cytosolic loop resulting in formation of N-terminal and C-terminal fragments. 
 
The discovery that mutations in the presenilins PS1 (Rogaev et al., 1995) or PS2 
(Sherrington et al., 1995) – similar to APP mutations – lead to elevated formation of 
Aβ1-42 in cell culture studies as well as in plasma and brains of FAD patients (Duff et 
al., 1996; Scheuner et al., 1996; Borchelt et al., 1996; Lemere et al., 1996; Citron et al., 
1997) gave further support to the amyloid cascade hypothesis. Wolfe and associates 
initially suggested that presenilins are directly responsible for γ-secretase activity and 
provided evidence that aspartate residues in each the N- as well as the C-terminal 
fragments are required for γ-secretase activity in a kind of aspartyl-protease manner 
(Wolfe et al., 1999). Later, other cofactors Nicastrin, aph-1 and pen-2 were identified 
that interact with presenilins in the γ-secretase complex (Yu et al., 2000; Kimberly et 
al., 2003). 
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1.3.3.2.1 Putative physiological roles for the presenilins 
Apart from their putative catalytic role in the the γ-secretase complex, presenilins seem 
to exert several functions in cell signaling and survival which are not yet completely 
understood. Presenilins have been shown to directly interact with APP (Weidemann et 
al., 1997; Waragai et al., 1997; Xia et al., 1997) and APLP (Naruse et al., 1998). They 
have also been suggested to regulate APP processing via modulation of intracellular 
APP trafficking (Naruse et al., 1998). Furthermore, presenilins interact with several 
proteins: with Notch (Wong et al., 1997; Struhl and Greenwald, 1999; De Strooper et 
al., 1999), catenins (Yu et al., 1998; Murayama et al., 1998), with the neuronal calcium-
binding protein calsenilin (Buxbaum et al., 1998a), with G0-proteins (Smine et al., 
1998), with µ-calpain (Shinozaki et al., 1998) and with components of the cytoskeleton 
(Zhang et al., 1998; Sych et al., 2000). PS1 can furthermore directly bind tau protein 
and glycogen synthase kinase GSK-3β, which is thought to be involved in the 
hyperphosphorylation of tau protein leading to neurofibrillary tangle formation in AD 
brains. PS1 mutations increase this interaction (Takashima et al., 1998) suggesting a 
role for presenilins in abnormal tau phosphorylation in AD brains. 
The generation of presenilin knockout mice was hindered by the fact that the 
homozygous knockout is lethal at early stages. Embryos of presenilin 1 knockout mice 
show abnormal sceletal deformations and early death before or shortly after birth (Shen 
et al., 1997; Qian et al., 1998). This effect is even more pronounced when PS1 and PS2 
are both knocked out (Herreman et al., 1999), which may be related to deficient Notch 
signaling, since presenilins have been shown to process Notch (De Strooper et al., 1999) 
and Notch knockout mice exhibit similar pathologies as PS knockout mice (Conlon et 
al., 1995; Wong et al., 1997). 
Recent advances in the analysis of effects of a presenilin knockout in adult animals have 
been made by generation of mice where the PS1 gene is selectively knocked out in adult 
mice (Yu et al., 2001). These mice show only subtle cognitive deficits. Mice transgenic 
for APP and with a knockout of PS1 show greatly reduced Aβ accumulation and 
restored long-term potentiation compared to APP transgenics. Cognitive deficits 
induced by the APP transgene were however not reversed by the PS1 knockout 
(Dewachter et al., 2002). These studies imply a role of presenilins in long-term 
potentiation, but further studies on these mouse models are needed to broaden the 
knowledge on physiological roles of the presenilins in cell biology. INTRODUCTION 
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Studies on cell culture models with overexpression of presenilins have produced 
conflicting results. Proapoptotic effects have been observed for wildtype PS1 (Wolozin 
et al., 1998) and wildtype PS2 (Wolozin et al., 1996; Deng et al., 1996; Janicki and 
Monteiro, 1997), for mutant PS1 (Guo et al., 1997; Wolozin et al., 1998; Bursztajn et 
al., 1998; Weihl et al., 1999), and mutant PS2 (Janicki and Monteiro, 1997). However, 
antiapoptotic effects of wildtype PS1 (Bursztajn et al., 1998) have also been reported. 
Furthermore, no proapaptotic effects of wildtype or mutant PS2 have been observed in a 
recent study in different cell types (Gamliel et al., 2003). These contradictory results 
could be due to different levels of PS overexpression, as it was recently reported that 
low expression of wildtype PS1 exhibited no propaoptotic effect, whereas high 
expression of wildtype PS1 did (Hashimoto et al., 2002). Similarly, in primary cultured 
neurons of transgenic rats expressing wildtype PS1, increased apoptosis correlated with 
the amount of PS1 expression (Czech et al., 1998). 
1.3.3.2.2 PS transgenic mice 
Several PS transgenic mouse models expressing human wildtype and/or mutant PS1 or 
PS2 have been developed so far (Duff et al., 1996; Borchelt et al., 1996; Citron et al., 
1997; Oyama et al., 1998; Qian et al., 1998; Davis et al., 1998; Leutner et al., 2000), but 
none of these mouse models exhibit Aβ plaque formation in brain parenchyma, despite 
increased formation of endogenouse rodent Aβ. This can probably be attributed to 
subtle differences in three amino acids in rodent Aβ compared to the human Aβ 
sequence, which confers a reduced tendency towards aggregation to the rodent peptide 
(Dyrks et al., 1993). 
Despite the absence of rodent Aβ plaques, mutant PS1 transgenic mice show 
accelerated neurodegeneration (Chui et al., 1999; Sadowski et al., 2004), suggesting that 
a proapoptotic role of mutant PS as identified in cell culture expression systems may be 
of relevance in animal models as well. Furthermore, PS transgenic mice exhibit altered 
long-term potentiation (Parent et al., 1999; Schneider et al., 2001b) and dysregulated 
calcium homeostasis (Begley et al., 1999; Yoo et al., 2000; Leissring et al., 2000; 
Eckert et al., 2001b; Schneider et al., 2001b). Similar effects have been observed in 
studies in peripheral cells from FAD patients bearing PS mutations (Gibson et al., 
1996), suggesting that the effects of PS mutations in cell culture and animal models may 
play a direct role in the pathology of FAD in humans. 
Expression of both mutant APP and mutant PS in transgenic mice results in INTRODUCTION 
     39 
dramatically accelerated plaque formation in the brains of these mice (Borchelt et al., 
1997; Citron et al., 1997; Holcomb et al., 1998), which is consistent with the effect of 
PS mutations on enhanced γ-secretase cleavage of APP. Furthermore, a triple transgenic 
mouse model of AD coexpressing mutant human APP, mutant PS1 and mutant tau has 
been recently described (Oddo et al., 2003). These mice show synaptic dysfunction and 
deficits in long-term potentiation, followed by Aβ plaque deposition and subsequent 
neurofibrillary tangle formation (Oddo et al., 2003), thereby closely mimicking AD 
neuropathology. Since Aβ deposition precedes the formation of tangles, a pathogenic 
role for Aβ species in eliciting tau pathology consistent with the amyloid cascade 
hypothesis has been suggested. 
1.3.4 A role for oxidative stress in AD? 
The pathogenic events that lead to the neurodegeneration observed in the brains of AD 
patients have not been discovered so far. Immunohistochemical studies of post mortem 
AD brains have established that neurons undergo apoptotic cell death (Su et al., 1994; 
Smale et al., 1995). Since reactive oxygen species can elicit apoptotic signaling (see 
1.1.3.5), the hypothesis that oxidative stress is involved in the pathogenic steps that lead 
to the development of AD has been proposed in the 1990s by several groups (Blass and 
Gibson, 1991; Benzi and Moretti, 1995; Smith et al., 1995; Markesbery, 1997). 
1.3.4.1 Oxidative stress in sporadic AD patients 
Oxidative stress has been associated with the risk factors for sporadic AD, most 
prominently with aging (see 1.2.3). Consequently, oxidative stress markers have also 
been analyzed in AD patients. However, some conflicting results have been reported, 
furthermore, some studies analyzed only singular aspects of oxidative toxicity which 
makes a comprehensive overall assessment of the contribution of oxidative stress to AD 
pathology difficult. 
Increased markers of oxidative stress, such as lipid peroxidation products, oxidatively 
modified proteins and nucleic acids, have been identified in sporadic AD patients 
[reviewed in (Christen, 2000; Pratico and Delanty, 2000; Gibson and Huang, 2002)]. 
Furthermore, samples from AD brains display a higher susceptibility towards in vitro 
oxidation (Hajimohammadreza and Brammer, 1990; McIntosh et al., 1997; Schippling 
et al., 2000). However, results are controversial as unchanged levels of lipid 
peroxidation products in brains from AD patients have also been reported INTRODUCTION 
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(Hajimohammadreza and Brammer, 1990; Hayn et al., 1996; Lyras et al., 1997; 
McIntosh et al., 1997). 
Since increased oxidative damage can be the result of either increased production or 
insufficient detoxification of ROS, both mechanisms have been studied, again with 
conflicting results. Deficiencies in mitochondrial proteins that could contribute to 
increased ROS formation have been detected in brains from AD patients (Parker, Jr. et 
al., 1990; Parker, Jr. et al., 1994; Mutisya et al., 1994; Fukuyama et al., 1996; 
Chandrasekaran et al., 1997; Aksenov et al., 1999; Kish et al., 1999; Maurer et al., 
2000). Furthermore, markers of inflammatory reactions have been detected in AD 
brains [reviewed in (Akiyama et al., 2000)] which could exacerbate oxidative stress 
toxicity. Other prooxidative factors identified in AD brains are increased monoamine 
oxidase B activity (Gottfries et al., 1983; Reinikainen et al., 1988; Kennedy et al., 2003) 
and increased levels of potentially prooxidative heavy metals like iron (Deibel et al., 
1996; Cornett et al., 1998).  
Antioxidant parameters in AD brains have been reported to be either increased (Lovell 
et al., 1995; Bruce et al., 1997; Ramassamy et al., 1999; Karelson et al., 2001), 
decreased (Marcus et al., 1998; Omar et al., 1999) or unchanged (Hayn et al., 1996). 
Moreover, the analysis of antioxidant parameters alone seemingly does not allow for a 
conclusion with regard to oxidative damage, since increased lipid peroxidation products 
have been identified in AD patients accompanied by either increased (Lovell et al., 
1995) or decreased (Marcus et al., 1998) antioxidant enzyme activities. 
In conclusion, although the majority of available experimental evidence supports the 
hypothesis that oxidative stress is involved in the pathogenesis of AD, conflicting 
results have been reported. Furthermore, it remains to be elcuidated whether oxidative 
stress occurs early in the disease or is just a consequence of disease progression. 
1.3.4.2 Oxidative stress and Aβ toxicity 
Since the proposal of the amyloid hypothesis of AD, toxic mechanisms of Aβ have been 
extensively studied. Cells exposed to Aβ undergo apoptotic (Loo et al., 1993; Forloni et 
al., 1993) or necrotic (Behl et al., 1994a) cell death, although relatively high 
concentrations are needed to elicit necrosis. The toxicity of Aβ has been shown to be 
mediated by ROS (Behl et al., 1994b; Mark et al., 1997). Furthermore, toxicity of Aβ 
depends on its aggregation state (Pike et al., 1991a), which can be influenced by 
oxidation: oxidized Aβ peptides tend to aggregate more quickly (Dyrks et al., 1992). INTRODUCTION 
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Thus, oxidative stress can cause formation of toxic Aβ species, which in turn can further 
exacerbate accumulation of ROS. 
Toxicity of Aβ has also been evidenced in animal models of the disease. Injection of 
fibrillar Aβ into the brains of rats leads to increased expression of iNOS in glial cells 
(Weldon et al., 1998). Furthermore, immunohistochemical studies have found increased 
markers of oxidative stress in brains of transgenic mice bearing APP mutations 
(Pappolla et al., 1998; Smith et al., 1998). Also, activated glial cells surrounding the 
plaques in transgenic mice and increased markers of inflammation have been identified 
(Matsuoka et al., 2001b). Since inflammatory reactions are linked to increased ROS 
production (see 1.1.2), a role for oxidative stress in the toxicity induced by Aβ seems 
possible. However, immunohistochemical studies do not allow for a functional analysis 
of the observed changes which necessitates a study of brain homogenates of transgenic 
mice with respect to functional oxidative stress parameters. 
1.3.4.3 Oxidative stress and presenilins 
Expression of presenilins in cell culture sensitizes cells to apoptotic stimuli by 
increasing ROS production (Guo et al., 1996), which could be reversed by antioxidants 
and Bcl-2 expression (Guo et al., 1997). Similarly, hippocampal neurons of PS1 
transgenic mice bearing an FAD mutation showed increased sensitivity to glutamate-
induced excitotoxic cell death, which was accompanied by increased ROS formation 
and mitochondrial damage (Guo et al., 1999b). ROS accumulation by mutant 
presenilins can also be closely linked to disturbed calcium homeostasis (Guo et al., 
1997; Eckert et al., 2001b). Our group has previously reported changes in oxidative 
stress parameters in the brains of 3 months old PS1 transgenic mice (Leutner et al., 
2000), which render brain tissue more susceptible to stimulated lipid peroxidation in 
vivo. However, direct evidence that basal oxidative damage is present in the brains from 
PS1 transgenic mice as well as a comparison of animals at different age is still lacking. 
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1.4 Aims of thesis 
The complexity of the pathology of Alzheimer’s disease AD has so far precluded any 
final conclusion as to the exact pathogenic steps that lead to the development of the 
disease. Consequently, no causal therapies for AD exist until today – necessitating the 
need for a better understanding of disease mechanisms for development of rational and 
causal future therapies. A promising hypothesis for the genesis of AD pathology lies in 
the contribution of oxidative stress mechanisms. 
The major aim of this thesis was therefore to investigate the contribution of oxidative 
stress to the pathogenesis of Alzheimer’s disease in several different models. By 
analyzing various parameters related to oxidative stress in animal models of FAD and in 
human postmortem brain tissue from sporadic AD patients, a comprehensive approach 
should be undertaken to identify causal disease mechanisms triggered by FAD 
mutations and sporadic AD risk factors. Furthermore, the value and relevance of 
transgenic mouse models compared to human AD brain tissue could be assessed. 
In the first part of this thesis, the influence of aging, the most important risk factor for 
sporadic AD, on oxidative stress-related markers should be elucidated. To this end, 
markers of oxidative stress and changes in antioxidant enzymatic defense were analyzed 
in brain tissue during aging in C57BL/6J mice. Furthermore, age-associated changes in 
ROS levels were also studied in splenic lymphocytes of these mice as a peripheral cell 
model. 
The effects of FAD mutations on oxidative stress parameters should be assessed in 
experiments on transgenic mice bearing human PS1 and/or APP. These mouse models 
have the C57BL/6J mouse strain, which was analyzed in the first part of this thesis, as 
genetic background. Transgenic mice were used at different age groups to elucidate the 
question whether aging and FAD mutations have additive effects on alterations in 
oxidative stress parameters. Furthermore, the transgenic mice display different 
formation of Aβ, which is a hypothetical causal agent for both the sporadic and familial 
forms of AD. Hence, putative correlations between various levels of Aβ accumulation 
and oxidative stress parameters could be established. Therefore, brains from transgenic 
mice were analyzed for lipid peroxidation products MDA and HNE as well as 
antioxidant enzyme activities in relation to the expression levels of human APP and Aβ. 
Furthermore, lymphocytes from PS1 transgenic mice were studied to investigate the 
effects of an FAD mutation on ROS levels in living cells. INTRODUCTION 
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In order to elucidate the influence of sporadic AD risk factors and for a comparison of 
the FAD-based transgenic mouse models with the much more common sporadic form of 
AD, post mortem brain tissue from sporadic AD patients was analyzed in the final part 
of this thesis. These studies should additionally allow for a correlation of risk factors for 
sporadic AD, like the Apo E genotype and female gender, with oxidative stress-related 
parameters. Furthermore, the relevance of transgenic mouse models for the study of 
mechanisms relevant to sporadic AD could thus be established. 
In conclusion, the contribution of FAD mutations as well as risk factors for sporadic AD 
to putative disease mechanisms related to oxidative stress could be assessed. The results 
should allow for an evaluation of the relevance of oxidative mechanisms in the disease 
pathogenesis and provide insight whether the concept of challenging ROS formation 
pharmacologically could offer a rewarding approach to new therapies of AD. 
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2.1 Materials 
2.1.1 Chemicals 
Acetic acid, glacial  VWR International, Darmstadt, Germany 
Acetonitrile  VWR International, Darmstadt, Germany 
Agarose  VWR International, Darmstadt, Germany 
Ammonium chloride, NH4Cl  VWR International, Darmstadt, Germany 
Bacillol®, surface desinfectant  VWR International, Darmstadt, Germany 
Blue juice, 10x gel loading buffer, Gibco™  Invitrogen, Karlsruhe, Germany 
BSA, Bovine serum albumine  Roche Diagnostics GmbH, Mannheim,  
   Germany 
Calcium chloride, CaCl2  VWR International, Darmstadt, Germany 
Carbon dioxide gas, CO2  Messer, Griesheim, Germany 
Chloroform  VWR International, Darmstadt, Germany 
Complete® Protease Inhibitor Cocktail  Roche Diagnostics GmbH, Mannheim, 
   Germany 
Desoxy-d-ribose, d-Rib  Sigma-Adrich, Taufkirchen, Germany 
Desoxy-nucleotide triphosphates, dNTPs  Eppendorf AD, Cologne, Germany 
4,5-Diaminofluorescein-diacetate, 
   DAF-2-DA 
Calbiochem, Schwalbach, Germany 
Dichlorodihydrofluorescein-diacetate, 
   DCFH-DA 
Molecular Probes, Leiden, Netherlands 
Dihydroethidium, 5mM stabilized solution 
   in DMSO 
Molecular Probes, Leiden, Netherlands 
Dihydrorhodamine 123, DHR  Molecular Probes, Leiden, Netherlands 
Dimethylsulfoxide, DMSO  VWR International, Darmstadt, Germany 
Dithiothreitol, DTT  Calbiochem, Schwalbach, Germany 
DNA Ladder, 100bp  New England Biolabs, Frankfurt, 
   Germany 
ECL, enhanced chemoluminescence 
   detection solution 
Amersham Pharmacia Biotech, Freiburg, 
   Germany 
Ethanole, absolute  VWR International, Darmstadt, Germany 
Ethidiumbromide, 2 % solution  VWR International, Darmstadt, Germany 
Ethylenediaminetetraacetic acid, EDTA, 
   disodium salt 
VWR International, Darmstadt, Germany 
FACSClean  Becton Dickonson GmbH, Heidelberg, 
   Germany 
FACSFlow Becton  Dickonson GmbH, Heidelberg, 
   Germany 
FACSRinse  Becton Dickonson GmbH, Heidelberg, 
   Germany 
Fetal calf serum, FCS  Sigma-Adrich, Taufkirchen, Germany 
Forene® (INN: Isofluran)  Abbott GmbH&Co., Wiesbaden 
Glutathione Reductase Assay Kit  Calbiochem, Schwalbach, Germany MATERIALS AND METHODS 
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Glutathione Peroxidase, Cellular, Assay Kit Calbiochem, Schwalbach, Germany 
Hank’s balanced salt solution (HBSS), dry 
powder 
Sigma-Adrich, Taufkirchen, Germany 
Hydrochloric acid, 37%  VWR International, Darmstadt, Germany 
Hydrochloric acid, 1 N solution  VWR International, Darmstadt, Germany 
Hydrogen peroxide 3%  Sigma-Adrich, Taufkirchen, Germany 
2-[4-(2-Hydroxyethyl)-1-piperazinyl]-
ethanesulfonicacid (HEPES) 
VWR International, Darmstadt, Germany 
Iron(III)chloride, FeCl3  VWR International, Darmstadt, Germany 
Isopropanole  VWR International, Darmstadt, Germany 
Kodak RPX-Omat developer  Kodak, Rochester, New York, USA 
Kodak RPX-Omat fixative  Kodak, Rochester, New York, USA 
Kodak Indicator Stop  Kodak, Rochester, New York, USA 
Magnesium sulfate, MgSO4 x 7 H2O  VWR International, Darmstadt, Germany 
Mercaptoethanole  VWR International, Darmstadt, Germany 
2-Morpholinoethanesulfonic acid, 
   monohydrate, MES 
VWR International, Darmstadt, Germany 
MES running buffer NuPage  Invitrogen, Karlsruhe, Germany 
Methanesulfonic acid  VWR International, Darmstadt, Germany 
Methanole  VWR International, Darmstadt, Germany 
1-Methyl-2-phenylindole VWR  International, Darmstadt, Germany 
Milk powder, non-fat dry  Nestle Carnation, USA 
Novex NuPage PreCast Gels, 4-12 % Bis- 
   Tris, 12 wells, 1 mm thickness 
Invitrogen, Karlsruhe, Germany 
Novex Tris-Glycine SDS Sample Buffer 2x  Invitrogen, Karlsruhe, Germany 
NuPAGE Transfer Buffer  Invitrogen, Karlsruhe, Germany 
Perform  Schülke&Mayr, Norderstedt, Germany 
Phenylmethylsulfonylfluoride, PMSF  Sigma-Adrich, Taufkirchen, Germany 
Phosphate buffered saline, PBS, 
   10x concentrate 
PAA Laboratories GmbH, Cölbe, 
   Germany 
Potassium hydrogen carbonate, KHCO3  VWR International, Darmstadt, Germany 
Primers (oligonucleotides) for PCR  MWG Biotech AG 
Protein marker, Magic Mark ™ for protein 
   electrophoresis 
Invitrogen, Karlsruhe, Germany 
Rhodamine 123, R123  Molecular Probes, Leiden, Netherlands 
RPMI 1640 medium, powder  Sigma-Adrich, Taufkirchen, Germany 
RPMI medium, sterile  PAA Laboratories GmbH, Cölbe, 
   Germany 
Sodium azide, NaN3  VWR International, Darmstadt, Germany 
Sodium chloride, NaCl  VWR International, Darmstadt, Germany 
Sodium dodecyl sulfate, SDS  VWR International, Darmstadt, Germany 
Sodium hydrogen carbonate NaHCO3  VWR International, Darmstadt, Germany 
Sodium hydroxide, NaOH  VWR International, Darmstadt, Germany 
Sodium hydroxide, 1 N solution  VWR International, Darmstadt, Germany MATERIALS AND METHODS 
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Sterilium®, desinfectant for hands  VWR International, Darmstadt, Germany 
Taq-polymerase (Thermophilus aquaticus)  Eppendorf AG, Cologne, Germany 
Tween 20 
   (Polyoxyethylensorbitanemonolaureate) 
Sigma-Adrich, Taufkirchen, Germany 
Tris(hydroxymethyl)-aminomethane, Tris  VWR International, Darmstadt, Germany 
Trypan Blue solution, 0.5% (w/V)  Biochrom AG, Berlin, Germany 
Water, ultrapure filtered and deionized  Millipore, Eschborn, Germany 
 
All reagents used were of analytical grade, if not otherwise specified. 
2.1.2 Kits 
Beta-Amyloid (Aβ) [1-40] colorimetric ELISA  Biosource GmbH, Solingen, Germany 
BioRad DC Protein Assay Kit  BioRad, Munich, Germany 
DNAEasy Tissue Kit  Quiagen, Hilden, Germany 
Glutathione Peroxidase, Cellular, Assay Kit  Calbiochem, Schwalbach, Germany 
Glutathione Reductase Assay Kit  Calbiochem, Schwalbach, Germany 
High Pure RNA Isolation Kit  Boehringer, Mannheim, Germany 
Lipid Peroxidation Assay Kit  Calbiochem, Schwalbach, Germany 
Master Taq Kit  Eppendorf AG, Cologne, Germany 
Superoxide Dismutase Assay Kit  Calbiochem, Schwalbach, Germany 
SuperScript II Kit  Invitrogen, Karlsruhe, Germany 
2.1.3 Antibodies 
Primary antibodies for Western blotting: 
•  W0-2 antibody: monoclonal mouse anti-human APP N-terminal, amino acids 4-
10 of Aβ sequence (Abeta GmbH, Heidelberg, Germany) 
•  anti-actin (I-19) sc-1616, goat polyclonal IgG, 200µg/ml (Santa Cruz 
Biotechnology Inc., Heidelberg, Germany) 
Secondary antibodies for Western blotting: 
•  goat anti-mouse-IgG, horseraddish-peroxidase conjugated, Calbiochem, 
Schwalbach, Germany 
•  rabbit anti-goat-IgG, horseraddish-peroxidase conjugated, Calbiochem, 
Schwalbach, Germany 
Antibodies for flow cytometry: 
Anti-mouse CD3 (ε-chain), PE-conjugated, clone 145-2C11, 0.2 mg/ml,  
anti-mouse CD4 (L3T4), PE-conjugated, clone RM4-5, 0.2 mg/ml,  
anti-mouse CD8a (Ly-2), PE-conjugated, clone 53-6.7, 0.2 mg/ml,  
rat isotype control IgG1 κ, PE conjugated, clone MOPC-31C, 0.2 mg/ml,  
all purchased from Becton Dickinson, Heidelberg, Germany. 
2.1.4 Buffers and media 
If not otherwise stated, all buffers and media were prepared in deionized and sterile-MATERIALS AND METHODS 
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filtered water (Millipore). pH was adjusted with a pH-meter every day. Due to 
interference of Tris with the pH-meter electrode, buffers containing Tris were adjusted 
with the use of special pH indicator sticks ranging from pH 6.5-10.0 with 0.3 pH 
intervals (VWR International, Darmstadt, Germany). 
2.1.4.1 Buffers used for brain tissue preparation and homogenization 
EDTA solution: 1 mM NaEDTA in 0.9% NaCl, pH 7.4 at 4°C. 
Tris buffer: 20 mM Tris in 0.84% NaCl, pH 7.4 at 4°C. 
2.1.4.2 Buffers used for lymphocyte preparation 
RPMI buffer: prepared from 1 vial of RPMI powder (10.4 g) in 1 litre of Millipore 
water, under addition of 10 mM HEPES (2.383 g/l) and 5% (V/V) fetal calf serum FCS. 
pH 7.4 at 4°C (before addition of FCS). If not otherwise stated, RPMI buffer was used 
for all experiments including isolation of lymphocytes, incubation of cells in 37°C 
waterbaths, washing steps after incubation of cells with dyes and resuspension of cells 
before FACS analysis. 
Erythrocyte lysis buffer: 0.83 g NH4Cl and 0.1 g KHCO3 in 100ml Millipore water. 
HBSS buffer: 1 vial of HBSS powder dissolved in 1 l Millipore water, under addition 
of 10 mM HEPES (2.383 g/l), 1 mM CaCl2 and 0.5 mM MgSO4, pH 7.4 at 37°C. HBSS 
buffer was used for stimulation of cells with hydrogen peroxide, since reducing agents 
and proteins in serum-containing RPMI buffer lead to quenching of radicals and gave 
only low increases in fluorescence intensity after staining with oxidation-sensitive dyes. 
RPMI buffer, sterile: 500  ml of sterile RPMI medium under addition of 
10  %  (V/V)  FCS. Sterile RPMI buffer was used for maintenance of cells in the 
incubator for up to 4 hours. 
2.1.4.3 Buffers for Western blots 
2.1.4.3.1 Tissue lysis buffers 
Tris lysis buffer: Tris 20 mM, 0.9 % NaCl, pH 7.4, plus Complete® was employed for 
lysis of brain tissue used for Western blotting and ELISA of soluble Aβ levels. 
SDS solution: 2 % SDS plus Complete® was used for resuspension of the residual 
pellet after Tris lysis and leads to dissolution of the remaining insoluble pool of Aβ. MATERIALS AND METHODS 
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SDS lysates were employed for Western blotting for detection of insoluble Aβ species. 
2.1.4.3.2 Buffers and solutions for SDS-PAGE, Western blot and protein 
detection 
SDS polyacrylamide gel electrophoresis buffer: MES Running Buffer from 
Invitrogen® was either diluted from the commercially available 20x stock solution or 
prepared as follows: 0.1 M MES, 0.1 M Tris-Base, 6.93 mM SDS and 2.05 mM EDTA 
were dissolved in 1 l Millipore water and pH was adjusted to pH 7.3. 500 µl of 0.5 M 
DTT solution was added to the inner chamber of the electrophoresis apparatus.  
Blotting buffer: 50  ml of NuPAGE® Transfer Buffer 20x stock were diluted with 
850 ml Millipore water, 100 ml methanol and 1 ml of 0.5 M DTT was added. 
PBS: 50 ml of PBS 10x stock were diluted with 450 ml Millipore water. 
TBST: A 10x concentrate was prepared from 24.2 g Tris, 80 g NaCl and 5 ml Tween in 
1 l Millipore water, pH 7.6. Immediately before use, this 10x concentrate was diluted 
with Millipore water. 
Milk: 10 % (w/V) of non fat dry milk were dissolved in TBST. 
Stripping buffer: 62.5 mM Tris, 2 % SDS and 10 mM Mercaptoethanol, pH 6.0. 
2.1.4.4 Buffers for DNA gel electrophoresis 
TAE buffer: 4.84 g Tris, 1.142 ml acetic acid, 1mM NaEDTA in 1 l millipore water, 
pH 7.4. 
2.1.5 Apparatus and other materials 
Calibrite beads, Becton-Dickinson, Heidelberg, Germany 
Centrifuge for Eppendorf caps, Microfuge R centrifuge, Beckman, Munich, Germany 
Centrifuge for polypropylene tubes and  microtiter plates, with buckets or  microplus         
carriers, Centrifuge GS-6R, Beckman, Munich, Germany 
Cell strainer sieve, BD Falcon™ 40µm, Becton-Dickinson, Heidelberg, Germany 
Chromatography paper 3 mm Whatman®, Millipore, Eschborn, Germany 
Combitips plus® 0.1 ml, 0.5 ml, 1 ml, 2.5 ml, 5 ml, Biopur, VWR International, 
Darmstadt, Germany 
Coverslips for Neubauer chamber, Superior, VWR, Germany 
Cryo tubes type Cryo.S, Greiner, Frickenhausen, Germany 
Cuvettes, disposable, Plastibrand®, PMMA semi-micro cuvettes, Brand, supplied by 
VWR, Germany 
Cuvettes, precision cells of special optical glass, Hellma GmbH&Co. KG, Müllheim, 
Germany MATERIALS AND METHODS 
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Ear clips for mice and compatible clamp, Hauptner, Herbolzheim, Germany 
FACSCalibur (E1034) flow cytometre, Becton-Dickinson, Heidelberg, Germany 
Fridge (4-8 °C), type Glassline KGT 3546, Liebherr-Hausgeräte GmbH, Ochsenhausen, 
Germany 
Freezer (-20 °C), Liebherr-Hausgeräte GmbH, Ochsenhausen, Germany 
Freezer (-80 °C), Heraeus Instruments, Hanau, Germany 
Gel electrophoresis system for DNA gels: BioRad Sub Cell Model 96 with BioRad 
PowerPac 300, BioRad, Munich, Germany 
Gel electrophoresis system for protein gels and Western blotting apparatus: X-Cell gel 
electrophoresis system, Invitrogen, Karlsruhe, Germany and BioRad Western blot 
transfer chamber Mini-Trans-Blot, with power supply from BioRad PowerPac 1000, 
BioRad, Munich, Germany 
Heating Block Unitek HB-130, CLF, Emersacker, Germany 
Hyperfilm™ ECL, Amersham Biosciences, Freiburg, Germany 
Ice machine Ziegra, Bader, Frankfurt, Germany 
Incubator Heraeus Type BB 6220, Heraeus Instruments GmbH, Hanau, Germany 
Injection needles, 20 gauge, Terumo, Leuven, Belgium 
Laminar flow hood, Heraeus Instruments GmbH, Hanau, Germany 
Magnetic agitator, type Variomag mono, H+P Labortechnik, VWR, Germany 
Microliter syringe, glass, 50µl, Hamilton, Bonaduz, Switzerland 
Microtiter plate reader, ASYS Hitech Digiscan, Eugendorf, Germany 
Microtiter plate reader, Wallac 1420 Victor
2 ™ plate reader (Perkin Elmer, Rodgau-
Jügesheim, Germany) 
Microtiter plates, 96 wells, flatt bottom, non-sterile, Greiner, Frickenhausen, Germany 
Microscope, Modell TMS, type I04, Nikon, Japan 
Millipore system for purified water Miili Q Plus PF, Millipore, Eschborn, Germany 
Multipette® plus, Eppendorf, Germany 
Neubauer chamber superior, VWR International, Darmstadt, Germany 
Nitrocellulose membrane Hybond ECL, Amersham Biosciences, Freiburg, Germany 
Parafilm® M, VWR International, Darmstadt, Germany 
PCR tubes, 0.2 ml, Greiner, Frickhausen, Germany 
pH indicator sticks, pH 6.5-10.0, VWR International, Darmstadt, Germany 
pH-meter, Multical® pH 526, Wissenschaftlich-Technische-Werkstätten WTW, 
Weilheim, Germany 
Photometer, Genesys 5 Spectrophotometer, Spectronic Instruments Inc., Rochester, 
USA 
Pipettes model Pipetman®, 20, 200, 1000µl, Abimed, Langenfeld, Germany 
Pipettes model Transferpette®, 1, 10, 100, 5000µl, Eppendorf Vertrieb Deutschland 
GmbH, Wesseling-Berzdorf, Germany 
Pipette tips for 10, 100, 200, 1000 µl and 5 ml, Greiner, Frickhausen, Germany 
Pipettes, sterile packed, for 5, 10 and 25 ml, Greiner, Frickhausen, Germany 
Pipettus®-akku, Hirschmann, VWR, Germany 
Polypropylene tubes, 15 and 50 ml, Greiner, Frickenhausen, Germany 
Polystyrene tubes Falcon 2050, Becton-Dickinson, Heidelberg, Germany 
PVDF membrane, Hybond-P 0.45µM, Amersham Biosciences, Freiburg, Germany 
Reaction tubes with cap, 1.5 ml or 2 ml, polypropylene, Greiner, Frickenhausen, 
Germany 
Scale type Mettler AB204 or AT 261 Delta Range®, Mettler-Toledo, Greifensee, 
Switzerland 
Scalpel Cutfix®, B.Braun, VWR International, Darmstadt, Germany 
Shaker IKA HS 250 basic, IKA Labortechnik, Staufen, Germany MATERIALS AND METHODS 
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Shaker Promax 1020, Heidolph, Kelkheim, Germany 
Shaker ST6 CAT, Zipperer GmbH, Staufen, Germany 
Sonifier Branson Cell Disruptor B15, Gerhard Heinemann, Schwäbisch Gmünd, 
Germany 
Tank for liquid nitrogen Arpege 70, Air Liquide, Paris, France 
Thermocycler PCR Cycler Gene Amp® PCR System 9700 PE Applied Biosciences 
Tissue culture plates, polystyrene, 24 wells, flat bottom, sterile, Dunn Labortechnik 
GmbH, Asbach, Germany 
Tissue culture plates, polystyrene, 48 wells, flat bottom, sterile, Iwaki, Dunn 
Labortechnik GmbH, Asbach, Germany 
Tissue homogenizer, Potter S, B. Braun Biotech International, Sartorius AG, Göttingen, 
Germany 
Transferpette®-8, 10-100 µl and 30-300 µl, Brand, Germany 
Ultracentrifuge Optima™ LE-80 K with rotor 70.1 Ti, Beckman, Munich, Germany 
UV transilluminator UVT-20 M/W, Herolab GmbH, Wiesloch, Germany 
Video camera Variocam, PCO computer optics GmbH, Lübeck, Germany 
Vortex, model REAX 2000, Heidolph, Kelkheim, Germany 
Water bath Thermomix_1440, B.Braun, Melsungen, Germany 
Water bath type 1003, GFL, Gesellschaft für Labortechnik mbH, Burgwedel, Germany 
2.1.6 Computer software 
FACSComp software (Becton-Dickonson, Heidelberg, Germany) 
Cell Quest pro software (Becton-Dickonson, Heidelberg, Germany) 
Graph Pad Prism 3.0 and 4.0 (GraphPad Software Inc., San Diego, CA, USA) 
Kodak ds1D software v. 2.03 (Kodak Scientific Imaging Systems, New Haven, CT, 
USA) 
Microsoft Excel 2000 software 
Mikrowin 3.0 software (Mikrotek Laborsysteme GmbH, Overath, Germany) 
Wallac 1420 Workstation Version 2.00 (release 9) for Wallac 1420 Victor2 ™ plate 
reader (Perkin Elmer Life Sciences, Rodgau-Jügesheim, Germany) 
Umax VistaScan software (Umax Systems GmbH, Willich, Germany) 
2.1.7 Mice 
Mice were housed in cages (Makrolon, type II, Altromin GmbH, Germay) with a 
maximum of 5 animals per cage. Each cage was supplied with a plastic tube and some 
sheets of cellulose. Mice were kept at room temperature and constant humidity under a 
12 hour dark/light circle with pelleted food (Standard 1320 Ratte/Maus Haltungsdiät, 
Altromin GmbH, Germany) and water ad libitum. Cages were replaced once weekly 
and cleaned with Perform desinfectant. All experiments described in this thesis are in 
concordance with the German law on animal care and handling of transgenic animals. 
Mice with skin lesions, splenomegaly, macroscopically visible tumors, aszites or mice, 
that were otherwise seemingly ill, were excluded from the experiments. 
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2.1.7.1 C57BL/6J mice 
For all experiments related to effects of aging and gender in mice, the Jackson strain of 
C57BL/6J mice were used. C57BL/6J@ICO mice were purchased from Iffa Credo, 
France. The C57BL/6J mouse was developed by Little in 1921 after crossing the female 
N°57 with the male N°52 from a commercial breeding centre in the USA (Miss Abby 
Lathrop). It was introduced into the Jackson laboratory in 1948 at the F22 generation 
and then to IFFA-CREDO in 1981. One infusion was done in 1986 at F159 (Jutta 
Davidson, Charles River Deutschland GmbH, personal communication).  
2.1.7.2 Transgenic mice 
The methods of generation and characterization of PS1, PDGF-APP or Thy1-APP 
transgenic mice have been described previously (Czech et al., 1997; Czech et al., 1998). 
In brief, mice were generated by pronuclei microinjection of the respective linearized 
DNA constructs into one of the two pronuclei of fertilized mouse embryos (C57BL/6J 
X SJL-F2 hybrids, IFFA CREDO). The embryos were transplanted into the oviduct of 
pseudopregnant foster mothers. Transgenic offspring were detected by southern blot 
analysis of DNA obtained from tail samples. Southern blot analysis also showed no 
major rearrangement or deletion of the transgene. 
All PS1, PDGF-APP or Thy1-APP transgenic mice were generated by Aventis Pharma, 
France, and kindly donated to our laboratory. 
With the exception of APP23 mice, where frozen brain tissue obtained, all other 
transgenic mice for the studies in this thesis were bred in the Biocenter facilities. 
Female C57BL/6J mice were obtained from Iffa Credo, France, and crossed with 
transgenic male mice. After approximately 3 weeks pregnancy, usually 3 to 10 mice 
were born per litter. The offspring was genotyped as described in 2.2.7 (page 74 et 
seqq.) and non-transgenic littermate animals were used as controls in all experiments. 
2.1.7.2.1 Presenilin-1 transgenic mice 
Transgene expression of either human wildtype presenilin 1 (PS1wt) or presenilin 1 
with the M146L mutation (PS1M146L) is under the control of a HMGCoA-reductase 
promoter. This results in a strong neuronal expression but also ubiquitous expression in 
peripheral tissues (Leutner et al., 2000). The M146L mutation in the presenilin sequence 
leads to reduced proteolytic cleavage of PS1 resulting in increased protein levels of full-
length PS1 compared to PS1wt mice, which was shown in brain tissue as well as in MATERIALS AND METHODS 
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lymphocytes (Leutner et al., 2000). Expression of PS1wt and PS1M146L in 
lymphocytes was verified by RT-PCR of RNA isolated from splenic lymphocytes as 
described in chapter 2.2.8. PS1 mutations lead to increased amyloidogenic processing of 
endogenous mouse APP, however no plaques can be detected in the brains of these 
mice. This seems to be due to differences in certain amino acids between rodent and 
human Aβ peptide and consequently lower aggregation properties of rodent compared 
to human Aβ (Dyrks et al., 1993). 
2.1.7.2.2 PDGF-APP transgenic mice 
Transgenic mice bearing the 695 amino acid form of human APP with the Swedish 
(KM670/671NL
1), Dutch (E693Q
1) and London (V717I
1) mutations under the control 
of a PDGF promotor were generated as described by Blanchard and coworkers 
(Blanchard et al., 2003). These heterozygous PDGF-APP transgenic mice do not 
develop Aβ plaques until age of 18 months. 
2.1.7.2.3 Generation of double transgenic PDGF-APP/PS1 transgenic mice 
For generation of double transgenic mice, PDGF-APP transgenic male mice were 
crossed with and PS1M146L transgenic female mice. The offspring were genotyped as 
described in chapter 2.2.7, and double transgenic male mice were used for further 
generation of double transgenic mice. The presence of both overexpressed human 
mutant PS1M146L and human mutant APP in double transgenic PDGF-APP/PS1 mice 
leads to much higher formation of Aβ caused by increased amyloidogenic cleavage of 
APP by PS1. Consequently, PDGF-APP/PS1 double transgenic mice show accelereated 
plaque deposition compared to single transgenic PDGF-APP mice with first plaque 
formation at the age of 6 months (Blanchard et al., 2003). 
2.1.7.2.4 Thy1-APP transgenic mice 
The 751 amino acid form of human APP with the Swedish (KM670/671NL
1), and 
London (V717I
1) mutations under the control of the murine Thy1 promotor were 
generated as described by Blanchard and coworkers (Blanchard et al., 2003). The Thy1 
promotor leads to high and selective expression in neurons. Furthermore, a Kozak 
element was introduced into the 5’-UTR region of the APP gene for optimization of 
expression. The 751 amino acid form of APP contains the 56 amino acid Kunitz 
                                                 
1 Amino acid numbers refer to the amino acid numbering of APP770. MATERIALS AND METHODS 
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protease inhibitor (KPI) region and has been shown to result in altered APP processing 
with a higher yield of Aβ levels in cell culture (Ho et al., 1996). Consequently, Aβ 
levels are much higher in the Thy1-APP mouse model compared to PDGF-APP mice 
and plaque formation is accelerated with first plaques appearing already at 6 months of 
age (Blanchard et al., 2003). 
2.1.7.2.5 APP23 transgenic mice 
In cooperation with Thomas A. Bayer and Stephanie Schäfer, Homburg/Saar, Germany, 
brains from another APP transgenic mouse model, APP23 mice, were analysed for 
Cu/Zn-SOD activity. APP23 transgenic mice were generated by Novartis Pharma Inc., 
Basel, Switzerland, and have been first described in 1997 by Sturchler-Pierrat and 
coworkers (Sturchler-Pierrat et al., 1997). These mice express the 751 amino acid form 
of human APP with the Swedish double mutation (KM670/671NL) under the control of 
the murine Thy1-promotor. Plaque formation is detectable from an age of 6 months 
(Sturchler-Pierrat et al., 1997), and neuron loss in brains of these mice has been 
described (Calhoun et al., 1998). APP23 transgenic mice were housed at Novartis 
Pharma facilities as described in detail previously (Bayer et al., 2003), and frozen brain 
tissue of these mice at an age of 15 and 21 months was obtained for analysis of Cu/Zn-
SOD activity. 
2.1.7.3 Summary of mice used in this thesis 
The following cohorts of transgenic and non-transgenic mice were used: 
Non-transgenic male and female littermate controls at an age of 3-4 months, 13-15 
months and 19-22 months bred in the Biocenter facilities and 3 and 25 months old 
female mice obtained from Iffa Credo were used for studying age- and gender-related 
effects on oxidative stress metabolism. 
PS1wt, PS1M146L, PDGF-APP, PDGF-APP/PS1 and non-transgenic littermate 
controls were studied at an age of 3-4 months, 13-15 months and 19-22 months. 
Thy1-APP transgenic mice and littermate controls were studied at an age of 3, 7, 12, 14 
and 18 months. 
Brain tissue from 15 and 21 months old APP23 transgenic mice was used for analysis of 
Cu/Zn-SOD activity. MATERIALS AND METHODS 
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2.1.8 Human brain tissue 
2.1.8.1 Cohort #1 
Post mortem brain tissue samples from four different brain regions (frontal cortex, 
parietal cortex, temporal cortex and cerebellum) from 11 Alzheimer’s disease patients 
(7 female, 4 male) and 10 non-demented age-matched controls (6 female, 4 male) were 
obtained from the Brain Bank, Department of Neuropathology, Institute of Psychiatry, 
King's College London, United Kingdom. All brain tissue was obtained with consent of 
the next of kin and according to the Local Ethics Committee Guidelines of King's 
College London. The Alzheimer's disease patients fulfilled the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease 
and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD (Mirra 
et al., 1991). The normal aged control brains were obtained from individuals with no 
history of neurological or psychiatric illness. All cases were assessed histologically 
using the CERAD criteria and all of the AD cases had a 'definite' diagnosis of AD 
(Tierney et al., 1988). The details of tissue characteristics for the different brain regions 
are given in Table 2.1. 
Table 2.1: Characterization of brain tissue samples analyzed in cohort #1. 
Brain 
region 
Frontal 
cortex 
FC 
Parietal 
cortex 
PC 
Temporal 
cortex 
TC 
Cerebellum 
 
Cer 
Group  Ctrl  AD  Ctrl  AD  Ctrl  AD  Ctrl  AD 
total number 
of subjects 
male 
female 
10 
 
4 
6 
9 
 
3 
6 
8 
 
3 
5 
9 
 
4 
5 
9 
 
4 
5 
9 
 
3 
6 
10 
 
4 
6 
10 
 
4 
6 
Age at death 
(years) 
(mean ± 95% 
C.I.) 
76.5 ± 
6.9 
77.6 ± 
6.2 
76.9 ± 
8.9 
78.2 ± 
5.8 
75.0 ± 
6.9 
78.8 ± 
4.9 
76.5 ± 
6.9 
77.5 ± 
5.5 
Post mortem 
interval 
(hours) 
(mean  ± 95% 
C.I.) 
27.9 ± 
5.8 
21.9 ± 
7.2 
28.4 ± 
7.3 
19.1 ± 
7.2 
27.7 ± 
6.6 
22.3 ± 
7.5 
27.9 ± 
5.8 
20.5 ± 
7.1 
Apo E4 alleles 
none 
heterozygous 
homozygous 
 
6 
4 
0 
 
2 
3 
4 
 
5 
3 
0 
 
1 
3 
5 
 
5 
4 
0 
 
2 
2 
5 
 
6 
4 
0 
 
2 
3 
5 
Ctrl = Control group, AD = Alzheimer’s disease patients. 
 
The mean age at death was not significantly different between controls and AD patients. MATERIALS AND METHODS 
     57 
AD patients showed a tendency towards lower post mortem intervals in parietal cortex 
and cerebellum (parietal cortex p = 0.053, cerebellum p = 0.084, unpaired t-test). 
Furthermore, brains from AD patients had a tendency towards lower weight than control 
brains, which is indicative of the neurodegenerative changes and loss of brain mass 
associated with the disease: mean weight ± S.E.M. was 1138 ± 46.97 g for AD patients 
and 1239  ±  33.74  g for controls (p = 0.10, t-test). Gender were distributed equally 
between the two groups. Among the AD patients, there were no statistically significant 
differences in age at death or post mortem interval among male and female patients. The 
major cause of death was cardiac disease in the control group and bronchopneumonia in 
AD patients, with no clear difference between gender. Control and patient groups 
differed with respect to Apo E status: among the control group, 4 subjects were 
heterozygous Apo E4 carriers, among the AD patients, 3 subjects (2 female, 1 male) 
were heterozygous and 6 subjects homozygous carriers (3 female, 3 male) (see Table 
2.1). This distribution reflects the association of Apo E4 allele with an increased risk of 
Alzheimer’s disease (Saunders et al., 1993). Due to lack of controls homozygous for 
Apo E4 and insufficient numbers of non-Apo E4 AD patients, statistical analysis on the 
effect of Apo E on antioxidant metabolism could not be performed. All tissue samples 
were stored at –80°C until sample preparation. 
2.1.8.2 Cohort #2 
In this study, only brain tissue samples from temporal cortex were used. Post mortem 
brain tissue samples from 16 Alzheimer’s disease patients (8 female, 8 male) and 14 
non-demented age-matched controls (6 female, 8 male) was provided by the Institute for 
Brain Aging and Dementia Tissue Repository, Irvine, California, USA. The mean age at 
death was 76.0 ± 2.9 and 76.8 ± 2.4 years (mean ± 95 % C.I.) for control and AD group 
respectively, the mean post mortem interval was 4.87  ±  1.12 hours for controls and 
5.12 ± 1.35 hours for AD patients (mean ± 95 % C.I.) with no statistically significant 
differences. As already observed in samples from cohort #1, brains from AD patients 
had lower weight than control brains, which was statistically significant: mean weight ± 
S.E.M. was 1126 ± 42.19 g for AD patients and 1299 ± 39.61 g for controls (t-test : p < 
0.01). The major causes of death were failure of the cardiovascular system for the 
control group and respiratory failure for AD patients. The Apo E4 allele distribution 
was again inhomogenous between controls and AD patients: in the control group, 6 
subjects were non-Apo E4 carriers and 3 subjects were heterozygous carriers, but no MATERIALS AND METHODS 
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homozygous Apo E4 control subject was available. For 5 control subjects, the Apo E4 
genotype was not determined. Among the AD group, the Apo E4 allele was much more 
frequent: only 5 AD patients carried no E4 alleles, whereas 6 patients were 
heterozygous and 3 patients homozygous E4 carriers. For 2 AD patients, the Apo E 
genotype was not available. Of note, 3 subjects in the study carried one Apo E2 allele 
and these E2 carriers were all classified as controls, confirming that the Apo E2 allele 
exerts a protective effect against the development of AD (Corder et al., 1994; Talbot et 
al., 1994; Locke et al., 1995; Polvikoski et al., 1995; Hyman et al., 1996; Lippa et al., 
1997). In this cohort, histological analysis of plaque load and numbers of paired helical 
filaments in hippocampus and frontal cortex as well as Braak stage were available for 
some of the brain tissue samples. Details are given in Table 2.2. AD patients had higher 
plaque load and number of paired helical filaments (PHF) in hippocampus as well as 
frontal cortex, which was not statistically significant. As would be expected, AD 
patients always had Braak stages of 4 to 6, while controls had Braak stages of 3 or less. 
All samples were stored at –80°C until sample preparation. 
Table 2.2: Results of histopathological analysis of brain samples from cohort #2. 
Parameter  Plaque load 
Frontal 
cortex 
% 
Plaque load
Hippo-
campus 
% 
PHFs 
Frontal 
cortex 
% 
PHFs 
Hippo-
campus 
% 
BRAAK 
stage 
Group  Ctrl  AD  Ctrl  AD  Ctrl  AD  Ctrl  AD  Ctrl  AD 
mean  ± 
95% C.I. 
4.67   
± 8.03 
7.17   
± 2.78 
6.28   
± 7.92 
11.0 ± 
5.40 
5.34  
± 14.9
16.8 ± 
20.8 
6.96  
± 14.1
24.9  
± 18.9 
2.33  
± 1.44 
5.50  
± 0.88
number of 
subjects 
analyzed 
5 13 8 13 5  11  8  11  3 6 
p-value  0.3696 
(t-test) 
0.2628 
(t-test) 
0.4424 
(t-test) 
0.1308 
(t-test) 
p < 0.05 
(Mann-
Whitney-test)
 
2.2 Methods 
2.2.1 Preparation of tissues and cells 
2.2.1.1 Preparation of murine brain tissue 
Mice were killed by decapitation and brains were quickly removed. Cerebellum and 
brain stem were removed and the remaining cerebrum was washed once in 1 ml of 
EDTA-solution and twice in 1 ml of Tris buffer. The tissue was shock-frozen in cryo 
tubes submerged in liquid nitrogen and stored at –80°C prior to tissue homogenization. MATERIALS AND METHODS 
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2.2.1.2  Homogenization of human and murine brain tissue for 
determination of antioxidant enzyme activities and lipid peroxidation 
products 
For determination of antioxidant enzyme activities and lipid peroxidation, human or 
murine brain tissue was minced in the fivefold volume of cold 20  mM Tris buffer 
utilizing the Potter homogenizer at 1200 rpm with 10 strokes. Human brain samples 
from cohort #2 were minced with 20 strokes. 
An aliquot of this homogenate was diluted 1:1 with Tris buffer resulting in a 10 % 
(w/V) homogenate, centrifuged at 4°C and 3000 × g for 10 min and supernatants were 
collected and stored at –80°C for lipid peroxidation assays. The remaining homogenate 
was centrifuged at 4°C and 8500 × g for 10 min and supernatants were collected and 
stored at –80°C for determination of antioxidant enzyme activities. 
2.2.1.3 Isolation of murine splenic lymphocytes 
Mice were killed by decapitation and abdomens were sprayed with 70 % isopropanol to 
avoid adhesion of fur and ensure semiaseptic preparation. Spleens were quickly 
removed and submerged in cold RPMI buffer. Spleens were cut open at one end, cells 
were gently smoothed out with a bent 20-gauge injection needle, dissociated with a 
1000 µl pipette and passed through a 50 µm sieve. After centrifugation at 300 × g for 5 
min at room temperature, cells were again passed through 50 µm sieves and washed 
twice in RPMI buffer. For lysis of erythrocytes, cells were resuspended in 2 ml of 
hypotonic erythrocyte lysis buffer and kept on ice. After 2 min, lysis was stopped by 
adding 10 ml of RPMI buffer and washed twice with buffer. For determination of ROS 
with fluorescent dyes, live cells were counted via Trypan blue exclusion in a Neubauer-
chamber and adjusted to 1 Mio/ml. 
2.2.2 Assays of antioxidant enzymes 
2.2.2.1 Superoxide dismutase assay 
The assay of Cu/Zn-SOD is based on the method described by Nebot and coworkers 
(Nebot et al., 1993). For elimination of interfering substances and Mn-SOD-activity, 
Cu/Zn-SOD enzyme activity was assayed after an extraction procedure with a mixture 
of chloroform and ethanol (37.5 % CHCl3 / 62.5 % ethanol). Under these conditions, 
Cu/Zn-SOD is resistant to denaturation, whereas MnSOD is inactivated by the solvent MATERIALS AND METHODS 
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treatment. Brain homogenates were transferred to glass test-tubes and the 1.6-fold 
volume of CHCl3/ethanole mixture was added, followed by thorough vortexing and 
centrifugation for 10 min at 3000 × g and 4°C. The clear upper layers were collected 
and stored on ice until assaying on the same day. For elimination of interfering 
mercaptanes, immediately prior to assay, samples were incubated with 1,4,6-trimethyl-
2-vinylpyridinium for 1 min at 37°C. The assay is based on the photometrical 
measurement of the autoxidation rates of the chromophore BXT-01050 at 37°C and 
pH 8.8 measured in the presence Vs and absence Vc of sample. The autoxidation of 
BXT-01050 observed at 525 nm at alkaline pH and in oxygen-saturated assay buffer 
shows a sigmoidal shape with a maximum oxidation rate in a short linear range of 12 to 
18 seconds. Autoxidation of BXT-01050 is accelerated by the presence of SOD activity. 
For each sample and controls, absorbance was measured for 2 minutes with intervals of 
6 seconds. The maximum oxidation rates Vs for samples and Vc for controls with water 
instead of sample was calculated from the maximum changes in absorbance observed 
over an interval of 18 seconds. Vs was always assayed in duplicates and Vc was assayed 
in at least quadruplicates per test day. SOD activity was calculated from the Vs/Vc ratio 
of the autoxidation rates by the following equation: 
Vs/Vc = 1 + [ SOD-525 units / (α*SOD-525 units) + β ] 
where  α = 0.073 and β = 0.93 U. Values for α and β are empirically determined 
constants (Nebot et al., 1993). Activities were calculated from the above equation with 
Microsoft Excel software. One SOD-525 unit is defined as the activity that doubles the 
autoxidation background (Vs/Vc = 2).  The  commercially available Superoxide 
Dismutase Assay Kit from Calbiochem® was used for all experiments. 
2.2.2.2 Glutathione peroxidase assay 
The assay of cytosolic glutathione peroxidase GPx is based on the reaction described by 
Paglia and Valentine (Paglia and Valentine, 1967) using the commercially available 
Cellular Glutathione Peroxidase Assay Kit from Calbiochem®. Tert-
butylhydroperoxide t-BOOH was used as substrate. The reduction of t-BOOH by GPx 
consumes reduced glutathione GSH, which is restored in a coupled enzymatic reaction 
of glutathione reductase GR in the presence of excess oxidized glutathione disulfide 
GSSG and NADPH: 
GPx: t-BOOH + 2 GSH → t-BOH + GSSG + H2O MATERIALS AND METHODS 
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GR:  GSSG + NADPH + H
+ → 2 GSH + NADP
+ 
The decrease in absorbance of NADPH at 340 nm can be measured photometrically. 
One unit of GPx is defined as the activity that converts 2 µmol of reduced glutathione 
(corresponding to 1 µmol NADPH) per minute at 25°C. Enzyme activity x (expressed 
as [U/litre]) was calculated from the decrease in NADPH absorbance observed in an 
interval of 3 minutes by the following equation: 
GPx activity [U/litre] = x µmol NADPH / (min*l) = change in absorbance at 340 nm per 
minute and 1 cm path length [delta Abs/(min*cm)] / 0.00622 [(Abs*litre)/(µmol*cm)], 
where 0.00622 [(Abs*litre)/(µmol*cm)] is the extinction coefficient for NADPH at 
340 nm. To determine the specific change in absorbance due to GPx activity for each 
sample, blank rates that control for autoxidation of NADPH by t-BOOH in the absence 
of sample and a control rate for unspecific oxidation of NADPH by the sample in the 
absence of t-BOOH were substracted from the total sample rate. Enzyme activities were 
always assayed in duplicates. Activities were calculated from the above equation with 
Microsoft Excel software. Finally, the results were multiplied with the dilution factor in 
the assay and divided by the protein content determined as described in section 2.2.9. 
GPx activities of human brain tissue samples from cohort #1 were measured in the 
Genesys 5 Spectrophotometer with 1 cm cuvette path length. All other samples were 
analyzed in microtiter plates in the Victor™ plate reader with a 355 nm filter with 40 nm 
bandpass. A correction factor of 3.026 for the unknown path length in microtiter plates 
filled with 240 µl assay volume compared to 1 cm path length in photometer cuvettes 
was determined from at least three different control enzyme samples analyzed on two 
separate days. 
2.2.2.3 Glutathione reductase assay 
Glutathione reductase activity was assayed photometrically by measuring NADPH 
consumption during the enzymatic reaction: in the presence of GSSG and NADPH, 
glutathione reductase reduces GSSG and oxidizes NADPH to yield NADP resulting in a 
decrease of absorbance at 340 nm (Mizuno and Ohta, 1986). We used the commercially 
available Glutathione Reductase Assay Kit from Calbiochem®. One unit of GR is 
defined as the activity that converts 1 µmol of NADPH per litre per minute at 25°C. 
Enzyme activity x (expressed as [U/litre]) was calculated from the decrease in NADPH 
absorbance observed in an interval of 5 minutes by the following equation: MATERIALS AND METHODS 
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GR activity [U/litre] = x µmol NADPH / (min*litre) = change in absorbance at 340 nm 
per minute and 1 cm path length [delta Abs/(min*cm)] / 0.00622 
[(Abs*litre)/(µmol*cm)], 
where 0.00622 [(Abs*litre)/(µmol*cm)] is the extinction coefficient for NADPH at 340 
nm. 
Directly prior to the assay, brain homogenates were diluted with an appropriate amount 
of sample diluent to ensure a sample activity with an absorbance change in the linear 
range of the assay. To determine the specific change in absorbance due to GR activity 
for each sample, a blank rates that control for unspecific oxidation of NADPH by the 
sample in the absence of GSSG were substracted from the total sample rate. Enzyme 
activities were always assayed in duplicates. Activities were calculated from the above 
equation with Microsoft Excel software. Finally, the results were multiplied with the 
dilution factor in the assay and divided by the protein content determined as described 
in section 2.2.9. 
GR activities of human brain tissue samples from cohort #1 were measured in the 
Genesys 5 Spectrophotometer with 1 cm cuvette path length. All other samples were 
analyzed in microtiter plates in the Victor™ plate reader with a 355 nm filter with 40 nm 
bandpass. A correction factor of 2.9704 for the unknown path length in microtiter plates 
filled with 250 µl assay volume compared to 1 cm path length in photometer cuvettes 
was determined from at least three different control samples analyzed on 4 separate 
days. 
2.2.3 Lipid peroxidation measurement 
Lipid peroxidation products malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) 
were determined by a photometrical method utilizing the lipid peroxidation assay kit 
from Calbiochem® which is based on the method of Esterbauer and Cheeseman 
(Esterbauer and Cheeseman, 1990). The colorimetric reaction is a condensation of the 
respective aldehyde with 1-methyl-2-phenylindole yielding chromophores with 
absorption maxima at 586 nm. Both aldehydes react with 1-methyl-2-phenylindole in 
the presence of methanesulfonic acid and ferric iron, while substitution of 
methanesulfonic acid by hydrochloric acid allows measurement of MDA alone due to 
an irreversible cyclization reaction of hydroxyalkenals (Gerard-Monnier et al., 1998). 
HNE levels were calculated from absorbance levels obtained by substracting MATERIALS AND METHODS 
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absorbance of samples after hydrochloric acid reaction from absorbance after 
methanesulfonic acid reaction. Concentrations of both aldehydes were calculated from 
standard curves of each aldehyde at concentrations from 0 to 20 nmol/ml. Basal levels 
of MDA and HNE were assayed after incubation of samples at 37°C for 30  min. 
Stimulated levels of MDA were assayed under the same conditions in the presence of 
either 50 µmol/l FeCl3 for mouse brain homogenates or 100 µmol/l FeCl3  for human 
brain tissue homogenates. Of note, other 2,3-unsaturated 4-hydroxy-aldehydes would 
give a similar reaction as HNE, but as HNE is by far the most abundant lipid 
peroxidation product (Mlakar and Spiteller, 1996), the resulting increase in absorbance 
was attributed to the presence of HNE in the samples. 
2.2.4  Determination of reactive oxygen species in isolated 
splenic lymphocytes 
2.2.4.1 Flow cytometric analysis of splenic lymphocytes 
2.2.4.1.1 Basic principles of flow cytometry 
Flow cytometry is a sensitive and rapid method for detection of single cells. The term 
derives from the measurement (“metry”) of single cells (“cyto”) that are passed through 
a thin capillary in solution (“flow”). This capillary is hit by a laser beam, and cells that 
pass the beam lead to scattering of the laser light, which is detected at two different 
angles: (1) the forward scatter (FSC) at low angle and (2) the sideward scatter (SSC) at 
90°. The intensity of the FSC signal is related to the size of the cell: big cells lead to a 
higher scattering than small cells, whereas the intensity of the SSC signal is related to 
the morphology of the cell: cells with a lot of granules like granulocytes exhibit higher 
sideward scatter than cells with little cellular structure like lymphocytes. The intensities 
of FSC and SSC thus allow for identification of different cell populations and also for 
identification of intact cells, since apoptotic cells exhibit smaller size and higher 
granularity. 
Furthermore, cells can be stained with different fluorescent dyes that are excited by the 
laser light and emit fluorescent light which is also detected at 90°. The optical system 
contains different filters which allows for simultaneous detection of several different 
dyes in a single cell. Figure 2.1 shows a schematic representation of the optical system 
in the Becton Dickinson FACSCalibur system. MATERIALS AND METHODS 
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Figure 2.1: Optical system of Becton Dickinson FACSCalibur flow cytometer. 
a. Graphical illustration. 
b. Schematic sketch of optical paths. 
 
The FACSCalibur system contains a 488nm blue laser, photodetectors for FSC and SSC 
with 488nm filters as well as photodetectors for three different fluorescence channels 
with filters of 530 nm (green), 585 nm (orange) and 650 nm (red). These different 
wavelengths are termed channels FL1, FL2 and FL3 respectively. Each single cells thus 
gives signals consisting of intensities in FSC, SSC and the three fluorescence channels. 
Figure 2.2 depicts representative densitiy plots (a, d) and histograms (b, c) of murine 
splenic lymphocytes stained with anti-CD4-PE antibody and dihydrorhodamine 123 
(DHR). 
Lymphocytes are cells of rather small size and granularity and thus give an FSC 
intensity signal between 200 and 400 and SSC intensity of around 200 (see Figure 
2.2 a). Staining with anti-CD4-PE antibody leads to an increase in FL2 intensity for 
CD4 positive cells resulting in a peak in FL2 intensity at higher intensity between 10
2 
and 10
3, while other lymphocytes like CD8-positive cells and B-cells remain unstained 
and give a peak of low intensity in FL2 between 10
0 and 10
1  that represents the 
autofluorescence signal of cells (see Figure 2.2 b). Staining with the ROS-sensitive dye 
dihydrorhodamine 123 (DHR) leads to an increased signal intensity detected in FL1 
between 10
2 and 10
3 (Figure 2.2 c). Since all lymphocytes are stained with DHR due to 
basal ROS production in living cells, no autofluorescence can be detected at low MATERIALS AND METHODS 
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intensities in FL1. In Figure 2.2 d, lymphocytes simultaneously stained with anti-CD4-
PE antibody and DHR were analyzed by flow cytometry, and fluorescence intensities in 
channel FL2 (PE) was plotted versus channel FL1 (DHR). This allows for selection of 
double stained cells in the upper right quadrant, i.e. CD4-positiv lymphocytes stained 
with the ROS-sensitive dye DHR, and single stained cells in the lower right quadrant, 
i.e. all other lymphocytes. 
Although the detectors of the different fluorescence channels are equipped with filters 
specific for a certain wavelength range, most fluorescent dyes show a broad emission 
peak and thus some light is also detected in the adjacent fluorescence channels. This 
overlap of emission spectra of different dyes has to be corrected by compensation if 
cells are simultaneously stained with several dyes. Compensation is the electronic 
subtraction of unwanted signal to remove the effects of spectral spillover. It allows for 
the specific measurement of the fluorescence intensity of the dye that is meant to be 
detected in the channel. MATERIALS AND METHODS 
66 
ab
cd
 
Figure 2.2: Representative density blots (a, d) and histograms (b,c) of splenic 
lymphocytes analyzed by flow cytometry. 
a. Density plot of sideward scatter intensity (SSC-H, Y-axis) plotted vs forward scatter intensity 
(FSC-H, X-axis). 
b. Histogram plot of FL2 fluorescence intensity of splenic lymphocytes stained with anti-CD4-PE 
antibody. 
c. Histogram plot of FL1 fluorescence intensity of splenic lymphocytes stained with 
dihydrorhodamine DHR. 
d. Density plots of lymphocytes double stained with DHR (X-axis) and anti-CD4-PE antibody 
(FL2-H, Y-axis). 
See text for details. 
 
2.2.4.1.2 Flow cytometry data analysis 
For quantification of ROS in splenic lymphocytes, cells were stained with ROS-
sensitive dyes and analyzed by flow cytometry using Becton Dickinson FACSCalibur 
flow cytometer and Cell Quest Pro software. A minimum of 8000 events were recorded 
per single measurement. MATERIALS AND METHODS 
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Lymphocytes were gated according to size and morphology in the SSC vs. FSC density 
plot (see Figure 2.3 a), and only the gated events, i.e. lymphocytes, were evaluated for 
the intensities of ROS-sensitive fluorescent dyes. 
ab
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Lymphocytes
 
Figure 2.3: Gating strategy for lympocytes or lymphocyte subpopulations. 
a. Gating of lymphocytes from the SSC vs. FSC density plot. 
b. Gating of lymphocyte subpopulations from density plots after double staining with ROS-
sensitive dyes (DHR, X-axis) and PE-conjugated antibodies, e.g. anti-CD4-PE antibody (FL2-H, 
X-axis). 
See text for details. 
 
For quantification of mitochondrial ROS in lymphocyte subgroups, cells were double 
stained with dihydrorhodamine 123 (DHR) and anti-CD3-, anti-CD4- or anti-CD8-PE 
antibodies, and double stained cells were gated from the density plots of FL1 (DHR) vs 
FL2 (PE) in the upper right quadrant (see Figure 2.3 b). 
For quantification of ROS, a histogram plot of gated events was analyzed for the mean 
peak fluorescence intensity of the respective ROS-sensitive dye. A threshold of more 
than 10
1 was applied to histogram analysis, since intensity values of less than 10
1 
represent only the inherent autofluorescence signals of cells even in the absence of 
fluorescent dyes. 
2.2.4.2 Staining of lymphocytes with ROS-sensitive fluorescent dyes 
In general, 1 Mio/ml splenic lymphocytes were incubated with ROS-sensitive dyes at 
37°C, washed twice and resuspended for FACS analysis. Cells were analyzed 
immediately after staining and always kept on ice in the dark until measurement. 
If lymphocyte subsets were costained with PE-conjugated anti-CD3-, anti-CD4- or anti-MATERIALS AND METHODS 
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CD8-antibodies and IgG isotype control antibody, cells were incubated with DHR, 
washed, incubated with 2 µl/ml antibody solution for 15 min on ice, washed again and 
resuspended for FACS analysis. Phycoerythrin PE is a 240 kDa protein containing 34 
phycoerythrobilin fluorochromes per molecule resulting in high fluorescence intensities. 
When excited by 488 nm laser light it shows an emission maximum at 564 nm and can 
be detected in FL2. 
Basal levels of ROS were assayed immediately after lymphocyte isolation in RPMI 
medium. Simulation of ROS formation was assayed after transferring lymphocytes to 
HBSS buffer and incubation with hydrogen peroxide at 1, 10 or 100 µM for 30 min at 
37°C. After stimulation, cells were centrifuged, resuspended in RPMI medium and 
stained with ROS-sensitive dyes as described above. 
Table 2.3 gives details on the fluorescene excitation and emission maximum 
wavelengths, concentrations, incubation times and ROS-specificity of dyes used for 
determation of various ROS in splenic lymphocytes. All dyes show an excitation 
maximum close to 488  nm and can thus be easily excited with the laser in the 
FACSCalibur. 
Table 2.3: Properties and staining parameters of ROS-sensitive dyes used in lymphocyte 
studies. 
Dye 
max. 
Exc 
(nm) 
max. 
Em 
(nm) 
FACS 
detection 
channel 
Concen-
tration 
Incubation 
time at 
37°C 
Dye 
specificity 
Dihydro-
rhodamine 123 
(DHR) 
507  529  FL1  10 µM  15 min 
peroxides, 
hydroxyl 
radical, 
mitochondrial 
ROS, 
peroxynitrite 
Rhodamine 123 
(R123)  507  529  FL1  1 µM  15 min 
mitochondrial 
membrane 
potential, 
substrate of    
P-glycoprotein 
Dichlorodihydro-
fluorescein-
diacetate 
(DCFH-DA) 
504  525  FL1  10 µM  30 min 
peroxides, 
cytosolic ROS, 
peroxynitrite 
Dihydroethidium 
(DHE)  523  604  FL2  5 µM  30 min  superoxide 
Diamino-
fluorescein-2-
diacetate 
(DAF-2-DA) 
495  515  FL1  2.5 µM  30 min  nitric oxide 
Emission and excitation maximum wavelengths, detection channels, concentrations and 
incubation times as well as ROS specificity of fluorescent dyes used for studies of ROS in 
murine splenic lymphocytes. 
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Dihydrorhodamine 123 (DHR) is the non-fluorescent reduced form of rhodamine 123 
(R123). Due to its lipophilicity it can easily diffuse through cell membranes. Inside the 
cell, it is oxidized by various ROS to the positively charged fluorescent rhodamine 
R123 which is incorporated into mitochondria in a manner dependent on mitochondrial 
membrane potential (Johnson et al., 1980). Although several ROS could be responsible 
for oxidation of DHR (Hempel et al., 1999), it has been described to be most sensitive 
towards oxidation by hydrogen peroxide (Walrand et al., 2003), especially in the 
presence of cytochrome c oxidase in mitochondria (Royall and Ischiropoulos, 1993) and 
can thus be used as a marker for mitochondrial ROS production. The emission 
maximum of R123 is at 529 nm and can be detected in channel FL1. 
Since the fluorescence signal obtained after staining of lymphocytes with DHR depends 
on two parameters, i.e. (1) oxidation of the dye and (2) incorporation into mitochondria, 
lymphocytes were also stained with the oxidized form of DHR, R123, to correct for 
possible mitochondrial defects that would affect uptake of oxidized DHR. R123 is 
widely used in several cell models as an indicator of mitochondrial membrane potential 
(Johnson et al., 1980). In lymphocytes, however, uptake of R123 into mitochondria is 
not useful for measurement of mitochondrial membrane potential, but rather a marker 
for lymphocyte activation accompanied by increased mitochondrial mass and activity 
(Nairn et al., 1979; Ferlini et al., 1995). Furthermore, R123 is a substrate for P-
glycoprotein (Efferth et al., 1989), which is expressed in murine lymphocytes and 
affects R123 staining of cells (Bommhardt et al., 1994). 
Dichlorodihydrofluorescein-diacetate (DCFH-DA) is a widely used ROS-sensitive dye. 
In its diacetate form, it readily diffuses across cell membranes, but it is converted to the 
more hydrophilic alcohol dichlorodihydrofluorescein (DCFH) by esterases in the 
cytosol and retained in the cell (Bass et al., 1983; Rothe and Valet, 1990). However, 
despite the higher polarity of DCFH, some dye still leaks from the cells. Therefore, 
FACS measurements were completed within 30 minutes after staining. DCFH is 
oxidized by various ROS to the fluorescent dichlorofluorescein DCF (Hempel et al., 
1999). Mainly hydrogen peroxide in combination with enzymatic peroxidase activity 
seems to be responsible for DCFH oxidation (Walrand et al., 2003). DCFH does not 
stain mitochondria (Diaz et al., 2003), but rather seems to be oxidized by ROS in the 
cytosol. Thus, it is a useful tool for monitoring cytosolic ROS levels. The emission 
maximum of DCF is at 525 nm and can be detected in channel FL1. MATERIALS AND METHODS 
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Both DHR and DCFH have been described to be also oxidized by peroxynitrite (Crow, 
1997). Peroxynitrite is formed in a reaction of the superoxide radical anion with nitric 
oxide (Huie and Padmaja, 1993). In order to assess a possible contribution of 
peroxynitrite to DHR and DCFH oxidation in our studies, we also monitored superoxide 
and nitric oxide levels. 
Superoxide anions are readily detected by oxidation of dihydroethidium (DHE) (Rothe 
and Valet, 1990). Upon oxidation, DHE forms ethidium that intercalates with DNA 
double strands in the cell. When stacked between the bases, the π-electrons of the dye 
interact with the π-electron systems of the DNA bases, resulting in altered fluorescence 
properties (Carter et al., 1994). The emission maximum of this complex is at 604 nm 
and can be detected in the FL2 channel. 
Nitric oxide levels have been measured with daminofluorescein-2-diacetate (DAF-2-
DA) (Kojima et al., 1998). In its diacetate form, DAF-2-DA is readily membrane-
permeable and becomes hydrolyzed by cytosolic esterases within the cell yielding 
diaminofluorescein DAF. In the presence of nitric oxide, DAF is converted to a 
fluorescent triazole derivate that shows an emission maximum at 515 nm and is detected 
in FL1. 
2.2.4.3 FACS analysis of splenic lymphocytes 
The flow cytometer FACSCalibur was calibrated with Calibrite Beads to check that the 
instrument was working well. This analysis was repeated in regular intervals of 2 
months. 
For analysis of splenic lymphocytes, the instrument settings were determined in 
preliminary experiments and maintained for all other experiments. The voltages of FSC 
and SSC detectors were set to E00 and 443, with amplitude gains of 2.00 and 1.00 for 
FSC and SSC respectively. Since the ROS-sensitive dyes show different fluorescence 
intensities, specific instrument settings were used for each dye. Details are given in 
Table 2.4. MATERIALS AND METHODS 
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Table 2.4: Instrument settings for FACS analysis of ROS-sensitive dyes. 
Voltage  Compensation (%) 
Dye 
FL1  FL2  FL3  FL1-FL2  FL2-FL1  FL2-FL3  FL3-FL2 
DHR,  R123  600  594  681  1 36 0 49 
DCF  600  580  681  1 19 0 49 
DHE 575  628  582  1  19  32.6  47.2 
DAF-2-DA  600  594  681  1 0 0  49 
 
2.2.5 Western Blot analysis of APP and Aβ 
Mouse brain hemispheres were homogenized in 1 ml of Tris lysis buffer (2.1.4.3) 
containing Complete® protease inhibitor cocktail with 10 strokes at 1200 rpm in the 
Potter homogenizer. Homogenates were centrifuged at 15,000 × g for 30 min at 4°C. 
Supernatants were collected and stored at –80°C until Western blotting for analysis of 
APP and soluble Aβ. The residual pellet was used for lysis in SDS solution and 
determination of insoluble Aβ. 
2.2.5.1 Preparation of brain samples for determination of soluble Aβ 
Soluble Aβ is defined as the proportion that remains in the supernatant after 
ultracentrifugation at 100,000 × g for 1 hour (Kuo et al., 1996). The correct isolation of 
soluble Aβ by centrifugation at 15,000 × g was tested by comparison of supernatants 
from 15,000  × g and 100,000  × g  ultracentrifugations: subsequent to a 30  min 
15,000 × g centrifugation, aliquots of supernatants were either frozen for Western 
blotting or further centrifuged at 100,000 × g for 1 h. The intensitiy of the Aβ band at 
4 kDa is not diminished by ultracentrifugation indicating that soluble Aβ is already 
isolated by centrifugation at 15,000 × g (Figure 2.4). Interestingly, the C99 band at 12 
kDa is reduced after ultracentrifugation which might indicate that C99 is contained in a 
membrane-bound form. This would be expected since the γ-scretase complex is a 
membrane-bound protein complex that cuts C99 intramembraneously (Kimberly and 
Wolfe, 2003). MATERIALS AND METHODS 
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Figure 2.4: APP/Aβ Western blot of Tris lysates from Thy1-APP transgenic mouse brains. 
Brain lysates were electrophoresed either directly after centrifugation for 30 min at 15,000 × g 
(lanes 1, 3, 5, 7) or after a second centrifugation procedure for 1 hour at 100,000 × g (lanes 2, 
4, 6, 8). 
 
2.2.5.2 Preparation of brain samples for determination of insoluble Aβ 
Our protocol is a modification of the method first described by Kuo and coworkers 
(Kuo et al., 2001), who reported that insoluble amyloid beta aggregates and plaques of 
APP transgenic mice are soluble in buffers containing 2% SDS. After homogenization 
of brain hemispheres in Tris lysis buffer and centrifugation at 15,000 × g for 30 min, 
pellets were resuspended in 500 µl of 2 % SDS solution containing protease inhibitors 
(Complete®) and lysed by sonification with 20 pulses on the Branson sonifier set to 
level 2, 40  % output scale. Samples were kept on ice for 30 min, vortexed and 
centrifuged at 15,000 × g and 4°C for 30 min. Supernatants were collected and stored at 
–80°C until Western blotting. 
2.2.5.3 SDS PAGE and Western Blotting of brain extracts 
Brain extracts were diluted in an appropriate amount of NOVEX 2x sample buffer 
containing 5% mercaptoethanol to give a protein concentration of either 1 or 2 µg/µl. 
Samles were then heated to 70°C for 10 min followed by quick centrifugation. NuPage MATERIALS AND METHODS 
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Bis-Tris gels with a 4-12 % concentration gradient were used for gel electrophoresis of 
proteins. Gels were placed in the X-Cell electrophoresis system filled with running 
buffer, loaded with 15 µl of diluted samples (either 15 or 30 µg of protein per lane) and 
electrophoresis was started at 60 Volts for approximately 5 min to ensure concentration 
of samples at the rim of the gel. Then, voltage was set to 200 Volts and electrophoresis 
continued for 30 min. Gels were removed from the gel cassettes and blotted on PVDF 
or nitrocellulose membranes. 
2.2.5.4 Detection of APP, C99 and Abeta 
After blotting, membranes were boiled in PBS for 5 min, washed in TBST and blocked 
with milk for 1  h at room temperature, followed by a washing step and overnight 
incubation at 4°C with the primary antibody W0-2 (Abeta GmbH) at a concentration of 
8 µg in 15 ml TBST containing sodium azide at a concentration of 0.02 % (m/V). The 
next day, membranes were washed and incubated with horseraddish-peroxidase-
conjugated secondary antibody anti-mouse-IgG (Calbiochem) at a dilution of 1:1000 in 
TBST for 1 h at room temperature. After another washing procedure, membranes were 
exposed to ECL solution according to the suppliers instructions, bands were detected 
with Amersham Hyperfilm ™ ECL and films were developd with Kodak solutions. 
For densitometric analysis, films were scanned with Umax Astra 4000 scanner and 
Umax VistaScan software. Density of protein bands was evaluated with Kodak ds1D 
software. 
2.2.5.5 Detection of actin as loading control 
After detection of APP and Aβ with W0-2 antibody, blots were incubated in stripping 
buffer at room temperature for 1 hour, blocked in milk for 1 hour at room temperature 
and incubated for 1 hour with goat anti-actin antibody (Santa Cruz) at a dilution of 
1:140 in 15 ml TBST containing sodium azide at a concentration of 0.02 % (m/V). 
Finally, membranes were incubated with secondary horseraddish-peroxidase conjugated 
anti-goat IgG antibody (Calbiochem) 1:1000 for 1 h at room temperature. Between each 
incubation, blots were thoroughly washed in TBST. Detection of protein bands was 
performed as described above (2.2.5.4). 
2.2.6 Quantification of Aβ1-40 by ELISA 
For quantification of levels of soluble Aβ1-40, mouse brain hemispheres or human brain MATERIALS AND METHODS 
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tissue samples were homogenized in the fivefold volume of Tris lysis buffer (2.1.4.3) 
containing Complete® protease inhibitor cocktail with 10 strokes at 1200 rpm in the 
Potter homogenizer. Homogenates were centrifuged at 15,000 × g for 30 min at 4°C. 
Supernatants were collected and stored at –80°C until ELISA analysis of soluble Aβ1-40. 
Beta-Amyloid (Aβ) [1-40] colorimetric ELISA from Biosource GmbH was used for 
quantification of human Aβ1-40 levels. The assay specifically detects human Aβ1-40 
peptides and does not cross-react with human Aβ1-42 or Aβ1-43 peptides (according to the 
supplier’s information). Furthermore, it is specific for human vs mouse Aβ, since brain 
homogenates from non-transgenic mice containing endogenous mouse Aβ yielded 
absorption levels corresponding to 2.017 pg/ml, which is below the minimum detectable 
dose of 10 pg/ml. 
The preparation of standard and sample dilutions and the assay procedure were 
conducted according to the supplier’s instructions. All sample and standard dilutions 
contained PMSF for elimination of protease activity. The assay principle is based on a 
standard sandwich ELISA which utilizes precoated plates, rabbit anti-human Aβ1-40 N-
terminal detection antibody and anti-rabbit IgG peroxidase-conjugated secondary 
antibody. Color development is started by addition of tetramethylbenzidine TMB 
yielding a yellow chromophore with absorbance at 450 nm. Absorbance was measured 
in Victor2™ plate reader (Perkin Elmer, Germany) using a 450 nm filter with 7 nm 
bandpass. Sample concentrations were determined from the Aβ1-40 standard curve, 
which was obtained from plotting the absorption of the standard dilutions versus the 
standard concentrations and calculation of the best-fit polynomial fourth order equation 
(Prism Graph Pad® Software). 
2.2.7 Genotyping of transgenic mice 
2.2.7.1 DNA isolation from rodent tails 
DNA from rodent tails was isolated with DNAeasy tissue kit according to the supplier’s 
manual. All steps were conducted in aseptic conditions and great care was taken to 
minimize possible cross-contamination between samples. Briefly, tissue samples were 
obtained by tail biopsy from mice weakly anaesthesized by isoflurane inhalation and 
mice were simultaneously marked with numbered ear clips for identification. Tail 
biopsy samples were lysed by addition of lysis buffer and proteinase K during an MATERIALS AND METHODS 
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overnight incubation in a 55°C water bath. After brief centrifugation for removal of 
residual hair, DNA in samples was precipitated by addition of ethanolic buffer, pipetted 
onto DNeasy mini columns, followed by several washing steps with ethanolic buffers 
and a final elution in ethanol-free buffer. 
2.2.7.2 PCR reaction 
The DNA eluate obtained was used in PCR reactions for human PS1, human APP and 
mouse fetal hemoglobin MFH as internal control for DNA isolation from mouse tails. 
PCR was performed utilizing MasterTaq Kit from Eppendorf. The PCR reaction mix 
contained 1  U of Taq-DNA-polymerase, each 2  µM of sense and antisense primers, 
0.2 mM dNTPs (0.2 mM each), 1 µl of sample DNA eluate and buffers according to the 
manufacturer’s instructions in a total of 25 µl volume. Samples were heated to 94°C for 
5 minutes and PCR reaction was done in 35 cycles of 1 minute at 94°C, 1 minute at 
55°C and 1:30 minutes at 72°C. After the reaction, samples were kept at 4°C until gel 
electrophoresis and detection of DNA bands. 
The following primers were used: 
PS1 genotyping:  sense:  5’-TAA TTG GTC CAT AAA AGG C-3’ 
   antisense:  5’-GCA  CAG  AAA GGG AGT CAC AAG-3’ 
APP genotyping:  sense:  5’-GTA GCA GAG GAG GAA GAA GTG-3’ 
   antisense:  5’-CAT  GAC CTG GGA CAT TCT C-3’ 
MFH genotyping: sense:  5’-GAT CAT GAC CGC CGT AGG-3’ 
    antisense:  5’-CAT GAA CTT GTC CCA GGC TT-3’ 
The PCR reaction gives a 425 bp product for PS1, a 324 bp or 492 bp product for the 
695 or 751 amino acid form of APP, respectively, and a 311 bp product for MFH. 
Positive controls with PS1 DNA template and APP695 DNA template and negative 
controls with autoclaved Millipore® water were conducted for controlling the PCR 
reaction and for exclusion of possible PS1, APP or MFH contamination of reagents. 
2.2.7.3 DNA gel electrophoresis 
Samples obtained from PCR reactions were electrophoresed in 1  % agarose gels 
containing 8 µl/100 ml ethidium bromide solution. Gels were prepared by boiling 1 g 
agarose in 100 ml TAE buffer for a short interval and adding 8 µl ethidium bromide 
solution after the gel solution has cooled down to approximately 70°C. Gel were cast 
into a 10x25 cm BioRad Sub cell Model 96 gel tray with two 51-well combs and MATERIALS AND METHODS 
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allowed to cool down and consolidate for 1 hour. The gels were then placed in the Sub 
Cell Chamber filled with an appropriate amount of TAE buffer to ensure complete 
submersion of gels, and the anode chamber was filled with 20 µl ethidium bromide 
solution. 15  µl of PCR reaction samples were mixed with 1  µl Blue juice 10x gel 
loading buffer and loaded onto the gel. Samples were electrophoresed with Bio Rad 
Power Pac 300 set to 80 Volts for approximately 1 hour. Gels were then placed on a UV 
transilluminator (Herolab) and bands were photographed with a video camera 
(Variocam) and printed for analysis. 
The MFH (mouse fetal hemoglobin) control yielded a band of the desired length (311 
bp) for every mouse DNA sample indicating that DNA was correctly isolated. Also, 
PS1 and APP695 positive contols always gave bands at 425 bp and 324 bp respectively. 
No other bands were detected indicating specificity of primers. Negative controls with 
deionized water instead of DNA templates always gave negative results. 
Figure 2.5 shows a representative picture of DNA gels after PCR reactions. 
a b
P
S
1
 
p
o
s
.
 
C
t
r
l
.
P
S
1
 
n
e
g
.
 
C
t
r
l
.
M
F
H
 
n
e
g
.
 
C
t
r
l
.
M
F
H
 
s
a
m
p
l
e
 
1
M
F
H
 
s
a
m
p
l
e
 
2
P
S
1
 
s
a
m
p
l
e
 
2
P
S
1
 
s
a
m
p
l
e
1
A
P
P
 
6
9
5
 
p
o
s
.
 
C
t
r
l
.
M
F
H
 
p
o
s
.
 
C
t
r
l
.
A
P
P
 
7
5
1
s
a
m
p
l
e
3
A
P
P
 
7
5
1
s
a
m
p
l
e
4
M
F
H
 
s
a
m
p
l
e
4
M
F
H
 
s
a
m
p
l
e
3
 
Figure 2.5: Representative DNA gel electrophoresis for genotyping of transgenic mice. 
PCR reaction products of DNA samples isolated from mouse tails were electrophoresed on 
agarose gel stained with ethidiumbromide. 
a. PS1 and MFH PCR reaction products: samples 1 and 2 PS1wt transgenic mice. 
b. APP and MFH reaction products: sample 3 non-transgenic littermate, sample 4 Thy1-APP 
transgenic mouse. 
Note the different retention of DNA bands according to the length of the PCR product: MFH 311 
bp, APP695 324 bp, PS1 425 bp, APP751 492 bp. 
2.2.8  RT-PCR analysis of APP and PS1 expression in splenic 
lymphocytes 
RNA was isolated from splenic lymphocytes utilizing High Pure RNA Isolation Kit 
from Boehringer as described in the manufacturer’s protocol. Briefly, 5 million cells 
were resuspended in 200 µl PBS and lysis was started by adding 400 µl lysis buffer. MATERIALS AND METHODS 
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Samples were pipetted onto columns, washed, incubated with DNAse, followed by 
several washing steps, and finally eluted and stored at –20°C until RT-PCR. 
Concentration of RNA was determined photometrically by measuring absorbance at 
260 nm. The concentration was calculated from the following equation (Wilfinger et al., 
1997): 1 Abs260nm = 40 µg / ml RNA. 
Reverse transcriptase (RT) reactions were performed with SuperScript II Kit from 
Invitrogen. 64 ng of RNA were used for RT-PCR. For first strand cDNA synthesis, 
RNA samples were incubated with 0.5 µg/ml oligo-dT primers and 1 mM dNTPs for 5 
minutes at 65°C to ensure annealing of primers to poly-A-tails of messenger RNA. In a 
second step, buffer, DTT, magnesium and RNAse inhibitor were added, followed by 
incubation at 42°C for 2 min. Then, reverse transcriptase was added and samples were 
incubated at 70°C for 15 minutes for reverse transcriptase reaction. In a final step, 
residual RNA was digested by RNAse treatment at 37°C for 20 min. Reaction products 
were stored at –20°C until PCR. PCR of PS1 and APP DNA was performed as 
described above (2.2.7.2). 
2.2.9 Determination of protein content 
Protein content was determined according to the method of Lowry (Lowry et al., 1951). 
In the first step of the assay, proteins react with copper tartrate in alkaline solution. In 
the second step, Folin reagent
1 is added and reduced by the protein-copper-complexes 
resulting in a characteristic blue color due to several reduced species. The color shows 
an absorbance minimum at 405 nm and a maximum at 750 nm (Peterson, 1979). 
The commercially available BioRad DC Protein Assay Kit was used. Briefly, 5 µl of 
sample dilution were mixed with 25  µl of reagent A (copper tartrate solution) and 
200 µl of reagent B (Folin reagent) in a microtiter plate. If detergents were present in 
the samples, reagent A was supplemented with 3  % reagent S. Protein standard 
solutions were prepared from BSA at concentrations of 200 to 1600 µg/ml protein in the 
respective sample homogenization buffer. Standards and samples were assayed in 
triplicates. After addition of reagents, the plate was incubated at room temperature for 
15 to 30 min. Absorption was read in the ASYS Hitech Digiscan microtiter plate reader 
with a 620 nm filter. Protein concentration was calculated from the standard curve with 
Mikrowin 3.0 software (Mikrotek Laborsysteme GmbH, Overath, Germany). 
                                                 
1 Folin reagent is a solution containing phospho-molybdic and phospho-tungstic acid. MATERIALS AND METHODS 
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2.2.10 Calculations and Statistics 
For evaluation of test results, the mean of assay results per duplicate or triplicate and 
division by the protein content of each sample were calculated with Microsoft Excel 
software. The values calculated with Excel software were transferred into GraphPad 
Prism tables with 1 replicate per sample to calculate error bars. Thus, 1 value in the 
statistical analysis always represents the mean of the assay results from 1 individual 
sample, i.e. samples taken from one individual subject or one animal. If not otherwise 
stated, all data are given as mean ± S.E.M. 
If not otherwise stated, Gaussian distribution was assumed for all statistical evaluations 
of parametric data. For direct comparison of differences between two groups, two-tailed 
t-test was calculated. For comparison of three or more groups, One-way ANOVA was 
utilized. If two independent parameters (e.g. aging and gender) had an effect on a 
variable, Two-way ANOVA was calculated. Analysis of lymphocyte preparations with 
ROS-sensitive flourimetric dyes was subject to high interday variations due to 
methodological reasons. Therefore, experiments on each individual test day were 
conducted in groups of samples consisting of similar numbers of each male and female 
controls and transgenic animals. Consequently, for statistical analysis of differences 
between groups in lymphocyte preparations, two-tailed paired t-test and repeated 
measures ANOVA were employed. ANOVA was followed by post hoc student’s t-test. 
Exceptions from Gaussian distributions include (i) the Braak stageing in cohort #2, 
which represents non-parametric data, hence significance of differences between the 
two groups was calculated with Mann-Whitney-test, (ii) stimulated MDA levels in AD 
brain study cohort #2, which were distributed bimodally and analyzed by calculation of 
chi-sqared test, and (iii) quantification of Aβ1-40 in human brain tissue, as these 
measurements were strongly modulated by the Apo E4 genotype and obviously not 
Gaussian distributed, hence differences between groups were calculated with Mann-
Whitney-test. 
Correlation between two different parameters was calculated assuming the data were 
either Gaussian distributed, giving the Pearson correlation coefficient rP, or 
nonparametrically distributed, yielding the Spearman coefficient rS. All data from 
biochemical assays was assumed to underly Gaussian distribution. Exceptions were 
made for the quantification of Aβ1-40 in human brain tissue, as these measurements were 
strongly modulated by the Apo E4 genotype (see Figure 3.44, page 139). Therefore, for MATERIALS AND METHODS 
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all correlations with Aβ1-40 levels, a nonparametric distribution was assumed. 
Furthermore, the values for MMSE status, i.e. a measure of cognitive abilities, of 
controls and AD patients in cohort #2 were assumed to be nonparametrically 
distributed. 
All calculations were done using Graph Pad Prism 3.0 ™ software (GraphPad Software 
Inc., San Diego, CA, USA). Results were termed significant for p < 0.05. 
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3.1 Effects of aging and gender on ROS metabolism in 
brain tissue and peripheral cells of mice 
3.1.1 ROS metabolism in C57BL/6J mice during aging 
C57BL/6J mice were used to study several parameters related to oxidative stress during 
aging, since this mouse strain represents the genetic background of the Alzheimer’s 
disease transgenic mouse models analyzed in later parts of this thesis. The average life 
span of C57BL/6J mice is approximately 820 days (27 months) (Kunstyr and 
Leuenberger, 1975; Goodrick, 1977). In order to avoid a strong influence of natural 
selection caused by aging, 25 months old mice were chosen as maximum age group. 
Accordingly, female mice of 3 to 4 different age groups were used for aging studies: 
young mice (3 months old), middle-aged mice (13-15 months old), aged mice (19-22 
months old) and highly aged (25 months old) mice. Table 3.1 gives details on the total 
number of animals used for studies of oxidative stress parameters during aging. 
Table 3.1: Age groups and number of mice used for aging studies. 
age group  young  middle-
aged  aged  higly aged*
age (months)  3-4  13-15  19-22  25* 
number of animals n  29  9  11  7* 
* Brains but not splenic lymphocytes of 25 months old animals were analyzed. 
 
Brains from these mice were analyzed for levels of lipid peroxidation products 
malondialdehyde MDA and 4-hydroxynonenal HNE and for activities of antioxidant 
enzymes Cu/Zn-SOD, GPx and GR. Levels of lipid peroxidation product MDA were 
also studied after in vitro stimulation. Splenic lymphocytes were isolated for direct 
analysis of various reactive oxygen species in living cells with ROS-sensitive 
fluorescent dyes. 
3.1.1.1  Oxidative damage and enzymatic antioxidant defense in murine 
brains during aging 
In brains from C57BL/6J mice, pronounced changes in markers for oxidative stress and 
antioxidant defense were observed. Levels of lipid peroxidation products paradoxically 
decrease with aging in mouse brains, which was found for MDA (Figure 3.1 a), the 
more abundant product of lipid peroxidation, as well as for HNE (Figure 3.1 b), which 
is derived mainly from oxidation of PUFAs. While MDA levels decreased steadily with RESULTS 
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aging, HNE levels showed some fluctuation in 19-22 months old animals. This may 
however be related to the higher variation of values associated with HNE measurement. 
Nevertheless, the mean value of 19-22 months old animals was still lower than that of 
3-4 months old mice. 
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Figure 3.1: Effect of aging on levels of lipid peroxidation products in brains from 
C57BL/6J mice. 
Lipid peroxidation products were determined in brain homogenates from young (3 months old, 
n = 26), middle-aged (13-15 months old, n = 12), aged (19-22 months old, n = 11) and highly 
aged mice (25 months old, n = 7). 
a. Malondialdehyde (MDA) levels (nmol/mg protein). One-way ANOVA p < 0.0001. Post hoc t-
test ** p < 0.01, *** p < 0.001 vs 3 months old mice. 
b. 4-Hydroxynonenal (HNE) levels (nmol/mg protein). One-way ANOVA p < 0.05. Post hoc t-test 
* p < 0.05, ** p < 0.01 vs 3 months old mice. 
 
As indirect markers of ROS metabolism, activities of several antioxidant enzymes were 
analyzed. These enzymes serve to detoxify ROS in subsequent reactions: Cu/Zn-
dependent superoxide dismutase Cu/Zn-SOD catalyses the dismutation of superoxide 
radical anions, which are mainly formed in the mitochondrial respiratory chain. The 
Cu/Zn-SOD reaction yields molecular oxygen and hydrogen peroxide H2O2, which is 
further decomposed either by catalase – at high concentrations of H2O2 – or by 
glutathione peroxidase GPx already at lower concentrations. Since catalase activity is 
low in brain, GPx activity represents the more important H2O2-utilizing enzyme under 
physiological conditions and was therefore analyzed. The GPx reaction requires and 
consumes reduced glutathione as cofactor, which is regenerated by the glutathione 
reductase GR reaction. Therefore, the reactions of Cu/Zn-SOD, GPx and GR work in 
concert to detoxify ROS. 
In good accordance with decreased levels of lipid peroxidation products, we found that 
activities of antioxidant enzymes are increased in aged mice (Figure 3.2). However, 
changes in enzyme activity were not uniform for the different enzymes. While activity RESULTS 
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of GPx steadily increased with aging (Figure 3.2 b), activities of Cu/Zn-SOD and GR 
increased until an age of 19-22 months but declined in 25 months old animals to the 
levels of young mice (Figure 3.2 a and c respectively). 
For analysis of ROS detoxification capacity in a functional assay, we conducted 
experiments of lipid peroxidation stimulation in vitro. Addition of ferric iron FeCl3 to 
brain homogenates propagates formation of reactive oxygen species via Fenton or 
Haber-Weiss reactions and thus favours decomposition of lipids to aldehydes. 
Accordingly, increased levels of MDA can be detected in brain homogenates after in 
vitro stimulation (Figure 3.3  a). During aging, stimulation of lipid peroxidation is 
decreased in 13-15 months old mice compared to young mice, but increases thereafter 
in older mice converging to the levels of young mice (Figure 3.3 b). 
These results show that antioxidant enzyme activities, rising with age, can protect 
against stimulation of lipid peroxidation in middle-aged mice but fail to do so in aged 
mice. Nevertheless, oxidative damage is not a prominent feature of aged brains since 
basal levels of lipid peroxidation were decreased in aged animals, which may be 
causally related to increased activities of antioxidant enzymes. RESULTS 
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Figure 3.2: Activities of antioxidant enzymes in brains from C57BL/6J mice during aging. 
Antioxidant enzyme activities were determined in brain homogenates from young (3 months old, 
n = 26), middle-aged (13-15 months old, n = 15-16), aged (19-22 months old, n = 11) and highly 
aged mice (25 months old, n = 7). 
a. Activity of Cu/Zn-superoxide dismutase Cu/Zn-SOD (U/mg protein). One-way ANOVA 
p < 0.01. Post hoc t-test ** p < 0.01 vs 3 months old mice, (+) p < 0.08 vs 13-15 months old 
mice. 
b. Activity of glutathione peroxidase GPx (mU/mg protein). One-way ANOVA p < 0.01. Post hoc 
t-test * p < 0.05, ** p < 0.01 vs 3 months old mice. 
c. Activity of glutathione reductase GR (mU/mg protein). One-way ANOVA p < 0.05. Post hoc 
t-test ** p < 0.01 vs 3 months old mice, (+) p = 0.1 vs 19-22 months old mice. 
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Figure 3.3: Stimulation of lipid peroxidation with FeCl3 in young mice (a) and differences 
in during aging (b). 
a. Effect of stimulation of lipid peroxidation with 50  µM FeCl3 for 30 min at 37°C in brain 
homogenates from young mice (3 months old, n = 22). 
b. Levels of stimulated MDA (nmol/mg protein) in brain homogenates from young (3 months old, 
n = 22), middle-aged (13-15 months old, n = 9), aged (19-22 months old, n = 8) and highly aged 
(25 months old, n = 6) mice. One-way ANOVA p < 0.05. Post hoc t-test * p < 0.05 vs 3 months 
old control mice, + p < 0.05 vs 13-15 months old mice, # p < 0.05 vs 19-22 months old mice. 
 
3.1.1.2 ROS levels in splenic lymphocytes during aging 
In addition to studying surrogate markers for oxidative stress at the levels of lipid 
peroxidation products in brains from aged mice, we furthermore isolated splenic 
lymphocytes to measure levels of reactive oxygen species (ROS) directly in living cells. 
Analysis of different ROS in splenic lymphocytes showed no clear elevation with aging. 
Although oxidation of the mitochondrial ROS-sensitive dye DHR is increased in 13-15 
months and 19-22 months old mice compared to young mice, this proved not to be 
statistically significant. Only a tendency towards increased ROS levels was observed in 
13-15 months old mice (Figure 3.4 a). As previous studies in our group had observed a 
higher vulnerability of CD4-positive lymphocytes to undergo apoptosis in AD patients 
(Schindowski et al., 2003), we were interested if CD4-positive lymphocytes display 
different changes during aging compared to the whole lymphocyte population. We 
therefore additionally stained lymphocytes with a fluorescent anti-CD4-antibody and 
evaluated only double-stained cells. In the subset of CD4-positive lymphocytes similar 
results as in the whole lymphocyte population were observed – with highest DHR 
staining in 13-15 months old animals – although DHR oxidation declined significantly 
from 13-15 months old to 19-22 months old animals (Figure 3.4  b). The increased 
fluorescence of DHR in middle-aged mice is not due to better dye retention in cells as 
evidenced by staining with the oxidized form of DHR, R123 (Figure 3.4 c). Staining 
with other ROS-sensitive dyes DCFH-DA for cytosolic ROS and DHE for superoxide RESULTS 
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radical anions showed no age-associated changes (Figure 3.4  d and e respectively). 
Only a prominent increase in nitric oxide levels with aging was observed (Figure 3.4 f). 
Although the dyes DHR and DCFH-DA have been described to be oxidized by 
peroxynitrite, the observation that nitric oxide levels are elevated in aged mice but DHR 
and DCFH-DA oxidation is not simultaneously increased suggests that – at least under 
our conditions – DHR and DCFH-DA are not significantly oxidized by peroxynitrite. 
This is furthermore supported by the observation that oxidation of DHE, which is 
specifically oxidized by superoxide radical anions, is not changed during aging. Since 
superoxide radicals are required for formation of peroxynitrite, is seems unlikely that 
the increased oxidation of DHR in middle-aged animals is caused by peroxynitrite. 
Overall the results of this aging study provide evidence that adaptive processes like 
upregulation of antioxidant enzymes take place during aging resulting in efficient 
detoxification of reactive oxygen species and prevention of oxidative damage in brains 
from mice. Moreover, the findings on brain tissue are in good accordance with the 
analysis of ROS in splenic lymphocytes, since in this cell type similarly no 
accumulation of ROS with aging was observed, suggesting that the normal 
physiological aging process is not inevitably accompanied by excessive ROS 
accumulation. RESULTS 
88 
3-4 months
13-15 months
19-22 months
50
75
100
125 (*)
+
C
D
4
+
 
l
y
m
p
h
o
c
y
t
e
s
M
F
I
 
D
H
R
%
 
o
f
 
c
o
n
t
r
o
l
3-4 months
13-15 months
19-22 months
50
75
100
125
(*)
M
F
I
 
D
H
R
%
 
o
f
 
c
o
n
t
r
o
l
3-4 months
13-15 months
19-22 months
50
75
100
125 *
M
F
I
 
D
A
F
2
-
D
A
%
 
o
f
 
c
o
n
t
r
o
l
3-4 months
13-15 months
19-22 months
50
75
100
125
M
F
I
 
R
1
2
3
%
 
o
f
 
c
o
n
t
r
o
l
3-4 months
13-15 months
19-22 months
50
75
100
125
M
F
I
 
D
H
E
%
 
o
f
 
c
o
n
t
r
o
l
3-4 months
13-15 months
19-22 months
50
75
100
125
M
F
I
 
D
C
F
H
-
D
A
&
 
o
f
 
c
o
n
t
r
o
l
ab
cd
ef
 
Figure 3.4: Levels of ROS in splenic lymphocytes fromC57BL/6J mice during aging. 
ROS levels were determined in splenic lymphocytes from young (3 months old, n = 14), middle-
aged (13-15 months old, n = 7) and aged (19-22 months old, n = 10) mice. Values are given as 
percentage of mean fluorescence intensity MFI relative to the mean of 3 months old control 
mice. 
a. Staining with ROS-sensitive dye dihydrorhodamine DHR. One-way ANOVA: n.s. Post hoc 
t-test (*) p < 0.1. 
b. Staining of CD4-positive lymphocytes with ROS-sensitive dye dihydrorhodamine DHR. One-
way ANOVA: p  =  0.06. Post hoc t-test (*) p < 0.1 vs 3-4 months old mice, + p < 0.05 vs 
13-15 months old mice. 
c. Staining with rhodamine R123. One-way ANOVA: n.s. 
d. Staining with ROS-sensitive dye dihydrodichlorofluorescein diacetate DCFH-DA. One-way 
ANOVA: n.s. 
e. Staining with superoxide-sensitive dye dihydroethidium DHE. One-way ANOVA: n.s. 
f. Staining with nitric oxide-sensitive dye DAF-2-DA. One-way ANOVA: p < 0.05. Post hoc t-test 
* p < 0.05. 
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3.1.2 Gender differences in ROS metabolism in C57BL/6J mice 
during aging 
During the experiments in this thesis, gender differences in antioxidant parameters in 
mice during aging were observed. Table 3.2 gives details on the number of animals used 
for studies of differences between male and female mice in oxidative stress parameters. 
Table 3.2: Age groups and numbers of mice used for studies of gender differences 
during aging. 
age (months)  3-4  13-15  19-22 
gender  female male  female male  female  male 
number of animals  29  12  16  11  11  10 
 
Brains from these mice were analyzed for levels of lipid peroxidation products MDA 
and HNE and for activities of antioxidant enzymes Cu/Zn-SOD, GPx and GR. Levels of 
lipid peroxidation product MDA were also studied after in vitro stimulation. Splenic 
lymphocytes were isolated for direct analysis of reactive oxygen species with 
fluorescent dyes. 
3.1.2.1 Gender differences in oxidative damage and enzymatic antioxidant 
defense in murine brains 
In brains from male and female mice, prominent differences in levels of lipid 
peroxidation products exist. Female mice show lower levels of MDA (Figure 3.5 a) and 
HNE (Figure 3.5 b) in different age groups. The relative difference was highest for 
HNE levels in 13-15 months old mice where female mice exhibited only 62 percent of 
the HNE levels relative to male mice of the same age group, although this marginally 
failed to reach statistical significance (p = 0.055) due to the rather large variation of 
values. 
Analysis of antioxidant enzyme activities revealed that activity of GPx is significantly 
increased in female compared to male mice (Figure 3.6 b), while no gender differences 
were observed in activities of Cu/Zn-SOD and GR (Figure 3.6 a and c respectively). 
Changes in GPx activity ranged from 10 % higher activity in 3-4 months old female 
mice to a 21  % and 15  % increase in 13-15 months and 19-22 months old mice, 
respectively. RESULTS 
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Figure 3.5: Gender differences in levels of lipid peroxidation products in mouse brains 
during aging. 
Lipid peroxidation products were analyzed in each female and male young (3 months, n = 26 
female, n = 12 male), middle-aged (13-15 months, n = 12 female, n = 7 male) and aged mice 
(19-22 months old, n = 11 female, n = 9-10 male). Values are presented as percentage relative 
to controls (% of 3 months old female mice). 
a. Levels of malondialdehyde MDA. Two-way ANOVA p < 0.001 effect of gender, p < 0.05 effect 
of age, interaction n.s. Post hoc t-test: * p < 0.05 male vs female mice of the same age group. 
b. Levels of 4-Hydroxynonenal HNE. Two-way ANOVA p < 0.01 effect of gender, effect of age 
n.s., interaction n.s. Post hoc t-test: (*) p = 0.055 male vs female mice of the same age group. 
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Figure 3.6: Gender differences in activities of antioxidant enzymes in mouse brains 
during aging. 
Legend continued on page 91. 
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Legend to figure 3.6 (continued): 
Enzyme activities were analyzed in each female and male young (3 months, n = 29 female, 
n  =  12 male), middle-aged (13-15 months, n  =  15-16 female, n = 10 male) and aged mice 
(19-22 months old, n = 11 female, n = 10 male). Values are presented as percentage relative to 
controls (% of 3 months old female mice). 
a. Activity of Cu/Zn-superoxide dismutase Cu/Zn-SOD. Two-way ANOVA effect of gender n.s., 
effect of age p = 0.06, interaction n.s. 
b. Activity of glutathione peroxidase GPx. Two-way ANOVA p < 0.001 effect of gender, p < 0.05 
effect of age, interaction n.s. Post hoc t-test: (*) p < 0.1, * p < 0.05, *** p < 0.001 male vs female 
mice of the same age group. 
c. Activity of glutathione reductase GR. Two-way ANOVA effect of gender n.s., effect of age 
p < 0.0001, interaction n.s. 
 
To test whether this difference in GPx activity might be of functional relevance in 
protection against ROS, levels of lipid peroxidation product MDA were analyzed after 
in vitro stimulation with FeCl3. Interestingly, female mice show lower formation of 
MDA under these conditions compared to male mice (Figure 3.7). 
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Figure 3.7: Gender differences in formation of lipid peroxidation product MDA after in 
vitro stimulation with FeCl3. 
Formation of malondialdehyde MDA was stimulated with 50 µM FeCl3 for 30 min at 37°C in 
brain homogenates from each female and male young (3 month old, n = 22 female, n = 9 male) 
mice, middle-aged (13-15 months old, n = 9 female, n = 8 male) and aged (19-22 months old, 
n = 8 female, n = 10 male) mice. Values are presented as percentage relative to controls (% of 
3 months old female mice). 
Two-way ANOVA: p < 0.05 effect of gender, p < 0.05 effect of age, interaction n.s. Post hoc t-
test: * p < 0.05 male vs female 3 months old mice. 
 
These results indicate that brains from female mice are effectively protected against 
oxidative damage as evidenced by lower levels of basal as well as stimulated lipid 
peroxidation products compared to male mice. The higher acitivity of the antioxidant 
enzyme GPx in brains from female mice might contribute to these observations. RESULTS 
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3.1.2.2 Gender differences in ROS levels in splenic lymphocytes 
Apart from gender differences in oxidative parameters in brain tissue, differences 
between male and female mice were also observed in splenic lymphocytes. In 
accordance with lower levels of lipid peroxidation products in brains from female mice, 
female mice show similarly reduced levels of mitochondrial ROS in splenic 
lymphocytes as evidenced by staining with DHR (Figure 3.8 a). A similar trend was 
seen for the subgroup of CD4-positive lymphocytes (Figure 3.8  b). This gender 
difference is not due to different dye retention in cells, which was controlled for by 
staining with R123 (Figure 3.8 c). Interestingly, levels of cytosolic ROS detected with 
DCFH-DA and levels of superoxide anions were not changed in female mice compared 
to male mice (Figure 3.8 d and e respectively). However, we noted a profound gender 
difference in levels of nitric oxide that was more pronounced in aged mice (Figure 
3.8 f). 
Since nitric oxide levels are increased in lymphocytes from female mice but DHR 
oxidation is decreased, it seems unlikely that DHR is oxidized to a significant part by 
peroxynitrite under these conditions. 
Overall the results indicate that profound gender differences in oxidative parameters 
exist between female and male mice. Female mice show reduced ROS levels in 
lymphocytes and also lower levels of lipid peroxidation products in brain tissue 
suggesting that female mice have lower levels of ROS in several tissues. Moreover, the 
higher activity of GPx in brains from female mice can significantly contribute to the 
observed lower levels of lipid peroxidation compared to male mice, supporting the 
concept that antioxidant enzymes are functionally involved in protection against 
damage by ROS. 
 
 
Figure 3.8 (page 93): Gender differences in ROS levels in splenic lymphocytes during 
aging. 
ROS levels were determined in splenic lymphocytes from each female and male young (3-
4 months old, n = 14-19 female, n = 4-5 male), middle-aged (13-15 months old, n = 7-13 female, 
n = 4-9 male) and aged mice (19-22 months old, n = 8 female, n = 10 male). Values are given 
as percentage of mean fluorescence intensity MFI relative to the mean of 3-4 months old female 
control mice. 
a. Staining with ROS-sensitive dye dihydrorhodamine DHR. Two-way ANOVA: p < 0.001 effect 
of gender, effect of aging n.s, interaction n.s. Post hoc t-test * p < 0.05 female vs male mice of 
the same age group. 
Legend continued on page 93. RESULTS 
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Legend to figure 3.8 (continued):  
b. Staining of CD4-positive lymphocytes with ROS-sensitive dye dihydrorhodamine DHR. Two-
way ANOVA: p = 0.06 effect of gender, p = 0.06 effect of aging, interaction n.s. 
c. Staining with rhodamine R123. Two-way ANOVA: n.s. 
d. Staining with ROS-sensitive dye DCFH-DA. Two-way ANOVA: n.s. 
e. Staining with superoxide-sensitive dye dihydroethidium DHE. n.d. = not determined. Two-way 
ANOVA over 13-15 and 19-22 months old age groups n.s. 
f. Staining with nitric oxide-sensitive dye DAF-2-DA. Two-way ANOVA: p < 0.01 effect of 
gender, effect of age n.s., interaction n.s. Post hoc t-test ** p < 0.01 female vs male 19-22 
months old mice. RESULTS 
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3.2 ROS metabolism in transgenic AD mouse models 
For studies of ROS metabolism in AD transgenic mice, different mouse models (see 
also 2.1.7.2, page 53 et seqq.) were studied in separate experiments: 
•  In one large set of experiments, mice transgenic either for (i) human wild-type 
presenilin 1 (PS1wt), (ii) human mutant presenilin 1 (PS1M146L), (iii) human 
APP695 with the Swedish, Dutch and London mutations (PDGF-APP) or (iv) 
double transgenic mice bearing mutant APP and mutant presenilin 1 (PDGF-
APP/PS1) were studied. PS1 transgenic mice display increased levels of 
endogenous rodent Aβ, but show no formation of Aβ plaques. Single PDGF-
APP transgenic mice form low levels of human Aβ, however, plaques could not 
be detected up to an age of 18 months, which was the oldest age group studied 
(Blanchard et al., 2003). In contrast, double transgenic PDGF-APP/PS1 mice 
display Aβ plaques in their brains from an age of 6 months. All mice express the 
respective transgene in brain tissue which was used for studies of lipid 
peroxidation products and antioxidant enzyme activities. The PS1wt and 
PS1M146L animals express the respective transgenic PS1 under the control of 
the HMG-CoA reductase promotor in brain tissue and in lymphocytes and could 
be used for direct analyis of ROS in living cells with fluorescent dyes, while 
expression of the APP transgene under control of the PDGF-promotor was not 
detectable in lymphocytes excluding APP transgenic mice from these 
experiments. 
•  In a different set of experiments, mice bearing mutant APP751 with the Swedish 
and London mutations under the control of a murine, neuron-specific Thy1-
promotor were studied (Thy1-APP). Only brains from these mice were studied 
since the transgenic APP is not expressed in lymphocytes. 
Furthermore, in cooperation with Thomas Bayer and Stephanie Schäfer (Homburg, 
Saar), brain tissue from APP23 transgenic mice could be assayed for Cu/Zn-SOD 
activity. Similar to Thy1-APP transgenic mice, APP23 mice express human APP751 
with the Swedish double mutation under the control of the murine, neuron-specific 
Thy1-promotor. 
Non-transgenic age- and gender-matched littermate animals (non-tg) were used as 
controls in all experiments. RESULTS 
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3.2.1  ROS metabolism in PDGF-APP and/or PS1 transgenic 
mice 
Brains from non-transgenic littermate mice and PS1wt, PS1M146L, PDGF-APP or 
PDGF-APP/PS1 transgenic mice at three different age groups were studied for levels of 
lipid peroxidation products and activities of antioxidant enzymes. Due to the onset of 
plaque deposition in PDGF-APP/PS1 transgenic mice at 6 months, the age groups were 
chosen as follows: young (3-4 months old) mice without any Aβ plaques, middle-aged 
(13-15 months old) mice of which the double PDGF-APP/PS1 transgenic display 
moderate plaque load in their brains, and aged (19-22 months old) mice, of which 
double PDGF-APP/PS1 transgenic mice have widespread plaques. Additionally, levels 
of ROS were determined in splenic lymphocytes from non-transgenic littermate mice 
and PS1wt or PS1M146L transgenic mice. Table 3.3 gives details on total numbers and 
age of animals used for these experiments. Gender differences in lipid peroxidation 
products and glutathione peroxidase activity in brains and in ROS levels in splenic 
lymphocytes during aging had been observed previously. Therefore, similar numbers of 
male and female mice were chosen for each group of transgenic mice in order to avoid 
possibly confounding gender effects. 
Table 3.3: Numbers and age of transgenic animals used for studies. 
Transgene  non-tg  PS1wt  PS1M146L PDGF-APP  PDGF-
APP/PS1 
age group  number of animals used 
young 
(3-4 months)  23 11 11 15 12 
middle-aged 
(13-15 months)  27 18 13 15 14 
aged 
(21 months) 
cohort #1* 
7* - 7* -  - 
aged 
(19-22 months) 
cohort #2 
21 10 12  7  8 
* Only splenic lymphocytes from these animals were studied for ROS levels. 
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3.2.1.1 Oxidative damage and enzymatic antioxidant defense in transgenic 
mouse brains 
In general, neither levels of lipid peroxidation products MDA and HNE nor activities of 
antioxidant enzymes were changed in 3-4 months old and 13-15 months old transgenic 
mice compared to non-transgenic littermate control mice (data not shown). 
The only difference between transgenic mice was observed in aged animals, where 
levels of HNE were increased in PS1M146L compared to PS1wt transgenic mice 
(Figure 3.9 b). 
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Figure 3.9: Lipid peroxidation products in aged transgenic mice. 
Brain homogenates from 19-22 months old non-transgenic littermate control mice (non-tg, 
n = 20-21) and mice transgenic for wildtype PS1 (PS1wt, n = 9-10), mutant PS1 (PS1M146L, 
n  =  11-12), mutant APP (PDGF-APP, n  =  6-7) or double transgenic mice expressing both 
mutant PS1 and mutant APP (PDGF-APP/PS1, n  =  7-8) were analyzed for MDA and HNE 
levels. 
a. MDA levels (nmol/mg protein). One-way ANOVA n.s. 
b. HNE levels (nmol/mg protein). One-way ANOVA n.s. Post hoc t-test * p < 0.05 PS1wt vs 
PS1M146L mice. 
 
Analysis of antioxidant enzyme activities however revealed no differences between 
transgenic mice (Figure 3.10). 
Furthermore, no differences in levels of MDA after in vitro stimulation of lipid 
peroxidation with 50 µM FeCl3 could be detected (data not shown). 
These results indicate that changes in HNE levels in PS1M146L transgenic mice occur 
independently of antioxidant enzyme activities. RESULTS 
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Figure 3.10: Activities of antioxidant enzymes in aged transgenic mice. 
Brain homogenates from 19-22 months old non-transgenic littermate control mice (non-tg, 
n  =  21) and mice transgenic for wildtype PS1 (PS1wt, n  =  9-10), mutant PS1 (PS1M146L, 
n = 12), mutant APP (PDGF-APP, n = 7) or double transgenic mice expressing both mutant PS1 
and mutant APP (PDGF-APP/PS1, n = 7-8) were analyzed for activities of antioxidant enzymes 
Cu/Zn-SOD, GPx and GR. 
a. Cu/Zn-SOD activity (U/mg protein). One-way ANOVA n.s. 
b. GPx activity (mU/mg protein). One-way ANOVA n.s. 
c. GR activity (mU/mg protein). One-way ANOVA n.s. RESULTS 
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3.2.1.2 Analysis of splenic lymphocytes from PS1 transgenic mice 
3.2.1.2.1 Expression of human PS1wt and PS1M146L in lymphocytes from 
PS1 transgenic mice 
The expression of human PS1 in lymphocytes from transgenic mice has been studied 
previously at the protein level (Schindowski, 2001). In order to verify PS1 expression in 
lymphocytes, RNA was isolated from cells and subjected to RT-PCR. DNA products 
were analyzed in ethidium bromide gels. Figure 3.11 shows a representative agarose gel 
of PCR products from RNA samples of splenic lymphocytes. As expected, human PS1 
is expressed in lymphocytes from PS1wt and PS1M146L transgenic animals, whereas 
no human transgenic PS1 RNA could be detected in lymphocytes from non-transgenic 
littermate mice. 
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Figure 3.11: Analysis of transgenic PS1 RNA expression in splenic lymphocytes. 
RNA samples from splenic lymphocytes derived from PS1M146L or PS1wt transgenic mice 
(lanes 4, 6, 7) show a PCR product of the same length as the positive control (lane 1). RNA 
samples from splenic lymphocytes isolated from non-transgenic littermate mice yield no 
detectable PCR products (lanes 2, 3, 5 and 8). 
 
In contrast to PS1 transgenic mice, no expression of APP could be detected in 
lymphocytes derived from PDGF-APP or Thy1-APP transgenic mice (data not shown). 
These APP transgenic mice were therefore excluded from studies of ROS in splenic 
lymphocytes. 
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3.2.1.2.2 ROS levels in lymphocytes from PS1 transgenic mice 
Splenic lymphocytes from PS1wt and PS1M146L transgenic mice and littermate control 
mice were isolated and analyzed for ROS levels. Three different age grous were 
analyzed, of which two cohorts of aged mice were studied (see Table 3.3). 
Lymphocytes were stained with DHR, which is sensitive mainly for mitochondrial 
ROS, DCFH-DA, which detects mainly cytosolic ROS, DHE, which is oxidized by 
superoxide radical anions, or DAF-2-DA, which is selective for nitric oxide. Retention 
of oxidized DHR in cells was controlled for by staining of lymphocytes directly with 
R123, the oxidized form of DHR. 
In young PS1 transgenic mice at 3-4 months of age, no difference in ROS levels was 
detected for any of the fluorescent probes used (data not shown). 
ROS levels in middle-aged mice 
Splenic lymphocytes from middle-aged, 13-15 months old PS1 transgenic mice showed 
unaltered basal ROS levels (Figure 3.12 a). Similarly, no differences were observed 
when lymphocytes were stained with other oxidation-sensitive probes DCFH-DA, DHE 
and DAF-2-DA or R123 under basal conditions in this age group (data not shown). 
However, DHR oxidation was elevated after serum withdrawal (Figure 3.12 b), which 
represents a mild stress condition and can trigger oxidative damage in cells (Atabay et 
al., 1996; Barroso et al., 1997). After further stimulation of lymphocytes with hydrogen 
peroxide, DHR oxidation was not different between littermate, PS1wt or PS1M146L 
mice (data not shown). 
ROS levels in aged mice, cohort #1 
In preliminary expriments, a cohort of 7 non-transgenic littermate control mice and 7 
PS1M146L transgenic mice at an age of 21 months were studied for ROS levels 
detected by staining with oxidation-sensitive DHR. Basal levels of ROS were elevated 
in lymphocytes from PS1M146L mice (Figure 3.13 a). This increased oxidation of DHR 
could not be attributed to a single subset of lymphocytes, since increased fluorescence 
was found in CD3-positive cells (total T-lymphocytes) as well as in subsets of CD4-
positive and CD8-positive T-lymphocytes (Figure 3.13 b). Of note, CD4-positive T-
lymphocytes display higher DHR oxidation than CD8-positive T-lymphocytes, while 
intermediate values are detected when CD3-positive lymphocytes, which represent the 
sum of CD4- and CD8-positive cells, are analyzed. RESULTS 
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Figure 3.12: Mitochondrial ROS levels in splenic lymphocytes from middle-aged PS1 
transgenic mice. 
Splenic lymphocytes from 13-15 months old non-transgenic littermate control mice (non-tg, 
n = 21-22) and mice transgenic for wildtype (PS1wt, n = 11) or mutant presenilin 1 (PS1M146L, 
n = 8-9) were analyzed for ROS levels with oxidation-sensitive dye DHR. 
a. Mean fluorescence intensity MFI of splenic lymphocytes stained with DHR under 
unstimulated (“basal”) conditions expressed as percentage relative to values of non-transgenic 
littermate control animals. One-way ANOVA: n.s. 
b. Mean fluorescence intensity MFI of splenic lymphocytes stained with DHR after serum 
withdrawal expressed as percentage relative to values of non-transgenic littermate control 
animals. One-way ANOVA: p = 0.08. Post hoc paired t-test * p < 0.05 PS1M146L vs non-tg. 
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Figure 3.13: Basal levels of mitochondrial ROS in lymphocytes from aged PS1M146L 
transgenic mice. 
Splenic lymphocytes from 21 months old non-transgenic littermate control mice (non-tg, n = 6-7) 
and mice transgenic for mutant presenilin 1 (PS1M146L, n = 7) were analyzed for ROS levels 
with the oxidation-sensitive dye DHR. 
a. Mean fluorescence intensity MFI of splenic lymphocytes stained with DHR under 
unstimulated (“basal”) conditions. Paired t-test * p < 0.05. 
b. Mean fluorescence intensity MFI of splenic lymphocyte subsets stained with DHR under 
unstimulated conditions. Two-way ANOVA p < 0.01 effect of transgene, p < 0.0001 difference 
between subsets, interaction n.s. Post hoc paired t-test (*) p < 0.1, * p < 0.05 PS1M146L vs 
non-tg. 
 
Furthermore, DHR oxidation in CD4-positive T-lymphocytes correlated positively and 
significantly with levels of apoptosis in lymphocytes quantified with 7-AAD staining 
(apoptosis data from C. Frey; Figure 3.14), indicating that increased ROS formation 
plays an important role for the apoptotic process in this lymphocyte subset. RESULTS 
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Figure 3.14: Correlation between mitochondrial ROS levels (DHR oxidation) in CD4-
positive lymphocytes and apoptosis levels in lymphocytes (7-AAD staining) from aged 
mice. 
CD4-PE antibody-stained splenic lymphocytes from 21 months old non-transgenic littermate 
control mice (non-tg) and mice transgenic for mutant presenilin 1 (PS1M146L) were analyzed 
for mitochondrial ROS levels with oxidation-sensitive dye DHR and for percentage of apoptotic 
cells (7-AAD staining, data from C. Frey). Correlation: rp = 0.7548, p < 0.01. 
 
After serum withdrawal, lymphocytes from PS1M146L mice still displayed higher ROS 
levels (Figure 3.15  a, left bars). Stimulation with 10 or 100  µM hydrogen peroxide 
induced DHR oxidation in a dose-dependent manner in cells from non-transgenic as 
well as from PS1M146L mice. The concentrations of H2O2 have been chosen according 
to reports that up to 100  µM have been measured in extracellular fluids under 
experimental conditions (Hyslop et al., 1995). Although ROS levels were increased in 
PS1M146L lymphocytes after stimulation with hydrogen peroxide, this effect failed to 
reach statistical significance (Figure 3.15 a, middle and right bars). Similar effects were 
observed after stimulation of cells for 4 hours with d-ribose, an agent that induces 
apoptosis via glutathione depletion (Barbieri et al., 1994; Kletsas et al., 1998). 10 mM 
and especially 50 mM d-ribose induced a large increase in DHR oxidation after 4 hours 
of incubation (Figure 3.15  b). Although unstimulated ROS levels after 4 hours of 
incubation showed a trend towards increased levels in cells from PS1M146L compared 
to non-transgenic mice, differences were again not significant after stimulation with d-
ribose (Figure 3.15 b). 
In summary, the relative difference in DHR oxidation between lymphocytes from non-
transgenic compared to PS1M146L transgenic animals that was already observed under RESULTS 
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basal conditions, was not increased after stimulation with any of the oxidizing agents 
hydrogen peroxide or d-ribose, suggesting that cells react similarly upon oxidative 
stimulation, independent of the transgene. 
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Figure 3.15: ROS levels in lymphocytes from aged PS1M146L transgenic mice after 
stimulation with hydrogen peroxide or d-ribose. 
Splenic lymphocytes from 21 months old non-transgenic littermate control mice (non-tg, n = 7) 
and mice transgenic for mutant presenilin 1 (PS1M146L, n = 7) were analyzed for ROS levels 
with oxidation-sensitive dye DHR. 
a. Mean fluorescence intensity MFI of splenic lymphocytes stained with DHR after serum 
withdrawal and stimulation with hydrogen peroxide for 15 minutes. Two-way ANOVA p < 0.01 
effect of transgene, p < 0.0001 effect of stimulation, interaction n.s. Post hoc paired t-test 
* p < 0.05 PS1M146L vs non-tg. 
b. Mean fluorescence intensity MFI of splenic lymphocyte subsets stained with DHR after 
stimulation with d-ribose for 4 hours. Two-way ANOVA p < 0.1 effect of transgene, p < 0.0001 
effect of stimulation, interaction n.s. Post hoc paired t-test (*) p < 0.1 PS1M146L vs non-tg. 
 
ROS levels in aged mice, cohort #2 
In subsequent experiments, ROS formation was studied in more detail with various 
oxidation-sensitive dyes in lymphocytes in a larger cohort of 19-22 months old non-
transgenic littermate control animals (non-tg) and mice transgenic for either human 
wildtype PS1 (PS1wt) or mutant PS1 (PS1M146L). 
As already observed in cohort #1, basal DHR oxidation is increased in lymphocytes 
from PS1M146L mice, but not from PS1wt mice (Figure 3.16 a). Also, retention of 
R123, which represents the oxidized form of DHR, is slightly increased in cells from 
PS1M146L mice (Figure 3.16  b), which might to a minor extent contribute to the 
observed increase in fluorescence after DHR staining. We additionally controlled for 
this effect by staining lymphocytes with another oxidation-sensitive dye, DCFH-DA, 
which is not retained in mitochondria and for which a transport by P-glycoprotein has RESULTS 
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not been decribed so far. Similar to DHR oxidation, DCFH-DA is also increasingly 
oxidized in PS1M146L cells (Figure 3.16 c). Furthermore, fluorescence values obtained 
after staining with DHR and DCFH-DA were significantly correlated in littermate, 
PS1wt and PS1M146L animals (Figure 3.16 d), indicating that they detect similar or 
related ROS in the transgenic animals. Formation of superoxide radical anions is 
however not increased in lymphocytes from transgenic mice (Figure 3.16 e), and levels 
of nitric oxide are only slightly increased in PS1M146L mice (Figure 3.16 f), again 
suggesting that DHR and DCFH-DA are not oxidized by peroxynitrite to a significant 
extent under our conditions. 
Increased oxidation of DHR in lymphocytes from PS1M146L mice was also found after 
serum withdrawal and stimulation with various concentrations of hydrogen peroxide 
(Figure 3.17). Of note, even lymphocytes from PS1wt mice showed a tendency towards 
increased DHR oxidation after stimulation with a relatively low hydrogen peroxide 
concentration of 1 µM (Figure 3.17 b). However, DHR oxidation was more pronounced 
and significantly increased at all concentrations of hydrogen peroxide in lymphocytes 
from PS1M146L transgenic mice. 
When comparing the stimulation data after hydrogen peroxide challenge with basal 
levels of DHR oxidation, it is obvious that stimulated DHR oxidation is not exacerbated 
in PS1M146L transgenic mice. This indicates that lymphocytes from PS1M146L mice 
already display elevated DHR oxidation under unstimulated conditions, but that 
lymphocytes react similarly upon stimulation independent of the transgene. This is in 
good accordance with the data obtained on brain tissue, where MDA formation was also 
not increased in PS1M146L mice after stimulation. 
Interestingly, oxidation of DHR in splenic lymphocytes was positively correlated with 
levels of the lipid peroxidation product HNE in brains from littermate control, PS1wt 
and PS1M146L mice (Figure 3.18), suggesting that the oxidative stress situation in 
brain tissue from these animals is also reflected in splenic lymphocytes. RESULTS 
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Figure 3.16: Basal levels of various ROS in lymphocytes from PS1wt and PS1M146L 
transgenic mice. 
Splenic lymphocytes from 19-22 months old non-transgenic littermate control mice (non-tg, 
n  =  20) and mice transgenic for human wildtype PS1 (PS1wt, n  =  10) or mutant PS1 
(PS1M146L, n  =  11) were analyzed under unstimulated conditions. Values are given as 
percentage of mean fluorescence intensity MFI relative to the mean of age-matched non-
transgenic littermate control mice (non-tg = 100 %). 
a. Staining with ROS-sensitive dye DHR. One-way ANOVA p < 0.01. Post hoc paired t-test 
* p < 0.05 PS1M146L vs non-tg. 
b. Staining with R123. One-way ANOVA p < 0.1. Post hoc paired t-test * p < 0.05 PS1M146L vs 
non-tg. 
c. Staining with ROS-sensitive dye DCFH-DA. One-way ANOVA n.s. Post hoc paired t-test 
** p < 0.01 PS1M146L vs non-tg. 
d. Correlation between DHR and DCFH-DA oxidation in lymphocytes from non-transgenic (non-
tg) littermate, PS1wt and PS1M146L mice, p < 0.001, rP = 0.5244. 
e. Staining with superoxide-sensitive dye DHE. One-way ANOVA n.s. 
f. Staining with nitric oxide-sensitive dye DAF-2-DA. One-way ANOVA n.s. Post hoc paired t-
test (*) p < 0.1 PS1M146L vs non-tg. 
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Figure 3.17: ROS levels in lymphocytes from PS1wt and PS1M146L transgenic mice after 
serum withdrawal and stimulation with hydrogen peroxide. 
Splenic lymphocytes from 19-22 months old non-transgenic littermate control mice (non-tg, 
n  =  20) and mice transgenic for human wildtype (PS1wt, n  =  10) or mutant presenilin 1 
(PS1M146L, n  =  11) were analyzed after serum withdrawal and stimulation with hydrogen 
peroxide H2O2 at various concentrations for 15 minutes. Cells were stained with DHR and 
values are presented as percentage of the mean fluorescence intensity relative to values from 
non-transgenic littermate controls (non-tg = 100 %). 
a. DHR oxidation after serum withdrawal. One-way ANOVA n.s. Post hoc paired t-test * p < 0.05 
PS1M146L vs non-tg. 
b. Stimulation with 1  µM hydrogen peroxide. One-way ANOVA n.s. Post hoc paired t-test 
(+) p < 0.1 PS1wt vs non-tg, ** p < 0.01 PS1M146L vs non-tg. 
c. Stimulation with 10 µM hydrogen peroxide. One-way ANOVA p < 0.05. Post hoc paired t-test 
* p < 0.05 PS1M146L vs non-tg. 
d. Stimulation with 100 µM hydrogen peroxide. One-way ANOVA p < 0.1. Post hoc paired t-test 
* p < 0.05 PS1M146L vs non-tg. 
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Figure 3.18: Correlation between DHR oxidation in splenic lymphocytes and HNE levels 
in brains from non-transgenic littermate control mice and mice transgenic for PS1wt and 
PS1M146L. 
Mean fluorescence intensity MFI of lymphocytes stained with DHR (expressed as percentage of 
values relative to controls) plotted against the concentration of lipid peroxidation product HNE 
(nmol/mg protein) in brain homogenates from non-transgenic littermate control mice, PS1wt 
mice and PS1M146L mice. Correlation: rP = 0.3378, p < 0.05. 
 
 
In summary, mutant PS1 leads to elevated ROS levels which were correlated with 
apoptosis in peripheral cells and increased HNE levels in brain tissue from transgenic 
mice. The increased HNE levels in brains from these mice can not be explained by 
altered antioxidant enzyme activities of Cu/Zn-SOD, GPx or GR. Moreover, brain 
tissue and splenic lymphocytes from PS1M146L transgenic mice did not react more 
sensitive towards oxidative stimuli, indicating that increased ROS levels and oxidative 
damage do not arise from impaired antioxidant defense. Of note, no differences in 
oxidative stress parameters could be detected in mice transgenic for mutant APP 
(PDGF-APP) or double APP and PS1 mutant transgenic mice (PDGF-APP/PS1). RESULTS 
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3.2.2 ROS metabolism in brains from Thy1-APP transgenic mice 
Oxidative stress parameters were furthermore studied in another AD transgenic mouse 
model, Thy1-APP mice, which displays high formation and accumulation of human Aβ. 
These mice show Aβ plaques in their brains from an age of 6 months, therefore mice at 
an age of 3 months, i.e. before plaque deposition, and mice at ages of 12 and 18 months, 
i.e. with widespread plaque deposition, were studied. Table 3.4 gives details on the total 
numbers and gender distribution of animals used in this study. 
Table 3.4: Numbers and gender distribution of Thy1-APP and non-transgenic animals 
used. 
Transgene  non-transgenic  Thy1-APP 
age group  total n  female  male  total n  female  male 
young 
(3 months)  18  14 4 15  12 3 
middle-aged 
(12 months)  14  8 6  10  6 4 
aged 
(18 months)  5  - 5 6  - 6 
 
Since the APP transgene is not expressed in lymphocytes from these mice, only brains 
were studied for markers of lipid peroxidation and antioxidant enzyme activities. RESULTS 
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3.2.2.1 ROS metabolism in brains from Thy1-APP transgenic mice during 
aging 
As already observed in aging studies of murine brains (see 3.1.1.1), levels of lipid 
peroxidation products MDA and HNE decline with rising age (Figure 3.19). The APP 
transgene did not affect the levels of lipid peroxidation product MDA (Figure 3.19 a), 
levels of HNE were however highly and significantly increased in 12 months old Thy1-
APP transgenic animals compared to age-matched controls (Figure 3.19 b). 
In order to asses a possible contribution of antioxidant defense to the observed changes 
in HNE levels, activities of antioxidant enzymes were assayed. The activity of Cu/Zn-
SOD is impaired in 3 and 12 months old Thy1-APP transgenic mice (Figure 3.20 a), 
which was significant only for the 12 month age group. Activities of GPx and GR were 
however not affected by the APP transgene (Figure 3.20 b and c, respectively). Activity 
of Cu/Zn-SOD showed a trend towards higher activity in aged animals (Two-way 
ANOVA p = 0.08 effect of age), and GR activity was signifcantly increased during 
aging (Two-way ANOVA p < 0.0001 effect of age). Similar results have been obtained 
before in aging studies (see chapter 3.1.1.1, page 82 et seqq.). The lack of significant 
upregulation of GPx activity during aging in this cohort is caused by the fact that the 18 
months old group consisted only of male animals. As male mice consistently display 
lower activity of GPx, the aging effect could not be detected in this cohort. 
Despite the reduced Cu/Zn-SOD activity, levels of stimulated MDA were not 
significantly different between non-transgenic and Thy1-APP transgenic mice in any of 
the age groups (Figure 3.21). 
In summary, these results suggest that the reduced Cu/Zn-SOD activity in 12 months 
old Thy1-APP transgenic mice could be causally related to the increased basal HNE 
levels. However, impaired Cu/Zn-SOD activity does probably not lead to alterations in 
MDA formation during stimulation of lipid peroxidation in vitro. RESULTS 
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Figure 3.19: Levels of lipid peroxidation products in Thy1-APP transgenic mice during 
aging. 
Lipid peroxidation products MDA and HNE were determined in brain homogenates from 3, 12 
and 18 months old non-transgenic littermate control animals (non-tg: white bars, 3 months 
n  =  9-10, 12 months n  =  14, 18 months n  =  5) and age-matched Thy1-APP transgenic mice 
(Thy1-APP: grey bars, 3 months n = 7, 12 months n = 9, 18 months n = 6). 
a. Levels of MDA (nmol/mg protein). Two-way ANOVA: effect of transgene n.s., p < 0.0001 
effect of age, interaction n.s. 
b. Levels of HNE (nmol/mg protein). Two-way ANOVA: effect of transgene p = 0.05, effect of 
age p < 0.01, interaction p = 0.08. Post hoc t-test: * p < 0.05. 
 
 RESULTS 
110 
a
b
c
3 months 12 months 18 months
1.5
2.0
2.5
3.0
g y
(*
) *
C
u
/
Z
n
-
S
O
D
 
a
c
t
i
v
i
t
y
U
/
m
g
 
p
r
o
t
e
i
n
3 months 12 months 18 months
15
20
25
30
G
P
x
 
a
c
t
i
v
i
t
y
m
U
/
m
g
 
p
r
o
t
e
i
n
3 months 12 months 18 months
5.0
7.5
10.0
12.5
15.0
G
R
 
a
c
t
i
v
i
t
y
m
U
/
m
g
 
p
r
o
t
e
i
n
Two-way ANOVA: p < 0.05 transgene
Two-way ANOVA: p < 0.0001 age
 
Figure 3.20: Activities of antioxidant enzymes in Thy1-APP transgenic mice during aging. 
Activities of Cu/Zn-SOD, GPx and GR were determined in brain homogenates from 3, 12 and 
18 months old non-transgenic littermate control animals (non-tg: white bars, 3 months n = 17-
18, 12 months n = 13-14, 18 months n = 5) and age-matched Thy1-APP transgenic mice (Thy1-
APP: grey bars, 3 months n = 15, 12 months n = 8-10, 18 months n = 6). 
a. Cu/Zn-SOD activity (U/mg protein). Two-way ANOVA: p < 0.05 effect of transgene, p = 0.08 
effect of age, interaction n.s. Post hoc t-test: (*) p = 0.07 3 months old Thy1-APP vs non-tg, 
* p < 0.05 12 months old Thy1-APP vs non-tg. 
b. GPx activity (mU/mg protein). Two-way ANOVA: effect of transgene n.s., effect of age n.s., 
interaction n.s. 
c. GR activity (mU/mg protein). Two-way ANOVA: effect of transgene n.s., effect of age 
p < 0.0001, interaction n.s. RESULTS 
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Figure 3.21: Stimulated levels of MDA in Thy1-APP transgenic mice during aging. 
Formation of malondialdehyde MDA was stimulated with 50µM FeCl3 for 30 min at 37°C in brain 
homogenates from non-transgenic littermate control animals (non-tg: white bars, 3 months 
n  =  10, 12 months n  =  14, 18 months n  =  5) and age-matched Thy1-APP transgenic mice 
(Thy1-APP: grey bars, 3 months n = 8, 12 months n = 10, 18 months n = 6). Two-way ANOVA: 
n.s. 
 
 
3.2.2.2  Gender differences in ROS metabolism in Thy1-APP transgenic 
mice 
Analyzing the changes in oxidative stress parameters in Thy1-APP transgenic mice in 
more detail, the 3 months and 12 months old groups were divided into each male and 
female subgroups. At 18 months of age, only male animals were studied, which could 
not be included in this analysis. 
At the level of lipid peroxidation parameters, a gender difference was observed in 
young mice. At 3 months of age, increased levels of MDA and HNE were found only in 
female Thy1-APP transgenic mice, whereas levels of MDA and HNE were similar in 
male Thy1-APP transgenic mice compared to controls (Figure 3.22 a and b, left bars). 
At an age of 12 months, both gender were similarly affected by the APP transgene 
leading to increased HNE levels in male and female Thy1-APP transgenic mice (Figure 
3.22  b, right bars). The relative increase in HNE levels was however higher in 12 
months old animals: female and male 12 months old Thy1-APP transgenic mice 
displayed 86  % or 79  % higher HNE levels, respectively, compared to 36  % higher 
HNE levels in 3 months old female Thy1-APP mice relative to age- and gender-
matched non-transgenic mice. Furthermore – as already observed previously in studies 
of non-transgenic C57BL/6J mice (3.1.2.1) – female mice displayed lower levels of 
MDA as well as HNE, irrespective of the transgene. RESULTS 
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Figure 3.22: Effect of gender on lipid peroxidation parameters in 3 and 12 months old 
Thy1-APP transgenic mice. 
Lipid peroxidation products MDA and HNE were determined in brain homogenates from 3 and 
12 months old female and male non-transgenic (non-tg, white bars) littermate control animals 
and Thy1-APP transgenic mice (Thy1-APP, grey bars). 3 months old female mice n = 5 non-tg, 
n = 4 Thy1-APP; 3 months old male mice n = 4 non-tg, n = 3 Thy1-APP; 12 months old female 
mice n = 8 non-tg, n = 5 Thy1-APP; 12 months old male mice n = 6 non-tg, n = 4 Thy1-APP. 
a. Levels of MDA (nmol/mg protein).  
3 months old animals: Two-way ANOVA: effect of transgene n.s., p < 0.01 effect of gender, 
interaction p = 0.05. Post hoc t-test * p < 0.05. 
12 months old animals: Two-way ANOVA: effect of transgene n.s., effect of gender p < 0.05, 
interaction n.s. 
b. Levels of HNE (nmol/mg protein). 
3 months old animals: Two-way ANOVA: effect of transgene p = 0.09, effect of gender p < 0.01, 
interaction n.s. Post hoc t-test * p < 0.05. 
12 months old animals: Two-way ANOVA: effect of transgene p < 0.01, effect of gender 
p < 0.05, interaction n.s. Post hoc t-test * p < 0.05. 
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Similarly, the activity of Cu/Zn-SOD in the 3 months old age group was reduced only in 
female Thy1-APP transgenic mice compared to female non-transgenic mice, whereas 
male Thy1-APP transgenic mice were not affected at that age (Figure 3.23, left bars). At 
12 months of age, both female and male Thy1-APP transgenic mice showed reduced 
activity of Cu/Zn-SOD compared to non-transgenic mice (Figure 3.23, right bars). 
Although the APP transgene did not affect the activities of GPx (Figure 3.24) or GR 
(data not shown), female mice in general exhibited higher activites of GPx compared to 
age-matched male mice (Figure 3.24), which was independent of the transgene. This 
effect had already been observed previously (see 3.1.2.1, page 90). 
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Figure 3.23: Effect of gender on Cu/Zn-SOD activity in 3 and 12 months old Thy1-APP 
transgenic mice. 
Activity of Cu/Zn-SOD was determined in brain homogenates from 3 and 12 months old female 
and male non-transgenic (non-tg, white bars) littermate control animals and Thy1-APP 
transgenic mice (Thy1-APP, grey bars). 3 months old female mice n = 13 non-tg, n = 12 Thy1-
APP; 3 months old male mice n = 4 non-tg, n = 3 Thy1-APP; 12 months old female mice n = 8 
non-tg, n = 4 Thy1-APP; 12 months old male mice n = 5 non-tg, n = 4 Thy1-APP. 
3 months old animals: Two-way ANOVA: effect of transgene n.s., effect of gender p < 0.05, 
interaction n.s. Post hoc t-test * p < 0.05. 
12 months old animals: Two-way ANOVA: effect of transgene p < 0.05, effect of gender n.s., 
interaction n.s. Post hoc t-test (*) p < 0.1. 
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Figure 3.24: Effect of gender on GPx activity in 3 and 12 months old Thy1-APP transgenic 
mice. 
Activity of GPx (mU/mg protein) was determined in brain homogenates from 3 and 12 months 
old female and male non-transgenic (non-tg, white bars) littermate control animals and Thy1-
APP transgenic mice (Thy1-APP, grey bars). 3 months old female mice n = 14 non-tg, n = 12 
Thy1-APP; 3 months old male mice n = 4 non-tg, n = 3 Thy1-APP; 12 months old female mice 
n = 8 non-tg, n = 4 Thy1-APP; 12 months old male mice n = 5 non-tg, n = 4 Thy1-APP. 
3 months old animals: Two-way ANOVA: n.s. 
12 months old animals: Two-way ANOVA: effect of transgene n.s., p < 0.01 effect of gender, 
interaction n.s. Post hoc t-test * p < 0.05 12 months old female vs male non-tg mice. 
 
 
Analysis of gender differences in levels of stimulated MDA revealed that female Thy1-
APP transgenic mice at an age of 12 months show significantly elevated MDA 
formation compared to age-matched, female non-transgenic mice (Figure 3.25), while 3 
months old transgenic mice are not affected. Furthermore, female non-transgenic mice 
exhibited lower levels of MDA after stimulation compared to male non-transgenic mice 
in both age groups, which is in accordance with the previous results on gender 
differences in C57BL/6J mice (see also chapter 3.1.2.1, figure 3.7, page 91). 
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Figure 3.25: Gender differences in stimulated MDA levels in 3 and 12 months old Thy1-
APP transgenic mice. 
Formation of malondialdehyde MDA was stimulated with 50 µM FeCl3 for 30 min at 37°C in 
brain homogenates from 3 and 12 months old female and male non-transgenic (non-tg, white 
bars) littermate control animals and Thy1-APP transgenic mice (Thy1-APP, grey bars). 3 
months old female mice n = 6 non-tg, n = 5 Thy1-APP; 3 months old male mice n = 4 non-tg, 
n = 3 Thy1-APP; 12 months old female mice n = 8 non-tg, n = 6 Thy1-APP; 12 months old male 
mice n = 6 non-tg, n = 3 Thy1-APP. 
3 months old animals: Two-way ANOVA: effect of transgene n.s., p < 0.05 effect of gender, 
interaction n.s. 
12 months old animals: Two-way ANOVA: effect of transgene n.s., effect of gender n.s., 
interaction p < 0.05. Post hoc t-test * p < 0.05 female non-tg vs Thy1-APP mice, # p < 0.05 
female vs male non-tg mice. 
 
 
In summary, female Thy1-APP transgenic mice were affected by increased HNE levels 
and reduced Cu/Zn-SOD activity earlier than male transgenic mice. Moreover, at an age 
of 12 months, only female Thy1-APP transgenic mice are vulnerable towards increased 
stimulation of MDA formation. These findings suggest a gender-specific earlier and/or 
higher vulnerability towards oxidative damage in female Thy1-APP transgenic mice 
compared to male Thy1-APP transgenic mice. 
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3.2.3 Cu/Zn-SOD activity in brains from APP23 mice 
In cooperation with Thomas A. Bayer and Stephanie Schäfer, Homburg/Saar, Germany, 
brain tissue samples from another APP transgenic mouse model, APP23 mice, could be 
analysed for Cu/Zn-SOD activity. Similar to the Thy1-APP transgenic mice described 
above, this mouse model expresses the 751 amino acid form of human APP under the 
control of the murine Thy1 promotor. The human APP gene contains only the Swedish 
double mutation (KM670/671NL). These mice develop Aβ plaques from an age of 6 
months (Sturchler-Pierrat et al., 1997). Two groups of mice at an age of 15 and 21 
months could be studied. Similar to Thy1-APP transgenic mice, activity of Cu/Zn-SOD 
was reduced in both age groups (Figure 3.26). 
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Figure 3.26: Cu/Zn-SOD activity is reduced in brains from APP23 mice. 
Activity of Cu/Zn-SOD was determined in brain homogenates from 15 and 21 months old non-
transgenic (non-tg, white bars) control animals and APP23 transgenic mice (APP23, streaked 
bars). 15 months old mice: n = 14 non-tg (5 female, 9 male), n = 11 APP23 (6 female, 5 male). 
21 months old mice: n = 17 non-tg (7 female, 10 male), n = 6 APP23 (3 female, 3 male).  
Two-way ANOVA: p < 0.001 effect of transgene, effect of age n.s., interaction n.s. Post hoc t-
test ** p < 0.05 15 months old APP23 vs non-transgenic mice, (*) p = 0.08 21 months old 
APP23 vs non-transgenic mice. 
 
In summary, the independent study of APP23 transgenic mouse brains confirms the 
previous observations in Thy1-APP transgenic mice that overexpression of APP and 
formation of Aβ can lead to a reduction in the activity of the antioxidant enzyme Cu/Zn-
SOD. This represents a newly identified mechanism by which oxidative toxicity due to 
APP mutations can be explained. RESULTS 
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3.2.4 Comparative analysis of human APP expression and Aβ 
expression levels in PDGF-APP, PDGF-APP/PS1 and Thy1-APP 
mouse models 
APP expression and Aβ levels were analyzed in brain homogenates from PDGF-APP, 
PDGF-APP/PS1 and Thy1-APP transgenic mice in order to compare Aβ accumulation 
between the different mouse models. For these studies, brains were initially 
homogenized in Tris-buffered saline for extraction of soluble Aβ followed by 
subsequent dissolution of the remaining pellet in SDS solution, which solubilizes the 
remaining insoluble Aβ fraction. Both Tris- and SDS-lysates were analyzed by Western 
blot, and Tris-homogenates from PDGF-APP, PDGF-APP/PS1 and Thy1-APP 
transgenic mouse brains were additionally employed for ELISA quantification of 
soluble Aβ1−40 levels. 
The numbers and gender distribution of the respective transgenic animals used in this 
study are given in Table 3.5. 
Table 3.5: Numbers and gender distribution of different APP transgenic mice used for 
analysis of APP expression and Aβ formation. 
Transgene  PDGF-APP  PDGF-APP/PS1  Thy1-APP 
age group  female  male  female  male  female  male 
3-4 months  1 1 1 1 4 3 
7 months  - - - - 2 - 
12 months  - - - - 6  4 
13-15 months  1 1 3 2 - 2 
18-22 months  1 1 3 3 - 2 
 
3.2.4.1 Western blot analysis of human APP and Aβ expression 
The antibody W0-2 is directed against the human Aβ sequence and hence detects full-
length human APP at approximately 100 kDa, soluble sAPPα at approximately 90 kDa, 
the C99 peptide at 12 kDa and the Αβ peptide at 4 kDa simultaneously. This allows for 
the convenient analysis of AD-relevant processes of APP cleavage at the same time in a 
single blot. However, sAPPα staining was very weak and therefore not analysed. RESULTS 
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Thy1-APP transgenic mice showed an age-associated elevation in the levels of soluble 
Αβ in Tris-soluble brain extracts, while expression of full-length APP during aging 
remained unchanged (Figure 3.27). Of note, some inter-individual variability in soluble 
Αβ exists in mice of the same age, despite quite homogenous expression of APP. There 
was also a slight increase in C99 levels with aging. 
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Figure 3.27: Effect of aging on accumulation of soluble Aβ in Thy1-APP transgenic mice. 
Brains were lysed in Tris-buffered saline and blotted for analysis of APP expression and soluble 
Aβ levels. APP is detected at approximately 100 kDa, the C99 peptide at 12 kDa and the Aβ 
peptide at 4 kDa. Other bands are unspecific staining as can be seen from a non-transgenic 
control sample blotted on lane 1. The Aβ band is almost undetectable in 3 months old mice 
(lanes 2-5), but the intensity sharply increases up to an age of 18 months (lanes 10, 11). Inter-
individual differences in the intensitiy of the Aβ band could be detected at 7 months (lanes 6, 7), 
14 months (lanes 8, 9) and 18 months of age (lanes 10, 11). 
 
PDGF-APP and double transgenic PDGF-APP/PS1 transgenic mice also showed an 
age-associated accumulation of Aβ, but levels of Aβ formation were much lower in 
these mouse models compared to age-matched Thy1-APP transgenic mice (Figure 
3.28 a). 
An age-related accumulation of Aβ in PDGF-APP, PDGF-APP/PS1 and Thy1-APP 
transgenic mouse models has also been obtained with SDS-soluble brain extracts 
representing the insoluble pool of Aβ (data not shown). It must however be noted that 
the intensity of insoluble Aβ bands in SDS brain lysates was always higher than that of RESULTS 
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soluble Aβ bands in Tris-buffered brain lysates (Figure 3.28  b), suggesting that the 
largest pool of Aβ is present in an aggregated, insoluble state. Levels of Aβ in soluble 
as well as insoluble fractions are seemingly correlated, since the relative intensities were 
similar in Tris- as well as SDS-lysates (see Figure 3.28  b, samples from the same 
individual animal have been blotted in lanes 1 and 4, 2 and 5 as well as 3 and 6, 
respectively). Furthermore, some inter-individual variability in the intensitiy of Aβ 
bands was observed in 13-15 months old PDGF-APP/PS1 mice despite similar 
expression levels of APP. 
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Figure 3.28: Levels of Aβ are higher in Thy1-APP compared to PDGF-APP and PDGF-
APP/PS1 transgenic mice (a). The largest pool of Aβ is present in insoluble fractions (b). 
a. Comparison of APP and soluble Aβ levels between Thy1-APP and PDGF-APP transgenic 
mice. Tris-lysates from 18 months old Thy1-APP transgenic (lane 1) or 19-22 months old 
PGDF-APP (lanes 2, 3) and 19-22 months old PDGF-APP/PS1 transgenic mice (lanes 4, 5) 
were blotted. The intensity of the Aβ band is highly increased in samples from the Thy1-APP 
transgenic mouse compared to the PDGF-APP single or double transgenics. 
b. Differences between Aβ levels in Tris- and SDS-lysates from APP transgenic mouse brains. 
Brains from 13-15 months old PDGF-APP/PS1 transgenic mice were either lysed in Tris-
buffered saline (lanes 1-3) or SDS-solution (lanes 4-6). The intensity of the Aβ band is much 
higher in SDS extracts. Lanes 1 and 4, 2 and 5 as well as 3 and 6 represent samples from the 
same animal. Levels of Aβ show some inter-individual variability in Tris-soluble as well as SDS 
extracts. 
 
As can be seen in Figure 3.29, expression of full-length APP was only slightly higher in 
Thy1-APP compared to PDGF-APP and PDGF-APP/PS1 transgenic mice. However, 
the levels of C99 peptide were much higher in Thy1-APP transgenic mice, furthermore, 
levels of Aβ peptide were increased already in young Thy1-APP transgenic mice RESULTS 
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(Figure 3.29, lanes 1-4). compared to middle-aged and aged single PDGF-APP 
transgenic mice (Figure 3.29, lanes 5,6,9,10). Coexpression of mutant PS1 in double 
transgenic PDGF-APP/PS1 mice led to higher formation of Aβ, but not C99 peptide 
(Figure 3.29, lanes 7,8,11,12) compared to single PDGF-APP transgenic mice. This is 
in good accordance with the anticipated effect, since mutant PS1 increases γ-secretase 
cleavage independently of β-secretase cleavage, leaving levels of C99 peptide derived 
from β-secretase cleavage unaffected. Again, PDGF-APP/PS1 transgenic mice at an age 
of 13-15 months showed rather large inter-individual variability in levels of Aβ 
(compare Figure 3.29, lanes 7 and 8). 
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Figure 3.29: Expression of APP and insoluble Aβ levels in SDS-lysates from APP 
transgenic mouse brains. 
Upper panel: SDS-buffer lysates of transgenic mouse brains were blotted for analysis of APP 
expression and insoluble Aβ levels. APP is detected at approximately 100 kDa. The longer 751 
amino acid isoform in Thy1-APP transgenic mice (lanes 1-4) gives a protein band above that of 
the 695 isoform expressed in PDGF-APP transgenic mice (lanes 5-12). f = female, m = male 
mice. 
Lower panel: Actin protein bands were detected as loading control. 
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In summary, the different APP transgenic mouse models used in this thesis express 
similar amounts of full-length APP. However, formation of the C99 peptide is highest in 
Thy1-APP transgenic mice, and similarly formation of Aβ decreases in the order of 
Thy1-APP > PDGF-APP/PS1 double transgenic mice > PDGF-APP single transgenic 
mice. 
Furthermore, a gender difference in the intensity of the C99 peptide and insoluble Aβ 
bands was detected in 3 months old Thy1-APP transgenic mice (Figure 3.29, lanes 1-4). 
This was analyzed in more detail in a larger group of animals. Densitometric 
quantification of band intensity revealed that Aβ levels are approximately 30 % higher 
in female Thy1-APP transgenic mice at 3 months of age (Figure 3.30). 
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Figure 3.30: Gender differences in levels of insoluble Aβ in Thy1-APP transgenic mice. 
a. Aβ protein band in Western blot of SDS brain lysates from 3 months old female and male 
Thy1-APP transgenic mice. 
b. Densitometric evaluation of Aβ protein band shown in a. t-test ** p < 0.01. 
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3.2.4.2  Quantitative analysis of soluble Aβ1-40 levels in APP transgenic 
mice with ELISA 
The results regarding the expression levels of Aβ obtained in Western blot analysis 
were further quantified with ELISA specific for human Aβ1-40. For this analysis, only 
Tris-buffered brain extracts representing the pool of soluble Aβ could be used. 
As already observed in Western blots, an increase in the levels of Aβ with aging was 
present in both the PDGF-APP/PS1 and the Thy1-APP transgenic mouse models. As 
can be seen in Figure 3.31, levels of Aβ1-40 were almost undetectable in non-transgenic 
littermate control mice and were still at very low levels in single PDGF-APP transgenic 
mice. In these mice, no increase in Aβ1-40 with aging could be observed (Figure 3.31, 
left bars). In contrast, the additional expression of human mutant PS1 in double 
transgenic PDGF-APP/PS1 mice led to formation of much higher Aβ1-40 levels and 
accumulation during aging (Figure 3.31, right bars, note the different scales of axes).  RESULTS 
     123 
non-tg
3-4 months
13-15 months
19-22 months
3-4 months
13-15 months
19-22 months
0.0
2.5
5.0
7.5
10.0
PDGF-
APP
PDGF-
APP/PS1
0
100
200
300
400
(*
)
** +
A
 
1
-
4
0
 
p
g
/
m
g
 
p
r
o
t
e
i
n
A
 
1
-
4
0
 
p
g
/
m
g
 
p
r
o
t
e
i
n
 
Figure 3.31: Levels of Aβ1-40 in PDGF-APP and PDGF-APP/PS1 transgenic mice during 
aging. 
Aβ levels were quantified with ELISA in Tris-buffered brain homogenates from non-transgenic 
littermate control mice (non-tg), PDGF-APP and PDGF-APP/PS1 transgenic mice at different 
ages. White bars: non-transgenic mice (n = 2), grey bars: single transgenic PDGF-APP mice 
(each age group n = 2), black bars: double transgenic PDGF-APP/PS1 mice (3-4 months n = 2; 
13-15 months n = 5, 19-22 months n = 6). One-way ANOVA PDGF-APP/PS1 mice: p < 0.01 
difference between age groups. Post hoc t-test: (*) p < 0.1 13-15 months vs 3-4 months, 
** p < 0.01 19-22 months vs 3-4 months, + p < 0.05 19-22 vs 13-15 months. Note the different 
scales of axes. 
 
Levels of soluble Aβ1-40 were however still higher in Thy1-APP transgenic mice and 
showed a marked accumulation with aging (Figure 3.32 a). Furthermore, the gender 
difference observed in insoluble total Aβ levels in Western blots was also found in 
soluble Aβ1-40 levels quantified with ELISA (Figure 3.32 b). Of note, the relative gender 
difference in 3 months old animals in levels of soluble Aβ1-40 quantified by ELISA is 
approximately 30% and very similar to the relative difference in levels of insoluble total 
Aβ quantified from densitometric evaluation of Western blot protein bands. This gender 
difference is still present in 12 months old animals, although absolute levels of Aβ1-40 
are much higher at that age. 
In summary, the different APP transgenic mouse models display very different 
formation and accumulation of Aβ. While Aβ levels are very low and remain at this RESULTS 
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level during aging in single PDGF-APP transgenic mice, double transgenic PDGF-
APP/PS1 mice show increased Aβ levels and an age-associated accumulation. Highest 
levels of Aβ are observed in Thy1-APP transgenic mice. Relative to age-matched 
PDGF-APP/PS1 transgenic mice, levels of Aβ in Thy1-APP transgenic mice are 18-, 
12- or 16-fold increased in 3-4, 12-15 or 18-22 months old mice, respectively. 
Furthermore, a gender difference was observed in Thy1-APP transgenic mice, where 
female mice show higher formation of Aβ compared to male mice. No such gender 
difference was detected in PDGF-APP/PS1 transgenic mice (data not shown). 
Of note, the gender difference in Aβ formation and accumulation during aging in Thy1-
APP mice may be causally related to our observations on oxidative stress-related 
parameters, since (i) female Thy1-APP transgenic mice display oxidative damage and 
reduced activity of Cu/Zn-SOD earlier than male Thy1-APP mice and (ii) female 12 
months old transgenic mice are more vulnerable towards oxidative in vitro stimulation 
of lipid peroxidation than male Thy1-APP mice. RESULTS 
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Figure 3.32: Accumulation of soluble Aβ1-40 with age (a) and (b) gender difference in 
Thy1-APP transgenic mice. 
Aβ levels were quantified with ELISA in Tris-buffered brain homogenates from non-transgenic 
littermate control mice (non-tg) and Thy1-APP transgenic mice in different age groups as 
indicated. 
a. Age-associated accumulation of soluble Aβ in Thy1-APP transgenic mouse brains. n = 2 for 
each group except n = 7 for 3 months old and n = 10 for 12 months old Thy1-APP transgenic 
mice. One-way ANOVA p < 0.0001 effect of aging. 
b. Gender difference in soluble Aβ levels in brains from female and male Thy1-APP transgenic 
mice. 3 months old mice n = 4 female, n = 3 male, 12 months old mice n = 6 female, n = 5 male. 
Two-way ANOVA: p < 0.05 effect of gender, p < 0.0001 effect of age, interaction p = 0.05. Post 
hoc t-test: * p < 0.05 female vs male 12 months old mice. Note the different scales of axes. RESULTS 
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3.3 ROS metabolism in brains from AD patients 
Sporadic Alzheimer’s disease patients represent the vast majority of AD cases, but the 
transgenic mouse models generated so far are all based on rare familial AD mutations 
and do not mimic the whole pathology of the disease in humans. Hence, we additionally 
studied frozen post mortem brain tissue from sporadic AD patients. Although post 
mortem tissue samples have limitations – as it is not possible to detect ROS directly and 
unknown confounding effects could be caused by the post mortem interval or tissue 
storage time – they nevertheless represent one of the best systems to study pathogenic 
events related to sporadic Alzheimer’s disease. Brain tissue samples from sporadic AD 
patients and age-matched controls were analyzed for markers of lipid peroxidation 
products MDA and HNE, activities of antioxidant enzymes Cu/Zn-SOD, GPx and GR 
as well as MDA levels after stimulation of lipid peroxidation in vitro. Furthermore, in a 
subset of samples, levels of Aβ1-40 were determined to allow for a correlation with 
oxidative stress-related parameters. 
 
3.3.1 Cohort #1 
In a first study, a total number of 11 AD patients (7 female, 4 male) and 10 age-matched 
controls (6 female, 4 male) were studied. Brain tissue samples were obtained from 4 
different brain regions: frontal cortex, parietal cortex, temporal cortex and cerebellum, 
which are differently affected by the disease in the order of temporal > frontal > parietal 
cortex (Delacourte et al., 1999), while cerebellar functions are not impaired by AD 
pathology. This allows for a broad screening of oxidative stress-induced alterations 
throughout various regions of the diseased brain. 
3.3.1.1 Increased antioxidant metabolism in AD patients 
Levels of lipid peroxidation products MDA and HNE were not significantly different 
between AD patients and controls (Figure 3.33 a and b, respectively). Levels of HNE 
showed however a tendency towards lower levels in cerebellum (Figure 3.33 b). RESULTS 
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Figure 3.33: Levels of basal lipid peroxidation products MDA (a) and HNE (b) in AD 
brains. 
Brain homogenates from frontal cortex (FC), parietal cortex (PC), temporal cortex (TC) and 
cerebellum (Cer) were analyzed for levels of lipid peroxidation products. n = 8-10 per group. 
a. Basal MDA levels (nmol/mg protein). Two-way ANOVA: difference between groups n.s. 
b. Basal HNE levels (nmol/mg protein). Two-way ANOVA: difference between groups n.s., 
difference between brain regions p = 0.08. 
 
Samples from AD patients showed significantly higher activities of Cu/Zn-SOD, GPx 
and GR (Figure 3.34). Thus, upregulation of antioxidant enzymes in AD patients may 
serve to inhibit increased formation of lipid peroxidation products. This upregulation is 
found in all brain regions analyzed, although to a different extent. In general, changes 
were most pronounced in samples from temporal cortex, which is a region severely 
affected by the disease (Detoledo-Morrell et al., 1997). RESULTS 
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Figure 3.34: Increased activities of antioxidant enzymes in different brain regions from 
AD patients. 
Brain homogenates from frontal cortex (FC), parietal cortex (PC), temporal cortex (TC) and 
cerebellum (Cer) were analyzed for activities of antioxidant enzymes. n = 8-10 per group. 
a. Cu/Zn-SOD activity (U/mg protein). Two-way ANOVA: p < 0.0001 difference between groups. 
Post hoc t-test: * p < 0.05, ** p < 0.01 vs controls in the same brain region. 
b. GPx activity (mU/mg protein). Two-way ANOVA: p < 0.0001 difference between groups. Post 
hoc t-test: * p < 0.05, ** p < 0.01 vs controls in the same brain region. 
c. GR activity (mU/mg protein). Two-way ANOVA: p < 0.05 difference between groups. Post hoc 
t-test: * p < 0.05 vs controls in the same brain region. 
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Moreover, enzyme activities showed significant and positive correlations in the 
different brain regions, see the example of frontal cortex in Figure 3.35 and Table 3.6 
for complete data. This indicates that not a single antioxidant enzyme is affected but 
rather that the whole cascade of antioxidant enzymatic defense is upregulated. 
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Figure 3.35: Correlation between Cu/Zn-SOD activity and GPx activity in samples from 
AD patients taken from frontal cortex. 
Correlation: rP = 0.8150, p < 0.01. 
 
 
 
Table 3.6: Summary of correlations between different antioxidant enzyme activities in 
different brain regions. 
Brain 
region  Group  Cu/Zn-SOD vs 
GPx 
Cu/Zn-SOD vs 
GR  GPx vs GR 
All  rP = 0.8014 ***  rP = 0.6465 **  rP = 0.7639 *** 
Control  rP = 0.5154 n.s.  rP = 0.2584 n.s.  rP = 0.5481 (*)  FC 
AD  rP = 0.8150 **  rP = 0.7721 *  rP = 0.8693 ** 
All  rP = 0.5768 *  rP = 0.5899 *  rP = 0.7442 *** 
Control  rP = 0.1299 n.s.  rP = -0.1118 n.s.  rP = 0.8228 *  PC 
AD  rP = 0.7515 *  rP = 0.8423 **  rP = 0.6457 (*) 
All  rP = 0.7378 ***  rP = 0.6590 **  rP = 0.6872 ** 
Control  rP = 0.3323 n.s.  rP = 0.4524 n.s.  rP = 0.6885 *  TC 
AD  rP = 0.7180 *  rP = 0.5790 n.s.  rP = 0.5073 n.s. 
All  rP = 0.8883 ***  rP = 0.7648 ***  rP = 0.6917 *** 
Control  rP = 0 9580 ***  rP = 0.5598 (*)  rP = 0.6243 *  Cer 
AD  rP = 0 8832 ***  rP = 0.8179 **  rP = 0.7753 ** 
Asterisks indicate significance of correlation. *** p < 0.001, ** p < 0.01, * p < 0.05, (*) p < 0.1, 
n.s. not significant. 
 RESULTS 
130 
After in vitro stimulation, levels of MDA formation were significantly lower in AD 
patients (Figure 3.36), suggesting that the higher antioxidant enzyme activities in AD 
patients protect against oxidative stimuli. 
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Figure 3.36: Stimulated MDA levels are reduced in AD brains. 
Formation of MDA (nmol/mg protein) was stimulated with 100 µM FeCl3 for 30 min at 37°C. 
Brain homogenates from frontal cortex (FC), parietal cortex (PC), temporal cortex (TC) and 
cerebellum (Cer) were analyzed. n = 8-10 per group. 
Two-way ANOVA: p < 0.01 difference between groups. RESULTS 
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3.3.1.2 Effect of gender on antioxidant metabolism in AD patients 
Based on epidemiological reports of a higher risk for AD in females, we additionally 
analyzed the subgroups of each male and female patients and controls for a putative 
gender difference in oxidative stress parameters. 
Interestingly, levels of HNE were higher in female compared to male AD patients 
(Figure 3.37). 
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Figure 3.37: Gender difference in HNE levels among AD patients. 
AD brain samples from frontal cortex (FC), parietal cortex (PC), temporal cortex (TC) and 
cerebellum (Cer) were analyzed for HNE levels (nmol/mg protein). n = 4-6. Two-way ANOVA: 
p < 0.05 difference between gender. 
 
Furthermore, upregulation of activities of Cu/Zn-SOD and GPx was more pronounced 
in female compared to male AD patients when comparing all brain regions (Figure 
3.38 a and b, respectively), while activity of GR was not different between the gender 
(Figure 3.38 c). No gender differences were found among male and female controls 
(data not shown). 
These results suggest that the AD-related upregulation of antioxidant defense is more 
pronounced in female compared to male AD patients, while female patients at the same 
time display higher oxidative damage at the level of HNE. Thus, female patients are 
seemingly more vulnerable towards oxidative damage despite higher activities of 
Cu/Zn-SOD and GPx. 
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Figure 3.38: Gender differences in antioxidant enzyme activities among AD patients. 
AD brain samples from frontal cortex (FC), parietal cortex (PC), temporal cortex (TC) and 
cerebellum (Cer) were analyzed for activities of antioxidant enzymes. n = 4-6. 
a. Cu/Zn-SOD activity (U/mg protein). Two-way ANOVA: p < 0.05 difference between gender. 
b. GPx activity (mU/mg protein). Two-way ANOVA: p < 0.001 difference between gender. Post 
hoc t-test * p < 0.05. 
c. GR activity (mU/mg protein). Two-way ANOVA: difference between gender n.s. 
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3.3.2 Cohort #2 
In a second study, only tissue samples from temporal cortex were analyzed, since the 
changes in oxidative stress parameters observed in cohort #1 were most pronounced in 
samples from temporal cortex, which is a severely affected brain region in AD. Tissue 
samples from a total of 14 controls (6 female, 8 male) and 16 sporadic AD patients (8 
female, 8 male) were studied. Clinical and neuropathological data as well as Apo E 
genotype were available for most of the tissue samples, allowing for correlations of the 
biochemical parameters with clinical and neuropathological findings and Apo E 
genotype in the individual AD patient or control. 
3.3.2.1 Changes in oxidative stress parameters in AD patients 
As already observed in cohort #1, basal levels of MDA were not significantly different 
between AD patients and controls (Figure 3.39 a), although they were increased in AD 
patients. Levels of HNE were however significantly increased (Figure 3.39 b). 
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Figure 3.39: Basal levels of lipid peroxidation products in AD patients. 
Brain homogenates from temporal cortex were analyzed for basal levels of MDA (a) and HNE 
(b). n = 14 for controls and n = 16 for AD patients. 
a. Basal MDA levels (nmol/mg protein). t-test n.s. 
b. Basal HNE levels (nmol/mg protein). t-test p < 0.01 AD patients vs controls. 
 
In good accordance with cohort #1, we found increased activities of antioxidant 
enzymes in brain samples from AD patients. However, the relative increase was not as 
pronounced as in cohort #1 and only significant for Cu/Zn-SOD and GPx, but not for 
GR activity (Figure  3.40 a, b and c,  respectively). Again, enzyme activities were 
positively and significantly correlated in subgroups of AD patients and controls (see RESULTS 
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Table 3.7), confirming that the whole cascade of antioxidant enzymes is affected as 
already observed previously in cohort #1. 
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Figure 3.40: Increased activities of Cu/Zn-SOD and GPx in AD patients. 
Brain homogenates from temporal cortex were analyzed for activities of antioxidant enzymes. 
n = 14 for controls and n = 16 for AD patients. 
a. Cu/Zn-SOD activity (U/mg protein). t-test * p < 0.05 controls vs AD patients. 
b. GPx activity (mU/mg protein). t-test * p < 0.05 controls vs AD patients. 
c. GR activity (mU/mg protein). t-test n.s. 
 
 
 
 
Table 3.7: Summary of correlations between different antioxidant enzyme activities in 
cohort #2. 
Group  Cu/Zn-SOD vs GPx  Cu/Zn-SOD vs GR  GPx vs GR 
All  rP = 0.9068 ***  rP = 0.7312 ***  rP = 0.7683 *** 
Control  rP = 0.8741 ***  rP = 0.7783 ***  rP = 0.8819 *** 
AD  rP = 0.8777 ***  rP = 0.7348 ***  rP = 0.7031 *** 
Asterisks indicate significance of correlations. *** p < 0.001. 
 
 
 
Higher levels of MDA were correlated with increased acitvities of each Cu/Zn-SOD, 
GPx and GR activity (see Table 3.8). Similar correlations were found for HNE levels, 
which was however only statistically significant for correlation with Cu/Zn-SOD but 
not GPx or GR activity (see Table 3.8 for complete data and Figure 3.41 as example). 
These results suggest that oxidative damage is accompanied by increased antioxidant 
defenses. RESULTS 
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Table 3.8: Correlations between different antioxidant enzyme activities and levels of lipid 
peroxidation products MDA or HNE. 
aldehyde 
vs 
enzyme 
Cu/Zn-SOD  GPx  GR 
MDA  rP = 0.6728 
p < 0.0001 
rP = 0.6525 
p < 0.0001 
rP = 0.5109 
p < 0.01 
HNE  rP = 0.3384 
p < 0.05  n.s. n.s. 
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Figure 3.41: Correlation between HNE levels and Cu/Zn-SOD activity. 
HNE levels (nmol/mg protein) were plotted against Cu/Zn-SOD activity (U/mg protein) in 
samples from controls and AD patients. Correlation. rP = 0.3801, p < 0.05. 
 
 
Stimulation of lipid peroxidation led to increased formation of MDA in samples from 
AD patients (Figure 3.42 a). However, in both the control and AD group, the effect of 
stimulation showed a large variability due to bimodal distribution of values: in both 
groups, local clusters of values well below and above 4 nmol/mg protein MDA 
formation after stimulation could be identified (Figure 3.42 b). RESULTS 
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Figure 3.42: Stimulated levels of MDA in AD patients. 
Brain homogenates taken from temporal cortex were analyzed for levels of MDA after 
stimulation with 100 µM FeCl3 for 30 min at 37°C. n = 14 for controls and n = 16 for AD patients. 
a. Bar graph. 
b. Scatterplot. In both control and AD group, samples that are resistant to stimulation – with 
stimulated MDA levels below an arbitrary threshhold value of 4 nmol/mg protein – as well as 
samples that can be stimulated – with levels above 4 nmol/mg protein – can be identified. In the 
control group, only 5 of 14 individual samples respresenting 36  % of subjects could be 
stimulated, whereas in the AD group, 12 of 16 individual samples representing 75 % could be 
stimulated. 
 
 
Due to this bimodal distribution, the t-test assuming Gaussian distribution is not the 
appropriate statistical instrument to use. Therefore, chi-squared test was calculated. If 
“responders” are defined by more than 4  nmol/mg  protein MDA formation after 
stimulation, 5 of a total of 14 subjects in the control group representing 36 % compared 
to 12 of a total of 16 subjects in the AD group representing 75 % can be classified as 
“responders” (Table 3.9). Calculating the chi-squared value for this distribution gives 
χ2 = 4.69, which is above the critical value of 3.841 for the 5 % limit of significance, 
indicating a significant difference between controls and AD patients (p < 0.05). 
Table 3.9: Distribution of samples from non-demented controls and sporadic AD patients 
classified as “responders” or “non-responders” according to the extent of MDA 
formation after stimulation with ferric iron. 
  “non-responder” “responder”  Total 
Controls  9 5  14 
AD patients  4 12  16 
Total  13 17 30 
 “Responder” were classified as samples that exhibit more than 4 nmol/mg protein elevated 
MDA levels after stimulation of brain homogenates with 100µM ferric iron for 30 min at 37°C. 
“Non-responder” represent samples where less than 4 nmol/mg protein MDA after stimulation 
were formed. χ
2 = 4.69, p < 0.05 significant difference between controls and AD patients. RESULTS 
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The factors that contribute to the MDA response after in vitro stimulation could not be 
elucidated. The groups of each responders and non-responders were not different in age, 
gender, post mortem interval, Apo E genotype or activities of antioxidant enyzmes. 
Also, the tissue storage time of samples, the cause of death and the neuropathological 
Braak staging, the disease duration or the MMSE score gave no clear indication of 
differences between responders and non-responders. Thus, either unknown factors or a 
combination of several singular factors, which can not be statistically elucidated in our 
rather small group with 30 subjects, may affect the outcome of MDA formation after in 
vitro stimulation. 
In contrast to cohort #1, no gender differences between male and female AD patients in 
the activities of antioxidant enzymes or lipid peroxidation products were found in this 
study (data not shown). 
3.3.2.2 Levels  of soluble Aβ1-40 in brains from AD patients – correlation 
with Apo E4 genotype 
Since the primary toxicity mediating the development of Alzheimer’s disease is 
hypothetically attributed to the Aβ peptide, levels of soluble Aβ1-40 were analyzed in a 
subgroup of 15 samples (7 controls, 8 AD patients). The mean Aβ1-40 concentration was 
significantly higher in AD patients compared to controls (Figure 3.43  a). A large 
overlap between the two groups exists, and few individual samples showed very high 
Aβ1-40 concentrations with more than 250 pg/ml in the control group and more than 750 
pg/ml in the AD group (Figure 3.43 b). RESULTS 
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Figure 3.43: Levels of soluble Aβ1-40 in AD patients and controls. 
Aβ1-40 levels (pg/mg protein) were quantified from Tris-soluble brain tissue homogenates with an 
ELISA specific for Aβ1-40. n = 7 for controls, n = 8 for AD patients. 
a. Bar graph. * p < 0.05 controls vs AD patients (Mann-Whitney-test). 
b. Scatterplot. Some overlap between groups exists, furthermore few samples contain very high 
Aβ1-40 levels. 
 
When analyzing subgroups of controls and AD patients according to the presence of 
Apo E4 alleles, the levels of Aβ1-40 were strongly elevated in Apo E4 homozygous 
carriers compared to heterozygous E4 and non-E4 carriers (Figure 3.44 a). Furthermore, 
a protective effect of Apo E2 alleles against Aβ1-40 elevation is observed when the exact 
Apo E genotype is analyzed (Figure 3.44  b), although statistical evaluation was 
precluded due to small numbers of subjects in the respective subgroups. Nevertheless, 
despite the fact that the number of homozygous Apo E4 carriers consisted of only 2 AD 
patients, the small variation in values argues for a prominent role of Apo E4 in 
formation and/or accumulation of Aβ in these subjects. Of note, the Apo E4 allele is the 
most important genetic risk factor for sporadic AD identified so far. RESULTS 
     139 
Apo E4 -/-
Apo E4 -/+
Apo E4 +/+
0
250
500
750
1000
A
 
1
-
4
0
 
p
g
/
m
g
 
p
r
o
t
e
i
n
**
***
2/3 2/4 3/3 3/4 4/4
0
250
500
750
1000
Apo E genotype
A
 
1
-
4
0
 
p
g
/
m
g
 
p
r
o
t
e
i
n
a
b
 
Figure 3.44: Aβ1-40 levels depend on Apo E4 genotype. 
Aβ1-40 levels (pg/mg protein) were quantified from Tris-soluble brain tissue homogenates with an 
ELISA specific for Aβ1-40. Results were analyzed according to Apo E4 genotype: 
a. Subjects were grouped according to the presence of Apo E4 alleles. n = 5 subjects without 
Apo E4 alleles (3 controls, 2 AD patients, Apo E4 -/-), n = 5 heterozygous Apo E4 subjects (2 
controls, 3 AD patients, Apo E4 -/+) and n = 2 homozygous Apo E4 carriers (2 AD patients, Apo 
E4 +/+) were analyzed. Aβ1-40 levels are strongly elevated in Apo E4 carriers. One-way ANOVA 
p < 0.0001. Post hoc t-test *** p < 0.001 Apo E4 -/- vs Apo E4 +/+, ** p < 0.01 Apo E4 -/+ vs 
Apo E4 +/+. 
b. Subjects were grouped according to the exact Apo E genotype. 
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3.3.2.3 Correlations of lipid peroxidation products and antioxidant enzyme 
activities with levels of soluble Aβ1-40 
Levels of Aβ1-40 showed a positive correlation with MDA levels, which just failed to 
reach statistical significance (p = 0.05, Figure 3.45). Aβ1-40 levels did not correlate with 
HNE levels or stimulated MDA levels (data not shown), but were positively correlated 
with activities of Cu/Zn-SOD and GPx (Figure 3.46 a and b, respectively) and showed a 
trend towards correlation with GR (rS = 0.4643, p = 0.08, data not shown). These results 
suggest that increased Aβ1-40 levels promote oxidative damage and at the same time 
cause upregulation of activities of Cu/Zn-SOD and GPx. 
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Figure 3.45: Correlation between MDA and Aβ1-40 levels in controls and AD patients. 
MDA levels (nmol/mg protein) were plotted against Aβ1-40 levels (pg/mg protein) in samples from 
controls and AD patients. Correlation: rS = 0.5107, p = 0.05. 
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Figure 3.46: Correlation between antioxidant enymes Cu/Zn-SOD (a) or GPx (b) and Aβ1-40 
levels in controls and AD patients. 
a. Cu/Zn-SOD activity (U/mg protein) was plotted against Aβ1-40 levels (pg/mg protein) in 
samples from controls and AD patients. Correlation: rS = 0.6714, p < 0.01. 
b. GPx activity (mU/mg protein) was plotted against Aβ1-40 levels (pg/mg protein) in samples 
from controls and AD patients. Correlation: rS = 0.7250, p < 0.01. 
 
3.3.2.4 Correlations of lipid peroxidation products and antioxidant enzyme 
activities with Apo E genotype 
Since the Apo E4 allele is the second most important risk factor – apart from aging – for 
sporadic AD, we speculated whether oxidative damage and changes in antioxidant 
defense may be related to the presence of one or two Apo E4 alleles. 
Levels of lipid peroxidation products MDA and HNE were elevated depending on the 
number of Apo E4 alleles (Figure 3.47). Differences were not significant for MDA, but 
showed a trend for HNE (One-way ANOVA p = 0.077). 
Activities of antioxidant enzymes were similarly elevated in homozygous Apo E4 
carriers (Figure 3.48), but this effect was not statistically significant for any of the 
antioxidant enzymes analyzed. 
These results suggest that Apo E4 alleles favour the formation of lipid peroxidation 
products. However, due to the lack of controls homozygous for Apo E4 this effect could 
also be inherently related to the fact that AD patients and controls were not distributed 
equally between the three groups. We therefore additionally evaluated only AD patients 
and controls separately and similar results were obtained, although this proved to be not 
statistically significant due to smaller numbers of subjects. Nevertheless, levels of HNE 
were still elevated in AD patients compared to controls in each the groups of non-E4 
carriers and heterozygous E4 carriers (Figure 3.49). RESULTS 
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Figure 3.47: Levels of lipid peroxidation products MDA and HNE in relation to Apo E4 
genotype. 
Levels of lipid peroxidation products MDA and HNE (nmol/mg protein) were analyzed according 
to Apo E4 genotype. n = 11 subjects without Apo E4 alleles (6 controls, 5 AD patients, Apo E4   
-/-), n  =  9 heterozygous Apo E4 subjects (3 controls, 6 AD patients, Apo E4 -/+) and n  =  3 
homozygous Apo E4 carriers (3 AD patients, Apo E4 +/+) were analyzed. 
MDA: One-way ANOVA n.s. 
HNE: One-way ANOVA: p = 0.077. Post hoc t-test * p < 0.05 Apo E4 -/- vs Apo E4 -/+. 
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Figure 3.48: Activities of antioxidant enzymes in relation to Apo E4 genotype. 
Activities of antioxidant enzymes Cu/Zn-SOD (a), GPx (b) and GR (c) were analyzed according 
to Apo E4 genotype. n = 11 subjects carrying no Apo E4 alleles (6 controls, 5 AD patients, 
Apo E4 -/-), n = 9 heterozygous Apo E4 subjects (3 controls, 6 AD patients, Apo E4 -/+) and 
n = 3 homozygous Apo E4 carriers (3 AD patients, Apo E4 +/+) were analyzed. Differences are 
not statistically significant in One-way ANOVA. Post hoc t-test (*) p = 0.09 GPx activity Apo E4  
-/+ vs Apo E4 +/+. 
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Figure 3.49: HNE levels in controls and AD patients in relation to Apo E4 genotype. 
HNE levels were analyzed according to Apo E genotype in control and AD group seperately. 
Apo E4 homozygous controls were not available (n.a.). n = 6 controls Apo E4 -/-, n = 5 AD 
patients Apo E4 -/-, n = 3 controls Apo E4 +/-, n = 6 AD patients Apo E4 +/-, n = 3 AD patients 
Apo E4 +/+. One-way ANOVA p = 0.10. Differences between controls and AD patients in the 
same Apo E genotype group are not statistically significant. 
 
3.3.2.5 Correlations of lipid peroxidation products and antioxidant enzyme 
activities with mini mental status (MMSE) score  
MMSE (mini mental status examination) data were available for 2 controls and 11 AD 
patients. The MMSE test is widely used as a routine measure of cognitive abilities in 
demented patients. Non-demented individuals can score a maximum of 30 points – 
depending on the age and degree of school education – whereas demented patients 
usually have much lower values. In our sample, two control individuals scored 29 and 
28 points indicating no cogitive impairment, whereas the AD patients scored 21 or less 
points indicating mild to severe cognitive impairment. One patient was even unable to 
conduct the test at all, scoring 0 points. 
We speculated whether the degree of cognitive impairment quantified with MMSE was 
related to increased oxidative damage as measured by the levels of lipid peroxidation 
products. Interstingly, levels of MDA were negatively correlated with the MMSE score, 
which just failed to reach statistical significance (p = 0.055, Figure 3.50). This indicates 
that oxidative damage at the level of MDA increases during the clinical progression of 
the disease. RESULTS 
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Figure 3.50: Correlation between MDA levels and MMSE score. 
MDA levels (nmol/mg protein) were plotted against mini mental status examination (MMSE) 
score. Correlation: rS = -0.5427, p = 0.055. 
 
Levels of HNE were however not linearly correlated with MMSE scores (Figure 
3.51 a). Patients with low MMSE scores had rather lower levels of HNE. Therefore, the 
data was further evaluated according to MMSE score. The mean MMSE score in AD 
patients was 8.6, therefore groups of AD patients with low MMSE scores of 8 or less 
and with moderate MMSE scores of 9 or higher were evaluated (Figure 3.51 b). Levels 
of HNE in the moderate MMSE AD patient group were significantly higher compared 
to the control group and were also significantly higher compared to AD patients with 
low MMSE scores. Therefore, it can be speculated that HNE levels are higher in earlier 
stages of the disease and decrease with the progression of the disease. RESULTS 
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Figure 3.51: Correlation between HNE levels and MMSE score. 
a. HNE levels (nmol/mg protein) were plotted against mini mental status examination (MMSE) 
score. No significant linear correlation was found between HNE levels and MMSE score. 
b. Mean HNE levels (nmol/mg protein) vary with cognitive impairment. Samples were grouped 
according to cognitive impairment: AD patients were divided into two groups depending on 
MMSE score, either below the mean MMSE score of 8.6 (AD, low MMSE; dark grey bar; n = 5) 
or above 8.6 (AD, moderate MMSE; bright grey bar; n = 6). The mean of the control group is 
represented by the white bar (n = 14). One-way ANOVA: p < 0.01. Post hoc t-test + p < 0.05 low 
vs moderate MMSE AD patients, *** p < 0.001 moderate MMSE AD patients vs controls. 
 
At the level of enzymatic antioxidant defense, no significant linear correlation with 
MMSE scores was observed for any of the enzymes Cu/Zn-SOD, GPx or GR, 
respectively (data not shown). When AD patients were divided into two groups with 
low and moderate MMSE scores, activities of Cu/Zn-SOD and GPx were highest in the 
moderate MMSE score group of AD patients, which showed a tendency towards 
significance for Cu/Zn-SOD (Figure 3.52  a) and was significant for GPx activity 
(Figure 3.52 b) compared to controls. In contrast to Cu/Zn-SOD and GPx activity, GR 
activity was highest in the group with low MMSE score, which was however not 
statistically significant (Figure 3.52 c). 
Levels of MDA formation after in vitro stimulation showed no striking differences 
between the control group and each the low and moderate MMSE AD patient groups 
(data not shown). RESULTS 
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Figure 3.52: Activities of antioxidant enzymes in AD patients according to cognitive 
impairment. 
Samples were grouped according to cognitive impairment: AD patients were divided into two 
groups depending on MMSE score, either below the mean MMSE score of 8.6 (AD, low MMSE; 
dark grey bar, n = 5) or above 8.6 (AD, moderate MMSE; bright grey bar; n = 6). The mean of 
the control group is represented by the white bar (n = 14). 
a. Activity of Cu/Zn-SOD (U/mg protein). One-way ANOVA n.s. Post hoc t-test (*) p < 0.1 AD 
moderate MMSE vs controls. 
b. Activity of GPx (mU/mg protein). One-way ANOVA p < 0.1. Post hoc t-test * p < 0.05 AD 
moderate MMSE vs controls. 
c. Activity of GR (mU/mg protein). One-way ANOVA n.s. 
 
It has to be noted that the MMSE score is dynamically changing during the disease pro-
gression with an average reduction of about 3 points per year (Salmon et al., 1990; Han 
et al., 2000; Ballard et al., 2001). Since the available MMSE score had in some cases 
been acquired several months prior to death, the time-span between the last MMSE 
assessment and death of the patient may have led to an additional loss in MMSE scores. 
Hence, the above effects were reevaluated with mathematically corrected MMSE scores 
assuming an average disease progression with a loss of 3 points in the MMSE per year. 
This evaluation produced essentially the same results (data not shown). 
In summary, dynamic alterations in oxidative stress parameters occur during the 
progression of the disease – raising the possibility that the search for antioxidant 
pharmacological interventions aimed at a modification of antioxidant capacity may 
result in future AD therapies which can halt or at least slow the disease progression. DISCUSSION 
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4 DISCUSSION DISCUSSION 
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The results obtained in the course of this thesis allow for an estimation of (i) age-
associated changes in oxidative stress parameters in mice and (ii) AD-relevant 
alterations in oxidative stress parameters studied in transgenic animals and human brain 
tissue. Aging is the most prominent risk factor for AD – with impact on the onset of 
disease in both the sporadic and the familial forms of AD – and aging also influences 
the accumulation of AD-associated neuropathology in transgenic mouse models. Hence 
the alterations in oxidative stress parameters observed in mice during aging and their 
relevance to the situation in humans will be discussed prior to the results on AD-
associated changes. 
4.1 Effects of aging and gender on ROS metabolism in 
C57BL/6J mice 
4.1.1  Effect of aging on oxidative stress parameters in brain 
tissue 
Among several organs, the brain is considered to be especially vulnerable towards 
oxidative stress due to its high metabolic rate, its high content of unsaturated fatty acids 
which are especially prone to free radical attack, the relative paucity of antioxidant 
defenses and limited ability to regenerate dead neuronal cells (Halliwell, 1992). As aged 
animals – rodents as well as non-human primates – exhibit cognitive deficits (Rapp and 
Amaral, 1989; Barnes et al., 1997) and as a loss of memory and cognitive abilities is 
present in aged humans (Ciocon and Potter, 1988; Albert, 2002), the contribution of 
oxidative stress to these age-associated deficits is a feasible hypothesis. 
Paradoxically reduced levels of lipid peroxidation products in aged mice 
Our results obtained on brain tissue homogenates from female mice during aging do 
however not unambigously support the oxidative stress hypothesis. The hypothesis 
would predict that aging leads to increased accumulation of ROS. As high levels of 
ROS provoke oxidative damage to cellular components, markers for oxidative stress 
like lipid peroxidation products should be increased in aged animals. Yet in our study, 
lipid peroxidation products MDA and HNE as markers of oxidative damage to fatty 
acids are paradoxically lower in brains of aged animals (see Figure 3.1, page 83). 
Comparing these results with published data analyzing mouse brains with similar 
methods, it is obvious that several groups obtained conflicting results (Table 4.1). DISCUSSION 
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Similarly conflicting results regarding changes in oxidative stress parameters with aging 
have been reported in other rodents, mostly rats. Thus, oxidative stress parameters show 
variable changes with age in different mammalian species and strains. Furthermore, 
striking differences seem to exist between different brain regions (Ramassamy et al., 
2001). The conflicting results can be further due to animal maintenance conditions, 
different experimental procedures and tissue preparation techniques. 
Table 4.1: Overview of studies on lipid peroxidation products during aging in mice. 
change with 
aging 
age groups 
analyzed 
mouse strain, 
gender  Reference 
increased  100-360 days  C57BL/6 X CBA/6J  (Cristiano et al., 1995) 
increased  2, 10, 16, 20 months NMRI, female  (Leutner et al., 2001) 
increased  8, 11 months  C57BL/6N, female  (Liu et al., 2003) 
increased  1.5-2, 19 months  Swiss albino, male  (Manda and Bhatia, 2003) 
peak at 10 months 1, 4, 10, 18 months  CBA, female  (Sobocanec et al., 2003) 
unchanged  2, 12, 28 months  C57BL/6 X DBA/2 
F1 hybrids  (Ceballos-Picot et al., 1992) 
unchanged 0-700  days  C57BL/6J X CB1     
F1 hybrids  (de Haan et al., 1992) 
unchanged  3, 25 months  C57BL/6 X DBA/2 
F1 hybrids  (Bonnes-Taourel et al., 1993)
unchanged  3, 13 months  C57BL/6J, male  (Ramassamy et al., 2001) 
unchanged  3, 12 months  C57BL/6J  (Oxenkrug and Requintina, 
2003) 
 
In the previous study by Leutner et al. on NMRI mice in our group (2001), essentially 
the same method of preparation and assay conditions have been employed. It is 
therefore possible that differences between C57BL/6J mice and NRMI mice in MDA 
levels during aging are due to inherent strain differences. Other studies have reported 
strain differences in oxidative stress parameters in mice (Ahotupa et al., 1993; Gerhard 
et al., 2002), albeit these studies did not analyze brain tissue and NMRI and C57BL/6J 
mice have not been compared directly. Nevertheless, strain differences likely account 
for some of the differences between our results and the study of Leutner et al. (2001). 
Changes in activities of antioxidant enzymes 
As oxidative damage can result from increased ROS production and/or insufficient 
detoxification, a higher antioxidant capacity of brain tissue from aged mice can explain 
the lower amounts of MDA and HNE. Our results on acitivites of antioxidant enzymes 
revealed that aging leads to increased antioxidant enzyme activities in murine brains. 
The three enzymes studied – Cu/Zn-SOD, GPx and GR – are affected differently by DISCUSSION 
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aging: while GPx activity is steadily increasing up to an age of 25 months, Cu/Zn-SOD 
and GR activities rise until 19-22 months but decline in 25 months old animals to nearly 
the levels of 3 months old mice (see Figure 3.2, page 85). In general, increased or 
unchanged activities of several antioxidant enzymes have been reported by the majority 
of comparable studies in murine brains (Table 4.2). Cu/Zn-SOD activity was mainly 
reported to be increased, whereas glutathione-related enzymes GPx and GR displayed 
differential changes with aging. 
Table 4.2: Overview of studies on antioxidant enzyme activities during aging in mice. 
change with 
aging 
age groups 
analyzed 
mouse strain, 
gender  Reference 
total SOD activity 
increased  3, 23-24 months  CD1, male  (Danh et al., 1983) 
increased  1, 6, 12, 24 months  C57BL/6N, male  (Hussain et al., 1995) 
decreased  12, 24 months  C57B1, male  (Mo et al., 1995) 
Cu/Zn-SOD activity 
increased 0-700  days  C57BL/6J X CB1     
F1 hybrids  (de Haan et al., 1992) 
increased  3, 12, 28 months  C57BL/6 X DBA/2 
F1 hybrids  (Ceballos-Picot et al., 1992) 
increased  100-360 days  C57BL/6 X CBA/6J  (Cristiano et al., 1995) 
increased  2, 10, 16, 20 months NMRI, female  (Leutner et al., 2001) 
unchanged  3, 23-24 months  CD1, male  (Danh et al., 1983) 
unchanged  3, 18, 34 months  C57B1  (Cardozo-Pelaez et al., 1999)
GPx activity 
increased  1, 6, 12, 24 months  C57BL/6N, male  (Hussain et al., 1995) 
increased  3, 12, 28 months  C57BL/6 X DBA/2 
F1 hybrids  (Ceballos-Picot et al., 1992) 
unchanged 0-700  days  C57BL/6J X CB1     
F1 hybrids  (de Haan et al., 1992) 
unchanged  3, 18, 34 months  C57B1  (Cardozo-Pelaez et al., 1999)
unchanged  2, 10, 16, 20 months NMRI, female  (Leutner et al., 2001) 
GR activity 
increased  2, 10, 16, 20 months NMRI, female  (Leutner et al., 2001) 
unchanged  3, 12, 28 months  C57BL/6 X DBA/2 
F1 hybrids  (Ceballos-Picot et al., 1992) 
decreased  12, 24 months  C57B1, male  (Mo et al., 1995) 
 
As antioxidant enzyme activities vary between brain regions (Carrillo et al., 1992; 
Hussain et al., 1995), show a different cellular localization in neurons and glial cells 
(Delacourte et al., 1988; Ceballos et al., 1991; Wilson, 1997) and a discrete subcellular 
localization (Vitorica et al., 1984), the method of brain tissue preparation can probably 
explain some of the divergent findings. However, as the methods used in this thesis are 
the same as in the study by Leutner et al. on NMRI mice in our group (2001), subtle DISCUSSION 
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differences between mouse strains seem to exist also at the level of antioxidant enzyme 
activities. While NMRI mice showed a large increase in Cu/Zn-SOD activity of 87 % 
already at an age of 10-12 months compared to 2-3 months old mice, the changes we 
observed in C57BL/6J mice were moderate with a maximum increase of 11 % in 19-22 
months old animals compared to 3 months old mice. Furthermore, NMRI mice showed 
no significant elevation of GPx activity during aging, whereas GPx activity steadily 
increases in C57BL/6J mice with aging. Age-associated changes in GR activity are 
however similar in both mouse models, with a 22 % and 20 % increase in 19-22 months 
old NMRI or C57BL/6J mice, respectively, over the levels of young mice. Thus, NMRI 
mice differ from C57BL/6J mice in terms of greatly increased Cu/Zn-SOD activity but 
unchanged GPx activity with aging. Interestingly, the ratio of SOD versus GPx has been 
implicated in oxidative damage (de Haan et al., 1995), as increased SOD activity 
without concomitantly upregulated GPx activity would lead to accumulation of 
hydrogen peroxide. Therefore, increased MDA levels with aging in NMRI mice can be 
explained by an imbalance of Cu/Zn-SOD over GPx activity. Conversely, the 
simultaneously rising Cu/Zn-SOD and GPx activity in our study of C57BL/6J mice 
could be responsible for the decreased levels of lipid peroxidation products MDA and 
HNE during aging in this mouse strain. 
From these results it can be postulated that the whole cascade of antioxidant enzymes is 
important in protection against oxidative damage. This is essentially not surprising, 
since the antioxidant network is a complex interplay between various factors, and in 
most studies a combination of several singular factors has shown the greatest benefit. In 
Drosophila melanogaster, the simultaneous overexpression of Cu/Zn-SOD and catalase 
led to increased life span accompanied by decreased oxidative protein damage (Orr and 
Sohal, 1994), whereas overexpression of Cu/Zn-SOD alone was ineffective (Orr and 
Sohal, 1993). Moreover, overexpression of Cu/Zn-SOD alone in mice even resulted in 
increased basal levels of lipid peroxidation products (Ceballos-Picot et al., 1992). 
Activities of antioxidant enzymes are obviously interrelated, as overexpression of 
Cu/Zn-SOD in mice can effect a in increase in other antioxidant enzymes Mn-SOD, 
catalase and GPx (Przedborski et al., 1992). Cell culture studies with Cu/Zn-SOD 
overexpression produced similar results, where murine fibroblast produced higher levels 
of GR activity after transfection with Cu/Zn-SOD (Kelner et al., 1995a; Lee et al., 
2001). However, overexpression of GPx does not alter activities of Cu/Zn-SOD (Kelner 
et al., 1995b), suggesting that Cu/Zn-SOD activity can affect downstream antioxidant DISCUSSION 
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enzymes GPx and GR, while vice versa GPx does not affect upstream Cu/Zn-SOD 
activity. This generally supports the hypothesis that changes in a singular antioxidant 
enzyme can affect other related enzymes, especially if these are located downstream in 
the antioxidant enzymatic cascade. 
Response to oxidative stimuli in vitro 
As the total antioxidant capacity of brain tissue can not be estimated merely from the 
activities of antioxidant enzymes, experiments of in vitro stimulation of lipid 
peroxidation were conducted on the brain homogenates. Exogenously added ferric iron 
ions Fe
3+ can be reduced to ferrous iron Fe
2+ by superoxide radicals (see 1.1.1, equation 
(II), page 4). Ferrous iron subsequently propagates hydroxyl radical formation from 
hydrogen peroxide (see 1.1.1, equation (I), page 4), which reacts to initiate lipid 
peroxidation chain reactions (see 1.1.3.3, page 10 et seqq.). The net reaction is the 
Haber-Weiss reaction, where iron catalyses the decomposition of superoxide radicals 
and hydrogen peroxide to yield hydroxyl radicals. The radical attack on unsaturated 
fatty acids leads to lipid hydroperoxide formation, which are finally degraded to lipid 
peroxidation products like MDA. Thus, the amount of MDA formation after in vitro 
stimulation with ferric iron is an indirect measure for the free radical scavenging 
abilities of brain homogenates. 
In our study on C57BL/6J mice, stimulation of MDA formation showed a U-shaped 
course during aging (Figure 3.3, page 86): samples from middle-aged 13-15 months old 
and aged 19-22 months old mice showed lower MDA formation after stimulation 
compared to young 3-4 months old mice, which is in good accordance with the 
increased activities of antioxidant enzymes in these age groups compared to young 
mice. Stimulation of lipid peroxidation was however increased in highly aged 25 
months old mice compared to middle-aged and aged mice. The decline in activities of 
Cu/Zn-SOD and/or GR in 25 months old mice could explain this observation. As 25 
months old animals show low Cu/Zn-SOD activity, superoxide radicals can accumulate 
in the sample homogenate giving rise to the Haber-Weiss reaction. Consequently, more 
radicals can participate in lipid peroxidation reactions. The diminished activity of GR 
would lead to depletion of reduced glutathione in the homogenate. Since glutathione can 
scavenge free radicals directly and is also a cofactor for the lipid hydroperoxide-
reducing enzyme PH-GPx (Imai and Nakagawa, 2003), lack of reduced glutathione 
additionally favours lipid peroxidation reactions. Hence the effects of in vitro DISCUSSION 
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stimulation of lipid peroxidation seem to reflect the overall free radical scavenging 
abilities of the different antioxidant enzymes. 
Interestingly, in the study of Leutner et al. (2001), similar results have been obtained, 
where NMRI mice at 10-11 and 16-17 months displayed lower MDA formation 
compared to 2-3 months old mice after in vitro stimulation with ferric iron. Thereafter, 
at an age of 20-21 months, MDA formation rises again to nearly the levels of 2-3 
months old mice. Such a U-shaped change of MDA formation after in vitro stimulation 
during aging was also observed in our studies on C57BL/6J mice. Hence – despite strain 
differences in C57BL/6J and NMRI mice in basal levels of lipid peroxidation products 
and activities of antioxidant enzymes SOD and GPx during aging – brain homogenates 
from C57BL/6J and NRMI mice display a similar reaction towards in vitro stimulation 
during aging. Although the results obtained in the different studies and mouse strains by 
our group correlate well, conflicting results have been reported by other researchers (see 
Table 4.3). Again, strain differences, animal maintenance conditions, different 
experimental procedures and tissue preparation techniques might serve to explain some 
of these variations. 
Table 4.3: Overview of studies on in vitro stimulation of lipid peroxidation during aging in 
mice. 
change with 
aging 
age groups 
analyzed 
mouse strain, 
gender  Reference 
linearly increased  0-700 days  C57BL/6J X CB1     
F1 hybrids  (de Haan et al., 1992) 
increased  12, 24 months  C57B1, male  (Mo et al., 1995) 
U-shaped course, 
lowest at 
10-11 months 
2, 10, 16, 20 months NMRI, female  (Leutner et al., 2001) 
peak at 12 months 3, 12, 28 months  C57BL/6 X DBA/2 
F1 hybrids  (Ceballos-Picot et al., 1992) 
unchanged  3, 13 months  C57BL/6J, male  (Ramassamy et al., 2001) 
 
Conflicting reports from other labs – possible explanations 
Apart from artefacts arising due to differences in methodologies between several 
research groups, the many divergent findings in various reports suggest two possible 
explanations for contradictory observations: 
•  The first possibility is that different animal species, strains, maintenance and 
environmental conditions have an impact on the adaption of organisms towards 
ROS during aging in such a way that the observed parameters – lipid 
peroxidation products and antioxidant enzymes – are differently regulated, DISCUSSION 
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serving to keep other parameters in balance. 
  In this respect, the GSH/GSSG ratio seems to be a quite robust marker. Various 
studies have reported a decreased GSH content or decreased GSH/GSSG ratio in 
aged mouse brains (Chen et al., 1989; de la Asuncion et al., 1996; Rebrin et al., 
2003; Wang et al., 2003; Manda and Bhatia, 2003). Although other studies have 
found increased or unchanged levels of GSH in various regions of aged mouse 
brains, synaptosomes or mouse brain mitochondria (Martinez et al., 1994; 
Hussain et al., 1995; Martinez et al., 1995), the GSH/GSSG ratio was not 
calculated in these studies. Thus, the most consistent results on oxidative stress 
parameters during aging in mouse brains have been obtained with the 
GSH/GSSG ratio so far. 
Our results on alterations in activities of antioxidant enzymes with aging could 
at least hypothetically be reconciled with a decreased GSH/GSSG ratio. As 
Cu/Zn-SOD activity increases with aging, higher levels of hydrogen peroxide 
H2O2 should be produced from the SOD reaction, which are then processed by 
the GPx reaction under consumption of reduced glutathione. As the GPx activity 
is steadily increasing up to 117.7  %, but GR activity is only 104.2  % in 25 
months old mice relative to young mice, it is conceivable that high GPx activity 
without simultaneously increased GR activity may result in an imbalance 
between the consumption and restoration of reduced GSH. Hence – although 
other factors have an impact on enzyme activity and availability of substrates in 
vivo – the ratio of GSH/GSSG could at least hypothetically be decreased in aged 
C57BL6/J mice. 
•  The other possibility to explain the conflicting results on activities of antioxidant 
enzymes and lipid peroxidation products in aging mouse brains may reside in 
the relatively mild changes that are observed in most studies. Although 
differences in lipid peroxidation products were as much as a maximum 33 % 
decrease for HNE in 25 months old mice, the changes in antioxidant enzyme 
activities ranged only up to a 19.7 % increase for GR activity in 19-22 months 
old animals compared to young mice. This maximum increase of less than 20 % 
on average may be difficult to be reproduced in further studies. Thus, if the 
changes in antioxidant enzyme activities during aging are rather small, the 
variances in different experiments may produce a slight but significant decrease 
in one study, while in another study the same variance may lead to a statistically DISCUSSION 
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significant increase as final outcome. 
  Yet the observations in our group do not support this reasoning: although 
changes in activities of antioxidant enzymes may be somewhat subtle, the results 
of Leutner et al. (2001) and the results presented in this thesis regarding 
activities of antioxidant enzymes during aging in mouse brains consistently 
show an elevation of enzyme activities during aging. Furthermore, these effects 
have been reproduced later in independent studies by other researchers in our 
group (I. Scherping, S. Hauptmann, S. Schmitt-Schillig, personal 
communications), suggesting that the increase in antioxidant enzyme activities 
in mouse brains from either NMRI or C57BL/6J mice is a robust and 
reproducible observation. 
Is the extent of antioxidant enzyme upregulation during aging sufficient? 
A very important question arising from changes of antioxidant enzymatic defense with 
aging is whether the extent of upregulation is sufficient for prevention of oxidative 
damage. It has to be considered that the animals included in our study were free of 
visible tumours and showed no splenomegaly, thus representing rather “healthy aging”, 
which may explain why the extent of alterations observed during aging are rather 
modest. The maximum increase in antioxidant enzyme activities observed in mouse 
brain was 10.8  % for Cu/Zn-SOD and 19.7  % for GR activity at an age of 19-22 
months, and 17.7 % for GPx activity at an age of 25 months compared to 3-4 months 
old mice. Are these changes of 10 to 20 % sufficient to be of functional relevance in 
aging brain tissue? 
Our results on basal and stimulated levels of lipid peroxidation products support the 
notion that antioxidant defense is functionally intact and increased in aged mice, but as 
we did not analyze other factors apart from the three antioxidant enymes it can not be 
definitely decided whether it is really the combination of increased Cu/Zn-SOD, GPx 
and GR activities that causes this protection against oxidative damage or whether 
another factor not analyzed in our studies mediates the effects. Interestingly, the extent 
of alterations in lipid peroxidation parameters were more pronounced, with a maximum 
decrease of 20 % for MDA and 33 % for HNE in 25 months old animals. Hence it must 
be considered whether a rather moderate increase in antioxidant enzyme activities can 
cause a more pronounced decline in oxidative stress parameters. An important point to 
be considered is that the enzymatic activities are measured in an assay where enzyme DISCUSSION 
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substrate is provided in excess to have a linear correlation between substrate 
consumption and amount of enzyme present. It is however questionable whether these 
rather high substrate concentrations are ever reached inside cells in vivo. Assuming 
saturable Michaelis-Menten enzyme kinetics for the antioxidant enzymes (Fee and Bull, 
1986; Kim and Kang, 1997; Sasaki et al., 1998; Hashida et al., 2002), the velocity of 
substrate consumption increases with rising substrate concentration. Hence, the amount 
of substrate, i.e. ROS, consumed in cells in vivo can be actually more pronounced than 
the relative increase in enzyme activities measured in the in vitro assays. 
Furthermore, it has to be considered that over-active antioxidant enzymes may even 
have deleterious effects. Thus, highly increased activity of Cu/Zn-SOD can result in 
overproduction of hydrogen peroxide with prooxidant effects (Ceballos-Picot et al., 
1992), especially when increased SOD activity is not counteracted by a rise in GPx 
and/or catalase activity (de Haan et al., 1996). Also, imbalanced activities of GPx and 
GR in highly aged mice could result in altered homeostasis of reduced GSH affecting 
the redox state of thiol-containing proteins, which may result in putative deleterious 
effects on cellular functions (Tanaka et al., 2001; Pastore et al., 2003). For these 
reasons, the relatively subtle increases in antioxidant enzymes during aging probably 
reflect physiological healthy aging and can be of functional relevance for efficient ROS 
detoxification. 
Is oxidative damage associated with cognitive deficits? 
Aging is associated with a slow deterioration of congitive performance in humans 
(Ciocon and Potter, 1988; Albert, 2002), and moreover mild cognitive impairment in 
elderly is a risk factor for the clinical development of later AD (Grundman et al., 2004). 
Similar observations of impaired cognitive function with aging have been made in 
C57BL/6 mice and other rodents (Dean et al., 1981; Gallagher and Nicolle, 1993), and 
furthermore administration of antioxidants has been shown to protect against memory 
loss in aged mice (Joseph et al., 1998; Joseph et al., 1999; Martinez et al., 2000; Liu et 
al., 2003). Studies on humans have produced similar results (Perrig et al., 1997; 
Paleologos et al., 1998; Schmidt et al., 1998; Grodstein et al., 2000; Morris et al., 
2002b). These findings raise the question whether oxidative damage contributes to age-
associated cognitive deficits. Although increased oxidative damage at the level of lipid 
peroxidation could not be demonstrated in whole brain homogenates in our experiments 
in mice, the results do not rule out that oxidative damage can occur at discrete cellular DISCUSSION 
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or subcellularly localized structures. It might be conceivable that the overall amount of 
lipid peroxidation products is decreased in brains as a whole, but that some small 
proportion of structures essential to cognitive function is nevertheless oxidatively 
damaged. Immunohistochemical detection of oxidatively modified proteins in aged 
rodent, primate and human brain tissue yielded highest staining in neuronal structures 
(Goyal, 1982; Horie et al., 1997; Gilissen et al., 1999; Vohra et al., 2001), therefore 
neurons might be oxidatively damaged although the brain as a whole does not reflect 
this damage. Furthermore, levels of lipid peroxidation products do not preclude that 
proteins or DNA are oxidatively modified. Hence our results do not rule out the 
possibility that neuronal structures can be affected by oxidative damage. 
In this regard, it is interesting to consider the different subcellular localization of 
antioxidant enzymes: while Cu/Zn-SOD has been detected mainly in neurons (Ceballos 
et al., 1991; Zhang et al., 1993; Bergeron et al., 1996), GPx and GR have been detected 
in astrocytes (Damier et al., 1993; Knollema et al., 1996). Localization of GPx and GR 
in astrocytes is accompanied by an increased content of glutathione in these cells as 
compared to neurons (Rice and Russo-Menna, 1998), which coincides with the 
proposed important role of astrocytes in brain glutathione metabolism (Desagher et al., 
1996; Dringen et al., 1999). We found that activity of Cu/Zn-SOD increases with aging 
until 19-22 months, whereas activity of GPx shows a steady increase with aging. It is 
therefore conceivable that rising Cu/Zn-SOD activity in aged mice leads to 
accumulation of hydrogen peroxide selectively in neurons, whereas increasing GPx 
activity offers only limited protection since it is localized mainly to astrocytes. This 
would result in the observed decrease in levels of lipid peroxidation products in whole 
brain homogenates from aged mice, while increased oxidative damage to neurons can 
not be ruled out at the same time. Thus, rising Cu/Zn-SOD activity in aging mice could 
contribute to selective oxidative vulnerability of neurons that would result in cognitive 
deficits. The importance of superoxide decomposition for maintenance of cognitive 
function has been elegantly demonstrated in a study by Liu and coworkers, where age-
related cognitive deficits in female C57BL/6 mice could be reversed by systemic 
administration of brain permeable superoxide dismutase/catalase mimetics (Liu et al., 
2003). Hence, the pharmacological augmentation of antioxidant defenses − thus giving 
futher support to the aging-induced upregulation of antioxidant enzymes − may prove 
beneficial in the prevention of age-associated cognitive deficits. DISCUSSION 
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Summary of aging-induced effects on oxidative stress parameters in brain tissue 
Taken together, our observations on basal and stimulated lipid peroxidation 
parameters and activities of antioxidant enzymes suggest that brain aging in 
C57BL/6J mice is accompanied by several adaptive changes, which serve to reduce 
oxidative damage. As basal lipid peroxidation is decreased and activities of 
antioxidant enzymes are concomitantly upregulated in brains from aged mice, the 
antioxidant system obviously works efficiently in the detoxification of ROS, even in 
highly aged animals at 25 months of age. Only after in vitro stimulation of lipid 
peroxidation could we observe an increased susceptibitlity towards oxidative damage 
in highly aged compared to middle-aged and aged animals. Nevertheless, this 
increased susceptibility was not significant when comparing highly aged with young 
mice. Therefore, brains from female C57BL/6J mice seem to be quite resistant 
towards oxidative damage with aging – at least under the conditions in our 
experiments. 
Although lipid peroxidation parameters can be influenced by an altered membrane 
lipid composition (Wood et al., 1984; Imre et al., 2000; Eckert et al., 2001d) or a rise 
in aldehyde-detoxifying enzymes (Cao et al., 1983; Martinez-Lara et al., 2003) during 
aging, which may have additionally affected the outcome of our measurements, our 
results nevertheless argue for a great importance of antioxidant enzymes in the 
protection against oxidative damage during aging. 
 
4.1.2 Effect of aging on ROS levels in peripheral cells 
Our studies on oxidative stress parameters in aging murine brains were extended to a 
peripheral cell model. We chose splenic lymphocytes since they offer several 
advantages: 
•  there seems to exist a close interaction between cells of the immune system and 
the central nervous system (Wekerle et al., 1987; Ringheim and Conant, 2004), 
suggesting that these peripheral cells can mirror some events in brain tissue, 
•  several studies on neurodegenerative diseases and brain aging in humans and 
mouse models have successfully used lymphocytes to monitor changes in brain 
tissue, including some studies of our own group (Eckert et al., 1994; Eckert et 
al., 1998; Schindowski et al., 2000; Eckert et al., 2001b; Gibson and Huang, DISCUSSION 
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2002; Schindowski et al., 2003), 
•  lymphocytes represent easily accessible peripheral cells, which can be 
conveniently and selectively analyzed by flow cytometry, 
and 
•  they can be used as a model of living cells, where ROS can be detected directly 
by the use of oxidation-sensitive fluorescent probes. 
These advantages make lymphocytes a valuable tool to study age-related effects on 
brain oxidative stress parameters in a corresponding peripheral cell model. 
Subtle increases in mitochondrial ROS during aging 
The oxidative stress hypothesis would predict that levels of ROS rise with aging. 
However, no such effects could be observed in our study. Although lymphocytes show a 
tendency towards elevated oxidation of the ROS-sensitive dye DHR in middle-aged 13-
15 months old animals, this effect was not further exacerbated in aged 19-22 months old 
animals (Figure 3.4, page 88). In the subset of CD4-positive lymphocytes, aged animals 
even display lower DHR oxidation than middle-aged animals. Therefore, the overall 
data on DHR oxidation during aging in splenic lymphocytes suggest that either 
increased ROS formation is not a major feature of aging – at least in these cell types 
under our conditions – or that antioxidant systems operate efficiently even in aged mice 
preventing excessive accumulation of ROS. 
Other oxidation-sensitive fluorescent dyes DCFH-DA and DHE displayed no alterations 
with aging. Furthermore, staining of lymphocytes with R123, the oxidized form of 
DHR, revealed no age-associated changes, suggesting that the results obtained with 
DHR are not confounded by altered mitochondrial retention of R123 or by interactions 
via P-glycoprotein. In conclusion, neither altered mitochondrial function nor increased 
superoxide production are features of splenic lymphocytes in aging mice. 
An overlap exists in the sensitivity of DHR and DCFH-DA towards oxidation by 
different ROS (see Table 2.3, page 68), as both dyes have been reported to be oxidized 
by peroxynitrite and peroxides (Bass et al., 1983; Kooy et al., 1994; Kooy et al., 1997; 
Hempel et al., 1999; Walrand et al., 2003). However, DCFH-DA seems to be oxidized 
mainly by cytosolic peroxides, whereas DHR has been reported to detect mainly 
mitochondrial ROS (Royall and Ischiropoulos, 1993; Diaz et al., 2003). From our 
results it can be estimated that cytosolic ROS are not increased during aging in splenic DISCUSSION 
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lymphocytes, whereas mitochondrial ROS are slightly but not significantly elevated in 
aged animals. Importantly, these increased levels of mitochondrial ROS are probably 
not related to profound mitochondrial damage, since superoxide radical production and 
mitochondrial membrane potential, as evidenced by staining with DHE and R123, were 
not altered. 
Increased NO levels in lymphocytes from aged female mice 
The oxidation-sensitive dyes DHR and DCFH-DA have both been described to be 
oxidized by peroxynitrite, which is formed from a reaction of nitric oxide with 
superoxide radical anions. Although levels of superoxide radical anions are not 
increased during aging as evidenced by DHE staining, we additionally controlled for 
this confounding effect by staining of splenic lymphocytes with DAF-2-DA, a nitric 
oxide-sensitive dye. DAF-2-DA staining of lymphocytes increases with aging, while 
DHR and DCFH-DA oxidation do not show simultaneously increased oxidation, 
suggesting that under our conditions DHR and DCFH-DA are not oxidized to a 
significant degree by peroxynitrite in splenic lymphocytes. 
Importantly, the increased NO levels with aging were only found in female mice (see 
also 4.1.3, page 165 et seqq.). The increased NO levels with aging may be related to 
deficient immune functions in aged mice (Quaglino and Ronchetti, 2001), as NO has 
been reported to inhibit T cell functions (van der Veen et al., 1999; van der Veen et al., 
2000; Kahl et al., 2004), probably by inducing apoptosis (Bustamante et al., 2000; Oates 
and Gilkeson, 2004). However, the exact cell type as well as the nitric oxide synthase 
NOS subtype contributing to the increased NO production remains to be elucidated, as 
these factors have not been studied during aging in mouse spleenocytes so far. Only 
data on virus-transformed B cells, B-cell-lymphoma cells and leukemic T-cells are 
avialable showing iNOS expression in B-cell-derived cells (Mannick et al., 1994; Koide 
et al., 2003) and iNOS and nNOS expression in T-cell-derived cells (Kamimura et al., 
2003). Furthermore, iNOS expression was identified in hepatic lymphocytes after 
hepatic injury (Leifeld et al., 2002). But from these data, no stringent conclusion can be 
drawn as to the type of NOS which causes the increase in nitric oxide levels in splenic 
lymphocytes from female mice during aging. DISCUSSION 
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A putative contribution of antioxidant enzyme activities to the observed changes in 
ROS levels during aging? 
Increased production of superoxide and hydrogen peroxide from mitochondria during 
aging has been described (Sohal and Sohal, 1991; Sohal et al., 1995). Superoxide 
radicals are however usually quickly decomposed to hydrogen peroxide H2O2 by 
mitochondrial Mn-SOD and cytosolic Cu/Zn-SOD, which has been detected in the 
intermembrane space of mitochondria (Okado-Matsumoto and Fridovich, 2001; 
Mattiazzi et al., 2002). Thus, if these enzymes work efficiently in aged cells and the 
increased production of H2O2 is not met by adequate activity of GPx in mitochondria 
(Timcenko-Youssef et al., 1985), the levels of hydrogen peroxide in mitochondria 
would be expected to rise, which can be detected by DHR oxidation. As GPx is also 
localized in even higher levels in cytosol compared to mitochondria (Timcenko-Youssef 
et al., 1985; Utsunomiya et al., 1991) and the cytosol is additionally protected by the 
presence of catalase in peroxisomes (Yamamoto et al., 1988; Makino et al., 1994), H2O2 
reaching the cytosol is then efficiently removed – consistent with unchanged DCFH-DA 
oxidation in middle-aged mice. A further increase in the activities of antioxidant 
enzymes, especially GPx, with aging could explain why increased DHR oxidation is no 
longer observed in aged mice. In two recent studies in aging rats, antioxidant enzymes 
and mitochondrial chain activities in lymphocytes isolated from blood were directly 
compared with brain tissue. Importantly, the changes observed in lymphocytes 
paralleled those seen in brain tissue (Sandhu and Kaur, 2002; Sandhu and Kaur, 2003). 
These results demonstrate that changes during the aging process can be detected 
similarly in brain tissue and peripheral cells. Thus, it is possible that increased activities 
of antioxidant enzymes in lymphocytes, similar to our results on brain tissue, prevent 
excessive accumulation of ROS during aging. 
Comparison with other reports 
Only few other comparable studies on aging lymphocytes and ROS have been published 
so far. In previous studies by Leutner in our group, young (2-3 months) and aged (20-21 
months) female NMRI mice were employed. Similar to our findings, DHR oxidation 
was not altered by aging in splenic lymphocytes (Leutner, 2001). Lymphocytes isolated 
from blood showed however elevated DHR oxidation in aged mice. This suggests that 
splenic lymphocytes have different properties compared to circulating cells – which is 
probably related to a different state of maturation and lower exposure of splenic DISCUSSION 
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lymphocytes to stimulants like cytokines compared with circulating lymphocytes. 
Studies on rat lymphocytes have shown elevated R123 staining in splenic lymphocytes 
from aged animals (Pieri et al., 1993) indicating that cells from aged animals display 
higher mitochondrial number and mass. Furthermore, rat lymphocytes displayed higher 
levels of oxidative damage to lipids and proteins (Tian et al., 1995). Studies on 
peripheral lymphocytes in humans have reported decreased activities of mitochondrial 
chain complexes with aging (Drouet et al., 1999), increased DHR oxidation (Leutner, 
2001) and increased oxidative damage (Barnett and King, 1995; Piperakis et al., 1998; 
Mendoza-Nunez et al., 2001). Thus, the results we observed in murine splenic 
lymphocytes during aging are not in line with the majority of other comparable studies 
– which may be either due to specific properties of splenic lymphocytes, as stated 
above, or due to a relative resistance of C57BL/6J mice to age-induced ROS 
accumulation and oxidative damage, which had already been observed in brain tissue 
from these mice (see 4.1.1). 
Summary of the effects of aging on ROS levels, lipid peroxidation products and 
antioxidant enzyme activities in C57BL/6J mice 
Overall, our results on peripheral cells and the observations in brain tissue from 
C57BL/6J mice suggest that aging leads to adaptive responses serving to keep ROS 
levels at a relatively constant level. Therefore, only a small but not significant 
increase in ROS levels was observed, which is probably met by an adequate 
upregulation of antioxidant enzyme activities during the aging process. This is 
supported by our results on levels of lipid peroxidation products, which were reduced 
in aged animals. As lipid peroxidative damage is a downstream event of ROS attack 
on cellular membranes, with antioxidant enzymes playing an important role in 
intercepting ROS, the lower levels of lipid peroxidation products in aged animals 
result from the increased antioxidant enzyme activities. In conclusion, our results 
underline a prominent role for the upregulation of antioxidant enzyme activities in the 
prevention of excessive ROS accumulation and oxidative damage during aging in 
C57BL/6J mice. 
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4.1.3 Gender differences in oxidative stress-related parameters 
in mice 
Gender differences in brain tissue 
Analysis of age-related effects on oxidative stress parameters in brain tissue and splenic 
lymphocytes from male and female C57BL/6J mice during aging revealed distinct 
gender differences in some parameters. In brain tissue, levels of lipid peroxidation 
products MDA and HNE are reduced in female compared to male mice (Figure 3.5, 
page 90), and conversely, female mice show higher activity of the antioxidant enzyme 
glutathione peroxidase across all age groups (Figure 3.6, page 90). This suggests that 
brains from female mice are less susceptible towards oxidative damage due to higher 
antioxidant GPx activity. This is further supported by the results of in vitro stimulation 
of lipid peroxidation, where MDA formation is lower in brain homogenates from female 
mice (Figure 3.7, page 91). Thus, the higher antioxidant enzyme activity of GPx seems 
to exert a protective effect against increased lipid peroxidation under basal as well as 
stimulated conditions in female mice. 
GPx activity has been shown to be protective against lipid peroxidation in in vitro 
systems (McCray et al., 1976; Ursini and Bindoli, 1987). Higher GPx activity results in 
more efficient detoxification of hydrogen peroxide, which can form hydroxyl radicals in 
Fenton reactions. Thus by scavenging of hydrogen peroxide, oxidative damage to lipids 
due to Fenton chemistry can be prevented. However, the gender differences in GPx 
activity and lipid peroxidation products could also be mediated by the opposite effects, 
i.e. that increased lipid peroxidation levels in male mice lead to a reduction of GPx 
activity, as HNE has been reported to lead to an inhibition of GPx activity in vitro 
(Bosch-Morell et al., 1999). It must be noted that HNE can also inactivate GR activity 
(Vander Jagt et al., 1997), but GR activity was not impaired in male mice. This can only 
be reconciled with our observations if (i) either these in vitro interactions of HNE with 
GPx and GR are not relevant in vivo at all, or (ii) the concentrations required for 
inactivation of GR are much higher than for GPx or (iii) a distinct subcellular 
localization of the respective enzyme and HNE leads to selective inactivation of only 
GPx in male mice. 
Apart from GPx activity, other factors may have an additional impact on reduced levels 
of lipid peroxidation products in female mice. For example, the activity of glutathione-DISCUSSION 
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S-transferase, which can lead to elimination of lipid peroxidation aldehydes by 
conjugation with glutathione, has been reported to be elevated in brains from female 
mice (Das et al., 1981). Thus, hormonal and/or genetic factors have a profound impact 
on antioxidant defense and parameters of oxidative damage in mouse brains. 
From the available literature on similar observations, the contribution of gonadal 
hormones is difficult to elucidate. Although estrogen has been described to increase 
expression of antioxidant enzymes MnSOD and GPx in several tissues in animal models 
and humans (Igarashi et al., 1983; Salminen et al., 1988; Massafra et al., 2000; Akcay et 
al., 2000; Barp et al., 2002; Sobocanec et al., 2003; Borras et al., 2003), these findings 
are controversial (Bolzan et al., 1997; Rush and Sandiford, 2003). Similarly, despite 
strong evidence that estrogens can influence activities of GPx, our results can not be 
explained by an effect of female gonadal hormones, as a gender difference in GPx 
activity was still present in 19-22 months old mice, where most female mice should be 
acyclic and have reduced estrogen levels (Nelson et al., 1995; Frick et al., 2000). 
Another possibility would be that male gonadal hormones specifically lead to a 
reduction of the activity of GPx, but again conflicting results have been reported 
(Azevedo et al., 2001). In summary – although we did not measure levels of gonadal 
hormones in our studies – a direct influence of gonadal hormones modulating activity of 
GPx seems unlikely. Therefore, other unknown factors – apart from direct effects of 
gonadal hormones – may be related to the sustained gender differences in oxidative 
stress parameters during aging in our study. 
Gender differences in ROS levels in splenic lymphcoytes 
In good accordance with the increased GPx activity and decreased levels of lipid 
peroxidation products in brain tissue from female mice compared to male mice, splenic 
lymphocytes similarly exhibited lower DHR oxidation in samples from female mice 
(Figure 3.8, page 92). Of note, only DHR oxidation, but not oxidation of other ROS-
sensitive dyes DCFH-DA or DHE was different between the sexes. Also, staining of 
lymphocytes with R123 revealed no gender differences, suggesting that mitochondrial 
functions are not altered. The selectively reduced oxidation of DHR in splenic 
lymphocytes from female mice may be related to the higher GPx activity in females. If 
the increased activity of GPx observed in brain tissue from female mice is also present 
in lymphocytes, in accordance with other studies (Sandhu and Kaur, 2002), hydrogen 
peroxide generated from mitochondria would be efficiently detoxified by GPx activity DISCUSSION 
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in mitochondria (Vitorica et al., 1984; Timcenko-Youssef et al., 1985) before reaching 
the cytosol. Thus, mitochondrial DHR oxidation would be decreased in female mice. 
The importance for GPx acitvity in protection against mitochondrial oxidative stress 
was also demonstrated in GPx knockout mice, which display increased mitochondrial 
peroxide release and oxidative damage (Esposito et al., 2000). The gender difference is 
no longer detectable in the cytosolic compartment as evidenced by unchanged DCFH-
DA oxidation between males and females, since (i) cytosolic GPx activity is higher than 
mitochondrial GPx activity (Timcenko-Youssef et al., 1985) resulting in efficient ROS 
decomposition even in male mice and (ii) cytosolic hydrogen peroxide can additionally 
be inactivated by the catalase reaction. 
A profound gender difference was furthermore noticed after DAF-2-DA staining, where 
lymphocytes from females display higher DAF-2-DA oxidation indicating higher levels 
of nitric oxide. This gender effect was not detectable in young animals but was 
pronounced in aged animals. Although estradiol treatment has been described to 
increase nitric oxide levels via transcriptional activation of nNOS and eNOS in several 
studies on cell culture (Garcia-Duran et al., 1999; Chiueh et al., 2003; Lee et al., 2003b) 
and after in vivo administration (Weiner et al., 1994), a direct influence of estrogen in 
our study is unlikely. Nitric oxide levels were significantly increased only in aged 
female mice at 19-22 months of age, which is much older than the average age at loss of 
cyclicity at 13-15 months of age in C57 mice (Nelson et al., 1995). Therefore, the vast 
majoritiy of female mice at 19-22 months of age should be acyclic due to ovarian failure 
(Frick et al., 2000). Consequently, estrogen levels would be expected to be decreased in 
these mice, which makes the above-mentioned effect of estrogen on nitric oxide levels 
unlikely in our model. Vice versa, reduced NO levels by androgens (Singh et al., 2000) 
are insufficient to explain our findings, as gender differences in NO levels caused by 
androgens should also have been detected in young mice. Furthermore, the overall data 
on the NO-modulating effects of androgens is controversial (Virdis et al., 2002). While 
tissues related to cardiovascular function and neuronal cells have been widely studied 
with respect to a hormonal influence on nitric oxide levels, studies utilizing 
lymphocytes are scarce (Pehlivanoglu et al., 2001), and the effects of gonadotropins on 
lymphocyte function during aging have not been explored. For these reasons, the 
observation that nitric oxide levels are selectively increased in lymphocytes from aged 
female mice can not be explained by the available literature. 
It would be of interest to investigate if similar changes in nitric oxide levels with aging DISCUSSION 
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and gender differences can be found in brain tissue, as nitric oxide is an important 
modulator of neuronal activity (Bredt, 1999) and has been suggested to play a role in 
brain aging in rodent models as well as humans (Tohgi et al., 1999; Siles et al., 2002). 
Interestingly, improvement of cognitive function by estrogen replacement therapy in 
humans has been suggested to be mediated by increased nitric oxide production (Lopez-
Jaramillo and Teran, 1999). Therefore, the effect of nitric oxide production on the aging 
brain and the modulation by gender provides an interesting field for further studies. 
Summary of gender differences in oxidative stress-related parameters 
In summary, gender differences in oxidative stress-related parameters can be detected 
in brain tissue – where female mice exhibit lower levels of lipid peroxidation 
products along with higher antioxidant activity of GPx – and in splenic lymphocytes 
– where DHR oxidation is similarly reduced in cells from female mice. Hence both 
brain tissue and splenic lymphocytes display similar gender differences – with female 
mice showing better protection against oxidative damage and ROS accumulation. 
Therefore, our results support the notion that central effects in brain tissue can also be 
mirrored in peripheral lymphocytes. 
In addition, our results indicate that activity of the antioxidant enzyme GPx is 
causally related to the observed gender differences, i.e. that female mice are 
seemingly provided with a higher protection against ROS accumulation and oxidative 
damage compared to male mice. In good accordance with our previous observations 
on the impact of aging in C57BL/6J mice, where rising antioxidant enzyme activities 
proved to be protective against oxidative damage, increased antioxidant GPx activity 
can similarly cause lower lipid peroxidation in female mice. Therefore, our results 
underscore the important role of antioxidant enzyme activity in the protection against 
ROS accumulation and oxidative damage. 
Furthermore, a gender-disparate effect on nitric oxide levels during aging was 
observed, as increased levels of nitric oxide in lymphocytes could be detected only in 
female mice during aging. Hence, apart from increased GPx activity, an antioxidant 
effect of nitric oxide could additionally contribute to decreased lipid peroxidation 
and/or mitochondrial ROS formation in aged female mice (see Figure 4.1). 
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Figure 4.1: Summary of gender differences in oxidative stress-related parameters 
observed in mice. 
Abbreviations: ROSmito/ROScyt = mitochondrial/cytosolic reactive oxygen species; GPx = 
glutathione peroxidase; LPO = lipid peroxidation. 
Female gender affects the activity of GPx, which results in efficient detoxification of ROS in 
mitochondria and in the cytosol. As a result, levels of lipid peroxidation products, which arise 
from downstream events of ROS attack on cellular membranes, are reduced in female mice. 
Exactly how increased GPx activity in female mice or vice versa reduced GPx activity in male 
mice is mediated – e.g. by an influence of gonadal hormones or gonadotropins on gene 
transcription – remains to be elucidated. Furthermore, rising nitric oxide levels during aging in 
female mice may contribute to decreased levels of lipid peroxidation products and/or 
mitochondrial ROS. 
 
Gender differences between males and females in animal models but also in humans are 
becoming increasingly recognized in recent years. Differences in mitochondrial ROS 
production, antioxidant enzymes and/or oxidative damage between males and females 
have been reported in animals and humans (Das et al., 1981; Carrillo et al., 1992; 
Mendoza-Nunez et al., 2001; Proteggente et al., 2002; Sobocanec et al., 2003; Borras et 
al., 2003), suggesting that female gender permits increased protection against oxidative 
damage in various species. Furthermore, these findings were linked with a 
simultaneously increased lifespan in females (Vina et al., 2003). The decreased 
mitochondrial ROS production in females has been suggested to be due to the activation 
of neuronal nitric oxide synthase expression by estrogen (Chiueh et al., 2003), followed 
by increased levels of antioxidant protein thioredoxin which in turn supposedly affects DISCUSSION 
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expression of antioxidant genes Mn-SOD and GPx. Increased levels of nitric oxide by 
estrogens have been implicated in the relative protection of females against 
cardiovascular disease before menopause (Virdis et al., 2002). Interestingly, we also 
observed increased nitric oxide levels in splenic lymphocytes from female mice, 
however this difference was only found in aged mice, making a direct influence of 
estrogen unlikely, as stated above. As GPx has been localized to cytosol but also to 
mitochondria (Timcenko-Youssef et al., 1985), the increased enzyme activity may 
contribute to protection of mitochondria against damaging ROS and may thus be of 
relevance for a higher life span in females. It has to be noted, however, that in C57BL/6 
no such higher life span in females has been reported so far (Storer, 1966; Goodrick, 
1975). Therefore, it is difficult to assess the functional relevance of increased GPx 
activity in brains from female C57BL/6 mice with respect to a different life span of 
male and female mice. However in humans, women have an increased life expectancy 
compared to men (Smith, 1989). Thus, it would be of interest to study if similar gender 
differences in oxidative stress parameters during aging can be found in humans and to 
elucidate a possible functional role for a gender-disparate life span. 
4.1.4 Summary of aging-induced effects on ROS and oxidative 
stress parameters in C57BL/6J mice 
Although a vast body of evidence has been accumulated that mitochondrial alterations 
and oxidative stress are a major feature of aging, our results do not unequivocally 
support these findings. 
Mitochondria are considered to be the most important intracellular source for ROS 
under physiological conditions (Boveris and Chance, 1973; Wei, 1998) and aging leads 
to increased mitochondrial proliferation (Barrientos et al., 1997; Lee et al., 2000; Pesce 
et al., 2001). This may be in an attempt to compensate for decreased activities of 
mitochondrial respiratory chain activities (Bowling et al., 1993; Ojaimi et al., 1999). 
Thus, an increased amount of mitochondria, which are however impaired in their 
function, might contribute to observations that ROS production from mitochondria 
increases during aging (Sohal and Sohal, 1991; Sohal et al., 1995). 
Despite the vast body of evidence for increased ROS production during aging, we were 
not able to detect profoundly increased levels of ROS in splenic lymphocytes from mice 
− only a slight but not significant elevation of DHR oxidation was observed. Similarly DISCUSSION 
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we did not find increased oxidative damage in brain tissue, in contrast, markers of lipid 
peroxidation products were even reduced in aged mice. Therefore, at least in C57BL/6J 
mice and under our conditions, profound oxidative damage does not seem to be a major 
feature of the aging process. However, our results may also be interpreted in a 
completely different view: as aging is a process that turns young animals into old ones, 
it can be argued that some factors must be present in young animals that determine their 
aging process (Dozmorov et al., 2002). Therefore, increased levels of lipid peroxidation 
products in young mice may be regarded as a causative factor for the aging process in 
these animals. 
Furthermore, ROS must play some role during aging because changes could be 
observed at the levels of antioxidant enzymes in brain tissue. Activities of antioxidant 
enzymes Cu/Zn-SOD, GPx and GR in brain tissue are elevated during aging, and it is 
well established that ROS can induce antioxidant responses in cell culture models (Shull 
et al., 1991; Yoshioka et al., 1994; Tate, Jr. et al., 1995; Jornot and Junod, 1997; 
Rohrdanz et al., 2001). Hence, upregulation of antioxidant enzyme activities in vivo 
may be mediated by only a minimal accumulation of ROS during aging, as a slight but 
not significantly increased DHR oxidation was observed in splenic lymphocytes. 
Overall, it seems that compensatory changes in antioxidant defense can counteract 
excessive ROS accumulation and lipid peroxidation damage in aging tissues. 
This is supported by the gender differences observed in brain tissue and splenic 
lymphocytes, where female mice exhibit higher GPx activity accompanied by reduced 
levels of lipid peroxidation products in brain tissue and reduced DHR oxidation in 
splenic lymphocytes compared to male mice. These gender differences demonstrate the 
importance of antioxidant enzymes in protection against lipid peroxidation and ROS 
accumulation. 
Conclusion 
In summary, activities of antioxidant enzymes play an essential role in ROS 
detoxification and seem to be modulated in such a way as to keep ROS levels at a 
relatively constant steady-state level during aging. As lipid peroxidation is a 
downstream event of ROS accumulation and antioxidant enzymes modulate the 
reactions leading from ROS to lipid peroxidation products, higher activities of 
antioxidant enzymes result in decreased levels of lipid peroxidation products in aged 
animals (summarized in Figure 4.2). DISCUSSION 
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Figure 4.2: Summary of changes in oxidative stress-related parameters during aging 
observed in mice. 
Abbreviations: ROSmito/ROScyt = mitochondrial/cytosolic reactive oxygen species; Cu/Zn-SOD = 
superoxide dismutase, GPx = glutathione peroxidase, GR = glutathione reductase; LPO = lipid 
peroxidation. 
During aging in mice, antioxidant enzymes are upregulated. This results in efficient 
detoxification of ROS in mitochondria (by GPx in the matrix and Cu/Zn-SOD in the 
intermembrane space) and in the cytosol (Cu/Zn-SOD, GPx and GR). As a result, levels of lipid 
peroxidation products, which arise from downstream events of ROS attack on cellular 
membranes, are reduced in aged mice. How antioxidant enzyme upregulation takes place – e.g. 
by activation of ROS-sensitive transcription factors – remains to be elucidated. Exogenous 
augmentation of antioxidant enzyme activities may represent a pharmacological approach to 
ameliorate age-induced deficits. 
 
As our study on brain tissue does not allow for an estimation of effects in single cell 
types in brain tissue or the subcellular localization, it remains to be resolved whether 
oxidative damage can be present in discrete structures, e.g. selectively in neurons or 
subcellularly located to mitochondria, which are not separately detected by our methods 
utilizing whole brain homogenates. 
Since activities of antioxidant enzymes increase during aging, it would be interesting to 
investigate whether a further augmentation of antioxidant defenses is of benefit in 
preventing age-associated deficits. It is noteworthy that, in a comparison of several 
mammalian species, activity of SOD was positively (Ono and Okada, 1984) and the 
peroxide-generating potential of tissues was negatively correlated with life span (Cutler, DISCUSSION 
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1985). Therefore, augmentation of antioxidant defenses might prolong life span. In 
recent years, caloric restriction has been proposed as a means of prolonging life span in 
rodents (Sohal and Weindruch, 1996) and non-human primates (Lane et al., 2001). 
Caloric restriction reduces oxidative damage in rodents (Youngman et al., 1992; Tian et 
al., 1995) and increases activities of antioxidant enzymes (Cadenas et al., 1994; 
Sreekumar et al., 2002). In brain tissue, exogenous administration of SOD mimetics 
reduced oxidative stress and improved cognition in aged mice (Liu et al., 2003). 
Pharmacologically, augmentation of endogenous enzymatic antioxidant defense in brain 
tissue was for example reported by nerve growth factor NGF in aged rat brains (Nistico 
et al., 1992) or by monoamonoxidase B inhibitors deprenyl and rasagiline, where 
upregulation of antioxidant enzymes was also associated with a concomitant 
prolongation of life span (Kitani et al., 1994; Carrillo et al., 2000). Furthermore, 
transcriptional activation or upregulation of antioxidant enzyme activities could be 
shown with Ginkgo biloba extract in vivo (Aricioglu et al., 2001; Bilgihan et al., 1994; 
Bridi et al., 2001; Lin and Chang, 1997; Seif-el-Nasr and El-Fattah, 1995) and in vitro 
(Soulie et al., 2002) or with Ginseng components (Kim et al., 1996). These results 
suggest that upregulation of antioxidant defense can hypothetically contribute to the 
neuroprotective properties of extracts from these medicinal plants (Youdim and Joseph, 
2001; Müller and Chatterjee, 2003; Eckert et al., 2003a). 
Although only experimental evidence is available so far, the available literature and our 
results suggest that pharmacological augmentation of antioxidant enzyme activities may 
therefore prove beneficial in age-associated neurodegenerative diseases. However, more 
studies correlating antioxidant effects with cognitive performance in vivo are needed. 
And it has to be kept in mind that – although age-associated deficits may be prevented 
by such strategies – not merely an extension of life span is warranted, but rather an 
extension of healthy life span and augmentation of quality of life during aging should be 
the principal aims of studies in humans. DISCUSSION 
172 
4.2  Oxidative stress-related parameters in transgenic 
mice bearing FAD mutations 
In the course of this thesis, different transgenic mouse models based on familial AD 
mutations in either PS1 or APP could be studied. Although familial AD mutations are 
only found in few families worldwide, carriers of these mutations display an early onset 
of dementia with clinical and neuropathological symptoms indistinguishable from the 
much more common sporadic form of AD. As familial AD mutations consistently lead 
to an increased production of amyloid beta Aβ in humans, the amyloid cascade 
hypothesis has been proposed as the underlying mechanism for the development of 
sporadic as well as familial AD (Hardy and Higgins, 1992; Hardy and Selkoe, 2002). 
Consequently, transgenic mice with increased Aβ formation represent one of the best 
models to study putative toxic mechanisms of Aβ accumulation in vivo. 
Different types of mice were used in this thesis, displaying different formation and 
accumulation of Aβ. Highest human Aβ levels are observed in Thy1-APP and in APP23 
transgenic mice, while PDGF-APP/PS1 transgenic mice display intermediate Aβ 
accumulation and single PDGF-APP transgenic mice show only very low formation of 
human Aβ and no accumulation during aging. In contrast to the different APP 
transgenic mice, PS1 transgenic mice only possess endogenous rodent APP and can 
consequently only form mouse but not human Aβ. Thus, the different mouse models 
allow for an elucidation of the effects of PS1 mutations and rodent Aβ on oxidative 
stress parameters separately from the effects of various degrees of human Aβ 
accumulation in the different APP transgenic mice. 
4.2.1 Effect of PS1 mutations on oxidative stress-parameters in 
transgenic mice 
The mutant PS1 transgenic mice studied in this thesis show no formation of plaques 
derived from endogenous rodent Aβ during aging, which is probably due to different 
aggregation properties of human and rodent Aβ (Dyrks et al., 1993) or due to further 
unknown factors in brain microenvironment preventing plaque accumulation under 
normal conditions in rodents (Wyss-Coray et al., 1997; Little et al., 2004). Despite the 
lack of human Aβ peptide, which is considered the toxic species in the amyloid 
hypothesis, PS1 mutant mice have been described to display neurodegeneration (Chui et DISCUSSION 
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al., 1999; Sadowski et al., 2004) and cognitive deficits (Pak et al., 2003), suggesting that 
either presenilin mutations have deleterious effects unrelated to Aβ production or that 
the endogenous rodent Aβ displays toxicity, which would be consistent with 
neurodegeneration observed in mice overexpressing rodent Aβ (LaFerla et al., 1995). 
In order to elucidate the specific effect of a familial PS1 mutation compared to the 
effect of human wildtype PS1 overexpression in mice, two types of transgenic mice 
were used in our studies: PS1wt transgenic mice expressing human wildtype PS1 and 
PS1M146L transgenic mice expressing human mutant PS1. PS1wt transgenic mice are 
even better controls than non-transgenic mice for effects observed in PS1M146L mice, 
as the expression of wildtype PS1 alone has been reported to exhibit cytotoxic effects in 
some cell culture models (Wolozin et al., 1998; Hashimoto et al., 2002). Both 
transgenes are expressed under the HMG-CoA reductase promotor, which leads to a 
strong expression in neurons but also ubiquitous expression in other tissues (Leutner et 
al., 2000). Hence peripheral cells like lymphocytes could be studied for direct analysis 
of transgene effects on ROS levels in live cells ex vivo. 
Analysis of brain tissue 
In brain tissue from PS1wt or PS1M146L transgenic mice, no striking effects on the 
levels of lipid peroxidation products as indicator of oxidative damage could be observed 
compared to non-transgenic mice in any age group. Merely in the group of aged 19-22 
months old mice, HNE levels were increased in PS1M146L mice compared to PS1wt 
mice (Figure 3.9, page 96). Thus it seems that PS1wt might exert a protective effect 
against lipid peroxidation at the level of HNE. However, due to rather large variation of 
values, differences were only significant in a direct comparison of PS1wt with 
PS1M146L transgenic mice, but not statistically significant in ANOVA. As no further 
animals of this high age were available during the time of this thesis, the results on HNE 
levels should be considered preliminary before they can be independently reproduced in 
another maybe larger cohort of animals. 
At the level of antioxidant enzyme activities in brain tissue, no differences could be 
observed in any age group for any of the enzymes analyzed (Figure 3.10, page 97). This 
suggests that either a failure of other antioxidant defenses or more likely a mechanism 
of increased ROS production is related to the observed elevated HNE levels in brains 
from PS1M146L mice. This is further supported by the results of in vitro stimulation of 
lipid peroxidation, which was not different between the PS1 transgenic animals. Hence, DISCUSSION 
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PS1 mutations do not cause deleterious effects via impairment of antioxidant defense 
mechanisms. 
ROS levels in splenic lymphocytes 
In order to characterize the respective type or subcellular localization of ROS that could 
be responsible for oxidative damage in brains from PS1M146L mice, levels of various 
ROS were further analyzed in splenic lymphocytes from these animals. Expression of 
the PS1 transgene could be detected by RT-PCR in these peripheral cells, confirming 
previous observations with Western Blot analysis of protein expression (Schindowski, 
2001). 
Aging sensitizes to the effect of the PS1 mutation 
An effect of aging could be observed: while no differences in ROS levels measured by 
DHR oxidation were observed in cells derived from young animals neither under basal 
nor under stimulated conditions, lymphocytes from middle-aged PS1M146L animals 
showed unaltered basal ROS levels but increased ROS levels after serum deprivation 
(Figure 3.12, page 100), which represents a mild stress condition leading to apoptosis 
induction in lymphocytes (Kawanishi, 1997; Maucher et al., 1998). Finally, in cells 
from aged animals, even basal levels of ROS were increased (Figure 3.13, page 100). 
Thus, the aging process seems to sensitize towards the ROS-elevating effect of the 
PS1M146L mutation, which is evident in middle-aged animals only after mild stress but 
can be readily detected in aged mice even under basal conditions. Of note, the presence 
of PS1wt in transgenic mice did not alter ROS levels in lymphocytes, suggesting that 
the increased ROS levels are specifically caused by the presence of the FAD mutation. 
It can only be speculated which factors cause this age-associated higher susceptibility 
towards ROS accumulation in PS1M146L cells. A slight but not significant elevation of 
mitochondrial ROS levels was observed in murine splenic lymphocytes during aging 
(see 4.1.2, page 158). Nevertheless, this slight elevation of ROS levels may lower the 
threshold of oxidative homeostasis in aged cells, leading to an exaggerated ROS 
accumulation in PS1M146L-expressing lymphocytes from aged mice. This would 
furthermore be in accordance with our observations on brain tissue from C57BL/6J 
mice, where antioxidant enzymes are upregulated during aging, which occurs probably 
in response towards ROS formation in aged animals. DISCUSSION 
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The PS1 mutation does not impair antioxidant defense 
In good accordance with the unchanged activities of antioxidant enzymes in brains from 
these animals, no exacerbation of ROS formation could be detected in splenic 
lymphocytes after oxidative stimulation. Neither stimulation with hydrogen peroxide, 
which can lead to hydroxyl radical formation via Fenton reactions and mitochondrial 
damage (Dumont et al., 1999), nor stimulation with d-Ribose leading to glutathione 
depletion (Barbieri et al., 1994) resulted in profundly elevated DHR oxidation as a 
measure of ROS accumulation in cells from PS1 transgenic mice (Figure 3.15, page 
102, and Figure 3.17, page 105). Although ROS formation was increased after 
stimulation in lymphocytes, the relative increase in cells from PS1M146L mice was not 
substantially higher than the increase in cells from non-transgenic mice. Rather it seems 
that the increased basal DHR oxidation in PS1M146L mice is conserved after 
stimulation but not further exaggerated by the PS1 mutation. Expression of PS1wt led to 
a statistically not significant and only small increase in DHR oxidation after stimulation 
with a low concentration of hydrogen peroxide (1 µM). As overexpression of wildtype 
PS1 in cell culture has been reported to predispose towards apoptotic stimuli (Wolozin 
et al., 1998; Hashimoto et al., 2002), it may be that the increased ROS formation after 
hydrogen peroxide stimulation is related to a similar hypersensitivity caused by PS1wt 
in our model. However, as the effect was not significant and no changes in antioxidant 
enzyme activities or in vitro stimulation of lipid peroxidation were observed in brains 
from PS1wt mice, this effects seems of minor importance. 
Specific elevation of mitochondrial and cytosolic ROS but not superoxide radicals 
caused by the PS1 mutation 
After an initial study of non-transgenic and PS1M146L transgenic mice, we had 
observed increased basal DHR oxidation in cells from aged PS1M146L mice. As 
various ROS are produced in living cells and can interact in complex reactions, we 
additionally conducted experiments in a second set of animals where lymphocytes were 
stained with several different ROS-sensitive dyes for an estimation of the exact type and 
the source of ROS that accounts for increased DHR oxidation caused by PS1M146L. 
The increased oxidation of DHR is indicative of elevated mitochondrial ROS levels 
(Royall and Ischiropoulos, 1993; Ischiropoulos et al., 1999). Additionally, increased 
DHR oxidation is specific for the mutant PS1M146L, as oxidation of DHR was not 
altered in PS1wt transgenic mice bearing human wildtype presenilin (Figure 3.16 a, DISCUSSION 
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page 104). Furthermore, cytosolic ROS levels measured by oxidation of DCFH-DA 
(Diaz et al., 2003) were similarly increased in PS1M146L mice, and DHR and DCFH-
DA fluorescence showed a significant and positive linear correlation, indicating that 
both dyes are oxidized by the same ROS (Figure 3.16 c and d, page 104). DHR and 
DCFH-DA have been reported to be oxidized by hydrogen peroxide and peroxynitrite 
(Crow, 1997). In order to elucidate a possible contribution of increased peroxynitrite 
levels towards DHR and DCFH-DA oxidation, lymphocytes were additionally stained 
with DAF-2-DA and DHE, which are nitric oxide- and superoxide-sensitive dyes, 
respectively, detecting the precursors of peroxynitrite formation. DHE oxidation was 
not affected by the PS1M146L transgene, and DAF-2-DA showed only a slight but not 
significant trend towards increased oxidation (Figure 3.16 e and f, page 104), suggesting 
that peroxynitrite is not a major contributor to the increased DHR and DCFH-DA 
oxidation in lymphocytes from PS1M146L transgenic mice. 
A possible confounding effect associated with DHR stimulation can arise from altered 
incorporation of the oxidized dye, R123, into mitochondria. This was controlled for by 
staining of lymphocytes directly with R123. R123 uptake into mitochondria was slightly 
but significantly increased in PS1M146L transgenic cells, which may contribute to the 
observed effects of increased DHR fluorescence (Figure 3.16 b, page 104). 
Nevertheless, the extent of increased R123 incorporation into mitochondria with 7.2 % 
relative to the mean values measured in cells from non-transgenic mice is not sufficient 
to explain the 42.1 % increase in DHR fluorescence. Therefore, the major part of 
increased DHR fluorescence must be due to oxidation of the dye. 
The increased staining of PS1M146L-expressing lymphocytes with R123 could be due 
to stimulation of lymphocyte activation by elevated ROS levels. R123 has been 
described to be increasingly incorporated to mitochondria after stimulation of 
lymphocyte proliferation (Nairn et al., 1979; Ferlini et al., 1995). As ROS can mimic 
mitogenic signaling resulting in lymphocyte activation (Roth and Droge, 1987), the 
increased R123 incorporation into mitochondria may be secondary to activation of cells 
after ROS production caused by the PS1M146L mutation. Additionally, we detected a 
slight but not significant elevation of NO levels in PS1M146L-expressing cells, and NO 
can stimulate mitochondrial proliferation (Nisoli et al., 2003). Hence, increased NO 
levels can be reconciled with increased R123 staining due to mitochondrial proliferation 
in PS1M146L cells. DISCUSSION 
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Similar vulnerability of lymphocyte subsets 
As previous studies from our group and others had identified a different vulnerability of 
lymphocyte subsets to apoptosis during aging and in AD patients (Schindowski et al., 
2002; Schindowski et al., 2003), we analyzed specific T-lymphocyte subsets from 
transgenic mice for a putative different formation of ROS. As a result, the effects of the 
PS1 mutation were not different in CD4- or CD8-positive lymphocyte subsets, 
suggesting that the transgene leads to similar effects independent of the cell type. 
However, we could observe that DHR oxidation was specifically higher in the CD4-
positive lymphocyte subset compared to CD8-positive lymphocytes, independent of the 
transgene. Interestingly, CD4-positive splenic lymphocytes also display higher levels of 
basal apoptosis compared to CD8-positive cells (Schindowski, 2001), suggesting that 
the increased DHR oxidation observed in CD4-positive cells may be causally related to 
the apoptotic process in these cells. 
Functional relevance of increased ROS levels in PS1M146L mice for apoptotic cell 
death 
Apoptosis measurement in splenic lymphocytes from PS1 transgenic mice was 
conducted by Claudia Frey, utilizing the DNA dye 7-AAD as indicator of apoptotic 
cells (Schmid et al., 1994). Correlation of apoptosis levels in lymphocytes (percentage 
of apoptotic cells) with values of DHR oxidation in CD4-positive splenic lymphocytes 
from each individual animal resulted in a significant and positive linear correlation 
(Figure 3.14, page 101). Hence, in CD4-positive lymphocytes, where basal ROS levels 
are already higher than in CD8 cells, increased mitochondrial ROS may be functionally 
related to apoptosis. This is in good accordance with the emerging important role of 
mitochondria as the central executioners in apoptotic signaling (Kroemer et al., 1997; 
Susin et al., 1998). Mitochondrial damage can trigger apoptosis – probably via 
glutathione depletion (Macho et al., 1997) – followed by oxidation of mitochondrial 
thiols and loss of mitochondrial membrane potential (Marchetti et al., 1997), providing 
a functional link between increased mitochondrial DHR oxidation in CD4-positive 
lymphocytes and apoptosis. Of note, a similar higher sensitivity towards apoptosis in 
CD4 cells has been reported before in a study of peripheral lymphocytes from AD 
patients (Schindowski et al., 2003), suggesting that this cell type specifically reacts 
more sensitive towards ROS accumulation and cell death in AD-relevant models. 
It is difficult to determine whether ROS initiate apoptosis or are a by-product of the DISCUSSION 
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apoptotic process, as both mechanisms have been described. While oxidative stress can 
cause a reduction of mitochondrial membrane potential (Macho et al., 1999) probably 
via glutathione depletion (Macho et al., 1997), the opposite effect is also possible, i. e. 
that loss of mitochondrial membrane potential results in simultaneously increased ROS 
production as measured by DHE oxidation (Zamzami et al., 1995), which is an indicator 
of superoxide radicals. However, a hypothetical mechanism of ROS formation as a 
second step after disruption of mitochondrial membrane potential in PS1M146L-
expressing cells is difficult to reconcile with some of our observations: 
(i) Lymphocytes were analyzed by FACS measurement and gated according to size and 
granularity. Thus, only viable lymphocytes, but not apoptosing cells, were chosen for 
evaluation. As a loss in mitochondrial membrane potential leads to rapid induction of 
apoptosis, it is unlikely that the gated cells represent a large pool of apoptosing cells.  
(ii) A decrease in mitochondrial membrane potential has been consistently reported to 
result in overproduction of superoxide radicals (Castedo et al., 1995; Zamzami et al., 
1995), probably released from mitochondrial respiratory chain complexes (Turrens, 
2003). However, we did not detect increased superoxide formation as evidenced by 
unaltered DHE oxidation. 
For these reasons, it is unlikely that the increased DHR oxidation observed in splenic 
lymphocytes from PS1M146L transgenic mice is a secondary event due to loss of 
mitochondrial membrane integrity and apoptotic processes. Rather, increased ROS 
formation can be considered as the trigger for lymphocyte apoptosis in PS1M146L 
transgenic mice. Figure 4.3 summarizes the effects of mutant PS1 on the various 
parameters studied. DISCUSSION 
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Figure 4.3: Alterations in ROS caused by PS1M146L in lymphocytes from PS1 transgenic 
mice. 
Mutant presenilin 1 PS1M146L leads to elevation of mitochondrial and cytosolic ROS, but not 
superoxide radical production in lymphocytes from PS1 transgenic mice. Nitric oxide levels are 
marginally and not significantly increased. R123 staining of mitochondria is slightly elevated. 
Increased mitochondrial ROS levels in CD4-positive lymphocytes were correlated with levels of 
apoptosis. 
Abbreviations: ROSmito/ROScyt = mitochondrial/cytosolic reactive oxygen species. 
 
Use of peripheral cells to study effects in brain tissue 
A close interaction seems to exist between cells of the immune system and the central 
nervous system – either by modulation of the immune system by neuroendocrine signals 
or neurotransmitters (Hanisch et al., 1996; Carson and Sutcliffe, 1999), or vice versa by 
an impact of immune cells on the CNS (Hickey et al., 1991; Wekerle, 1993; Nitsch et 
al., 2004). Many neurological disorders are accompanied by changes in immune cell 
function (Schwarz et al., 2001; Fiszer, 2001) which led to studies of alterations in the 
function of lymphocytes and other peripheral cells as easily accessible models in 
neurodegenerative disease states (Eckert et al., 2001a; Gibson and Huang, 2002). 
As many correlates between observations on brain tissue and peripheral cells of AD 
patients have been obtained in these studies, it seems feasible that changes in peripheral 
cells can be used to monitor alterations in brain tissue from AD patients. In an attempt DISCUSSION 
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to extend these observations in humans to PS1 transgenic mice, a probable interaction 
between ROS levels measured in splenic lymphocytes and oxidative damage in brain 
tissue was analyzed. Correlation of DHR oxidation in lymphocytes with levels of HNE 
in brain tissue from each individual animal yielded a positive and significant linear 
relationship (Figure 3.18, page 106), suggesting that oxidative stress in brain tissue can 
be mirrored in peripheral cells. Of note, similar results have been obtained in the 
analysis of gender differences in mice, where lower levels of lipid peroxidation products 
in brain tissue from female compared to male mice were accompanied by lower DHR 
oxidation in peripheral lymphocytes (see 4.1.3, page 163). Hence the overall conclusion 
would be that similar oxidative stress-related mechanisms operate in cells from the 
central nervous system and in peripheral cells, adding further importance and relevance 
of the numerous studies conducted on peripheral cell models in neurodegenerative 
diseases so far (Eckert et al., 2001a; Cecchi et al., 2002; Gibson and Huang, 2002; 
Schindowski et al., 2003). 
Putative sources of increased ROS production in PS1M146L transgenic mice 
Under physiological conditions, mitochondria are considered to be the main 
intracellular source for ROS. In our experiments, ROS levels in PS1M146L cells were 
most profoundly increased in the mitochondrial compartment (42.1 % increase in DHR 
fluorescence relative to non-transgenic mice) as compared to the cytosol (20.5  % 
increase in DCFH-DA fluorescence), which could suggest a primary formation of ROS 
in mitochondria and then a subsequent leak into the cytosol. The more pronounced 
increase in mitochondrial as compared to cytosolic ROS levels could be explained by 
the relatively lower activity of GPx in mitochondria compared to cytosol (Timcenko-
Youssef et al., 1985) – affording less protection against mitochondrial as compared to 
cytosolic ROS accumulation. 
Mitochondrial ROS mostly arise from electron leakage from the respiratory chain, 
where the primary ROS formed is usually superoxide. However, superoxide formation 
was not increased in PS1M146L-bearing lymphocytes. Therefore, increased 
mitochondrial ROS could result from elevated flow of electrons along the mitochondrial 
respiratory chain with simultaneously rapid and very efficient removal of the generated 
superoxide by SOD enzymes. Although activities of antioxidant enzymes were not 
assayed in lymphocytes, enzyme activites are probably not impaired in these cells, as 
stimulation with oxidative stressors led to similar responses in non-transgenic and PS1-DISCUSSION 
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expressing cells. Furthermore, no effect on antioxidant enzyme activities in brains from 
PS1 transgenic mice was detected. Hence, it is possible that increased ROS production 
in mitochondria with radical leak from the respiratory chain and rapid conversion to 
hydrogen peroxide results in the observed increased DHR oxidation, while increased 
superoxide radicals can not be detected. 
Our results moreover suggest that mitochondria are not directly damaged in PS1M146L 
cells, as uptake of R123 into mitochondria was not impaired. In contrast, R123 staining 
was even elevated, suggesting that the number and mass of mitochondria in PS1M146L 
cells may be increased. An increase in the absolute number of mitochondria, but not 
mitochondrial impairment, could explain why overall DHR oxidation is increased in 
PS1M146L cells without a simultaneous rise in superoxide radical production. 
Mitochondrial proliferation has been described in response to nitric oxide (Nisoli et al., 
2003), which could explain the observation of slightly but not significantly elevated NO 
levels (106.7  % relative to controls) and increased R123 uptake by mitochondria 
(107.2 % relative to controls). Alternatively, ROS can trigger lymphocyte activation 
(Roth and Droge, 1987), which is associated with an increased mitochondrial mass and 
R123 uptake (Darzynkiewicz et al., 1981; Ferlini et al., 1995). Therefore, the effects of 
increased mitochondrial ROS production in PS1M146L cells could be secondary to 
mitochondrial proliferation. 
In summary, on the basis of our results it can not be decided whether increased ROS 
formation caused by mutant PS1M146L originates from mitochondrial or from 
cytosolic sources. Nevertheless, a direct and prominent damage of mitochondria seems 
unlikely as superoxide production is not elevated by the PS1 mutation and R123 uptake 
into mitochondria is not impaired. 
Which mechanism can be responsible for increased ROS production in PS1M146L-
expressing lymphocytes? Increased production of Aβ by presenilin mutations has been 
established as the main factor for presenilin toxicity. However, in murine lymphocytes, 
only rodent Aβ can be formed, and oxidative toxicity of rodent Aβ has not been 
investigated so far. Thus, although rodent Aβ is different from human Aβ in three 
amino acids that also have impact on the aggregation and oxidative properties of the 
peptide in vitro (Dyrks et al., 1993; Brzyska et al., 2001), it can not be excluded that the 
increased mitochondrial ROS formation is due to toxicity of endogenous murine Aβ. 
Furthermore, high levels of intracellular Aβ have been detected in neurons from mutant DISCUSSION 
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PS1 transgenic mice, which also displayed neurodegeneration (Chui et al., 1999; 
Sadowski et al., 2004), raising the possibility that endogenous rodent Aβ may be toxic. 
This is supported by the finding that overexpression of rodent Aβ in transgenic mice led 
to neurodegeneration (LaFerla et al., 1995). 
Apart from increased Aβ formation caused by mutant presenilins, several proteins and 
intracellular signaling cascades have been described to interact with presenilins, among 
these are Bcl-XL (Passer et al., 1999) and Bcl-2 (Alberici et al., 1999). Bcl-2 and Bcl-XL 
display antioxidant and antiapoptotic properties (Hockenbery et al., 1993; Kane et al., 
1993). Thus, an impairment of Bcl-2 and Bcl-XL function by presenilin mutations could 
explain the increased mitochondrial ROS production. However, whether these effects 
can operate in PS1M146L cells remains speculative as interactions with wildtype PS1 
have been studied, but the effects of FAD PS1 mutations on these interactions are 
unknown. 
Even more interesting are the effects of presenilins on intracellular calcium levels, as 
increased calcium levels can trigger several mechanisms of ROS formation, and 
mechanisms of interference of PS1 with calcium signaling pathways have been 
described, such as interactions with calsenilin (Buxbaum et al., 1998a), G0-proteins, 
phospholipase C, IP3-signaling and ryanoidine receptors (Smine et al., 1998; Chan et al., 
2000; Popescu et al., 2004) and calpain (Maruyama et al., 2000). Additionally, the 
subcellular localization of presenilins in ER and colocalization with ryanoidine 
receptors (Chan et al., 2000) makes them a likely candicate for interference with ER 
calcium stores. Apart from direct effects of PS1M146L on intracellular calcium levels, 
disrupted calcium homeostasis in PS1M146L-expressing cells could also be mediated 
by oxidative stress, for example due to interference of ROS or HNE with phospholipase 
C activity (Rossi et al., 1988; Wang et al., 2001). HNE furthermore has been shown to 
impair calcium-ATPases (Siems et al., 2003), which may additionally contribute to 
increased intracellular calcium levels. 
Numerous studies have established defective calcium signaling in cell culture (Guo et 
al., 1996; Leissring et al., 1999; Leissring et al., 2000) and transgenic mice bearing PS1 
with FAD mutations (Begley et al., 1999; Guo et al., 1999b; Chan et al., 2000; 
Schneider et al., 2001b; Stutzmann et al., 2004). Deficits in intracellular calcium 
regulation have moreover been detected in peripheral cells from FAD patients bearing 
PS1 mutations and in sporadic AD patients (Eckert et al., 1994; Ito et al., 1994; Gibson DISCUSSION 
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et al., 1996; Etcheberrigaray et al., 1998), suggesting a pathological role for disturbed 
calcium homeostasis as a final common pathway of both forms of AD. Furthermore, in 
an earlier study in our group, splenic lymphocytes from 3 months old PS1 transgenic 
mice bearing five mutations in PS1 showed unchanged basal levels of calcium, but 
increased calcium levels after mitogenic stimulation (Eckert et al., 2001b), which lends 
further support to findings of impaired calcium homeostasis as a contributor to toxic 
effects of mutant PS1. Of note, the animals studied were of young age (3 months). As 
we observed a profound effect of aging on ROS accumulation caused by the PS1M146L 
transgene, it is possible that the defect in calcium regulation becomes similarly impaired 
in aged mice already under unstimulated conditions, which can explain some of our 
findings of elevated basal ROS levels in aged PS1M146L transgenic mice. 
Increased intracellular calcium levels would fit well into our observations that cytosolic 
as well as mitochondrial ROS levels are increased in PS1M146L transgenic mice, as 
calcium can stimulate ROS formation by a variety of pathways. Calcium can activate 
phospholipase A resulting in increased arachidonic acid cascade activation and ROS 
production from lipoxygenase and cyclooxygenase reactions (O'Donnell et al., 1995; 
Gunasekar et al., 1998). Furthermore, neuronal and endothelial nitric oxide synthases 
are activated by increased calcium concentrations resulting in increased formation of 
nitric oxide, which was also detected in our studies, albeit only to a weak extent. 
Although pronounced elevations in nitric oxide levels caused by mutant PS1 had been 
observed in cell culture transfection studies before (Guo et al., 1999a; Hashimoto et al., 
2002), profoundly increased NO levels could not be detected in our system, suggesting 
that transfection experiments on cell culture can lead to much more exaggerated PS1 
effects as compared to the analysis of transgenic mouse cells. 
Finally, manifold interactions between calcium and mitochondria exist (Chakraborti et 
al., 1999; Berridge et al., 2000). As an example, increased intracellular calcium levels 
can be buffered by mitochondria (Rizzuto et al., 1993), which in turn results in 
stimulation of mitochondrial metabolism and increased ATP synthesis (Berridge et al., 
2000) and is followed by increased ROS formation (Dykens, 1994; Kowaltowski et al., 
1995). Increased mitochondrial metabolism is in good accordance with the observed 
elevated uptake of R123 into mitochondria and elevated mitochondrial ROS production 
without a simultaneous rise in superoxide production, as mitochondria are not directly 
damaged. In summary, all the effects we observed could be reconciled with increased 
intracellular calcium levels in cells bearing presenilin mutations (see Figure 4.4). DISCUSSION 
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Figure 4.4: Putative mechanisms of increased ROS formation by PS1M146L in transgenic 
mice. 
Elevation of mitochondrial and cytosolic ROS caused by PS1M146L can lead to lipid 
peroxidation, elevation of HNE levels and disruption of calcium homeostasis, linking further 
ROS production from cytosolic and mitochondrial sources in a vicious cycle. Straight arrows 
represent findings from this thesis, whereas dotted arrows represent putative interactions 
described by other groups. See text for further details. 
Abbreviations: COX cyclooxygenase, HNE 4-Hydroxynonenal, InsP3R inositol-triphosphate 
receptor, IP3 inositol-1,4,5-triphosphate, LOX lipoxygenase, NOS nitric oxide synthase, NO nitric 
oxide, PLA phospholipase A, PLC phospholipase C, ROSmito/ROScyt mitochondrial/cytosolic 
reactive oxygen species, RyR ryanoidine receptor. 
 
It is however difficult to speculate whether a disturbed calcium homeostasis is the 
primary effect resulting in increased ROS generation or whether – vice versa – 
increased ROS levels lead to disturbed calcium levels, as widely described (Macho et 
al., 1997; Chakraborti et al., 1999). Previous findings by our groups in young PS1M5 
transgenic mice – where basal ROS levels but not basal calcium levels were elevated – 
suggest a primary role for ROS-induced calcium dyshomeostasis. Similarly, in a study 
on PS1 transfected PC12 cells (Guo et al., 1996), a PS1 mutation led to increased 
intracellular calcium levels, ROS production and apopotis after Aβ stimulation. The rise 
in intracellular calcium levels was obviously ROS-dependent, as vitamin E was able to 
completely prevent the rise in intracellular calcium and ROS levels. However, neither 
the L-type calcium channel antagonist nifedipin nor dantrolene, an inhibitor of calcium DISCUSSION 
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release from ER stores, were able to completely inhibit ROS formation, suggesting that 
ROS can be produced independently from intracellular calcium levels in cells 
overexpressing mutant PS1. Thus, it is likely that increased ROS production caused by 
PS1 mutations is primarily responsible for calcium dyshomeostasis, which in turn can 
further exacerbate ROS formation in a vicious cycle. Therefore, the interactions 
between effects of presenilin mutations on ROS generation and intracellular calcium 
levels would be an interesting objective for future analyis in PS1 transgenic animals. 
Summary of mutant PS1-induced effects 
In summary, our results on changes in oxidative stress-parameters observed in brain 
tissue and peripheral cells support the hypothesis of oxidative toxicity caused by 
specifically the mutant PS1M146L when compared to PS1wt transgenic or non-
transgenic mice. 
The mechanism is probably related to increased ROS formation but not impaired 
detoxification, as we observed neither an impairment of antioxidant enzyme activities 
in brain tissue nor a different susceptibility towards oxidative stimuli in brain tissue 
and in lymphocytes. Moreover, oxidative toxicity of the PS1M146L mutation is 
evident only in aged animals, arguing for a combined effect of aging – the most 
important risk factor for the development of sporadic AD – and the FAD mutation on 
an elevated sensitivity towards ROS accumulation. Mild changes could be observed 
in brain tissue at the level of HNE (13.3  % increase relative to non-transgenic 
controls), while more pronounced effects could be detected when ROS levels were 
measured directly in splenic lymphocytes from PS1M146L transgenic animals. Of 
note, levels of mitochondrial ROS were 42.1 % and cytosolic ROS 20.5 % higher in 
PS1M146L cells relative to cells from non-transgenic littermate control mice, 
pointing to mitochondria as the main source of ROS. At the same time, superoxide 
production remained unchanged and R123 retention in mitochondria was not 
impaired, indicating that mitochondria are not profoundly damaged in living cells 
from PS1M146L mice. Hence, severe mitochondrial damage as a source of ROS in 
PS1M146L mice could be excluded from our experiments. 
In addition, our observations emphasize a functional relevance for measurement of 
mitochondrial ROS levels in living cells, as DHR oxidation in CD4-positive 
lymphocytes was correlated with apoptosis levels. Furthermore, changes could be 
detected in both brain tissue as well as lymphocytes from PS1M146L mice, i.e. in DISCUSSION 
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central as well as peripheral compartments, underscoring the suitability of 
lymphocyte studies in neurodegenerative diseases. 
 
4.2.2  Effects of APP mutations on oxidative stress-related 
parameters 
4.2.2.1 Analysis of PDGF-APP and PDGF-APP/PS1 double transgenic mice 
A major confounding finding in this thesis is the fact that the single PS1 mutation in 
PS1M146L mice leads to elevated HNE levels in brain tissue, but no similar elevation is 
found in brains from double transgenic PDGF-APP/PS1 mice (Figure 3.9, page 96). 
Although the results need to be reproduced in another cohort, it is striking that HNE 
levels are not further increased but rather seem to be decreased in PDGF-APP/PS1 
compared to PS1M146L transgenic mice, although differences are not statistically 
significant. This is unexpected since the effects of mutant PS1 on oxidative stress 
should at least be confirmed in the double transgenic mice and, furthermore, probably 
even exacerbated – based on numerous reports of oxidative toxicity for Aβ in vitro 
(Behl et al., 1994b; Butterfield et al., 1996). 
A prominent accumulation of Aβ in the brains of double transgenic PDGF-APP/PS1 
mice was demonstrated in Western blot and ELISA (Figure 3.31, page 123), and 
formation of Aβ plaques in the brains of these mice has been described previously 
(Blanchard et al., 2003), suggesting that merely the presence of human APP and/or the 
accumulation of Aβ in brains of transgenic mice during aging is insufficient to result in 
oxidative toxicity – at least oxidative damage was undetectable with our methods. It can 
only be speculated that either (i) APP expression and/or low formation of C99 peptide 
and Aβ do not exhibit prooxidative properties under the conditions in PDGF-APP or 
PDGF-APP/PS1 mouse brains, that (ii) the subcellular localization or the rate of APP 
expression, C99 and Aβ production determine oxidative pathology or (iii) that Aβ 
accumulation leads to adaptive responses in these transgenic mice that result in an 
overall efficient removal of ROS generated by Aβ – apart from enzymatic activities of 
Cu/Zn-SOD, GPx and GR, which were not affected (Figure 3.10, page 97). 
The lack of a statistically significant difference in HNE levels in double transgenic 
PDGF-APP/PS1 mice is in contrast to increased HNE levels in single transgenic DISCUSSION 
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PS1M146L mice. Is it possible that the additional expression of APP alters the effects of 
mutant PS1 in a way that abolishes oxidative toxicity? The overexpression of APP in 
brains from mice may lead to formation not only of Aβ, but also to increased formation 
of the N-terminal fragment sAPPα from endogenous α-secretase cleavage. As sAPPα 
exhibits neuroprotective properties (Guo et al., 1998), overexpression of APP in brains 
from PDGF-APP and PDGF-APP/PS1 transgenic mice may lead to increased formation 
of sAPPα thus counteracting oxidative toxicity caused by the PS1 mutation in single 
PS1M146L transgenic mice. 
Alternatively, the toxicity or at least some part of the toxicity of mutant PS1 may be 
unrelated to formation of Aβ, since several effects of PS1 mutations on cell death and 
susceptibility towards apoptotic stimuli have been described (Chan et al., 2000; Kim et 
al., 2001). Furthermore, presenilins interact with various signaling cascades – apart 
from APP [reviewed in (Steiner and Haass, 2001)]. Moreover, the rate of increased Aβ 
production by different PS1 mutations is not related to the clinical onset of FAD in 
patients (Gomez-Isla et al., 1999; Lleo et al., 2004), suggesting that an increased 
production of Aβ may not be the only mechanism relevant for neurotoxic effects of 
presenilin mutations in AD pathogenesis. Overall it can be speculated that deficits in 
several intracellular singalling cascades in PS1M146L single transgenic mice can result 
in oxidative toxicity. Coexpression of APP in double transgenic PDGF-APP/PS1 mice 
may however lead to a significant degree of PS1 interaction with the overexpressed 
APP proteins (Waragai et al., 1997; Xia et al., 1997) or to a different subcellular 
localization caused by interaction of PS1 with APP (Cai et al., 2003). Thus, interaction 
with transgenic APP could intercept PS1 proteins from signaling routes which cause 
oxidative toxicity in single transgenic PS1M146L mice. 
Conclusion from studies on PDGF-APP and PDGF-APP/PS1 transgenic mice 
Taken together, neither the presence of Aβ and/or APP nor the deposition of Aβ 
plaques in brain tissue is sufficient for triggering oxidative stress pathology in PDGF-
APP and PDGF-APP/PS1 transgenic mice. 
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4.2.2.2 Analysis of Thy1-APP transgenic mice 
Oxidative stress-related parameters 
A very different picture emerged when transgenic mice bearing the 751 amino acid 
form of APP under the control of a neuron-specific murine Thy1-promotor were 
analyzed. In these mice, oxidative damage detected by elevated HNE content was found 
already at 3 months of age (115 % of non-transgenic controls), which was even more 
pronounced and significantly different from non-transgenic mice at 12 months of age 
(184 % of non-transgenic controls). Surprisingly, however, no difference was observed 
in 18 months old Thy1-APP transgenic mice (see Figure 3.19, page 109). Thus, 
elevation of HNE levels starts early during the life span of Thy1-APP transgenic mice, 
reaches a peak at mid age and declines to the levels of non-transgenic mice at high age. 
Furthermore, oxidative damage in this mouse model can be detected only with HNE but 
not with MDA – reminiscent of the results in mutant PS1 transgenic mice (see Figure 
3.9, page 96) and AD patients (see Figure 3.39, page 133). Thus, the aldehydes seem to 
detect different kinds of oxidative damage, which will be discussed in more detail in 
sections 4.3.2.2, page 215 et seqq., and 4.4.2, page 229 et seqq. 
Analysis of enzymatic antioxidant defense revealed that an impairment of Cu/Zn-SOD 
activity is present in Thy1-APP transgenic mice, which parallels the increased oxidative 
damage at the level of HNE: enzyme activity showed a tendency towards reduced levels 
in 3 months old Thy1-APP transgenic animals, was significantly reduced in 12 months 
old animals, but receded to the levels of non-transgenic mice in 18 months old Thy1-
APP transgenic mice (Figure 3.20, page 110). Thus, impairment of Cu/Zn-SOD activity 
in young and middle-aged Thy1-APP transgenic mice may be causally related to 
increased HNE levels in brains from these mice. It may be that the upregulation of 
antioxidant enzymes during aging observed previously in C57BL/6J mice counteracts 
the effects of the transgenic APP on Cu/Zn-SOD activity in aged (18 months old) 
transgenic mice, hence reduced Cu/Zn-SOD activity and increased HNE levels can no 
longer be detected in this age group. 
Although impairment of Cu/Zn-SOD activity may be causally responsible for increased 
basal lipid peroxidation levels in young and middle-aged Thy1-APP transgenic mice, 
the extent of in vitro stimulation of lipid peroxidation with ferric iron was not different 
between Thy1-APP transgenic and age-matched non-transgenic mice (Figure 3.21, page 
111). These results suggest that reduced Cu/Zn-SOD activity is not a major contributor DISCUSSION 
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to  in vitro accumulation of ROS and formation of lipid peroxidation products after 
oxidative stimulation with ferric iron in this assay. 
Previously made observations in brain tissue from non-transgenic C57BL/6J mice (see 
section 3.1.1.1) that levels of lipid peroxidation products decline whereas activities of 
antioxidant enzymes rise during aging could be reproduced in this cohort of mice (see 
Figure 3.19, page 109 for lipid peroxidation, and Figure 3.20, page 110 for enzyme 
activities). The effect just failed to reach statistical significance for Cu/Zn-SOD 
(ANOVA p < 0.08 affect of aging) and was not significant for GPx activity – as only 
male mice with inherently lower activity of GPx were studied in the 18 months old 
group precluding an evaluation of increased GPx activity with aging. GR activity was 
however significantly increased in aged mice (ANOVA p < 0.0001 effect of aging). 
Furthermore, gender differences (see 3.1.2.1) – i.e. that female mice exhibit lower levels 
of lipid peroxidation products and higher activity of GPx – could be reproduced in this 
cohort, which is independent of the Thy1-APP transgene (see Figure 3.22, page 112, 
and Figure 3.24, page 114). 
However, a transgene-specific gender difference was detected in the onset of oxidative 
changes: at 3 months of age, female Thy1-APP transgenic mice showed increased HNE 
levels and reduced Cu/Zn-SOD activity compared to female non-transgenic mice, while 
male Thy1-APP transgenic mice at that age were not affected (Figure 3.22, page 112). 
Curiously, MDA levels were also elevated in 3 months old female Thy1-APP transgenic 
mice, however the extent of increase in MDA levels (107.8 % relative to non-transgenic 
controls) is much lower than that of HNE levels (135.7 % relative to non-transgenic 
controls) and thus seems of minor importance. At 12 months of age, both gender of 
Thy1-APP transgenic mice were affected to a similar extent by elevated HNE levels and 
impaired Cu/Zn-SOD activity compared to age- and gender-matched control animals 
(Figure 3.23, page 113). At 18 months of age, only male animals could be studied for 
reasons of availability, which precluded analysis of gender differences at that age. 
Furthermore, 12 months old female Thy1-APP transgenic mice displayed increased 
MDA formation after stimulation of lipid peroxidation with ferric iron in vitro 
compared to age-matched non-transgenic female mice (Figure 3.25, page 115). Hence, 
it can be concluded that female Thy1-APP transgenic mice do not only display changes 
in oxidative stress-related parameters earlier than male mice, but also that at mid-age 
female Thy1-APP transgenic mice react more sensitive towards stimulation of lipid 
peroxidation. DISCUSSION 
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Expression of APP and formation of Aβ during aging 
In an attempt to clarifiy some of our observations, we analyzed levels of APP 
expression and Aβ formation in brains of Thy1-APP transgenic mice during aging. 
Western blot analysis revealed that expression levels of the transgenic full-length APP 
protein remain relatively constant during aging and are independent of gender (Figure 
3.29, page 120). However, levels of Aβ and C99 peptide accumulate with aging, and a 
gender-disparate higher formation of Aβ and C99 peptide was observed in brains from 
female transgenic mice. As both Aβ and C99 levels were increased in brains from 
female mice, the gender difference is probably caused by altered β-secretase cleavage of 
APP but not by γ-secretase cleavage nor by altered accumulation of the Aβ peptide. The 
differences in insoluble Aβ levels observed in Western blot were confirmed by ELISA 
analysis of the soluble Aβ1-40 pools, where female transgenic mice consistently 
displayed approximately 30 % higher Aβ levels compared to male mice. Of note, this 
gender difference in Aβ production is conserved during aging, despite the high rate of 
accumulation of Aβ with aging in this mouse model. 
As female mice show higher β-amyloidogenic cleavage of APP and display increased 
HNE levels and reduced Cu/Zn-SOD activity earlier than male mice, the observed 
changes in oxidative stress-related parameters seem to be closely correlated with the 
presence of C99 peptide and/or Aβ. The gender-disparate increased levels of Aβ in 12 
months old female Thy1-APP transgenic mice combined with reduced Cu/Zn-SOD 
activity could furthermore be related to the higher susceptibility towards in vitro 
stimulation of lipid peroxidation of female transgenic mice at this age group. It is 
however difficult to explain the complete lack of oxidative damage and/or reduced 
Cu/Zn-SOD activity in 18 months old Thy1-APP transgenic mice. It may be that 
adaptive changes take place during aging – for example, we had observed an 
upregulation of Cu/Zn-SOD activity and other antioxidant enzymes and a reduction in 
the levels of lipid peroxidation products in non-transgenic mice during aging (see 
3.1.1.1). Hence, these adaptive processes in aged mouse brains may counteract the 
deleterious effects of the APP transgene. Alternatively, an altered subcellular 
distribution of Aβ in aged mouse brains could contribute to this effect, which will be 
discussed in more detail on page 195 et seqq. DISCUSSION 
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Summary and discussion of oxidative stress-related changes in Thy1-APP transgenice 
mice 
In summary, our results show oxidative stress pathology in Thy1-APP transgenic 
mice as measured by increased levels of the lipid peroxidation product HNE, which is 
probably related to impaired Cu/Zn-SOD activity. Furthermore, oxidative pathology 
is first observed in brains from 3 months old female Thy1-APP mice, which display 
higher formation of Aβ and C99 than male mice, and notably before the onset of 
plaque deposition. Our results underscore the role of Aβ and/or C99 accumulation in 
oxidative stress pathology and suggest a direct and causal relationship between 
increased Aβ and/or C99 levels, reduced Cu/Zn-SOD activity and oxidative damage. 
Impaired Cu/Zn-SOD activity in Thy1-APP mice can lead to increased formation of lipid 
peroxidation products 
From our results on aging mouse brain tissue and on gender differences in enyzmatic 
antioxidant defense and levels of lipid peroxidation products, it can be concluded that 
the activities of antioxidant enzymes are a major contributor to the protection against 
free radical attack on cellular membranes and formation of lipid peroxidation products. 
This is supported by two observations: (i) aged animals exhibit higher levels of Cu/Zn-
SOD, GPx and GR and correspondingly lower levels of lipid peroxidation products and 
(ii) female mice in general have higher activities of GPx and correspondingly lower 
levels of lipid peroxidation products. Vice versa, reduced activity of Cu/Zn-SOD in 
Thy1-APP transgenic mice supposedly favours the accumulation of superoxide radicals 
that lead to oxidative damage resulting in increased HNE levels in brains from these 
mice. Exactly how superoxide radicals can mediate lipid peroxidation processes is not 
completely understood in detail, but it is conceivable that lipid peroxidation reactions 
are initiated through hydroxyl radicals generated via Haber-Weiss and Fenton reactions 
(Halliwell and Gutteridge, 1999) or that not superoxide itself but its protonated from, 
the perhydroxyl radical, can initiate lipid peroxidation reactions (Aikens and Dix, 
1991). Another superoxide-dependent mechanism of lipid peroxidation has been 
attributed to increased formation of peroxynitrite from nitric oxide and superoxide (Radi 
et al., 1991). Addition of superoxide dismutase to in vitro systems of lipid peroxidation 
studies prevented lipid peroxidation (Tien et al., 1981; Gutteridge et al., 1983; 
Gutteridge, 1984). Consequently, superoxide  dismutase/catalase mimetics have been 
shown to protect against oxidative damage and cognitive deficits in a murine model of DISCUSSION 
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aging (Liu et al., 2003), and mice transgenic for Cu/Zn-SOD exhibit lower levels of the 
lipid peroxidation product HNE (Bonnes-Taourel et al., 1993). It is therefore 
conceivable that reduced activity of Cu/Zn-SOD in Thy1-APP mice causes increased 
formation of HNE. 
Additionally, Cu/Zn-SOD proved to be directly protective against APP or Aβ toxicity in 
a variety of paradigms: endothelial deficits in APP transgenic mice could be reversed by 
either exogenous application of Cu/Zn-SOD or coexpression of Cu/Zn-SOD (Iadecola 
et al., 1999). Furthermore, overexpression of Cu/Zn-SOD in SHSY5Y cells protected 
against Aβ-induced cell death (Celsi et al., 2004), and Cu/Zn-SOD expression in APP 
transgenic mice rescued embryonic lethality due to overexpression of APP (Carlson et 
al., 1997). Thus, pathogenic events related to the overexpression of APP and/or Aβ 
accumulation may be mediated by increased superoxide radical formation and can be 
counteracted by SOD enzymes.  
Overexpression of APP in transgenic mice leads to reduced Cu/Zn-SOD activity 
A primary factor that can lead to impaired activity of Cu/Zn-SOD in Thy1-APP mice 
probably resides in the interaction of APP or Aβ with metal ions. Full-length APP as 
well as Aβ can bind copper ions in vitro (Hesse et al., 1994; Atwood et al., 1998), and 
these findings may be involved in regulation of copper homeostasis by APP in vivo: 
APP knockout mice show increased levels of copper ions in their brains (White et al., 
1999), whereas APP overexpression in different transgenic mouse models leads to 
reduced levels of copper (Maynard et al., 2002; Phinney et al., 2003). In an independent 
study of still another APP transgenic mouse model, APP23 transgenic mice, we 
observed reduced copper levels as well as reduced Cu/Zn-SOD activity [see Figure 
3.26, page 116, and (Bayer et al., 2003)], suggesting that overexpression of APP 
consistently leads to loss of copper ions from the brains of APP transgenic mice 
resulting in detectable impairment of Cu/Zn-SOD activity. Furthermore, 
supplementation of copper ions in the drinking water of APP23 mice augmented Cu/Zn-
SOD activity towards the levels of non-transgenic control animals and also led to a 
significant reduction in Aβ levels (Bayer et al., 2003). Therefore, reduced availability of 
copper ions in the brains of APP transgenic mice is likely involved in impaired enzyme 
activity and may moreover affect Aβ formation and/or accumulation. 
Although we can not exclude direct effects of APP on Cu/Zn-SOD activity, in the study 
by Maynard and coworkers (Maynard et al., 2002), a copper deficiency was evident not DISCUSSION 
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only in mice overexpressing full-length APP but also in mice transgenic for the C100 
fragment representing the 100 carboxy-terminal amino acids of APP. Similarly, our 
results suggest that increased levels of C99 or Aβ are responsible for reduced Cu/Zn-
SOD activity since (i) we did not observe impaired enzyme activity in PDGF-APP-
expressing mice despite similar overexpression of full-length APP and (ii) 3 months old 
female Thy1-APP mice, which exhibit higher levels of C99 and Aβ, show impaired 
enzyme activity while male mice of the same age do not, despite similar expression 
levels of full-length APP751. 
So far, only one study analyzing antioxidant defense in human post mortem brain 
specimen from familial AD patients bearing APP mutations has been published. 
Bogdanovic and coworkers analyzed activities of antioxidant enzymes and found that 
activity of Cu/Zn-SOD showed a trend towards reduced activity in familial AD patients 
with the Swedish APP mutation compared to sporadic AD patients (Bogdanovic et al., 
2001). This study provides important evidence that mutant APP and/or increased β-
amyloidogenic processing of APP accompanied by increased formation of Aβ can lead 
to impairment of Cu/Zn-SOD activity also in humans. 
Gender differences in transgenic mouse models of AD and human sporadic AD 
In several different APP transgenic mouse models, female mice have been reported to 
exhibit increased or accelerated plaque formation compared to male transgenic mice: in 
Tg2576 mice (Callahan et al., 2001; Lee et al., 2002), in APP23 mice (Bayer et al., 
2003) as well as in double transgenic PDAPP/PS1A246E mice (Wang et al., 2003). 
Despite the differences in length of APP, number of APP mutations and promotors used 
to drive transgene expression as well as divergent genetic background between the 
different mouse models, female mice consistently show elevated formation of Aβ and 
plaque deposition. Therefore it is likely that these observations are not merely artefacts 
of some special property of a single mouse model but rather that sex and/or unknown 
endocrine factors modulate APP processing towards the β-amyloidogenic pathway in 
general. 
In contrast to Thy1-APP mice, we could not observe gender differences in Aβ formation 
in PDGF-APP or PDGF-APP/PS1 transgenic mice. The coexpression of mutant PS1 
does not abolish gender differences seen in single transgenic APP-expressing mice, as 
Wang and colleagues have reported gender differences in APP and PS1 double 
transgenic mice (Wang et al., 2003). It may rather be that gender differences in Aβ DISCUSSION 
194 
levels are undetectable in PDGF-APP/PS1 mice due to the relatively slow accumulation 
of Aβ and hardly detectable levels of C99 peptide. Alternatively, the gender differences 
in Thy1-APP transgenic mice could be due to a saturation effect of pathways that 
metabolize the C99 peptide and Aβ in female mice. Such a saturation effect would only 
be observed in Thy1-APP mice where high levels of C99 and Aβ can accumulate, but 
not in PDGF-APP and PDGF-APP/PS1 mice where low C99 and Aβ levels prevent 
their accumulation. 
With respect to epidemiological studies reporting a higher prevalence of AD in females 
and corresponding gender differences in Aβ accumulation in APP transgenic mouse 
models, the effects of estrogen on APP processing have gained considerable attention 
and were studied in cell culture (Jaffe et al., 1994; Xu et al., 1998) and in APP-
transgenic mouse models (Zheng et al., 2002; Levin-Allerhand et al., 2002). The general 
conclusions drawn from these studies were that estrogen treatment can decrease 
formation of Aβ. This is in contrast to our observations that female mice – where 
estrogen levels are supposed to be higher than in male mice – show higher Aβ 
formation compared to male mice. Later studies analyzing the modulation of Aβ by 
estrogen in mouse models have however produced conflicting results: Heikkinen and 
colleagues could not detect a beneficial effect of estrogen supplementation against 
accumulation of Aβ in APP and PS1 double transgenic mice (Heikkinen et al., 2004). 
Moreover, it remains unexplained why 17-α-estradiol with no affinity for estrogen 
receptors was even more effective in protecting against Aβ formation than the natural 
ligand 17-β-estradiol in the study by Levin-Allerhand and colleagues (2002). Hence, 
from these results and our observations it seems unlikely that endogenous levels of 
estrogens in transgenic mice reduce β-amyloidogenic processing of APP to a relevant 
extent in vivo. In accordance with this possibility, luteinizing hormone has been recently 
shown to increase beta-amyloidogenic cleavage of APP in cell culture (Bowen et al., 
2004), hence it is possible that not only gonadal but also pituitary hormones can affect 
AD-relevant processes. 
Although direct evidence is still controversial that – in the sporadic form of AD – 
women show higher β-amyloidogenic cleavage of APP (Sandberg et al., 2001), 
increased Aβ load in elderly women (Corder et al., 2004) and in female AD patients 
(Johnson et al., 1998) as well as a gender difference in the distribution of plaques 
(Kraszpulski et al., 2001) have been reported, providing first evidence that gender DISCUSSION 
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differences in APP processing observed in mouse models might be relevant for the 
disease in humans. 
Oxidative stress occurs in Thy1-APP mice independently of plaque formation 
In our study, we were able to demonstrate that oxidative damage is present already in 3 
months old female Thy1-APP mice. These mice develop first plaques at the age of 6 
months, thus, oxidative damage is an early event and occurs independent of plaque 
formation. In other studies on different APP transgenic mice, markers for oxidative 
damage have been consistently detected only in Tg2576 mice (Pappolla et al., 1998; 
Smith et al., 1998; Pratico et al., 2001; Matsuoka et al., 2001a). However, mitochondrial 
alterations have also been identified in other mouse models: in Tg2576 (Reddy et al., 
2004), in Thy1-APP (Blanchard et al., 2003) and in YAC-APP transgenic mice (Aliev 
et al., 2003). Furthermore, markers for nitrosative stress were increased in APP23 mice 
(Luth et al., 2001). While initial findings used immunohistochemical methods and 
detected HNE-modified proteins associated with Aβ plaques, it was thought that 
oxidative stress is caused by the deposition of Aβ plaques (Pappolla et al., 1998; Smith 
et al., 1998). However, a later report by Pratico and coworkers reversed these 
assumptions by providing evidence that isoprostanes as increased markers of oxidative 
damage can be detected already in 8 months old Tg2576 mice, which is 2-3 months 
prior to the onset of plaque deposition in these mice (Pratico et al., 2001). We were able 
to detect oxidative damage even earlier, already at an age of 3 months in female Thy1-
APP transgenic mice which display onset of plaque formation from an age of 6 months. 
These findings support the notion that oxidative stress is an early pathogenic event in 
APP transgenic mice and occurs independently of plaque formation. 
The mechanisms of APP cleavage, Aβ trafficking and deposition in APP transgenic 
mice have been studied in detail (LaFerla et al., 1996; Li et al., 1999; Wirths et al., 
2001; Wirths et al., 2002; Blanchard et al., 2003). Prior to plaque deposition, Aβ was 
detected intracellularly, while in aged animals with severe plaque deposition, 
intracellular Aβ staining was no longer present. Similar findings were obtained in 
human brain autopsy samples, where Aβ was found intracellularly before the formation 
of plaques (LaFerla et al., 1997; Gouras et al., 2000). The intracellular pool of Aβ might 
play a pivotal role in oxidative stress toxicity, as it was shown that early intraneuronal 
Aβ accumulation in Thy1-APP/PS1 transgenic mice was associated with markers for 
mitochondrial dysfunction like cytochrome c and bax proteins (Blanchard et al., 2003). DISCUSSION 
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Moreover, high intraneuronal Aβ may also contribute to the reported neurodegeneration 
in these animals, as neuron loss exceeded the areas of Aβ plaque formation (Schmitz et 
al., 2004). A later reduction of intracellular Aβ levels in aged animals (Wirths et al., 
2002) could also explain why we could no longer detect increased HNE levels in 18 
months old Thy1-APP transgenic mice. Hence it can be hypothesized whether oxidative 
stress is caused by intracellular Aβ accumulation in Thy1-APP transgenic mice. 
4.2.2.3 Reduced activity of Cu/Zn-SOD in APP23 transgenic mice 
As already observed previously in Thy1-APP transgenic mice, activity of the 
antioxidant enzyme Cu/Zn-SOD was similarly reduced in APP23 transgenic mice [see 
Figure 3.26, page 116, and (Bayer et al., 2003)]. Hence, the observation that 
overexpression of APP with familial AD mutations in transgenic mice leads to 
impairment of antioxidant defence by the enzyme Cu/Zn-SOD could be independently 
reproduced. Thus, our results suggest that failure of antioxidant systems to intercept free 
radicals can cause oxidative damage in APP transgenic mouse models, and the 
identification of reduced Cu/Zn-SOD activity represents a novel mechanism to explain 
oxidative toxicity triggered by mutant APP. Moreover, similar mechanisms of APP 
toxicity may operate in human carriers of APP mutations, as total SOD activity showed 
a trend towards reduced activity in a study of brain tissue from familial AD patients 
with the Swedish APP mutation compared to sporadic AD patients (Bogdanovic et al., 
2001). 
The relative extent of reduction of Cu/Zn-SOD activity in Thy1-APP and APP23 
transgenic mouse brains was slightly different (see Table 4.4). 
Although transgenic mouse brains were only available at different ages, it is obvious 
that the relative reduction in Cu/Zn-SOD activity is more pronounced in APP23 mice. 
Furthermore, this reduced activity was still detectable in 21 months old APP23 mice, 
while 18 months old Thy1-APP mice showed no difference relative to non-transgenic 
age-matched controls. DISCUSSION 
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Table 4.4: Relative reduction of Cu/Zn-SOD activity in Thy1-APP and APP23 transgenic 
mouse brains. 
age  Thy1-APP  APP23 
3 months  6.58 n.a. 
12 months  8.83 n.a. 
15 months  n.a. 20.1 
18 months  -0.35 n.a. 
21 months  n.a. 16.17 
Values represent the percentage of reduction in Cu/Zn-SOD activity relative to age- and gender-
matched non-transgenic control animals. 
n.a. = not available 
 
Both these observations may be explained by a slight difference between the two mouse 
models, as the Thy1-APP mouse model contains an additional familial AD mutation. 
The two APP transgenic mouse models express the 751 amino acid form of human APP 
under the control of the murine Thy1 promotor. However, in APP23 transgenic mice 
only the Swedish double mutation is present, whereas the APP transgene in Thy1-APP 
mice contains the Swedish double and the London mutations. The London mutation 
V717I leads to increased formation of longer Aβ1-42 and Aβ1-43 species (Suzuki et al., 
1994; Scheuner et al., 1996; Eckman et al., 1997), which have a higher tendency to 
aggregate, accumulate and form Aβ plaques in brain tissue (Iwatsubo et al., 1994). As 
Aβ has been described to bind copper ions (Atwood et al., 1998), with an especially 
high binding affinity of the Aβ1-42 species (Atwood et al., 2000), it seems possible that 
accumulation of the longer Aβ1-42 species in brains from Thy1-APP transgenic mice 
during aging leads to a higher binding and retention of copper ions in brains of these 
mice compared to APP23 transgenic mice. Hence, the relative reduction in activity of 
Cu/Zn-SOD would not be as pronounced as in APP23 transgenic mice and would be 
ameliorated with aging. 
A second contributing factor may be that the relative formation of Aβ1-40 species would 
be higher in APP23 mice with only the Swedish mutations compared to Thy1-APP 
transgenic mice with the extra London mutation which favours Aβ1-42 formation. If 
copper ions are transported out of the brains of APP transgenic mice in a soluble form 
bound to Aβ species, a relatively higher amount of soluble Aβ1-40 in brains from APP23 
transgenic mice would result in a higher export of copper ions out of the brain of these 
mice. Consistent with this hypothesis, the APP23 transgenic mouse model was reported DISCUSSION 
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to display high accumulation of vascular amyloid deposition relative to other APP 
transgenics (Sturchler-Pierrat and Staufenbiel, 2000; Kalback et al., 2002; Mueggler et 
al., 2002), suggesting that a high proportion of Aβ species in this mouse model is 
transported from neurons, the site of Aβ production, to the brain vasculature. Hence, a 
putatively higher loss of copper via a mechanism of Aβ excretion from the brains of 
APP23 transgenic mice may result in the higher degree of Cu/Zn-SOD activity 
reduction in this mouse model. However, this remains speculation, as the APP23 
(generated by Novartis Pharma) and the Thy1-APP (generated by Aventis Pharma) 
transgenic mouse models have not been compared in a direct study analysing Aβ 
formation and deposition so far. 
Conclusion 
In summary, although the extent of impairment of Cu/Zn-SOD activity in APP23 
transgenic mice was more pronounced than in Thy1-APP transgenics, our findings of 
reduced Cu/Zn-SOD activity in APP transgenic mice could be independently 
reproduced and thus identify a novel mechanism for oxidative toxicity caused by 
mutant APP. 
 
4.2.3 Comparison of different AD transgenic mouse models 
In summary, our results show divergent oxidative stress pathology in different 
transgenic mouse models of Alzheimer’s disease. While MDA seems to be an 
inappropriate marker for studying oxidative damage associated with FAD mutations, 
increased levels of HNE could be detected in mutant PS1 transgenic and Thy1-APP 
transgenic mice. Interestingly, no changes were observed in PDGF-APP and PDGF-
APP/PS1 transgenic mice. 
What are the major differences between PDGF-APP and Thy1-APP transgenic mice 
that can explain the lack of oxidative damage in PDGF-APP transgenic mice? 
As shown by Western blot analysis of APP expression, levels of the full-length protein 
are rather similar in PDGF-APP and Thy1-APP transgenic mice (Figure 3.29, page 
120). Thus, not merely the amount of full-length APP can serve to explain discrepancies 
between the two mouse models. The most striking differences between the two models 
therefore reside in the following factors: DISCUSSION 
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(i) The type of APP expressed: the 695 amino acid form expressed in PDGF-APP mice 
with the Swedish, Dutch and London mutations versus the 751 amino acid form 
expressed in Thy1-APP transgenic mice with the Swedish and London mutations. The 
751 amino acid form of APP contains a Kunitz-type serine protease inhibitor (KPI) 
domain and has been reported to yield higher levels of Aβ by increasing β-secretase 
cleavage of APP compared to the 695 amino acid form (Ho et al., 1996). This difference 
may explain the higher rate of C99 formation from β-secretase cleavage and also higher 
Aβ accumulation in Thy1-APP mice expressing APP751 (see Figure 3.29, page 120, 
Figure 3.31, page 123, and Figure 3.32, page 125). Of note, neurodegeneration and 
cognitive deficits have also been identified in mice expressing only the C-terminus of 
APP, suggesting that neurotoxicity can be exerted also by the C99 peptide 
(Kammesheidt et al., 1992; Oster-Granite et al., 1996; Neve et al., 1996; Nalbantoglu et 
al., 1997). Hence, the relatively low formation of C99 may explain why PDGF/APP 
and/or PDGF-APP/PS1 transgenic mice did not show any changes in oxidative stress-
related parameters − despite the presence of Aβ and Aβ plaques − compared to Thy1-
APP transgenic mice, which display high C99 formation. Interestingly, APP isoforms 
containing KPI domains may moreover be especially relevant for pathogenic events in 
AD brains, as a relative increase of KPI-containing APP isoforms over the APP695 
isoform has been detected in brain tissue from AD patients (Tanaka et al., 1992; Zhan et 
al., 1995; Rockenstein et al., 1995; Moir et al., 1998; Preece et al., 2004). Moreover, 
similar to Thy1-APP transgenic mice, increased levels of the C-terminal fragment of 
APP have been detected in AD brains (Evin et al., 2003), supporting an important role 
of this protein in AD pathogenesis. 
(ii) The different FAD mutations present in APP: PDGF-APP mice express APP with 
the Swedish, Dutch and London mutations, whereas Thy1-APP transgenic mice express 
APP bearing only the Swedish and London mutations. While the Swedish mutations – 
located at the β-secretase cleavage site – lead to increased β-amyloidogenic cleavage of 
APP resulting in elevated levels of total Aβ species (Citron et al., 1992; Mullan et al., 
1992), the London mutation – located near the γ-secretase cleavage site – leads to a 
specific elevation of Aβ1-42 (Suzuki et al., 1994; Scheuner et al., 1996; Eckman et al., 
1997). The Dutch mutation, localized at the α-secretase cleavage site and within the Aβ 
sequence, alters proteolytical processing of APP towards formation of lower levels of 
sAPPα (Haass et al., 1994) and alters fibril formation of Aβ species resulting in DISCUSSION 
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accelerated Aβ aggregation (Levy et al., 1990; Wisniewski et al., 1991; Fraser et al., 
1992; Clements et al., 1993). Thus, the additional presence of the Dutch mutation in 
PDGF-APP relative to Thy1-APP transgenic mice may result in altered aggregation 
properties of Aβ species in these animals, which probably also affects the localization in 
brain tissue, as a large pool of vascular Aβ deposits can be found in human carriers of 
the Dutch mutation (Levy et al., 1990) and in APPDutch transgenic mice (Herzig et al., 
2004). Therefore, different aggregation properties, altered intra- or extracellular 
concentrations or spatial distribution of Aβ could have an outcome on the presence of 
oxidative stress pathology in different APP transgenic mice. 
(iii) The cellular or subcellular localization of APP, as the PDGF promotor leads to 
only moderate and more homogenous expression in mouse brains while the Thy1-
promotor leads to especially high expression levels in some neurons (Blanchard et al., 
2003). As β-secretase activity was demonstrated to be high in neurons but low in 
astrocytes in APP transgenic mice (Zhao et al., 1996), high neuronal expression of APP 
in Thy1-APP mouse brains can explain the higher levels of C99 peptide derived from β-
secretase cleavage of APP in these animals compared to PDGF-APP transgenic mice. 
Therefore, high neuronal expression and increased β-secretase processsing of APP may 
be necessary for stimulation of oxidative stress toxicity in APP transgenic mouse 
models. 
(iv) The rate of Aβ accumulation, which occurs much faster in Thy1-APP transgenic 
mice and leads to formation of larger and more widespread plaques (Blanchard et al., 
2003). 
Thus the overall impression would be that high formation of Aβ and/or C99 peptide, 
which is facilitated in Thy1-APP transgenic mice bearing APP with the KPI insert, 
coupled with high neuronal expression due to the Thy1-promotor and accompanied by a 
quick rate of Aβ accumulation leads to oxidative damage, while less pronounced Aβ 
accumulation caused by a more homogenous but only moderate expression of APP in 
neuronal cells from PDGF-APP transgenic mice does not elicit oxidative damage. The 
elucidation of the mechanisms of Aβ formation, the varying Aβ expression levels and 
the subcellular localization in different APP transgenic mouse brains may shed some 
more light on the exact molecular mechanisms that are causative for triggering 
oxidative stress in the different transgenic mouse models for AD. DISCUSSION 
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Summary of observations in FAD transgenic mouse models 
In summary, our results lead to the following conclusions: 
(i) In PS1 transgenic mice, enzymatic antioxidant defense was not impaired 
suggesting that oxidative stress in these mice does not stem from impaired ROS 
detoxification but rather from increased ROS formation, which may be caused by 
elevated levels of endogenous mouse Aβ or by mechanisms unrelated to Aβ 
formation. Importantly, elevated ROS levels in cells from PS1M146L transgenic 
mice were only detected in aged animals (19-22 months old), suggesting that the 
aging process increases the vulnerability towards formation of ROS. This would be 
consistent with our previous results on C57BL/6J mice where aging causes a 
compensatory upregulation of activities of antioxidant enzymes, which occurs 
probably in response to elevated ROS formation. 
(ii) In Thy1-APP transgenic mice, increased HNE levels and simultaneously reduced 
Cu/Zn-SOD activity could be detected. Moreover, the finding of reduced Cu/Zn-SOD 
activity could be independently reproduced in another APP transgenic mouse model, 
APP23 mice, suggesting that impairment of antioxidant defence via Cu/Zn-SOD 
caused by mutant APP is a common mechanism for oxidative toxicity in APP 
transgenic mouse models. Furthermore, a gender effect was observed: changes in 
these oxidative parameters were first detected in brains from 3 months old female 
Thy1-APP mice, which is notably before the onset of plaque deposition (Blanchard et 
al., 2003), and female mice display higher formation of Aβ and C99 than male mice. 
Our results underscore the role of Aβ and/or C99 accumulation, but not plaque 
formation, for triggering oxidative stress pathology and suggest a direct and causal 
relationship between increased Aβ and/or C99 levels, reduced Cu/Zn-SOD activity 
and oxidative damage. Interestingly, oxidative damage and impaired Cu/Zn-SOD 
activity were no longer detectable in aged Thy1-APP transgenic mice (18 months 
old), suggesting that the upregulation of activities of antioxidant enzymes during 
aging - which had been observed previously in C57BL/6J mice - can counteract 
deleterious effects of mutant APP in these mice. 
(iii) The fact that plaque deposition is of minor importance for oxidative stress 
pathology is additionally supported by our findings that no alterations in oxidative 
stress-related parameters were observed in double transgenic PDGF-APP/PS1 mice, 
despite the presence of plaques in brains from these animals from an age of 6 months DISCUSSION 
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(Blanchard et al., 2003). Reports from various other groups suggest that rather the 
intracellular accumulation of Aβ may play a pivotal role in neurotoxicity (LaFerla et 
al., 1997; Chui et al., 1999; Takahashi et al., 2002; Oddo et al., 2003). 
Figure 4.5 summarizes the effects on oxidative stress-related parameters and putative 
mechanisms for oxidative toxicity in different AD transgenic mouse models studied 
in the course of this thesis. 
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Figure 4.5: Summary of oxidative stress-related alterations observed in different AD 
transgenic mouse models and putative mechanisms for oxidative toxicity. 
In Thy1-APP transgenic mice, high formation of C99 and/or Aβ, which is additionally increased 
in female transgenic mice, leads to impairment of Cu/Zn-SOD activity and elevation of HNE 
levels. This effect can be no longer observed in aged animals, as aging induces a 
compensatory rise in Cu/Zn-SOD activity. Reduced activity of Cu/Zn-SOD was also detected in 
APP23 mice. Oxidative damage and reduced Cu/Zn-SOD activity were however not detectable 
in PDGF-APP or PDGF-APP/PS1 transgenic mice – despite the deposition of Aβ plaques in 
PDGF-APP/PS1 transgenic mice – suggesting that slow accumulation of Aβ or extracellular 
deposition do not cause oxidative damage. In contrast, a putative accumulation of intracellular 
Aβ may be responsible for oxidative toxicity. Increased HNE levels were also detected in mutant 
PS1 transgenic mice. In this mouse model, aging facilitates mechanisms of increased ROS 
formation. 
Text in italics represents the respective familial AD mutations present in the different APP-
transgenic mouse models. See text for further details. 
* Only Cu/Zn-SOD activity was studied in APP23 mice. 
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In summary, oxidative damage is a feature of some, but not all transgenic mouse 
models. Furthermore, the mechanisms of origin of oxidative stress are heterogenous 
between PS1 and APP mutations: the PS1M146L mutation increases the formation of 
ROS but does seemingly not impair antioxidant defense, and this effect is more 
pronounced in aged animals (19-22 months old), suggesting that aging increases the 
vulnerability towards ROS formation. In contrast, mutant APP in Thy1-APP 
transgenic mice provokes oxidative damage by an impairment of Cu/Zn-SOD 
activity. In an independent study in another APP transgenic mouse model, APP23 
mice, activity of Cu/Zn-SOD was similarly reduced. Hence, diminished antioxidant 
activity of the enzyme Cu/Zn-SOD represents a novel mechanism to explain 
oxidative toxicity of mutant APP in mouse models. 
In conclusion, different mechanisms, i.e. increased ROS production triggered by PS1 
mutations or impaired antioxidant activity of Cu/Zn-SOD caused by increased β-
amyloidogenic processing of APP in mutant APP transgenic mice, can consistently 
lead to elevated levels of oxidative stress. Hence, our results support the hypothesis 
that oxidative damage constitutes a common pathway for neurodegeneration in 
familial AD patients carrying different FAD mutations. 
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4.3  Changes in oxidative stress-related parameters in 
sporadic AD patients 
Although the discovery of familial AD mutations led to valuable insights into 
pathogenic mechanisms – mostly related to excessive formation of Aβ – and also 
provided the basis for generation of transgenic mouse models for AD, the vast majority 
of AD patients suffer from the sporadic form of the disease. It is therefore essential to 
prove that any pathogenic event identified in familial AD cases or transgenic models 
can be transferred to the situation in sporadic cases. Hence, we furthermore used post 
mortem brain tissue from sporadic AD patients and age-matched controls for analysis of 
lipid peroxidation products MDA and HNE as markers of oxidative damage and 
enzymatic antioxidant defense by Cu/Zn-SOD, GPx and GR. In a first set of samples, 
brain tissue from four different brain regions was employed including three different 
cortical brain regions and the cerebellum. This allowed for a broad screening of 
oxidative stress-induced alterations throughout various regions of the diseased brain. 
The results from this study prompted us to conduct a second set of experiments on a 
larger cohort of tissue samples from temporal cortex, as this was the brain region where 
changes were most pronounced in the first set of samples. In this second cohort, 
neuropathological data as well as a clinical assessment of dementia severity were 
available, which could be correlated with the biochemical parameters, providing 
important insights into putative causal relationships between oxidative stress-related 
parameters, sporadic AD risk factors and the clinical progression of the disease.  
4.3.1 Cohort #1 
In the first set of samples, a total number of 11 AD patients (7 female, 4 male) and 10 
age-matched controls (6 female, 4 male) were studied. Brain tissue samples were 
obtained from 4 different brain regions: frontal cortex, parietal cortex, temporal cortex 
and cerebellum. These cortical regions are differently affected by the disease in the 
order of temporal > frontal > parietal cortex (Delacourte et al., 1999), while cerebellar 
functions are not impaired by the AD process. The samples were chosen to be matched 
as closely as possible for mean age at death and post mortem interval. As stated in 
2.1.8.1 (page 56 et seqq.), the distribution of Apo E4 alleles was higher in AD patients 
compared to controls, reflecting the well-known epidemiological association of the E4 
allele with the risk to develop AD. DISCUSSION 
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4.3.1.1 Upregulation of antioxidant defense prevents oxidative damage 
We observed no differences in basal levels of lipid peroxidation products MDA or HNE 
between AD samples and controls (see Figure 3.33, page 127). Although the mean HNE 
levels were slightly increased in AD patients relative to controls in every brain region, 
the difference was not statistically significant due to the large variation of values. 
However, there was a trend towards lower HNE levels in control and AD samples from 
cerebellum (ANOVA p = 0.08). As cerebellar functions are not compromised by the 
disease, it can be speculated whether reduced HNE levels constitute one of the factors 
that contribute to a selective resistance of cerebellar neurons against degeneration. 
Although comparable studies have found increased levels of lipid peroxidation products 
in brains from AD patients, these results are not unequivocal, as several other groups 
found lipid peroxidation levels to be unchanged (Table 4.5). While earlier studies 
mostly employed the TBARS (thiobarbituric acid-reactive substances) test for analysis 
of lipid peroxidation products, this method is prone to produce artefacts arising from 
interference with further sample components giving false positive results (Janero, 
1990). Consequently, recent studies employing more specific and sensitive 
methodology have produced more consistent results, showing that lipid peroxidation 
products are mostly increased in AD brains (Lovell et al., 1997; Markesbery and Lovell, 
1998; Montine et al., 1998; Nourooz-Zadeh et al., 1999; Karelson et al., 2001; Reich et 
al., 2001; Musiek et al., 2004). However, comparison of results is complicated by 
findings that different brain regions exhibit distinct vulnerability or resistance to lipid 
peroxidation, which is seemingly consistent with a different vulnerability of several 
brain regions towards the disease progress (Karelson et al., 2001). Additionally, 
unsaturated lipids and lipid peroxidation products are relatively unstable and prone to 
undergo decomposition reactions, hence the length of the post mortem interval can 
affect the outcome of the different studies. Therefore, direct comparisons between 
different studies are difficult to draw, and conflicting results on lipid peroxidation 
parameters can be due to a variety of factors including methodology and sample 
specifications. 
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Table 4.5: Overview on reports of markers for lipid peroxidative damage in AD brains 
change observed  parameters 
studied  brain region  Reference 
increased basal and 
stimulated in FC  TBARS FC,  Cer  (Subbarao et al., 
1990) 
increased basal and 
stimulated in FC  TBARS  FC, Hip, Cer  (Richardson, 1993) 
  increased in FL,     
motorC, sensC  TBARS 
Amyg, Hip, FL, motorC, 
BNM, PHG, sensC, OC, 
Cer and others  
(Balazs and Leon, 
1994) 
increased basal and 
stimulated in ITG  TBARS  ITG, STG, IPL, SFG, 
sensC, motorC, occipC 
(Palmer and Burns, 
1994) 
increased in            
Hip, Amyg, Pyr  TBARS    Amyg, Hip, Pyr, MFG, 
SMTG, IPL, OP, Cer  (Lovell et al., 1995) 
increased  HNE  CSF  (Lovell et al., 1997) 
increased in            
Amyg, PHG  HNE  MFG, SMTG, IPL, PHG, 
Amyg, BNM, Cer 
(Markesbery and 
Lovell, 1998) 
increased F2-isoprostanes CSF  (Montine et al., 1998; 
Montine et al., 1999) 
increased in            
PC, TC and Hip  neuroprostanes  PC, TC, Hip, Cer  (Reich et al., 2001) 
increased   F4-neuroprostanes  TC  (Musiek et al., 2004) 
increased in TC  TBARS  FC, TC, Cer  (Marcus et al., 1998) 
increased in FC, OC 
PC, unchanged in TC  TBARS  FC, OC, PC, TC  (DiCiero et al., 2000) 
increased              
in TC and FC 
lipid 
hydroperoxides 
FC, sensPC,          
OPC, TC 
(Karelson et al., 
2001) 
increased  TBARS  TC  (Yu et al., 2003) 
basal unchanged, 
stimulated increased     
in PC and TC 
TBARS  OC, PC, TC, Cer  (Hajimohammadreza 
and Brammer, 1990) 
unchanged  TBARS  FC  (Hayn et al., 1996) 
increased              
in OL and TL  F4-isoprostanes  OL, PL, TL  (Nourooz-Zadeh et 
al., 1999) 
unchanged TBARS  FL, PL, OL, TL,         
STG, MTG, Hip  (Lyras et al., 1997) 
basal unchanged, 
stimulated increased in 
TC 
TBARS TC,  Cer  (McIntosh et al., 
1997) 
unchanged TBARS  FC  (Ramassamy et al., 
1999) 
unchanged TBARS  Hip  (Ramassamy et al., 
2000) 
Abbreviations: Amyg = amygdala, BNM = basal nucleus of meynert, Cer = cerebellum, CSF = 
cerebrospinal fluid, EC = entorhinal cortex, FC = frontal cortex, FL = frontal lobe, FP = frontal 
pole, Hip = hippocampus, IPL = inferior parietal lobe, ITG = inferior temporal gyrus, motorC = 
motor cortex,  MFG = middle frontal gyrus, MTG = middle temporal gyrus, OC = occipital cortex, 
OL = occipital lobe, OP = occipital pole, OPC = occipital primary cortex, PC = parietal cortex, 
PHG = parahippocampal gyrus, PL = parietal lobe, Pyr = pyriform cortex, sensC = sensory 
cortex, sensPC = sensory postcentral cortex, SFG = superior frontal gyrus, SMTG = superior 
and middle temporal gyrus, STG = superior temporal gyrus, TBARS = thiobarbituric acid-
reactive substances, TC = temporal cortex, TL = temporal lobe. 
Studies from cooperating groups, as judged by the author list of the respective publications, are 
given in the same section. 
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Due to limitations of measurement of lipid peroxidation products from post mortem 
material, we additionally analyzed activities of antioxidant enzymes, which are only an 
indirect measure for oxidative stress-related events, but represent a more stable system 
as compared to lipid peroxidation products. Analysis of antioxidant enzyme activities 
revealed that activities of Cu/Zn-SOD, GPx and GR are upregulated in AD patients 
(Figure 3.34, page 128), which is in good agreement with the majority of other reports 
(see Table 4.6). Interestingly, these changes in antioxidant enzyme activities were most 
pronounced in temporal cortex, which is a brain region that is severely affected by AD 
pathology (Detoledo-Morrell et al., 1997). The higher antioxidant enzyme activities in 
AD brains may be the result of compensative upregulation following increased 
oxidative stress, which has been repeatedly shown to occur in cell culture models (Shull 
et al., 1991; Yoshioka et al., 1994; Tate, Jr. et al., 1995; Jornot and Junod, 1997; Yatin 
et al., 1998; Yoo et al., 1999; Rohrdanz et al., 2001). Furthermore, significant 
correlations between antioxidant enzyme activities were found in AD patients, 
indicating that the whole cascade of antioxidant enzymatic defense is similarly affected 
(Table 3.6, page 129). This is essentially not surprising as antioxidant defense is 
afforded by several factors, and the different enzymes act in concert to detoxify ROS. 
Our observation that Cu/Zn-SOD enzyme activity was also increased in AD samples 
from cerebellum was unexpected. Research on cerebellum has been largely neglected in 
AD research since cerebellar functions are not affected by the disease. Nevertheless, it 
was found that Aβ levels are also increased in samples from cerebellum of sporadic AD 
patients, although the presence of Aβ containing plaques could not be shown (Larner, 
1997). Severe cerebellar Aβ deposition was only reported in a study of brains from 
familial AD patients bearing a mutation in PS1 (Lemere et al., 1996). Since Aβ itself 
can cause oxidative stress even without being deposited as plaques (Behl et al., 1994b), 
which we had already observed in studies of PS1 and Thy1-APP transgenic mice, 
increased cerebellar Aβ levels may result in higher oxidative pressure on the cells 
leading to an upregulation of antioxidant enzyme capacity even in the cerebellum. 
Furthermore, it is possible that oxidative stress is a common feature affecting the whole 
organism, allowing to detect markers for oxidative stress in several tissues from AD 
patients, even in peripheral cells [reviewed in (Gibson and Huang, 2002)]. Thus, it can 
be argued that oxidative markers can similarly be altered in unaffected brain regions 
like the cerebellum. DISCUSSION 
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Table 4.6: Overview of reports on antioxidant enzyme activities in AD brains. 
change observed  brain region  Reference 
total SOD activity 
increased in NC and CGC  HT, NC, Hip, CGC  (Marklund et al., 1985) 
increased in OC 
Amyg, Hip, FL, motorC,           
BNM, PHG, sensC, OC,          
Cer and others  
(Balazs and Leon, 1994) 
increased in Hip, Amyg, 
Pyr, SMT 
Amyg, Hip, Pyr, MFG,           
SMTG, IPL, OP, Cer  (Lovell et al., 1995) 
increased in TC  FC, sensC, OPC, TC  (Karelson et al., 2001) 
unchanged  FC, PC, TC, OC, basal ganglia, 
Hip, Amyg, NBM, EC  (Gsell et al., 1995) 
unchanged  FC  (Hayn et al., 1996) 
unchanged  FC  (Ramassamy et al., 1999) 
unchanged  Hip  (Ramassamy et al., 2000) 
reduced in FC, Hip, Cer  FC, Hip, Cer  (Richardson, 1993) 
reduced in FC, Hip, Cer  FC, Hip, Cer  (Chen et al., 1994) 
Cu/Zn-SOD activity 
increased  Hip, SMT, A9  (Bruce et al., 1997) 
reduced in FC, TC  FC, TC, Cer  (Marcus et al., 1998) 
GPx activity 
increased in Hip  Amyg, Hip, Pyr, MFG,          
SMTG, IPL, OP, Cer  (Lovell et al., 1995) 
increased mRNA  Hip  (Aksenov and Markesbery, 
2001) 
increased  FC  (Ramassamy et al., 1999) 
increased  Hip  (Ramassamy et al., 2000) 
unchanged  FC, Hip, Cer  (Richardson, 1993) 
unchanged  FC, Hip, Cer  (Chen et al., 1994) 
unchanged  FC  (Hayn et al., 1996) 
unchanged  FC, TC, Cer  (Marcus et al., 1998) 
GR activity 
increased in Hip, Amyg  Amyg, Hip, Pyr, MFG,           
SMTG, IPL, OP, Cer  (Lovell et al., 1995) 
increased mRNA  Hip  (Aksenov and Markesbery, 
2001) 
Abbreviations: A9 = cortical area 9, Amyg = amygdala, Cer = cerebellum, CGC = cortex gyrus 
cinguli, EC = entorhinal cortex, FC = frontal cortex, Hip = hippocampus, HT = hypothalamus, 
NBM = nucleus basalis Meynert, NC = nucleus caudatus, OC = occipital cortex, OPC = occipital 
primary cortex, PC = parietal cortex, sensC = sensory postcentral cortex, SMT = superior-
middle temporal gyrus, TC = temporal cortex. 
Studies from cooperating groups, as judged by the author list of the respective publications, are 
given in the same section. 
 
In summary, our results suggest that cortical areas are effectively protected against lipid 
peroxidation by the higher antioxidant enzyme activities in AD brains. This is supported 
by the results of in vitro stimulation of lipid peroxidation, where significantly lower DISCUSSION 
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levels of MDA were formed in AD samples (Figure 3.36, page 130). Although we can 
not exclude that the different formation of lipid peroxidation products after in vitro 
stimulation may be due to a change in lipid composition in AD brains with less amounts 
of unsaturated lipids that would favour the formation of MDA during the lipid 
peroxidation process (Soderberg et al., 1991; Prasad et al., 1998), our results confirm 
previous observations of a higher antioxidant capacity in AD samples (Russell et al., 
1999). 
4.3.1.2  Gender differences in antioxidant metabolism and oxidative 
damage in AD patients 
Analysis of subgroups of male and female AD patients revealed a gender-specific 
upregulation of Cu/Zn-SOD and GPx activities especially in female AD patients (Figure 
3.38, page 132). No comparable results have been reported so far. In humans, only 
studies on peripheral tissues are available, reporting higher GPx activity in 
premenopausal females (Massafra et al., 2002; Rush and Sandiford, 2003), which 
suggests an inherent gender-specific upregulation of GPx. However, female subjects 
included in our study were all postmenopausal women older than 60 years. 
Furthermore, we found no difference between gender in GPx activity in control brains 
which argues for a rather AD-specific correlation between GPx upregulation and gender 
than for a general effect of female sex on GPx activity. 
Interestingly, GR activities were not increased in female compared to male AD patients. 
An increase in activities of SOD and GPx without a concomitant increase of GR activity 
would result in insufficient restoration of reduced glutathione levels. Reduced 
glutathione is one of the most important cellular antioxidants (Sies, 1999; Schulz et al., 
2000) and is critically required for cell survival (Bains and Shaw, 1997). Thus, the lack 
of GR upregulation in female AD patients would result in higher vulnerability of female 
brains towards oxidative damage in AD. 
Consequently, we found increased levels of HNE specifically in female AD patients 
compared to male patients (Figure 3.37, page 131). Thus, oxidative damage is present 
despite the higher activities of SOD and GPx, and the lack of upregulation of GR in 
brains from female AD patients may lead to oxidative damage. GR activity is required 
for restoration of reduced glutathione. Apart from being critical to cell survival, reduced 
glutathione is also a cofactor for the enzyme phospholipid hydroperoxide glutathione 
peroxidase [reviewed in (Imai and Nakagawa, 2003)], an enzyme that catalyzes the DISCUSSION 
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reduction of lipid hydroperoxides. These hydroperoxides give rise to toxic end products 
of lipid peroxidation like 4-hydroxynonenal. Furthermore, reduced glutathione is also a 
cofactor for the detoxification of HNE by glutathione-S-transferases (Spitz et al., 1990; 
Canuto et al., 1993; Ullrich et al., 1994). Thus, lack of reduced glutathione would result 
in increased HNE levels as is the case in brains from female AD patients. 
A gender difference in the prevalence and incidence of AD has been reported in several 
studies, with women being at higher risk (Rocca et al., 1986; Jorm et al., 1987; Zhang et 
al., 1990; Hagnell et al., 1992; Fratiglioni et al., 1997; Seshadri et al., 1997; Gao et al., 
1998; Andersen et al., 1999; Copeland et al., 1999; Ruitenberg et al., 2001). Our results 
show increased activities of antioxidant enzymes in AD brains and especially in brains 
from female AD patients. On the assumption that higher antioxidant enzyme activities 
are a compensation for increased oxidative stress, which has been repeatedly shown in 
cell culture experiments (Shull et al., 1991; Yoshioka et al., 1994; Tate, Jr. et al., 1995; 
Jornot and Junod, 1997; Yatin et al., 1998; Yoo et al., 1999; Rohrdanz et al., 2001), one 
might speculate that levels of oxidative stress are higher in brains from female AD 
patients. Accordingly, levels of HNE were increased in samples from female AD 
patients. The differences in antioxidant enzyme activities and HNE levels between male 
and female AD patients might help to explain the above-mentioned epidemiological 
findings that females have a gender-disparate higher risk to suffer from AD. 
This gender-disparate higher risk may be related to higher formation of Aβ in females 
(Johnson et al., 1998; Corder et al., 2004) and/or to gender differences in the distribu-
tion of plaques (Kraszpulski et al., 2001). Furthermore, this result is in good accordance 
with our findings on Thy1-APP transgenic mice, where female animals show higher β-
amyloidogenic cleavage of APP and oxidative stress earlier than male mice. 
It seems possible that gender differences in AD patients are modulated by 
Apolipoprotein E genotype. Notably, the Apo E4 allele appears to be a risk factor for 
AD specifically in females (Poirier et al., 1993; Payami et al., 1996; Farrer et al., 1997; 
Bretsky et al., 1999; Breitner et al., 1999; Molero et al., 2001) and leads to an increased 
Aβ plaque load in females (Corder et al., 2004). Additionally, the Apo E4 isoform 
sensitizes towards Aβ-induced oxidative stress [see our results on cohort #2 discussed 
on page 213 and (Ramassamy et al., 1999; Butterfield et al., 2002; Mazur-Kolecka et 
al., 2002)], and Apo E plays a role in detoxification of HNE, where the Apo E4 allele is 
least efficient (Pedersen et al., 2000). Taken together, higher vulnerability towards DISCUSSION 
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oxidative stress due to Aβ in the presence of Apo E4 could be especially pronounced in 
females. A mechanistic explanation for these observations has been provided by 
Lambert and colleagues who detected an isoform-specific higher expression of Apo E4 
by estrogen (Lambert et al., 2004), although it is questionable whether estrogen effects 
are of relevance in our study utilizing postmenopausal female patients. Nevertheless, the 
cohort of samples consisted of a majority of homozygous Apo E4 carriers, with a 
similar distribution in male (3 homozygous, 1 non-Apo E4) and female (3 homozygous, 
3 heterozygous, 1 non-Apo E4) AD patients. Therefore, the increased HNE levels in 
female AD patients may be the result of a higher vulnerability towards oxidative 
damage caused by the combined effects of Apo E4 and female gender. 
4.3.1.3 Summary of observations in cohort #1 
In summary, the results from this study provided evidence that 
(i) activities of antioxidant enzymes are upregulated in AD patients, 
(ii) changes are most pronounced in temporal cortex, which is a severely affected 
brain region in AD, 
(iii) increased activities of antioxidant enzymes seemingly provide effective 
protection against lipid peroxidation in vitro, 
and 
(iv) antioxidant defense and oxidative damage are modulated by gender, with female 
AD patients showing a higher vulnerability towards oxidative damage. 
4.3.2 Cohort #2 
As upregulation of antioxidant enzyme activities was most pronounced in temporal 
cortex, a larger cohort of samples from temporal cortex was analyzed in a second set of 
experiments. For these samples, neuropathological and clinical data were available and 
could be correlated with the results of the biochemical assays. 
4.3.2.1  Increased oxidative damage despite partial upregulation of 
antioxidant defense 
In good accordance with the results from cohort #1, basal levels of MDA were not 
significantly different between controls and AD patients. However, levels of HNE were 
significantly increased to 132 % of the level in controls (Figure 3.39, page 133). Hence, DISCUSSION 
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HNE seems to be the more specific marker for AD-relevant processes, which is in 
accordance with a study of lipid peroxidation products in serum from AD patients 
(McGrath et al., 2001) and also with our results in PS1M146L and Thy1-APP 
transgenic mice, where only HNE levels, but not MDA levels, were elevated. 
Activities of antioxidant enzymes were again increased in AD patients, but significance 
was only obtained for activities of Cu/Zn-SOD and GPx, whereas the extent of GR 
upregulation was too small to produce statistical significance (Figure 3.40, page 134). 
As observed previously, activities of antioxidant enzymes showed highly significant and 
positive correlations, indicating that the whole cascade of antioxidant enzymes is 
similarly upregulated, acting in concert to detoxify ROS (Table 3.7, page 134). 
The in vitro stimulation of lipid peroxidation with ferric iron produced a somewhat 
unexpected result, as (i) levels of MDA formation were significantly increased in AD 
samples despite upregulation of antioxidant enzyme activities (Figure 3.42, page 136) 
and (ii) values were subject to a bimodal distribution that remains unexplained, as none 
of the available parameters (age, gender, post mortem interval, tissue storage time of 
samples, activities of antioxidant enzymes, Apo E genotype, disease duration, MMSE 
score, cause of death or neuropathological Braak staging) could differentiate samples 
with high levels of MDA formation after stimulation from those with low levels. Thus, 
either further unknown factors or a combination of several singular factors, which can 
not be statistically elucidated in our rather small group with 30 subjects, may affect the 
outcome of MDA formation after in vitro stimulation. 
4.3.2.2  Correlation of oxidative stress-related parameters with levels of 
amyloid beta, Apo E genotype and clinical severity of dementia 
Correlations with levels of soluble Aβ1-40 
As the amyloid cascade hypothesis centers around the accumulation of Aβ as the major 
factor mediating neurotoxicity in AD, we determined levels of soluble Aβ1-40 in a subset 
of control and AD samples. Although the mean Aβ1-40 levels were greatly increased in 
AD patients (415 % of controls), this increase was not statistically significant due to a 
large variation in individual values. Furthermore, some overlap between the control and 
AD group exists (Figure 3.43, page 138). 
A detailed analysis revealed that levels of Aβ1-40 are strongly influenced by the Apo E 
genotype, with gradually rising levels in the order of E2/E3 < E2/E4 < E3/E3 < E3/E4 < DISCUSSION 
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E4/E4 (Figure 3.44, page 139). This is a perfect reflection of epidemiological studies 
which found the risk of AD to be lowest in carriers of the E2 allele and highest in E4 
carriers (Saunders et al., 1993; Poirier et al., 1993; Corder et al., 1993). The formation 
of Aβ plaques in human brains is facilitated by the Apo E4 isoform (Schmechel et al., 
1993; Olichney et al., 1996; Berg et al., 1998; Johnson et al., 1998; Ghebremedhin et 
al., 2001; Tiraboschi et al., 2004a), and a positive correlation between levels of soluble 
Aβ1-40 and the presence of Apo E4 alleles has been described (Lue et al., 1999). These 
studies provide evidence that the Apo E4 allele can increase the risk for AD by 
increasing the formation and/or deposition of Aβ, thus supporting the amyloid cascade 
hypothesis. However, as control and AD groups show some overlap, Aβ1-40 levels can 
not completely differentiate controls from AD patients, suggesting that either Aβ is not 
the only factor that provokes the development of AD or that some special form of Aβ – 
oligomers, protofibrils or specifically Aβ1-42 – determine the pathogenesis of AD. 
Levels of Aβ1-40 showed a positive correlation with MDA levels, which however just 
failed to reach statistical significance (p = 0.05, see Figure 3.45, page 140). Aβ1-40 levels 
did not correlate with HNE levels or stimulated MDA levels, but were positively 
correlated with activities of Cu/Zn-SOD and GPx (Figure 3.46 a and b, respectively, 
page 141), and showed a trend towards positive correlation with GR activity (p = 0.08). 
These results suggest that increased Aβ1-40 levels can promote oxidative damage and at 
the same time influence the upregulation of activities of Cu/Zn-SOD and GPx, and to a 
lesser extent also GR. This in vivo correlation fits well into in vitro obervations that Aβ 
can induce accumulation of cellular peroxides and upregulate antioxidant enzyme 
activity (Bruce et al., 1997; Yatin et al., 1998). However, further factors apart from 
soluble Aβ1-40 may mediate oxidative toxicity in AD brains, as HNE levels, which were 
significantly increased in AD patients, showed no correlation with Aβ1-40 levels. 
Correlations of oxidative stress-related parameters with the Apo E genotype 
As stated above, the Apo E4 genotype is a major risk factor for the development of 
sporadic AD. In order to elucidate a putative causal relationship between the presence 
of different Apo E isoforms and oxidative stress, the data on lipid peroxidation and 
antioxidant enzyme activities were evaluated according to the Apo E genotype. Both 
lipid peroxidation parameters MDA and HNE were lowest in non-E4 carriers 
(composed of E2/E3 and E3/E3), intermediate in heterozygous E4 carriers (E2/E4 and DISCUSSION 
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E3/E4) and were highest in homozygous E4 carriers (E4/E4) (Figure 3.47, page 142). 
While differences were not statistically significant for homozygous Apo E4 carriers due 
to small numbers of subjects in this group (n = 3), HNE levels were significantly 
increased in heterozygous Apo E4 carriers compared to non-E4 carriers. These results 
are in good accordance with in vitro and in vivo studies of different Apo E isoforms, 
where the the Apo E4 isoform was least effective in protecting against oxidative insults 
(Miyata and Smith, 1996; Butterfield et al., 2002; Mazur-Kolecka et al., 2002), and with 
studies on human brain tissue, where oxidative damage was related to the number of 
Apo E4 alleles (Montine et al., 1997; Ramassamy et al., 1999; Ramassamy et al., 2000). 
The different effects of Apo E isoforms could be due to direct antioxidant properties, as 
the isoforms differ in two amino acids: while E2 contains two cysteine residues, E3 
contains one and E4 contains none. These cysteine residues can either exert direct 
antioxidant effects through their thiol moiety or bind electrophilic, oxidizing reagents, 
e.g. lipid peroxidation aldehydes. Thus, Apo E isoforms have been described to differ in 
their HNE binding ability in the order of E2 > E3 > E4 (Pedersen et al., 2000), which 
can at least partially explain our observations. 
Of course, a confounding factor is that the groups of control and AD patients are not 
homogenously distributed throughout the respective Apo E genotype groups. As stated 
above, the presence of the Apo E4 allele is a risk factor for the development of AD, 
while the E2 isoform exerts a protective effect, which is also reflected in our cohort of 
control and AD samples: the homozygous Apo E4 group consists of only 3 AD patients, 
the heterozygous group is composed from 3 controls and 6 AD patients, and the non-E4 
group represents 6 controls and 5 AD patients. Hence, the Apo E effects in our analysis 
may not be causally related to the presence of different Apo E isoforms but may instead 
reflect an inherent elevation of lipid peroxidation products in those groups that are 
composed of the majority of AD patients, i.e. the heterozygous and above all the 
homozygous Apo E4 groups. In order to eliminate this confounding fact, we 
additionally evaluated only the AD and control groups separately. Similar results were 
obtained in these subgroups, although differences were no longer statistically significant 
due to smaller numbers of subjects. Of note, although HNE levels increased with rising 
copies of Apo E4 alleles, levels in the non-E4 and heterozygous Apo E4 AD groups 
were still higher than in the respective non-E4 and heterozygous Apo E4 control group 
(Figure 3.49, page 143). Hence it can be concluded that Apo E alleles modulate the 
extent of HNE formation, but the AD-specific process still leads to a further increase in DISCUSSION 
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HNE levels, which is independent of the Apo E genotype. 
An evaluation of putative Apo E allele effects on the activities of antioxidant enzymes 
produced no statistically significant differences between the different Apo E subgroups. 
Although enyzme activities were highest in homozygous Apo E4 carriers, this proved to 
be not statistically significant. While no comparative data on modulation of GR activity 
by Apo E genotype are available, total SOD activity was reported to be unchanged with 
Apo E4 genotype in frontal cortex as well as hippocampus (Ramassamy et al., 1999; 
Ramassamy et al., 2000). Reports on GPx activity are conflicting and seem to depend 
on the brain region analyzed: GPx activity in homozygous E4 AD patients compared to 
homozygous E3 patients has been reported to be increased in frontal cortex 
(Ramassamy et al., 1999) but decreased in tissue from hippocampus (Ramassamy et al., 
2000). No comparable data are available for temporal cortex. Hence the overall 
conclusion from our results would be that the Apo E genotype does modifiy the extent 
of oxidative damage, but does not have a major impact on the activities of antioxidant 
enzymes. 
Correlations of oxidative stress-related parameters with mini mental status MMSE 
Among the set of samples, the clinical degree of cognitive impairment as assessed by 
the mini mental status examination MMSE was available for 11 AD patients and 2 
controls. The controls scored 28 and 29 points, respectively, which is within the 
expected values for cognitively normal subjects [usually, normal values are ranging 
from 24 points to 30 points, depending on educational level and age (Osterweil et al., 
1994; Ostrosky-Solis et al., 2000)]. The AD patients scored a mean value of 8.6 points, 
with individual values ranging from 0 to 21 points. 
Correlation of lipid peroxidation products with MMSE scores in individual samples 
produced divergent results for MDA and HNE levels. MDA levels were negatively 
correlated with MMSE scores (p = 0.055, Figure 3.50, page 144), indicating that MDA 
formation accompanies the progression of the disease. Whether increased MDA levels 
do significantly contribute to the progression of AD or are just a consequence of 
increased neurodegeneration remains to be elucidated. Levels of HNE however show a 
different pattern with disease progression: while HNE levels are high in AD patients 
with moderate cognitive impairment, they decrease in subjects with severe cognitive 
impairment (Figure 3.51, page 145). This suggests that HNE levels are highest in earlier 
stages of the disease and recede to the almost levels of controls when the disease is DISCUSSION 
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proceeding to a severe state. Interestingly, similar observations have been made in a 
study by Nunomura and coworkers, who reported that immunohistochemically detected 
levels of nitrotyrosine residues and 8-hydroxyguanine as markers for oxidative stress 
were quantitatively greatest in early clinical stages of the disease and reduced with 
disease progression (Nunomura et al., 2001). These findings led the authors to voice the 
provocative statement that “oxidative damage is the earliest event in AD”. Although our 
results do not unambiguously support this, as MDA levels increase with disease 
progression, it is nevertheless possible that different markers for oxidative damage 
detect different processes during clinical progression of AD and hence can be distinctly 
changing with increasing severity of the disease. As HNE levels are especially high in 
earlier clinical stages of the disease, neurotoxicity due to HNE may play an important 
role in the initiation of early AD-related neurodegenerative events.  
In this respect, it is interesting to analyze a putative time-course of neuropathologic 
changes in AD. It seems that early intraneuronal accumulation of Aβ is one of the 
primary events, whereas extracellular Aβ plaques are formed at later stages after neuron 
death (LaFerla et al., 1997; Gouras et al., 2000). Tau pathology seems to be initiated 
after Aβ accumulation and to increase constantly during disease progression, as do 
gliosis and synaptic loss (Rozemuller et al., 1989; Naslund et al., 2000; Ingelsson et al., 
2004; Schonheit et al., 2004; Tiraboschi et al., 2004b). Progressive gliosis caused by 
amyloid deposition may lead to inflammatory reactions accompanied by additional ROS 
formation by activated microglia and astrocytes in AD brains (McGeer and McGeer, 
1995; Meda et al., 1995; Klegeris and McGeer, 1997; McDonald et al., 1997; Bianca et 
al., 1999; Wang et al., 2002). Considering such a time-course of events, it may be 
possible that increased HNE levels in earlier stages of the disease reflect initial 
oxidative stress caused by accumulation of intraneuronal Aβ. As intraneuronal Aβ 
disappears at later stages, HNE levels simultaneously recede, which would be consistent 
with our observations in Thy1-APP transgenic mice, where only HNE levels, but not 
MDA, were elevated in young female and middle-aged mice, but HNE levels later 
returned to the levels of non-transgenic mice in 18 months old animals. 
Contrary to HNE, the constantly rising MDA levels during clinical progression of AD 
may represent oxidative damage related to inflammatory reactions and progressive 
gliosis. A putative mechanism for MDA formation under conditions of inflammation 
may be represented by cyclooxygenase reactions, where the pentacyclic ring bridged by 
an epidioxy moiety can decompose under formation of MDA (Spiteller, 2001). Both DISCUSSION 
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increased expression of cyclooxygenase 1 and 2 has been identified in AD brains 
(Kitamura et al., 1999). Hence, different neuropathological processes related to 
intraneuronal Aβ accumulation or inflammatory reactions triggered after extracellular 
deposition of Aβ may be accompanied by distinct changes in lipid peroxidation 
parameters. Exploration of the mechanisms that lead to formation of the different lipid 
peroxidation aldehydes in vivo may shed more light on this issue. 
Analysis of antioxidant enzyme activities suggests that different antioxidant responses 
are activated during the progression of AD. Both Cu/Zn-SOD and GPx activity showed 
highest activity in the moderately affected AD patient group (Figure 3.52, page 146). 
While Cu/Zn-SOD activity showed a trend towards higher activity, GPx activity was 
significantly increased in this group. Both enzyme activities however receded towards 
lower levels in the severely impaired AD patient group, although they were still higher 
than values of controls, but not statistically significant. In contrast to Cu/Zn-SOD and 
GPx activity, GR activity shows no such peak in the moderately affected AD patient 
group. Instead, GR activity was highest in the group of severely cognitively impaired 
AD patients, although not statistically significant (Figure 3.52, page 146). Hence, 
Cu/Zn-SOD and GPx activities seem to be the enzymes that respond early to oxidative 
pressure, whereas upregulation of GR activity is a rather late event. Comparing the 
dynamic alterations in antioxidant enzyme activities with those of HNE levels, it can be 
speculated whether the lack of GR upregulation at early stages of the disease is 
responsible for the observed increase in HNE levels. Insufficient restoration of reduced 
glutathione GSH by GR may lead to accumulation of HNE, as glutathione-dependent 
detoxification of HNE by glutathione-S-transferase as well as reduction of lipid 
hydroperoxides by PH-GPx would be compromised. The selective contribution of 
different antioxidant enzymes to the accumulation of lipid peroxidation aldehydes 
should be explored in future studies. This may provide some more insight into the 
question  if and, more importantly, how different antioxidant enzyme activities can 
specifically influence the formation of MDA or HNE. 
In summary, although the results should be considered preliminary, as the statistical 
power with only 11 AD subjects is limited, they provide evidence that dynamic changes 
of several oxidative stress-related parameters can take place during the progression of 
AD. Whether the changing pattern of antioxidant enzyme activities during the 
progression of AD does significantly contribute to the accumulation of neurotoxic HNE, 
and whether this has impact on the initiation and progression of sporadic AD will pose a DISCUSSION 
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challenging field of research for future studies. Rigorous analysis of these changes and 
identification of pharmacological substances that allow for a selective modification of 
these pathologic events may offer an approach for development of therapeutic agents 
that can ameliorate disease progression once it has started. 
4.3.2.3 Summary of observations in cohort #2 
In summary, the results from this study provided evidence that 
(i) activities of antioxidant enzymes Cu/Zn-SOD and GPx, but not GR, are 
upregulated in AD patients, 
(ii) basal levels of HNE, but not MDA, are increased in AD patients, 
(iii) the increase in activities of Cu/Zn-SOD and GPx does not provide protection 
against stimulation of MDA formation in vitro, 
(iv) accumulation of Aβ, which is strongly modulated by the Apo E genotype, can 
promote oxidative damage and upregulation of antioxidant defenses, since Aβ levels 
are positively correlated with MDA levels and activities of Cu/Zn-SOD and GPx, 
(v) the presence of Apo E4 alleles increases oxidative damage without an impact on 
antioxidant enzymes, 
and 
(vi) dynamic changes occur during the progression of the disease: while HNE levels 
are highest in earlier stages, MDA levels are steadily increasing with clinical 
progression of dementia severity. 
4.3.3 Comparison of results from cohort #1 and #2 
Summarizing the changes in oxidative stress-related parameters observed in the two 
different cohorts of controls and AD patients, some parameters produced conflicting 
results while others could be independently reproduced in the second set of samples. 
Table 4.7 summarizes the main outcomes of both studies, considering only the data 
from temporal cortex in cohort #1. 
The differences between the two cohorts are a good reflection of the various conflicting 
findings in comparable reports, as mentioned earlier (see Table 4.5 for lipid 
peroxidation products and Table 4.6 for antioxidant enzymes). Therefore, the results of 
a single study should not be overemphasized, especially as the evaluation of cohort #2 DISCUSSION 
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provided evidence that sample properties like Apo E genotype, clinical progression of 
the disease and Aβ levels can modulate oxidative stress-related parameters. Hence, 
further studies utilizing still larger sets of samples may prove beneficial in elucidating 
multifactorial relationships between oxidative stress markers and sample properties.  
Nevertheless, it a can be concluded from Table 4.7 that measurement of Cu/Zn-SOD 
and GPx activity produces the most reliable results, as an upregulation of these enzyme 
activities in AD patients relative to controls was found in both independent studies. 
However, the extent of upregulation expressed as percentage relative to controls was 
different in the two studies: in cohort #1 the differences were in general more 
pronounced than in cohort #2 (Table 4.8). 
 
Table 4.7: Comparison of results from two independent studies on human brain tissue 
samples. 
Parameter  cohort #1  cohort #2 
basal MDA levels  o o 
basal HNE levels  o + 
stimulated MDA levels     o 
1  + 
Cu/Zn-SOD activity  + + 
GPx activity  + + 
GR activity  + o 
gender difference female / 
male AD patients in Cu/Zn-
SOD, GPx or HNE 
   o 
1  o 
+ indicates significant increase, o indicates no significant change relative to controls. 
1 differences in cohort #1 were only significant in Twoway-ANOVA over the 4 brain regions 
analyzed, but not in temporal cortex alone. 
 
 
 
Table 4.8: Relative increases in activities of antioxidant enzymes in AD brain tissue from 
temporal cortex compared to non-demented controls in cohort #1 and #2. 
Study  Enzyme  Cu/Zn-SOD  GPx  GR 
relative 
increase (%) 23.4 41.1 16.8 
Cohort #1 
t-test  p < 0.01  p < 0.01  p < 0.05 
relative 
increase (%) 19.2 20.9 6.4 
Cohort #2 
t-test  p < 0.05  p < 0.05  n.s. 
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The differences in upregulation of antioxidant enyzme activities may help to explain 
some of the discrepancies between the two studies. Thus, the lack of an increase in basal 
HNE levels in AD patients seen in Cohort #1 might be related to the finding that 
relative increases in antioxidant enzymes are higher in this cohort, providing a higher 
degree of protection against oxidative damage. Furthermore, GR activity was not 
significantly increased in cohort #2. Hence insufficient GR upregulation might promote 
oxidative damage at the level of HNE. Similar observations were made 
(i) in brains from female AD patients in cohort #1, where only Cu/Zn-SOD and GPx 
activity, but not GR activity, were significantly increased, which was accompanied by 
increased levels of HNE,  
and  
(ii) in the correlation of oxidative stress-related parameters with the clinical degree of 
cognitive impairment, where HNE levels were highest accompanied by increased 
Cu/Zn-SOD and GPx, but not GR activity, in the group of AD patients with moderate 
cognitive impairment. 
Hence, insufficient upregulation of GR activity may specifically result in increased 
HNE accumulation. GR activity is needed for restoration of reduced glutathione in the 
cell, which is also a cofactor for the enzyme phospholipid hydroperoxide glutathione 
peroxidase [reviewed in (Imai and Nakagawa, 2003)] that catalyzes the reduction of 
lipid hydroperoxides. These hydroperoxides are precursors of toxic lipid peroxidation 
end products like HNE. Furthermore, reduced glutathione is a cofactor for the 
detoxification of HNE by glutathione-S-transferases (Spitz et al., 1990; Canuto et al., 
1993; Ullrich et al., 1994). Hence, an insufficient restoration of reduced glutathione by 
the GR reaction may lead to accumulation of HNE. 
Also, the extent of MDA formation after in vitro stimulation with ferric iron may be 
related to the activities of antioxidant enzymes: in cohort #1 enzyme activities were 
highly upregulated resulting in efficient inhibition of lipid peroxidation in all brain 
regions, whereas the limited upregulation of enzyme activities does not afford 
protection in cohort #2. 
Another major difference in our results between the two studies is the lack of a gender 
difference in upregulation of antioxidant enzyme activities and HNE levels in cohort #2. 
It must be noted that gender differences in cohort #1 were only significant in Two-way 
ANOVA over all brain regions but not statistically significant in temportal cortex alone. DISCUSSION 
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Nevertheless the larger number of subjects employed in cohort #2 could have overcome 
the weak statistical significance. The mean age at death was not different between AD 
patients from cohort #1 and #2, also the major cause of death was similar between the 
two cohorts, where most AD patients died of pulmonary insufficiency. However, in 
cohort #2, we found significant effects of MMSE, a measure of cognitive decline, on 
HNE levels and GPx activity as well as a tendency on affecting Cu/Zn-SOD activity. 
Hence the clinical state of disease progression could have affected the results of gender 
differences in cohort #1. Unfortunately, no clinical data were available for patients in 
cohort #1. Therefore, it can only be speculated which factors could have influenced the 
different outcome. 
A likely explanation for the conflicting results on gender differences in oxidative stress-
related parameters in AD patients could nevertheless reside in the strikingly different 
distribution of Apo E alleles between the two cohorts: in cohort #1 the majoritiy of AD 
patients were homozygous Apo E4 carriers, whereas in cohort #2 only a minority of 
patients was homozygous for Apo E4 (see Table 4.9). 
Table 4.9: Comparison of Apo E genotype of AD patients in cohort #1 and #2. 
Set of samples  unknown  non-Apo E4 hetero-
zygous E4 
homo-
zygous E4 
Cohort #1      
Total AD patients    2 2 5 
female    1 2 3 
male    1 0 2 
Cohort #2      
Total AD patients  2 5 6 3 
female  2 2 3 1 
male  0 3 3 2 
 
Hence, the relative numbers of Apo E4 homozygous subjects in cohort #1 (5 of 9 AD 
patients) are higher than in cohort #2 (3 of 14 AD patients, 2 patients with unknown 
Apo E genotype). As the Apo E4 genotype was shown to be associated with a higher 
risk for AD especially in females (Poirier et al., 1993; Payami et al., 1996; Farrer et al., 
1997; Bretsky et al., 1999; Breitner et al., 1999; Molero et al., 2001) and numerous 
interactions of Apo E and estrogens have been described [reviewed in (MacLusky, 
2004)], the relatively higher numbers of Apo E4 carriers in cohort #1 could have 
produced the gender difference in HNE levels and upregulation of antioxidant enzymes 
Cu/Zn-SOD and GPx, while no such gender difference was observed in cohort #2. 
However, the numbers of subjects in both cohorts are too small to reevaluate the data DISCUSSION 
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with respect to gender-disparate changes in oxidative stress-parameters in only the 
subgroup of Apo E4 homozygous AD patients. Therefore, this issue can only be 
investigated in more detail in a still larger cohort of samples. 
A further difference between cohort #1 and cohort #2 is present in the mean post 
mortem interval, with a mean PMI (mean ± 95 % C.I.) of 24.52 ± 4.36 hours in samples 
from cohort #1 and only 5.0 ± 0.84 hours in cohort #2. This can explain the differences 
in the absolute levels of lipid peroxidation products between the two cohorts. Oxidized 
lipids are chemically instable and probably prone to undergo decomposition reactions 
during the PMI interval, resulting in the observed higher basal levels of lipid 
peroxidation products in cohort #1 as compared with cohort #2, whereas the stimulation 
of MDA formation was less pronounced in cohort #1 – probably due to already 
substantial decay of lipids in tissue samples during the longer PMI, resulting in less 
efficient in vitro stimulation and consequently lower levels of MDA formation in cohort 
#1 as compared to cohort #2. 
Nevertheless, the major finding that activities of antioxidant enzymes are specifically 
upregulated in AD patients could be independently reproduced in cohort #2. This may 
be related to the fact that activities of antioxidant enzymes obviously remain relatively 
stable during the post mortem interval (Brannan et al., 1982). Hence the outcome of the 
results was similar between the two cohorts despite significant differences in post 
mortem interval. Of course, it can be speculated which factors may mediate the 
upregulation of antioxidant enzymes. Cell culture models have shown that treatment 
with oxidative stressors leads to an increased expression and/or activity of several 
antioxidant enzymes (Shull et al., 1991; Yoshioka et al., 1994; Tate, Jr. et al., 1995; 
Jornot and Junod, 1997; Yatin et al., 1998; Yoo et al., 1999; Rohrdanz et al., 2001), 
hence the upregulation of antioxidant enzymes may be a response to increased ROS 
accumulation in AD brains. In accordance with this, increased levels of HNE as a 
marker for oxidative damage were found in AD brain in cohort #2, suggesting that AD 
brains operate under increased oxidative pressure. However, the exact factors which 
mediate the upregulation of antioxidant enzymes on a molecular level have yet to be 
identified. 
So far, several putative binding sites have been identified in the upstream reagion of the 
human Cu/Zn-SOD gene (Kim et al., 1994), among these sites for NF-κB and Ap-1 
binding. NF-κB and Ap-1 have also been shown to be important for GPx and catalase DISCUSSION 
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transcription in response of muscle cells to oxidative stress (Zhou et al., 2001). 
Regulation of GR transcription in mammalian cells is unknown, but dependance on 
Ap-1 has been described in yeast (Grant et al., 1996). Thus, NF-κB and Ap-1 are the 
most widely studied factors in mediating transcriptional regulation of a variety of 
antioxidant enzymes, although other factors probably play a role as well (Seo et al., 
1996; Merante et al., 2002; Ermak et al., 2004; Hussain et al., 2004). 
In this respect, Aβ and/or APP-derived proteins have been shown to activate a variety of 
stress responses in vitro – including activation of NF-κB (Behl et al., 1994b; Barger and 
Mattson, 1996; Akama et al., 1998; Cardoso and Oliveira, 2003; Casal et al., 2004) and 
the MAP kinase pathway (Greenberg et al., 1994; Anderson et al., 1995; Tamagno et 
al., 2003; Marques et al., 2003) with subsequent c-jun kinase activation that could 
influence AP-1 DNA binding activity (see 1.1.3.4, page 13). NF-κB and c-jun kinase 
activation could also be detected in brains from AD patients (Anderson et al., 1994; 
Kaltschmidt et al., 1997; Zhu et al., 2001). Furthermore, Aβ has been shown to induce 
Cu/Zn-SOD activity in vitro (Bruce et al., 1997; Yatin et al., 1998; Cardoso and 
Oliveira, 2003). 
Apart from Aβ, also HNE – the lipid peroxidation aldehyde that was specifically 
elevated in AD patients and moreover elevated at early stages of the disease (see Figure 
3.39, page 133, and Figure 3.51, page 145) – has been shown to activate MAP kinases 
(Tamagno et al., 2003), AP-1 binding (Camandola et al., 2000a) and to induce the heat 
shock transcription factor (Cajone and Crescente, 1992). Interestingly, in rat astroglial 
cultures, HNE treatment modified GPx and GR activity in a way similar to our 
observations, resulting in increased GPx but decreased GR activity (Ahmed et al., 
2002). This resembles the situation in human AD brains in cohort #2 with moderate 
MMSE scores, where HNE levels are elevated accompanied by increased GPx, but not 
GR activity (see Figure 3.51, page 145, and Figure 3.52, page 146). 
In conclusion, Aβ accumulation in AD brains could – in concert with other factors that 
have yet to be identified – result in increased oxidative stress, accumulation of HNE and 
a direct or indirect activation of protective antioxidant cascades. Furthermore AICD, the 
intracellular domain of APP resulting from γ-secretase cleavage, can act as a 
transcription factor (Leissring et al., 2002), but target genes are yet unidentified. Hence, 
several putative mechanisms of gene activation can be induced by APP and APP-
derived proteins or Aβ, either directly or indirectly, e.g. via increased ROS production DISCUSSION 
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and/or HNE formation. These mechanisms may explain why activities of antioxidant 
enzymes are upregulated in AD patients in our studies. However, upregulation of 
antioxidant enzymes is either not sufficient to protect against accumulation of oxidative 
damage, or the relative failure in upregulation of GR activity may result in insufficient 
protection against accumulation of HNE. 
Summary of observations in human AD brain tissue 
Figure 4.6 summarizes the results obtained in studies of human AD brain tissue in the 
course of this thesis. 
Taken together, our results from two independent studies of human brain tissue show 
that activities of Cu/Zn-SOD and GPx and to a lesser extent GR are elevated in AD 
patients relative to non-demented controls. This upregulation of antioxidant enzyme 
activities probably occurs in response to increased ROS levels but is not sufficient to 
protect against oxidative damage, because elevated levels of the lipid peroxidation 
product HNE were detected in AD brains. 
Furthermore, alterations in oxidative stress-related parameters were subject to 
modulation by important sporadic AD risk factors. Accordingly, activites of Cu/Zn-
SOD and GPx are even more profoundly increased in female AD patients 
accompanied by increased HNE levels, suggesting that female gender predisposes to 
pathogenic alterations in oxidative stress-related parameters, which is consistent with 
epidemiological reports of a higher risk for sporadic AD in women. Moreover, the 
Apo E genotype has an impact on the extent of oxidative damage, as MDA and HNE 
levels were dose-dependently increased in Apo E4 carriers. Additionally, levels of Aβ 
were correlated with MDA levels and activities of Cu/Zn-SOD, GPx and to a lesser 
extent GR, suggesting that soluble Aβ can be an important mediator of oxidative 
damage and antioxidant response in brains from AD patients. 
Finally, dynamic alterations in oxidative stress-related parameters take place during 
the progression of the disease: while HNE levels are highest in moderately 
cognitively impaired AD patients, MDA levels are steadily increasing with clinical 
progression of the disease. Hence, HNE may be a relevant neurotoxic factor in earlier 
disease stages whereas MDA can constitute a continuously rising damaging factor 
during the disease progression. 
In conclusion, the changes in oxidative stress-related parameters identified in brains DISCUSSION 
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from sporadic AD patients, the modulation by important AD risk factors like female 
gender and the Apo E4 genotype as well as the correlation with levels of soluble Aβ 
and the clinical status of dementia support the hypothesis that oxidative stress plays a 
major role in AD-relevant pathogenic processes. The identification of the molecular 
links between Aβ accumulation, APP processing and upregulation of antioxidant 
enzyme activites can therefore provide new pharmacological targets for augmentation 
of antioxidant defenses in AD brains. 
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Figure 4.6: Summary of effects on oxidative stress-related parameters observed in brain 
tissue from sporadic AD patients. 
Accumulation of Aβ in AD brains, which is strongly modified by the Apo E genotype, leads to an 
upregulation of antioxidant enzymes, mostly Cu/Zn-SOD and GPx. GR activity is however not 
sufficiently upregulated, which may facilitate accumulation of toxic HNE. Activities of antioxidant 
enzymes Cu/Zn-SOD and GPx and HNE levels as a measure of oxidative damage are 
furthermore modified by gender. While HNE is elevated early in the disease progression, MDA 
is highest at later stages and correlates with the levels of Aβ. Levels of MDA and HNE are 
modulated by the Apo E genotype. See text for further details. 
Straight lines represent findings from this thesis, whereas dotted lines represent well-
established events from other reports. Hypothetical events are marked by questionaires. 
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4.4 Comparative summary and perspectives 
The results obtained in the course of this thesis allow for an estimation of the 
contribution of oxidative stress to the pathogenesis of AD and for a comparison of 
relevant transgenic mouse models with the situation in brains from sporadic AD 
patients. The suitability of transgenic mice as models for AD, the common findings in 
mice and sporadic AD patients that HNE but not MDA levels are selectively increased 
and that oxidative stress-related parameters are subject to modification by gender will 
be discussed here in more detail. Furthermore, the results of this thesis will be reviewed 
with respect to strategies utilizing antioxidants for the prevention and/or therapy of AD. 
4.4.1 Suitability  of  transgenic mice to study AD-relevant 
pathogenic mechanisms 
The generation of different lines of transgenic mice expressing human proteins with 
familial AD mutations has provided valuable models for AD research [reviewed in 
(Seabrook and Rosahl, 1999; Hock, Jr. and Lamb, 2001; Higgins and Jacobsen, 2003)]. 
One of the most important steps in mimicking AD pathology in mouse brains was the 
generation of APP transgenic mouse models, which display accumulation of Aβ and 
formation of plaques at later stages (Games et al., 1995; Hsiao et al., 1996; Sturchler-
Pierrat et al., 1997) and reactive gliosis (Frautschy et al., 1998; Stalder et al., 1999). 
Furthermore, neuronal loss has been described in some models (Calhoun et al., 1998; 
Schmitz et al., 2004), although some of these results are controversial (Irizarry et al., 
1997; Takeuchi et al., 2000), probably due to methodological difficulties inherent to 
assessment of neuron counts (Dickson, 2004). 
Despite the progress in modelling AD pathology in transgenic mice, it can not be denied 
that these mouse models have some limitations. Confounding factors that have been 
observed in several APP transgenic mice are behavioural abnormalities like 
hyperactivity and/or aggressiveness (Moechars et al., 1996; Moechars et al., 1998; Van 
Dam et al., 2003), a phenotype which was also present in Thy1-APP and APP23 
transgenic mice employed in this thesis. Although the occurence of neuropsychiatric 
abnormalities like increased irritability and aggressive behaviour has been documented 
in a large percentage of AD patients (Devanand, 1997; Hope et al., 1999), it is not clear 
whether the behavioural disturbances in mice are causally linked to AD-relevant 
processes due to APP/Aβ expression or whether they constitute a confounding artefact. DISCUSSION 
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The fact that relatively high levels of overexpression of APP are needed to elicit the 
deposition of Aβ plaques raises concerns about possible artefacts due to unphysiological 
protein levels. Knowledge of further factors that can influence Aβ deposition in mice 
may lead to development of mouse models with more physiological protein levels. In 
this respect, several studies provided evidence that factors related to immune activation 
can modulate accumulation of Aβ (Wyss-Coray et al., 1997; Wyss-Coray et al., 2001; 
Little et al., 2004). Furthermore, disruption of estrogen receptor beta results in Aβ 
deposits in non-transgenic mouse brains (Zhang et al., 2004), and environmental 
enrichment accelerates plaque deposition in APP transgenic mice (Jankowsky et al., 
2003). Thus, augmentation of plaque formation by similar approaches in APP-bearing 
mice may allow for the development of AD mouse models without unphysiological 
levels of APP overexpression. 
Furthermore, the plaques formed in transgenic mouse brains during the relatively short 
life span of 2-3 years are distinctly different from plaques in human brains accumulating 
over a much longer period of time (Kuo et al., 2001; Kalback et al., 2002). In addition, 
APP transgenic mice mimic plaque pathology to some extent, but not the extensive 
neurodegeneration and tau pathology as observed in human brains. The recent 
development of triple transgenic mice expressing mutant APP, PS1 and tau protein 
(Oddo et al., 2003) may overcome some of these problems. Importantly, neurofibrillary 
pathology in mice bearing mutant tau protein depends on the presence of Aβ (Götz et 
al., 2001; Lewis et al., 2001), giving further support to the amyloid hypothesis. 
Finally – despite progress in the development of mice with plaque and neurofibrillary 
tangle pathology – transgenic mice do not mimic the whole pathology seen in AD 
brains. For example, microglial activation and immune responses in APP transgenic 
mice are different from the situation in human AD brains (Schwab et al., 2004), which 
may explain why our results on several transgenic mouse lines are different from the 
situation in human AD brains (see section 4.3). Although oxidative stress could be 
detected in PS1 and Thy1-APP transgenic mice, no such observation was made in 
PDGF-APP or PDGF-APP/PS1 mice. Hence, the deposition of plaques is not inevitably 
associated with increased oxidative stress. Similarly, an impairment of Cu/Zn-SOD 
activity was only found in Thy1-APP and APP23 transgenic mice, but not in the other 
transgenic mouse models, whereas activities of antioxidant enzymes were clearly 
upregulated in sporadic AD patients. Hence it can be concluded that oxidative damage 
as elevated HNE levels in sporadic AD brains can be reproduced in some but not all DISCUSSION 
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transgenic mouse models, whereas the upregulation of antioxidant enzyme activities 
seen in AD brains is completely absent in the transgenic mice analyzed in this thesis. It 
seems that especially adaptive processes towards oxidative damage are differently 
regulated in transgenic mouse brains compared to human brains. To close the gap 
between mouse models based on FAD mutations and sporadic AD patients, it would be 
necessary to analyze brain tissue from FAD cases, which are however very rare and 
therefore difficult to obtain. Such studies would allow to elucidate (i) whether the 
pathogenesis of both familial and sporadic AD results in the same final pathway, i.e. 
neurotoxicity mediated by oxidative stress and increased HNE levels, and also (ii) 
whether this final pathway is caused by different mechanisms, i.e. impaired antioxidant 
defense in carriers of APP mutations and increased ROS production by PS1 mutations 
in contrast to insufficient upregulation of antioxidant enzymes in sporadic AD patients. 
Furthermore, our results on APP transgenic mice allow to conlcude that oxidative stress 
is not a feature of amyloid deposition under all conditions, as we detected neither 
increased HNE nor MDA levels in brains from PDGF-APP/PS1 transgenic mice at any 
age, despite plaque formation from an age of 6 months (Blanchard et al., 2003). In this 
respect it has to be noted that the amyloid hypothesis in its original form had to be 
modified in recent years to better fit all experimental evidence (Hardy and Selkoe, 
2002). Reports that Aβ is neurotrophic (Whitson et al., 1989; Whitson et al., 1990; 
Yankner et al., 1990) and is formed also under physiological conditions (Haass et al., 
1993) have stimulated the search for a special toxic species of Aβ. Accumulating 
evidence has been provided that Aβ plaques are probably not a major factor initiating 
pathogenic processes but can be rather considered as a non-toxic epiphenomenon 
caused by misguided APP and/or Aβ processing. Several factors argue for this opinion: 
neurodegeneration has been observed in PS1 mice without formation of amyloid 
plaques (Chui et al., 1999), cognitive deficits and elevated oxidative stress both precede 
the deposition of plaques (Pratico et al., 2001; Van Dam et al., 2003) and neurodegene-
ration exceeds the areas of plaque deposition (Schmitz et al., 2004). Furthermore, the 
plaque load in humans gives only a poor correlation with the clinical status of cognitive 
impairment in human AD patients (Braak and Braak, 1991; Nagy et al., 1995; Gomez-
Isla et al., 1997; Giannakopoulos et al., 2003; Guillozet et al., 2003). Instead, soluble 
Aβ species, i.e. oligomers up to 100 kDa, or protofibrils (Kuo et al., 1996; Walsh et al., 
1999; Haass and Steiner, 2001; Klein et al., 2001; Takahashi et al., 2002; Gong et al., 
2003) may constitute the main neurotoxic agents. The rigorous analysis of these Aβ DISCUSSION 
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species in human and transgenic mouse brains may provide better ways of identifying 
mouse models which more closely mimic AD-relevant pathogenic events. 
4.4.2 Is HNE a major toxic factor in AD? 
It is striking that we found specifically elevated levels of HNE, but not MDA, in brains 
from sporadic AD patients (cohort #2) as well as in two different mouse models based 
on familial AD mutations: in aged mice transgenic for mutant PS1 and in young and 
middle-aged Thy1-APP transgenic mice bearing the Swedish and London mutations in 
APP. Hence it can be speculated whether increased HNE levels are a common toxic 
principle in sporadic as well as familial AD. 
First of all, a large body of evidence points to an increase in HNE levels in brain and 
CSF from sporadic AD patients (Lovell et al., 1997; Markesbery and Lovell, 1998), 
which is supported by studies of HNE-modified proteins (Sayre et al., 1997; Ando et al., 
1998; Butterfield et al., 2002). Furthermore, increased HNE but not MDA levels were 
found in serum from AD patients compared to controls (McGrath et al., 2001), which 
confirms our observations that selectively HNE levels are increased in brains from AD 
patients and transgenic mouse models. 
HNE has been shown to be formed in vitro after treatment of cell cultures with Aβ 
(Mark et al., 1997; Tamagno et al., 2003), and HNE displays neurotoxic properties in 
several models (Kruman et al., 1997; Soh et al., 2000; Malecki et al., 2000; Camandola 
et al., 2000a). Neurotoxic mechanisms described for HNE include activation of c-jun 
kinase (Soh et al., 2000; Tamagno et al., 2003) and mitochondrial toxicity – ranging 
from inactivation of mitochondrial proteins like cytochrome c oxidase (Chen et al., 
1998; Chen et al., 1999), complex II and III of the respiratory chain (Picklo et al., 
1999), the adenine-nucleotide translocator (Vieira et al., 2001), α-ketoglutarate 
dehydrogenase (Humphries and Szweda, 1998; Korotchkina et al., 2001) and pyruvate 
dehydrogenase (Korotchkina et al., 2001) to an alteration of mitochondrial membrane 
fluidity (Chen and Yu, 1994). Of note, deficiencies in cytochrome c oxidase (Wong-
Riley et al., 1997; Maurer et al., 2000; Bosetti et al., 2002) and the pyruvate 
dehydrogenase complex activity (Sorbi et al., 1983) have been identified in brains from 
AD patients. Furthermore, HNE can interfere with neuronal signaling by an impairment 
of intracellular calcium homeostasis via inactivation of ion-motive ATPases (Mark et 
al., 1997; Siems et al., 2003), by interaction with G proteins (Blanc et al., 1997) and 
proteinkinase C (Chiarpotto et al., 1999), and by inactivation of glutamate transport into DISCUSSION 
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glial cells (Blanc et al., 1998; Lauderback et al., 2001). Finally, HNE inhibits 
dephosphorylation of tau (Mattson et al., 1997) and induces proteasomal dysfunction 
(Hyun et al., 2002), which can propagate the development of abnormal protein 
accumulation and NFT pathology in AD brains. Hence, several mechanisms of impaired 
neuronal function, neurotoxicity and progression of AD neuropathology can be 
mediated by HNE. 
A major question to be answered is why HNE, but not MDA levels, are increased in 
mutant PS1 and Thy1-APP transgenic mice as well as in AD patients. Mechanisms of 
formation of these aldehydes in vivo are difficult to elucidate. In vitro studies of lipid 
peroxidation systems revealed that the structural requirement for HNE formation are 
present in lipid hydroperoxides from n-6 polyunsaturated fatty acids (Pryor and Porter, 
1990; Schneider et al., 2001a) – which can arise from cyclooxygenase or lipoxygenase 
reactions with arachidonic acid. Interestingly, increased immunostaining for 12/15-
lipoxygenase has been identified in brains from AD patients (Pratico et al., 2004). The 
reaction of 12/15-lipoxygenase with e.g. arachidonic acid can provide lipid 
hydroperoxides that have the structural prerequisite for formation of HNE. In contrast, 
MDA can be formed from a larger variety of unsaturated fatty acids due to less 
structural requirements, which may explain why MDA is the more abundant lipid 
peroxidation product. n-6 polyunsaturated fatty acids like arachidonic acid yield high 
levels of HNE after microsomal oxidation (Esterbauer et al., 1986) or oxidation with 
iron ascorbate (Mlakar and Spiteller, 1996). Recently it was also shown that HNE can 
be formed in vitro from oxidation of lipid hydroperoxides by heme-iron-containing 
proteins like cytochrome c (Hayashi et al., 2004), which is present in complex IV of the 
mitochondrial respiratory chain. Hence, disturbed mitochondrial functions, loss of 
mitochondrial membrane potential, increased mitochondrial ROS formation and release 
of cytochrome c from the respiratory chain may favour the formation of HNE, 
especially as mitochondrial membranes have a high content of PUFAs (Zabelinskii et 
al., 1999; Gutierrez et al., 2002). 
Previous studies from our own group and others have linked APP overexpression and/or 
exposure to Aβ with mitochondrial damage (Canevari et al., 1999; Casley et al., 2002; 
Aliev et al., 2003; Marques et al., 2003), which was also detected in Thy1-APP 
transgenic mice (Blanchard et al., 2003; Keil et al., 2004). Furthermore, HNE levels in 
brain tissue and mitochondrial ROS levels in peripheral cells were positively correlated 
in the study on PS1 transgenic mice, supporting the notion that HNE can arise from DISCUSSION 
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mitochondrial ROS. Therefore, a hypothetical mechanism of formation of HNE in vivo 
after mitochondrial damage, arising specifically from lipid hydroperoxide formation by 
mitochondrial ROS and from further oxidation by cytochrome c can be postulated. 
Alternatively, HNE could be the mediator of the toxic effects of Aβ on mitochondria 
(Keller et al., 1999). Both mechanisms should be explored in future studies. 
4.4.3 Gender  differences  in  AD and hormone replacement 
therapy 
A gender difference in the prevalence and incidence of AD has been widely described, 
with women being at higher risk, even when the longer life expectancy for women is 
taken into account and data are compared to age-matched men (Rocca et al., 1986; Jorm 
et al., 1987; Zhang et al., 1990; Hagnell et al., 1992; Fratiglioni et al., 1997; Seshadri et 
al., 1997; Gao et al., 1998; Andersen et al., 1999; Copeland et al., 1999; Ruitenberg et 
al., 2001). Although these findings are still controversial (Rocca et al., 1998; Yamada et 
al., 1999; Ganguli et al., 2000; Hebert et al., 2001; Graff-Radford et al., 2002; 
Fitzpatrick et al., 2004) and may be confounded by a longer survival after diagnosis of 
AD in women (Corder et al., 1995), the gender difference is still striking. Furthermore, 
a gender-specific higher risk for AD in women seems to be more pronounced in carriers 
of Apo E4 alleles (Poirier et al., 1993; Payami et al., 1996; Farrer et al., 1997; Bretsky 
et al., 1999; Breitner et al., 1999; Molero et al., 2001).  
Based on these epidemiological studies it was suggested that the lack of protective 
gonadal hormones, especially estrogen, after menopause may increase the risk for AD 
in females. Some biochemical studies support this notion as decreased levels of gonadal 
hormones or elevated sex-hormone binding globulin have been measured in AD patients 
(Manly et al., 2000; Hoskin et al., 2004), however the issue is controversial (Hogervorst 
et al., 2003). Consequently, several retrospective studies have established that use of 
hormone replacement therapy during menopause was associated with a reduced risk for 
sporadic AD (Henderson et al., 1994; Paganini-Hill and Henderson, 1994; Tang et al., 
1996; Baldereschi et al., 1998; Waring et al., 1999; Steffens et al., 1999; Slooter et al., 
1999) – although, again, conflicting results have been published (Brenner et al., 1994; 
Seshadri et al., 2001). Nevertheless, prospective clinical trials have been initiated 
utilizing gonadal hormones in the treatment of AD, with only marginal (Fillit et al., 
1986; Schneider et al., 1996; Yoon et al., 2003) or no benefit at all (Mulnard et al., 
2000; Wang et al., 2000). The disappointing results from hormone therapy as a DISCUSSION 
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treatment option for AD have shifted the focus of attention on the possibility that 
hormones may rather be effective in the prevention of AD. But again, despite positive 
results from initial, smaller studies, the results of recent large clinical trials were 
disappointing (Henderson et al., 2000; Seshadri et al., 2001; Shumaker et al., 2003). 
In conclusion, the overall results from studies utilizing gonadal hormones in the 
prevention or treatment of AD led to the current recommendation that – due to limited 
or no efficacy but considerable side effects – hormone replacement therapy can not be 
recommended, neither for the treatment nor the prevention of AD (Henderson, 2004). 
Despite several further questions to be explored, the negative results from hormone 
studies may allow to conclude that hormone treatment does not have a major impact on 
the development of AD or may even be harmful, based on results from a recent trial 
where hormone replacement therapy even increased the risk to suffer from probable 
dementia (Shumaker et al., 2003). This would be in accordance with our data in Thy1-
APP transgenic mice, where a gender-disparate higher formation of Aβ was detectable 
in female mice from an age of 3 months and still present in 12 months old female mice, 
although a considerable proportion of female mice should already be acyclic at that 
stage. Hence, it can be concluded that female gonadal hormones rather may increase Aβ 
formation, which may be related to the above-mentioned higher risk for dementia after 
hormone replacement therapy. Alternatively, other factors apart from gonadal hormones 
may determine the gender-disparate formation of Aβ. In this respect, it was recently 
demonstrated in cell culture that luteinizing hormone can increase β-amyloidogenic 
cleavage of APP and that treatment of mice with leuprolide, which suppresses 
gonadotropin secretion and subsequently the synthesis of gonadal hormones, can reduce 
formation of Aβ in female mice in vivo (Bowen et al., 2004). Although no comparable 
findings in humans are available, these results nevertheless suggest that a higher risk for 
AD in women may be related to increased levels of gonadotropins after menopause, 
which may negatively affect APP processing and lead to accumulation of Aβ especially 
in females (Johnson et al., 1998; Kraszpulski et al., 2001; Corder et al., 2004). 
Apart from differences after menopause, it may also be possible that gender differences 
exist, cumulating over the whole life time, which increase the risk to develop AD. 
Consequently, the results from Thy1-APP transgenic mice suggest that female mice 
show an inherent higher β-amyloidogenic cleavage of APP, which seems to be 
independent of gonadal function as it was still present in 12 months old mice. DISCUSSION 
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Therefore, hormone-independent factors like e.g. differences in brain morphology and 
neuron number between males and females (Breedlove, 1992; Carrer and Cambiasso, 
2002), which are found in rodents (De Vries, 2003) as well as in humans (Pakkenberg et 
al., 2003), may explain a different sensitivity of female versus male brain tissue towards 
AD-specific neurodegenerative processes. Further exploration of these gender 
differences may shed more light on AD-relevant pathogenic processes. 
4.4.4 Is it possible to prevent AD by antioxidants?  
Several therapeutic approaches for treatment of AD are focusing on the use of 
antioxidants, but this rationale is mainly based on one clinical trial (Sano et al., 1997) 
where extremely high doses of vitamin E (2000 IU daily) were able to delay the 
progression of disease. However, the endpoint in this study was poorly defined 
including a relatively large variety of events, and the results were only significant after 
adjustment for the baseline MMSE scores, as the placebo and treatment group differed 
in this parameter despite randomization. Nevertheless, antioxidants could be explored as 
further therapeutic options or in the prevention of AD, with the advantage that side-
effects are usually either none (vitamin E) or only mild (vitamin C) – with the exception 
of vitamin A (Beta Carotene Cancer Prevention Study Group, 1994; Albanes et al., 
1996; Omenn et al., 1996). However, for a causal therapy it has to be established first 
whether oxidative stress is a primary event in the disease pathogenesis or just a side-
effect of the neurodegenerative process. 
Although our results in general confirm that oxidative stress plays a role in the 
pathogenesis of AD, we can not completely establish whether oxidative damage is 
indeed causally related to the disease progress. However, some observations argue for 
oxidative damage as an early event in the pathogenesis. First of all, our data on sporadic 
AD patients show that HNE levels can be elevated in early stages of the disease, where 
the clinical degree of cognitive impairment is relatively moderate. This is in line with 
studies that oxidative markers are quantitatively highest in early stages of the disease 
(Nunomura et al., 2001; Abe et al., 2002). Also, studies utilizing brain tissue from 
subjects with mild cognitive impairment, which is considered to be a prodromal stage of 
AD (Grundman et al., 2004), have found increased markers for oxidative stress (Pratico 
et al., 2002; Rinaldi et al., 2003; Mecocci, 2004). Furthermore, our results on Thy1-APP 
transgenic mouse brains revealed that increased HNE levels can be detected as early as 
at 3 months of age and even before the deposition of plaques, in good accordance with DISCUSSION 
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another study of a different APP transgenic mouse model (Pratico et al., 2001). Hence, 
it can be speculated that oxidative damage constitutes an early event in the pathogenesis 
of AD. 
In addition, some experimental evidence argues for manifold causal roles of oxidative 
stress in accelerating Aβ accumulation, either in vitro by increasing amyloid 
aggregation (Dyrks et al., 1992) or in vivo, as it was recently shown that breeding APP 
transgenic mice on a heterozygous MnSOD knockout background, which causes 
oxidative stress, increases the accumulation of Aβ levels and plaque burden in brains 
from these mice (Li et al., 2004a). Furthermore, early vitamin E supplementation in 
young but not in aged APP transgenic mice reduces lipid peroxidation markers, Aβ 
levels and plaque burden (Sung et al., 2004). Apart from Aβ toxicity and plaque 
pathology, oxidative stress might also be involved in the formation of neurofibrillary 
tangles (Mattson et al., 1997; Perez et al., 2002) and be causally relevant for loss of 
nicotinic and muscarinic acetylcholine receptors in AD brains (Fawcett et al., 2002; Yu 
et al., 2003). This evidence suggests that the buildup of both major neuropathological 
features plaques and tangles as well as loss of acetylcholine receptor function in AD 
brains may be prevented or slowed down by administration of antioxidants. 
Hence, it seems possible that an early intervention by treatment with antioxidants or, 
even more promising, preventive approaches can slow disease progression or even 
reduce the risk for development of AD. In accordance with this notion, recent studies 
reported a reduced risk of AD in subjects with a high intake of antioxidants, where 
vitamin C and E were proven to be effective either alone (Morris et al., 1998; Engelhart 
et al., 2002; Morris et al., 2002a) or only in combination (Zandi et al., 2004). Although 
these studies were prospective, the design was only observational, so that a multitude of 
antioxidant supplements and various dosage regimens are included. Furthermore, the 
conclusion that antioxidant use is effective in prevention of AD can not be drawn with 
certainty from these studies because concentrations of antioxidants were not measured 
directly in blood samples. Therefore, some speculation remains about the validity of 
antioxidant intake assessments. Nevertheless, these studies spur further motivation for 
investigation of this issue in an interventional design. Several of such studies have been 
initiated, but results will become available only in months ahead. Nevertheless, there is 
already considerable evidence today that augmentation of antioxidant defenses may 
delay the onset of AD, which would at least reduce the prevalence of this disease in the 
future. SUMMARY / ZUSAMMENFASSUNG 
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5.1 Summary 
The aim of this thesis was to investigate a putative contribution of oxidative stress to the 
pathogenesis of Alzheimer’s disease (AD) in several different models. By analyzing 
various parameters related to oxidative stress in transgenic mouse models based on 
familial AD (FAD) mutations and in human post-mortem brain tissue from sporadic AD 
patients, a comprehensive approach should be undertaken to identify causal disease 
mechanisms triggered by FAD mutations and sporadic AD risk factors. Furthermore, 
the relevance of transgenic mice compared to studies of brains from sporadic AD 
patients could be assessed. 
5.1.1 The influence of aging studied in mice 
In the first part of this thesis, the influence of aging, the most important risk factor for 
sporadic AD, on oxidative stress-related markers was analyzed in mice. For these 
studies, brain tissue and splenic lymphocytes as a peripheral cell model from C57BL/6J 
mice were studied, as the C57BL/6J strain is the genetic background for the FAD mouse 
models analyzed in further studies in this thesis. In brain tissue from these mice, aging 
led to an upregulation of the activities of Cu/Zn-superoxide dismutase (SOD), 
glutathione peroxidase (GPx) and glutathione reductase (GR), while levels of lipid 
peroxidation products malondialdehyde (MDA) and 4-hydroxynonenal (HNE) were 
simultaneously reduced in aged animals. Also in vitro stimulation of lipid peroxidation 
yielded reduced or unchanged MDA levels in aged animals, suggesting that antioxidant 
enzymes provide a major contribution to the protection against oxidative damage in vivo 
and  in vitro. In splenic lymphocytes, mitochondrial reactive oxygen species (ROS) 
levels were only slightly but not significantly increased in aged animals. 
Furthermore, profound gender differences were observed in C57BL/6J mice. In brain 
tissue, female mice showed elevated GPx activity and reduced basal and stimulated 
levels of lipid peroxidation products compared to male mice. Similarly, splenic 
lymphocytes from female mice displayed lower levels of mitochondrial ROS. 
Therefore, female mice are seemingly better protected against ROS accumulation and 
oxidative damage in brain tissue as well as peripheral cells, and higher GPx activity 
probably contributes to these observations. 
The overall conclusion from the studies on C57BL/6J mice is that physiological aging 
in healthy animals leads to a compensatory upregulation of antioxidant enzymes, which SUMMARY / ZUSAMMENFASSUNG 
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play a primary role in preventing excessive ROS accumulation and oxidative damage. 
5.1.2 Effects of FAD mutations on oxidative stress parameters 
The effects of FAD mutations on oxidative stress parameters were assessed in 
experiments on transgenic mice bearing mutant human PS1 and/or APP. 
In PS1M146L transgenic mice, increased oxidative damage could be detected only in 
aged 19-22 months old animals, which argues for a higher susceptibility towards 
oxidative stress caused by the aging process. In brain tissue, HNE levels were 34.8 % 
increased in PS1M146L compared to PS1wt mice, while MDA levels were not altered. 
Antioxidant defense was not impaired, as neither were the activities of antioxidant 
enzymes reduced nor was the in vitro stimulation of lipid peroxidation altered in 
samples from PS1M146L mice. In splenic lymphocytes from PS1M146L mice, which 
express the transgenic PS1, mitochondrial and cytosolic ROS were elevated to 142.1 % 
and 120.5  % the levels of non-transgenic mice, respectively. In summary, the 
PS1M146L mutation exerts oxidative toxicity in aged mice via a mechanism of 
increased ROS formation. Although severe damage to mitochondria could be excluded 
from our experiments, the exact steps leading to ROS accumulation remain to be 
elucidated. 
As further AD mouse models, mice bearing PDGF-APP and double transgenic PDGF-
APP/PS1 mice were studied. No changes in any of the parameters analyzed could be 
detected in brains from these mice in any age group. PDGF-APP transgenic mice form 
only low levels of Aβ, but double transgenic PDGF-APP/PS1 mice show profound 
accumulation of Aβ during aging, as detected by Western blot and ELISA, and have 
been described to display Aβ plaques from an age of 6 months. Hence, the mere 
presence of Aβ plaques is not sufficient to trigger oxidative stress. 
In contrast to PDGF-APP transgenic mice, Thy1-APP transgenic mice show 
pronounced oxidative damage. These mice express similar levels of full-length APP as 
PDGF-APP transgenic mice, but show elevated β-secretase cleavage of APP with much 
higher formation of the C-terminal fragment C99 and Aβ. Increased levels of HNE 
could be detected from an age of 3 months (115 % of non-transgenic controls), which 
was even more pronounced and statistically significant at 12 months of age (184 % of 
non-transgenic controls). These increased HNE levels were accompanied by reduced 
activity of Cu/Zn-SOD in 3 and 12 months old animals (93.4 % and 91.2 % of non-SUMMARY / ZUSAMMENFASSUNG 
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transgenic controls, respectively), suggesting that impaired antioxidant defence by 
Cu/Zn-SOD is causally responsible for increased formation of HNE. However, no 
alterations were observed in 18 months old animals, which may be due to adaptive 
processes – like the upregulation of antioxidant enzymes observed previously in 
C57BL/6J mice during aging. In the age groups of 3 and 12 months, both male and 
female transgenic mice were studied, and profound gender differences were observed. 
Although both gender show similar expression of full-length APP in brain tissue, female 
Thy1-APP transgenic mice display higher β-secretase cleavage resulting in increased 
formation of C99 and Aβ compared to male mice. Both the pools of insoluble as well as 
soluble Aβ were approximately 30 % increased in female mice. Therefore, increased 
formation of C99 and subsequently Aβ from APP by increased β-amyloidogenic 
cleavage but not altered aggregation or deposition of Aβ in brain tissue is responsible 
for the gender difference in Aβ levels. Consistent with increased formation of Aβ and/or 
C99 in female mice, increased levels of HNE and reduced activity of Cu/Zn-SOD could 
be detected earlier in female compared to male Thy1-APP transgenic mice, i.e. already 
at an age of 3 months, suggesting that increased β-amyloidogenic cleavage of APP with 
increased C99 and/or Aβ formation causes impaired Cu/Zn-SOD activity and effects 
increased formation of HNE. Furthermore, as Thy1-APP transgenic mice have been 
described to display formation of Aβ plaques from an age of 6 months, oxidative 
damage constitutes an early event in this mouse model and occurs independently from 
the presence of plaques, which again confirms our previous observations in PDGF-
APP/PS1 mice that Aβ plaques do not provoke oxidative stress in APP transgenic mice. 
In an independent study, reduced activity of Cu/Zn-SOD was also found in another APP 
transgenic mouse model, APP23 mice. This confirms the observations on Thy1-APP 
mice, i.e. that overexpression of APP with familial AD mutations can lead to reduced 
activity of Cu/Zn-SOD. Therefore, our studies identify impaired Cu/Zn-SOD activity as 
a novel and causal mechanism for oxidative toxicity of APP mutations. 
5.1.3 Studies on human brain tissue from sporadic AD patients 
In order to analyze the influence of sporadic AD risk factors and for a comparison of the 
transgenic mouse models based on FAD mutations with the much more common 
sporadic form of AD, post mortem brain tissue from sporadic AD patients was analyzed 
in the final part of this thesis. SUMMARY / ZUSAMMENFASSUNG 
     239 
In a first set of human tissue samples, brain tissue from four different brain regions, i.e.  
frontal, parietal and temporal cortex as well as cerebellum, was analyzed. The major 
findings were that activities of antioxidant enzymes were upregulated in AD samples in 
several brain regions, of which samples from temporal cortex − a brain region that is 
severely affected by the disease − showed the most pronounced changes. Levels of lipid 
peroxidation products MDA and HNE were not elevated in AD samples. However, a 
trend towards lower levels of HNE in cerebellum was found in control and AD brains, 
suggesting that low levels of this aldehyde may be responsible for the resistance of 
cerebellar neurons against neurodegeneration in AD. The functional relevance of 
upregulation of antioxidant enzyme activities was con-firmed by in vitro stimulation of 
lipid peroxidation, where significantly lower levels of MDA were formed in samples 
from AD patients. Furthermore, the observed alterations were modified by gender, as 
female AD patients showed higher activities of Cu/Zn-SOD and GPx, but not GR, 
compared to male patients. HNE levels were simultaneously increased, suggesting that 
brains from female patients are more vulnerable towards oxidative damage − despite the 
upregulation of Cu/Zn-SOD and GPx. 
In a second set of samples, only tissue from temporal cortex was analyzed in a larger 
number of samples. Again, activities of antioxidant enzymes Cu/Zn-SOD (119.2 % of 
controls) and GPx (120.9 % of controls), but not GR, were increased in AD samples. 
This was accompanied by increased levels of HNE (131.8 % of controls), but not MDA. 
Furthermore,  in vitro stimulation of MDA formation led to increased levels in AD 
samples, suggesting that upregulation of Cu/Zn-SOD and GPx in AD brains is not 
sufficient to protect against oxidative damage. 
As Aβ is hypothesized to be the main toxic factor in AD pathogenesis, levels of soluble 
Aβ1-40 were determined and shown to be increased in AD brains (415 % of controls), 
but there was a considerable overlap between AD patients and controls, suggesting that 
soluble Aβ1-40 can not be the only toxic agent in AD pathogenesis. Nevertheless, Aβ 
levels were positively correlated with MDA levels and activities of Cu/Zn-SOD and 
GPx, and showed a trend towards positive correlation with GR. Hence Aβ can cause 
oxidative damage and at the same time induce upregulation of antioxidant enzymes. 
Results were furthermore evaluated according to the Apo E4 genotype, which is the 
strongest genetic risk factor associated with sporadic AD known so far. The Apo E 
genotype has a major influence on the levels of Aβ, which were lowest in carriers of SUMMARY / ZUSAMMENFASSUNG 
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Apo E2 alleles and highest in homozygous Apo E4 carriers. Furthermore, lipid 
peroxidation products MDA and HNE were modulated by Apo E4 genotype with a gene 
dosage effect, as levels of both aldehydes were lowest in non-E4 carriers and highest in 
homozygous Apo E4 carriers, although these differences failed to reach statistical 
significance due to relatively low numbers of subjects in the respective subgroups. 
Nevertheless, they confirm that the AD risk factor Apo E4 increases oxidative damage 
in brain tissue, while the activities of antioxidant enzymes are not affected. 
Important information as to putative alterations of oxidative stress-related parameters 
with the progression of AD could be obtained from correlations with MMSE scores, 
which are a measure of cognitive abilities. Interestingly, MDA levels were negatively 
correlated with MMSE scores, indicating that oxidative damage at the level of MDA 
increases with the clinical progression of disease. HNE levels showed however a 
different pattern, as they were highest AD patients with moderate cognitive impairment 
and receded to almost the levels of controls in severely affected AD patients. Hence, 
MDA and HNE detect different kinds of oxidative damage during progression of AD, 
and HNE levels may be especially important for initiation of neurodegenerative events 
early in the disease pathogenesis. 
In summary, alterations in oxidative stress-related parameters were found in brains from 
sporadic AD patients, and these changes were additionally shown to be correlated with 
Aβ levels and to be modulated by gender and the Apo E4 genotype. These results 
support the hypothesis that oxidative stress, being subject to an influence of important 
risk factors for sporadic AD, contributes to the pathogenesis of Alzheimer’s disease in 
humans. 
5.1.4 Comparative summary and conclusions 
As a novel approach to investigate the pathogenesis of AD, different models for the 
disease have been directly compared in the course of this thesis. Taken together, 
oxidative damage could be detected in brains from sporadic AD patients as well as in 
various transgenic mouse models, although different causative mechanisms seem to 
operate in the different models, i.e. increased ROS formation by the PS1M146L 
mutation, impaired antioxidant defense via Cu/Zn-SOD caused by APP mutations and 
insufficient compensative upregulation of antioxidant enzymes in sporadic AD patients. 
Nevertheless, these different mechanisms consistently converge in the accumulation of SUMMARY / ZUSAMMENFASSUNG 
     241 
oxidative damage, which underscores the importance of these findings. Hence it could 
be demonstrated that various risk factors for sporadic AD as well as the presence of 
FAD mutations result in oxidative stress as common final pathway. 
Interestingly, in transgenic mouse models as well as in human brain tissue, only levels 
of HNE but not MDA were elevated, suggesting that the two lipid peroxidation 
aldehydes detect different kinds of oxidative damage, where HNE is the more specific 
marker for lipid peroxidation processes in AD-relevant models. Furthermore, as levels 
of neurotoxic HNE are elevated in sporadic AD patients with relatively moderate 
cognitive impairment and can be detected as early as in 3 months old Thy1-APP 
transgenic mice, it seems that HNE can constitute an early and causative factor for 
neurodegenerative processes in Alzheimer’s disease. 
Hence, the results of this thesis strongly support the further exploration of 
pharmacological approaches that augment antioxidant defenses for the prevention 
and/or treatment of AD. 
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5.2 Zusammenfassung 
Ziel dieser Arbeit war es, einen möglichen Beitrag von oxidativem Stress zur 
Pathogenese der Alzheimer Krankheit in unterschiedlichen Modellen zu erforschen. Die 
Untersuchung verschiedener Parameter, die in Zusammenhang mit oxidativem Stress 
stehen,  − sowohl in transgenen Mausmodellen, beruhend auf familiären Alzheimer-
Mutationen, als auch in humanem post mortem Gehirngewebe von sporadischen 
Alzheimerpatienten  − sollte eine umfassende Analyse zur Identifizierung kausaler 
Krankheitsmechanismen ermöglichen, die durch familiäre Alzheimer-Mutationen und 
durch Risikofaktoren für die sporadische Alzheimer Krankheit ausgelöst werden. 
Zudem könnte so die Relevanz transgener Mausmodelle im Vergleich zu Studien an 
Gehirngewebe von sporadischen Alzheimerpatienten beurteilt werden. 
5.2.1 Alterseffekte in Mäusen 
Im ersten Teil dieser Arbeit wurde der Einfluss des Alterns, was den wichtigsten 
Risikofaktor für die sporadische Alzheimer Krankheit darstellt, auf oxidativen Stress in 
Mäusen untersucht. Dafür wurden Gehirngewebe und Milzlymphozyten als peripheres 
Zellmodell von C57BL/6J Mäusen verwendet, da dieser Mausstamm den genetischen 
Hintergrund der transgenen Mäuse bildet, die für weitere Untersuchungen im Rahmen 
dieser Dissertation eingesetzt wurden. Im Gehirngewebe dieser Mäuse führte der 
Alterungsprozess zu erhöhten Aktivitäten der Enzyme Cu/Zn-Superoxiddismutase 
(Cu/Zn-SOD), Glutathionperoxidase (GPx) und Glutathionreduktase (GR), während 
gleichzeitig die Spiegel an Lipidperoxidationsprodukten Malondialdehyd (MDA) und 4-
Hydroxynonenal (HNE) in alten Tieren erniedrigt waren. Auch die in vitro Stimulation 
der Lipidperoxidation führte zu erniedrigten oder unveränderten MDA-Spiegeln in 
gealterten Tieren, so daß antioxidative Enzyme einen großen Beitrag zum Schutz gegen 
oxidative Schäden in vivo und in vitro leisten. In Milzlymphozyten von alten Tieren 
waren die Spiegel an mitochondrialen reaktiven Sauerstoffspezies (ROS) nur leicht, 
aber nicht signifikant erhöht. 
Außerdem wurden deutliche Geschlechtsunterschiede in C57BL/6J Mäusen beobachtet. 
Im Gehirngewebe zeigten weibliche Mäuse erhöhte GPx-Aktivität und erniedrigte 
basale und stimulierte Spiegel an Lipidperoxidationsprodukten im Vergleich zu 
männlichen Mäusen. Gleichermaßen wiesen Milzlymphozyten von weiblichen Mäusen 
niedrigere Spiegel an mitochondrialen ROS auf. Daher sind weibliche Tiere SUMMARY / ZUSAMMENFASSUNG 
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anscheinend besser gegen die Akkumulation von ROS und oxidative Schäden sowohl 
im Gehirn als auch in peripheren Zellen geschützt, was wahrscheinlich durch die höhere 
GPx-Aktivität verursacht wird. 
Insgesamt lässt sich also aus den Untersuchungen an C57BL/6J Mäusen schließen, dass 
der physiologische Alterungsprozess in gesunden Tieren kompensatorisch zu einer 
Erhöhung der antioxidativen Enzymaktivitäten führt, die eine wichtige Rolle im Schutz 
gegen Akkumulation von ROS und oxidative Schäden spielen. 
5.2.2 Einfluß von familiären Alzheimer-Mutationen 
Der Einfluss von familiären Alzheimer-Mutationen auf oxidative Parameter wurde in 
Experimenten an transgenen Mäusen untersucht, die menschliches PS1 und/oder APP 
mit Mutationen tragen. 
In PS1M146L-transgenen Mäusen wurden erhöhte oxidative Schäden nur in 19-22 
Monate alten Tieren gefunden, was dafür spricht dass der Alterungsprozess eine erhöhte 
Empfindlichkeit gegenüber oxidativem Stress verursacht. Im Gehirngewebe waren die 
HNE-Spiegel in PS1M146L transgenen Mäusen um 34.8  % im Vergleich zu PS1wt 
transgenen Mäusen erhöht, wohingegen die MDA-Spiegel unverändert waren. 
Antioxidative Mechanismen sind dabei nicht beeinträchtigt, da weder die Aktivitäten 
der antioxidativen Enzyme erniedrigt noch die in vitro Stimulation der 
Lipidperoxidation in Proben von PS1M146L transgenen Mäusen erhöht waren. In 
Milzlymphozyten, die das transgene PS1 exprimieren, waren mitochondriale und 
cytosolische ROS jeweils auf 142.1  % und 120.5  % der Spiegel in nicht-transgenen 
Mäusen erhöht. Zusammenfassend verursacht die PS1M146L Mutation oxidative 
Schäden in alten Mäusen über einen Mechanismus erhöhter ROS-Bildung. Obwohl eine 
direkte Schädigung von Mitochondrien in unseren Experimenten ausgeschlossen 
werden konnte, bleiben die genauen Einzelschritte, die zur Akkumulation von ROS 
führen, ungeklärt. 
Als weitere Mausmodelle wurden PDGF-APP und doppelt transgene PDGF-APP/PS1 
Mäuse verwendet. In diesen Mäusen wurden in keiner Altersgruppe Veränderungen in 
irgendeinem der untersuchten oxidativen Parameter festgestellt. Mittels Western Blot 
und ELISA konnte gezeigt werden, daß PDGF-APP transgene Mäuse nur sehr niedrige 
Mengen an Aβ bilden, wohingegen PDGF-APP/PS1 Mäuse deutliche Akkumulation 
von Aβ mit dem Alter zeigen. Zudem wurde die Plaquebildung ab einem Alter von 6 SUMMARY / ZUSAMMENFASSUNG 
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Monaten für diese Mäuse beschrieben. Somit ist die bloße Anwesenheit von Aβ Plaques 
nicht ausreichend, um oxidativen Stress auszulösen. 
Im Gegensatz dazu zeigen Thy1-APP transgene Mäuse deutliche oxidative Schäden. 
Diese Mäuse exprimieren ähnliche Mengen an APP wie PDGF-APP transgene Mäuse, 
weisen allerdings erhöhte β-Sekretasespaltung von APP unter verstärkter Bildung des 
C-terminalen Fragments C99 und von Aβ auf. Erhöhte HNE-Spiegel konnten schon im 
Alter von 3 Monaten gemessen werden (115 % der nicht-transgenen Kontrolltiere), was 
noch ausgeprägter und statistisch signifikant in 12 Monate alten Tieren war (184 % der 
nicht-transgenen Kontrolltiere). Diese erhöhten HNE-Spiegel waren begleitet von 
reduzierter Cu/Zn-SOD-Aktivität in 3 und 12 Monate alten Tieren (jeweils 93.4 % und 
91.2  % der nicht-transgenen Kontrolltiere), so daß die beeinträchtigte antioxidative 
Abwehr durch geringere Cu/Zn-SOD-Aktivität eventuell ursächlich an der erhöhten 
Bildung von HNE beteiligt ist. Jedoch wurden keinerlei Veränderungen in 18 Monate 
alten Tieren gesehen, was eventuell auf adaptive Prozesse zurückzuführen ist – wie 
beispielsweise eine Erhöhung der antioxidativen Enzymaktivitäten mit dem Alter, was 
in C57BL/6J Mäusen beobachtet wurde. In den 3 und 12 Monate alten Mäusen wurden 
jeweils männliche und weibliche transgene Mäuse untersucht, und deutliche 
Geschlechtsunterschiede konnten beobachtet werden. Obwohl die Expression von APP 
in beiden Geschlechtern gleich ist, zeigen weibliche Tiere erhöhte β-Sekretasespaltung 
von APP mit verstärkter Bildung von C99 und Aβ im Vergleich zu männlichen Tieren. 
Sowohl unlösliches als auch lösliches Aβ waren in weiblichen Tieren um etwa 30 % 
erhöht. Deshalb ist eine erhöhte Bildung von C99 und nachfolgend Aβ durch verstärkte 
β-Sekretasespaltung von APP, nicht jedoch eine veränderte Aggregation oder 
Ablagerung von Aβ im Gehirngewebe für die Geschlechtsunterschiede verantwortlich. 
In guter Übereinstimmung mit den erhöhten Aβ-Spiegeln konnten verstärkte HNE-
Bildung und erniedrigte Cu/Zn-SOD-Aktivität in weiblichen Tieren früher als in 
männlichen Tieren, nämlich schon in einem Alter von 3 Monaten, gemessen werden, so 
daß wahrscheinlich die vermehrte β-Sekretasespaltung von APP mit erhöhten C99- 
und/oder Aβ-Spiegeln ursächlich für die verringerte Cu/Zn-SOD-Aktivität und erhöhten 
HNE-Spiegel verantwortlich ist. Außerdem treten oxidative Schäden zu einem frühen 
Zeitpunkt in Thy1-APP transgenen Mäusen und unabhängig von der Plaquebildung auf, 
die in diesem Mausmodell ab einem Alter von 6 Monaten beschrieben ist. Dies bestätigt 
noch einmal die Beobachtungen an PDGF-APP/PS1 transgenen Mäusen, daß Aβ SUMMARY / ZUSAMMENFASSUNG 
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Plaques selbst keine oxidativen Schäden in APP-transgenen Mäusen verursachen. 
In einer unabhängigen Untersuchung konnte auch in einem weiteren APP-transgenen 
Mausmodell, APP23 Mäusen, verringerte Cu/Zn-SOD-Aktivität festgestellt werden. 
Dies bestätigt die Befunde an Thy1-APP-Mäusen, daß Überexpression von APP mit 
familiären Alzheimer-Mutationen zu verminderter Cu/Zn-SOD-Aktivität führen kann. 
Unsere Untersuchungen konnten somit eine reduzierte Cu/Zn-SOD-Aktivität als einen 
neuen und kausalen Mechanismus für oxidative Toxizität von APP-Mutationen 
identifizieren. 
5.2.3  Untersuchungen an humanem Gehirngewebe von 
sporadischen Alzheimerpatienten 
Um den Einfluss von Risikofaktoren der sporadischen Alzheimer Demenz zu 
untersuchen und die Vergleichbarkeit der auf familiären Mutationen basierenden 
transgenen Mausmodelle mit der zahlenmäßig sehr viel bedeutenderen sporadischen 
Form der Alzheimer Demenz beurteilen zu können, wurde im letzten Teil dieser Arbeit 
post mortem Gehirngewebe von sporadischen Alzheimerpatienten untersucht. 
In einer ersten Testreihe wurden Gewebeproben aus vier verschiedenen Gehirnregionen, 
dem frontalen, parietalen und temporalen Cortex sowie dem Cerebellum, untersucht. 
Die Aktivitäten der antioxidativen Enzyme waren in verschiedenen Gehirnregionen von 
Alzheimerpatienten erhöht, wobei die Veränderungen im temporalen Cortex − einer von 
der Krankheit stark betroffenen Gehirnregion − am deutlichsten waren. Die 
Lipidperoxidationsprodukte MDA und HNE waren in Proben von Alzheimerpatienten 
nicht erhöht. Allerdings wurde eine Tendenz zu erniedrigten HNE-Spiegeln in Proben 
aus dem Cerebellum beobachtet, so daß spekuliert werden kann, ob die relativ niedrigen 
Spiegel dieses Aldehyds möglicherweise für die Resistenz der Neurone im Cerebellum 
gegenüber degenerativen Prozessen bei der Alzheimer Demenz verantwortlich sind. Die 
funktionelle Bedeutung der erhöhten antioxidativen Enzymaktivitäten wurde durch in 
vitro Stimulation der Lipidperoxidation bestätigt, wobei in Proben von 
Alzheimerpatienten weniger MDA gebildet wurde. Außerdem werden die beobachteten 
Veränderungen durch das Geschlecht beeinflusst, da weibliche Alzheimerpatienten 
höhere Enzymaktivitäten von Cu/Zn-SOD und GPx aufweisen. Dabei waren die HNE-
Spiegel erhöht, was darauf hinweist, dass Gehirngewebe von weiblichen Patienten 
empfindlicher gegenüber oxidativen Schäden ist − trotz der erhöhten Aktivitäten von SUMMARY / ZUSAMMENFASSUNG 
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Cu/Zn-SOD und GPx. 
In einer zweiten Testreihe wurde nur Gewebe aus dem temporalen Cortex an einer 
größeren Anzahl von Proben untersucht. Wiederum waren die Enzymaktivitäten von 
Cu/Zn-SOD (119.2 %) und GPx (120.9 % der Kontrollen), nicht jedoch von GR, in 
Proben von Alzheimerpatienten erhöht. Begleitend wurden höhere Spiegel von HNE 
(131.8 % der Kontrollen), nicht jedoch von MDA, gefunden. Außerdem führte die in 
vitro Stimulation der MDA-Bildung zu erhöhten Werten in Proben von 
Alzheimerpatienten, so daß die erhöhten Enzymaktivitäten von Cu/Zn-SOD und GPx 
nicht ausreichend gegen oxidative Schädigung schützen. 
Da angenommen wird, daß Aβ der wichtigste toxische Faktor bei der Pathogenese der 
Alzheimer Krankheit ist, wurden die Spiegel an löslichem Aβ1-40 bestimmt. Diese waren 
in Proben von Alzheimerpatienten stark erhöht (415 % der Kontrollen), allerdings gab 
es eine beträchtliche Überschneidung zwischen Alzheimerpatienten und Kontrollen, so 
daß lösliches Aβ1-40 nicht der einzige toxische Faktor bei der Pathogenese der 
Erkrankung sein kann. Dennoch waren die Aβ-Spiegel positiv mit MDA-Spiegeln und 
Aktivitäten von Cu/Zn-SOD und GPx korreliert, und zeigten auch eine Tendenz zu 
positiver Korrelation mit GR. Dies weist darauf hin, daß Aβ oxidative Schäden 
verursachen und gleichzeitig zu einer erhöhten Aktivität antioxidativer Enzyme führen 
kann. 
Die Ergebnisse wurden außerdem nach dem Apo E4 Genotyp ausgewertet, welches der 
wichtigste bisher bekannte genetische Risikofaktor für die sporadische Alzheimer 
Demenz ist. Der Apo E Genotyp hat großen Einfluss auf die Aβ-Spiegel, die in Trägern 
des Apo E2 Allels am niedrigsten und in homozygoten Apo E4-Trägern am höchsten 
waren. Außerdem werden die Lipidperoxidationsprodukte MDA und HNE durch Apo 
E4 gendosisabhängig moduliert, da die Konzentrationen beider Aldehyde in Proben von 
nicht-E4-Trägern am niedrigsten und in homozygoten E4-Trägern am höchsten waren, 
obwohl diese Unterschiede aufgrund der geringen Probenzahlen in den jeweiligen 
Untergruppen nicht signifikant waren. Dennoch bestätigen diese Ergebnisse, daß der 
Risikofaktor Apo E4 oxidative Schäden in Gehirngewebe erhöht, ohne die Aktivitäten 
antioxidativer Enzyme zu beeinflussen. 
Wichtige Rückschlüsse im Hinblick auf Veränderungen in oxidativen Parametern 
während des klinischen Fortschreitens der Erkrankung konnten durch Korrelationen mit 
den MMSE-Werten, einem Maß für kognitive Fähigkeiten, gezogen werden. SUMMARY / ZUSAMMENFASSUNG 
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Interessanterweise waren die MDA-Spiegel negativ mit den MMSE-Werten korreliert, 
was darauf hinweist, daß oxidative Schäden auf Ebene des MDA mit dem klinischen 
Fortschreiten der Erkrankung zunehmen. HNE-Spiegel waren dagegen am höchsten in 
Alzheimerpatienten mit relativ moderater kognitiver Beeinträchtigung und niedriger, 
fast auf dem Niveau der Kontrollen, in schwer dementen Patienten. Daher scheinen 
MDA und HNE verschiedene Arten von oxidativen Schäden während des 
Fortschreitens der Erkrankung zu erfassen, und erhöhte HNE-Spiegel spielen eventuell 
eine wichtige Rolle bei der Neurodegeneration zu einem frühen Zeitpunkt der 
Alzheimer Krankheit. 
Zusammenfassend wurden Veränderungen in oxidativen Parametern in Gehirnen von 
sporadischen Alzheimerpatienten gefunden, und es konnte zusätzlich gezeigt werden, 
dass diese Veränderungen mit den Aβ-Spiegeln korrelieren und durch das Geschlecht 
und den Apo E4 Genotyp beeinflusst werden. Diese Ergebnisse unterstützen die 
Hypothese, dass oxidativer Stress, welcher durch wichtige Risikofaktoren für die 
Alzheimer Krankheit moduliert wird, zur Pathogenese der Erkrankung beim Menschen 
beiträgt. 
5.2.4 Vergleichende Zusammenfassung und Fazit 
Als neuartiger Ansatz, einen Beitrag zur Aufklärung der Pathogenese der Alzheimer 
Demenz zu leisten, wurden im Rahmen dieser Arbeit erstmalig unterschiedliche 
Modelle der Alzheimer Krankheit vergleichend untersucht. Insgesamt konnten oxidative 
Schäden sowohl in Gehirngewebe von sporadischen Alzheimerpatienten als auch in 
verschiedenen transgenen Mausmodellen nachgewiesen werden, obwohl 
unterschiedliche Mechanismen dafür kausal verantwortlich zu sein scheinen, nämlich 
erhöhte ROS-Bildung durch die PS1M146L Mutation, beeinträchtigte antioxidative 
Aktivität des Enzyms Cu/Zn-SOD verursacht durch APP-Mutationen und ungenügende 
kompensatorische Erhöhung der antioxidativen Enzymaktivitäten in sporadischen 
Alzheimerpatienten. Dennoch bewirken diese Mechanismen gleichermaßen eine 
Akkumulation oxidativer Schäden, was die wichtige Bedeutung dieser Befunde 
unterstreicht. Somit konnte gezeigt werden, dass verschiedene Risikofaktoren für die 
sporadische Alzheimer Demenz wie auch die Anwesenheit von familiären 
Alzheimermutationen in oxidativem Stress als gemeinsamer Endstrecke resultieren. 
Interessanterweise waren im Gehirngewebe von transgenen Mäusen wie auch von SUMMARY / ZUSAMMENFASSUNG 
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Alzheimerpatienten nur HNE-, nicht jedoch MDA-Spiegel erhöht, so daß die zwei 
verschiedenen Lipidperoxidationsprodukte unterschiedliche Arten von oxidativen 
Schäden detektieren, wobei HNE der spezifischere Marker in relevanten Modellen der 
Alzheimer Krankheit ist. Außerdem waren die HNE-Spiegel in Alzheimerpatienten mit 
relativ moderater kognitiver Beeinträchtigung am höchsten, und erhöhte HNE-Spiegel 
können auch schon ab einem Alter von 3 Monaten in Thy1-APP transgenen Mäusen 
gemessen werden, so daß HNE möglicherweise einen frühen und für die 
Neurodegeneration kausalen Faktor bei der Alzheimer Krankheit darstellt. 
Daher unterstützen die im Rahmen dieser Doktorarbeit erhobenen Befunde 
grundsätzlich die weitere Erforschung pharmakologischer Ansätze zur Verbesserung 
der antioxidativen Abwehr als Therapie oder auch zur Prophylaxe der Alzheimer 
Krankheit. 
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Aβ  amyloid beta 
Abs  photometrical absorption unit 
AD Alzheimer’s  disease 
AGE  advanced glycation end product 
AICD  APP intracellular domain 
Apo E  apolipoprotein E 
APLP APP-like  protein 
APP  amyloid precursor protein 
ARE  antioxidant response element 
ATP adenosin  triphosphate 
BSA  bovine serum albumine 
°C degrees  Celsius 
C.I. confidence  interval 
DAF diaminofluorescein 
DAF-2-DA diaminofluorescein-2-diacetate 
DCF dichlorofluorescein 
DCFH-DA dihydrodichlorofluorescein-diacetate 
DHE dihydroethidium 
DHR dihydrorhodamine  123 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic  acid 
dNTP desoxynucleotidetriphosphate 
dT desoxy-thymidin 
DTT dithiothreitol 
ECL enhanced  chemoluminescence 
EDTA ethylenediaminetetraacetate 
eNOS  endothelial nitric oxide synthase 
FACS  fluorescence activated cell sorting 
FAD  familial Alzheimer’s disease 
FADH  flavine adenine dinucleotide, reduced 
FSC forward  scatter 
FCS  fetal calf serum 
g gramm 
g  centrifugal force unit 
GPx glutathione  peroxidase 
GR glutathione  reductase 
h hour(s) 
HBSS  Hank’s balanced salt solution 
HMGCoA hydroxymethylglutaryl-coenzym-A 
HEPES 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonicacid 
HNE 4-hydroxynonenal 
iNOS  inducible nitric oxide synthase 
IP3 inositol-1,4,5-triphosphate ABBREVIATIONS 
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IU international  unit 
KPI  Kunitz-type serine protease inhibitor 
l litre 
MDA malondialdehyde 
MES 2-(N-morpholino)-ethanesulfonicacid 
MFH  mouse fetal hemoglobin 
min minute(s) 
ml millilitre 
MMSE  mini mental status examination 
NAD  nicotine adenine dinucleotide 
NADH  nicotine adenine dinucleotide, reduced 
NADPH  nicotine adenine dinucleotide phosphate, reduced 
nNOS  neuronal nitric oxide synthase 
NOS nitric  oxide  synthase 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor 
PHF  paired helical filament 
PMI  post mortem interval 
PMSF phenylmethylsulfonylfluoride 
PS1 presenilin-1 
PS1M146L  mutant human presenilin-1 with the M146L mutation 
PS1wt human  wildtype  presenilin-1 
PSAP presenilin-associated  protein 
PUFA  polyunsaturated fatty acid 
PVDF polyvinyldifluoride 
R123 rhodamine  123 
RNA ribonucleic  acid 
RNS  reactive nitrogen species 
ROS  reactive oxygen species 
RPMI  Roswell Park Memorial Institute 
RT reverse  transcriptase 
sAPP  soluble APP fragment 
SDS  sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec second(s) 
SOD superoxide  dismutase 
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